STUDYID,USUBJID,SUBJID,SITEID,AGE,AGEU,SEX,RACE,RACEN,COUNTRY,COUNTRYC,REGION,REGIONN,SAFFL,ITTFL,HITTFL,TEVLFL,CAEVLFL,ARM,TRTP,TRTPN,TRTA,TRTAN,HENT1ST,HENT1STN,AESEQ,AETERM,AEDECOD,AEBODSYS,AESTDTC,ASTDT,AEENDTC,AENDT,AESTDY,AESER,AEREL,AERELN,AETOXGR,AETOXGRN,AEACN,AEACNOTH,AEPATT,AEOUT,AESDTH,AESHOSP,AECONTRT,TRTEMFL
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ADBOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2010-10-19,2010-10-19,,,-14.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2010-10-20,2010-10-20,,,-13.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,EDEMA BOTH LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-21,2010-12-21,2011-01-04,2011-01-04,50.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ERYSIPELAS,Erysipelas,INFECTIONS AND INFESTATIONS,2011-01-07,2011-01-07,2011-01-25,2011-01-25,67.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2011-01-17,2011-01-17,2011-01-25,2011-01-25,77.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-01-24,2011-01-24,2011-01-25,2011-01-25,84.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-08,2011-02-08,2011-02-15,2011-02-15,99.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-08,2011-02-08,2011-02-15,2011-02-15,99.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-08,2011-03-08,2011-04-19,2011-04-19,127.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,EDEMA BOTH LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-08,2011-03-08,2011-04-19,2011-04-19,127.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-03,2011-05-03,2011-05-24,2011-05-24,183.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-03,2011-05-03,2011-05-24,2011-05-24,183.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-07,2011-06-07,2011-06-30,2011-06-30,218.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-07,2011-06-07,2011-06-30,2011-06-30,218.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,EDEMA BOTH LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-03,2011-05-03,2011-06-30,2011-06-30,183.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-04,2011-05-04,2011-05-10,2011-05-10,184.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-14,2011-07-14,2011-07-28,2011-07-28,255.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,NIGHT SWEAT,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06-30,2011-06-30,,,241.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-14,2011-07-14,2011-07-14,2011-07-14,255.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07-14,2011-07-14,2011-07-14,2011-07-14,255.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-07-14,2011-07-14,,,255.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-14,2011-07-14,2011-07-28,2011-07-28,255.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,GALLSTONE PAIN,Cholelithiasis,HEPATOBILIARY DISORDERS,2011-07-14,2011-07-14,2011-07-14,2011-07-14,255.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-28,2011-07-28,2011-08-05,2011-08-05,269.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-05,2011-08-05,2011-08-12,2011-08-12,277.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,EDEMA LOWER LIMBS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-28,2011-07-28,2011-08-05,2011-08-05,269.0,N,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-12,2011-08-12,2011-08-18,2011-08-18,284.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,DYSPNOE,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-18,2011-08-18,2011-08-18,2011-08-18,290.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,EDEMA LOWER LIMBS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-05,2011-08-05,2011-08-18,2011-08-18,277.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30.0,EDEMA LOWER LIMBS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-18,2011-08-18,2011-08-22,2011-08-22,290.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,31.0,PULMONARY EDEMA,Pulmonary oedema,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-26,2011-08-26,2011-08-30,2011-08-30,298.0,Y,NOT RELATED,1.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,32.0,PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2011-08-05,2011-08-05,2011-08-12,2011-08-12,277.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,33.0,NOCTURIA,Nocturia,RENAL AND URINARY DISORDERS,2011-06-30,2011-06-30,,,241.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-001-001,01001001,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,34.0,PROGRESSION OF PANCREATIC METASTATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-08-18,2011-08-18,2011-08-22,2011-08-22,290.0,Y,UNLIKELY,2.0,2,2.0,,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOCYTOPAENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-18,2011-05-18,2011-05-24,2011-05-24,16.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-03,2011-05-03,2011-05-05,2011-05-05,1.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-05-03,2011-05-03,2011-05-05,2011-05-05,1.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-03,2011-05-03,2011-07-07,2011-07-07,1.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,RASH ON THIGHS AND NECK,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-05-03,2011-05-03,2011-05-31,2011-05-31,1.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-05-03,2011-05-03,2011-07-14,2011-07-14,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-05-24,2011-05-24,2011-05-25,2011-05-25,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-06-07,2011-06-07,2011-07-07,2011-07-07,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-14,2011-06-14,2011-07-14,2011-07-14,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,UTI,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-07-07,2011-07-07,2011-07-14,2011-07-14,66.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ALLERGIC REACTION AFTER CT SCAN - DETAILS UNKNOWN,Hypersensitivity,IMMUNE SYSTEM DISORDERS,2011-04-18,2011-04-18,2011-04-18,2011-04-18,-15.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,NEUTROPAENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-12,2011-08-12,2011-08-19,2011-08-19,102.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-12,2011-08-12,2011-08-19,2011-08-19,102.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,EYE INFECTION,Eye infection,INFECTIONS AND INFESTATIONS,2011-08-19,2011-08-19,2011-09-06,2011-09-06,109.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-09-15,2011-09-15,2011-09-23,2011-09-23,136.0,Y,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-09-25,2011-09-25,2011-10-06,2011-10-06,146.0,Y,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-09-13,2011-09-13,,,134.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-001-005,01001005,001,46.0,YEARS,F,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,INFECTION AFTER STENTING PROCEDURE (FEVER AND ELEVATED CRP),Post procedural infection,INFECTIONS AND INFESTATIONS,2011-09-23,2011-09-23,2011-10-06,2011-10-06,144.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,HYDRONEPHROSIS,Hydronephrosis,RENAL AND URINARY DISORDERS,2011-05-10,2011-05-10,2011-05-18,2011-05-18,1.0,Y,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOPAENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-18,2011-05-18,2011-06-07,2011-06-07,9.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-06-21,2011-06-21,2011-07-07,2011-07-07,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-001-006,01001006,001,69.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HEMOGLOBIN LOW (CLINICALLY SIGNIFICANT),Haemoglobin decreased,INVESTIGATIONS,2011-06-21,2011-06-21,2011-06-28,2011-06-28,43.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-10-13,2011-10-13,2011-11-04,2011-11-04,-19.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-001-008,01001008,001,70.0,YEARS,M,WHITE,5.0,NOR,NORWAY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-11-03,2011-11-03,2011-11-07,2011-11-07,3.0,Y,UNLIKELY,2.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-03,2011-02-03,2011-05-10,2011-05-10,15.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-20,2011-01-20,2011-02-10,2011-02-10,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-01-20,2011-01-20,2011-01-27,2011-01-27,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-01-21,2011-01-21,2011-01-23,2011-01-23,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-14,2011-02-14,2011-02-14,2011-02-14,26.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,INTERMITTENT HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-03-03,2011-03-03,2011-03-23,2011-03-23,43.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,LOSS OF APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-02-17,2011-02-17,2011-03-10,2011-03-10,29.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-30,2011-03-30,,,70.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,LOSS OF APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-03-17,2011-03-17,2011-04-20,2011-04-20,57.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-23,2011-03-23,2011-04-12,2011-04-12,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-03-23,2011-03-23,2011-04-28,2011-04-28,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-23,2011-03-23,2011-04-12,2011-04-12,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-17,2011-03-17,2011-03-17,2011-03-17,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-23,2011-03-23,2011-03-23,2011-03-23,63.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-06,2011-02-06,2011-02-24,2011-02-24,18.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-25,2011-05-25,2011-06-08,2011-06-08,126.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-25,2011-05-25,2011-06-08,2011-06-08,126.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-06-15,2011-06-15,2011-07-06,2011-07-06,147.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-07-06,2011-07-06,2011-08-23,2011-08-23,168.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,PRE-RENAL INSUFFICIENCY,Prerenal failure,RENAL AND URINARY DISORDERS,2011-09-08,2011-09-08,2011-09-23,2011-09-23,232.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-09-08,2011-09-08,2011-09-08,2011-09-08,232.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-09-08,2011-09-08,2011-09-21,2011-09-21,232.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-10,2011-09-10,2011-09-21,2011-09-21,234.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-09-08,2011-09-08,2011-09-20,2011-09-20,232.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,VERTIGO,Vertigo,EAR AND LABYRINTH DISORDERS,2011-08-18,2011-08-18,2011-08-18,2011-08-18,211.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,LEFT INGUINAL HERNIA DU TO ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-07-20,2011-07-20,2011-08-23,2011-08-23,182.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-001,01003001,003,61.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,LEFT INGUINAL HERNIA DU TO ASCITES,Inguinal hernia,GASTROINTESTINAL DISORDERS,2011-07-20,2011-07-20,2011-08-23,2011-08-23,182.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-26,2011-05-26,2011-05-27,2011-05-27,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-01,2011-06-01,2011-06-02,2011-06-02,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-07,2011-06-07,2011-06-08,2011-06-08,13.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-16,2011-06-16,2011-06-18,2011-06-18,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-21,2011-06-21,2011-07-06,2011-07-06,27.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-02,2011-07-02,2011-07-03,2011-07-03,38.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,PANCREATIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-01,2011-06-01,,,7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,EPIGASTRIC HERNIA,Abdominal hernia,GASTROINTESTINAL DISORDERS,2011-07-19,2011-07-19,2011-07-28,2011-07-28,55.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-04,2011-08-04,2011-08-09,2011-08-09,71.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-10,2011-08-10,2011-08-12,2011-08-12,77.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-02,2011-09-02,2011-09-05,2011-09-05,100.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-07,2011-09-07,2011-09-12,2011-09-12,105.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,DILATATION OF INTRA-HEPATIC BILIARY TRACT,Dilatation intrahepatic duct acquired,HEPATOBILIARY DISORDERS,2011-10-26,2011-10-26,2011-11-04,2011-11-04,154.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,PNEUMOCOCCEMIA,Pneumococcal sepsis,INFECTIONS AND INFESTATIONS,2011-10-26,2011-10-26,2011-11-04,2011-11-04,154.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-30,2011-10-30,,,158.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-21,2011-12-21,2012-01-03,2012-01-03,210.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,GASTRO-OESOPHAGAL REFLUX,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2011-10-13,2011-10-13,,,141.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-16,2011-12-16,2011-12-16,2011-12-16,205.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-13,2011-10-13,2011-11-08,2011-11-08,141.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-25,2012-01-25,,,245.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-003-002,01003002,003,63.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-10,2012-01-10,2012-01-10,2012-01-10,230.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-15,2011-06-15,2011-06-19,2011-06-19,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-21,2011-06-21,2011-07-07,2011-07-07,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-14,2011-07-14,2011-08-09,2011-08-09,31.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-003,01003003,003,73.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-06,2011-09-06,,,85.0,N,DEFINITELY,4.0,1,1.0,DRUG WITHDRAWN,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-07,2012-01-07,2012-01-17,2012-01-17,5.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-15,2012-01-15,2012-01-15,2012-01-15,13.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-02,2012-02-02,2012-02-03,2012-02-03,31.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-22,2012-02-22,,,51.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-05,2012-03-05,2012-03-05,2012-03-05,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,WORSENING HEPATITIS B,Hepatitis B,INFECTIONS AND INFESTATIONS,2012-05-10,2012-05-10,2012-06-03,2012-06-03,129.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,,,129.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-05-10,2012-05-10,,,129.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,PYROSIS,Dyspepsia,GASTROINTESTINAL DISORDERS,2012-04-11,2012-04-11,2012-04-26,2012-04-26,100.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,PROGRESSION OF PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-05-26,2012-05-26,2012-07-18,2012-07-18,145.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CHOLANGITIS,Cholangitis,HEPATOBILIARY DISORDERS,2012-06-03,2012-06-03,2012-07-18,2012-07-18,153.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-003-005,01003005,003,61.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2012-06-03,2012-06-03,2012-07-18,2012-07-18,153.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-02-17,2011-02-17,,,-13.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,INTERMITTENT NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-03,2011-03-03,,,2.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-03-16,2011-03-16,2011-04-05,2011-04-05,15.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-04-06,2011-04-06,,,36.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-15,2011-04-15,,,45.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-03-20,2011-03-20,2011-04-20,2011-04-20,19.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-04-21,2011-04-21,,,51.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-03-24,2011-03-24,2011-04-15,2011-04-15,23.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-04-15,2011-04-15,,,45.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-005-001,01005001,005,62.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-04-18,2011-04-18,,,48.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,POST-PRANDIAL ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-03-31,2011-03-31,,,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-31,2011-03-31,2011-04-06,2011-04-06,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-06,2011-04-06,2011-05-25,2011-05-25,7.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-07,2011-04-07,2011-04-12,2011-04-12,8.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-14,2011-04-14,2011-04-19,2011-04-19,15.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-07-02,2011-07-02,,,94.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DYSGEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-04-22,2011-04-22,,,23.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-27,2011-06-27,,,89.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-25,2011-05-25,2011-06-08,2011-06-08,56.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-08,2011-06-08,2011-06-15,2011-06-15,70.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-15,2011-06-15,2011-06-22,2011-06-22,77.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-07-05,2011-07-05,84.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-05,2011-07-05,2011-07-06,2011-07-06,97.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-005-003,01005003,005,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-06,2011-07-06,,,98.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-03-18,2011-03-18,2011-03-22,2011-03-22,8.0,Y,NOT RELATED,1.0,4,4.0,"DOSE REDUCED, DRUG INTERRUPTED","CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-04-10,2011-04-10,2011-04-14,2011-04-14,31.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,INFECTIOUS SYNDROM (NO FURTHER DETAILS),Infection,INFECTIONS AND INFESTATIONS,2011-04-10,2011-04-10,,,31.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,EDEMA (LIMB INFERIOR),Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-10,2011-04-10,,,31.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,SOMNOLENCE,Somnolence,NERVOUS SYSTEM DISORDERS,2011-04-14,2011-04-14,,,35.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CONFUSION,Confusional state,PSYCHIATRIC DISORDERS,2011-04-10,2011-04-10,2011-04-14,2011-04-14,31.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HEPATIC ENCEPHALOPATHY,Hepatic encephalopathy,NERVOUS SYSTEM DISORDERS,2011-04-10,2011-04-10,,,31.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-03-18,2011-03-18,,,8.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-18,2011-03-18,,,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,CONJUNCTIVAL JAUNDICE,Ocular icterus,EYE DISORDERS,2011-03-18,2011-03-18,,,8.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,MUCOCUTANEOUS JAUNDICE,Jaundice,HEPATOBILIARY DISORDERS,2011-03-18,2011-03-18,,,8.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,HYPERCREATININE,Hypercreatininaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-18,2011-03-18,2011-03-19,2011-03-19,8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ASCITE,Ascites,GASTROINTESTINAL DISORDERS,2011-03-18,2011-03-18,,,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,RENAL INSUFFICIENCY,Renal failure,RENAL AND URINARY DISORDERS,2011-03-18,2011-03-18,2011-03-22,2011-03-22,8.0,Y,NOT RELATED,1.0,4,4.0,"DOSE REDUCED, DRUG INTERRUPTED",PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-03-25,2011-03-25,2011-04-08,2011-04-08,15.0,Y,NOT RELATED,1.0,4,4.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,PANCREATIC CARCINOMA METASTATIC,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-04-10,2011-04-10,2011-05-01,2011-05-01,31.0,Y,NOT RELATED,1.0,5,5.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-007-002,01007002,007,66.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,RENAL INSUFFICIENCY,Renal failure,RENAL AND URINARY DISORDERS,2011-03-25,2011-03-25,2011-04-08,2011-04-08,15.0,Y,NOT RELATED,1.0,4,4.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-05,,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-06-08,2011-06-08,2011-06,,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-05,2011-07-05,,,28.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,Y,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CYTOLYSIS,Cell death,METABOLISM AND NUTRITION DISORDERS,2011-06-08,2011-06-08,,,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-06-29,2011-06-29,15.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-15,2011-06-15,,,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DRY MOUTH,Dry mouth,GASTROINTESTINAL DISORDERS,2011-06,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,DERMAL TOXICITY (NAILS),Nail toxicity,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06,,2011-06,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,RENAL FAILURE,Renal failure,RENAL AND URINARY DISORDERS,2011-07-05,2011-07-05,2011-07-26,2011-07-26,28.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-07-05,2011-07-05,,,28.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-05,2011-07-05,,,28.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,EDEMA OF THE LOWER EXTREMITIES,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-05,2011-07-05,,,28.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,HYPOPHOSPHATEMIA,Hypophosphataemia,METABOLISM AND NUTRITION DISORDERS,2011-06-29,2011-06-29,2011-07-06,2011-07-06,22.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-06-08,2011-06-08,2011-07-06,2011-07-06,1.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,HYERCALCEMIA,Hypercalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-06-08,2011-06-08,2011-07-05,2011-07-05,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,HICCUPS,Hiccups,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07,,2011-07,,,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,SEPSIS,Sepsis,INFECTIONS AND INFESTATIONS,2011-07-12,2011-07-12,,,35.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,CONFUSION,Confusional state,PSYCHIATRIC DISORDERS,2011-07-24,2011-07-24,,,47.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,DROWSINESS,Somnolence,NERVOUS SYSTEM DISORDERS,2011-07-24,2011-07-24,,,47.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-15,2011-06-15,2011-07-04,2011-07-04,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,ELEVATED BILIRUBIN,,,2011-06-29,2011-06-29,2011-07-07,2011-07-07,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-003,01007003,007,63.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,ELEVATED BILIRUBIN,,,2011-07-08,2011-07-08,,,31.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-20,2011-06-20,,,-3.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,SUBDIAPHRAGMATIC PAIN (ABDOMINAL PAIN),Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-22,2011-06-22,2011-06-23,2011-06-23,-1.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07,,,,,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-09,2011-06-09,2011-07-06,2011-07-06,-14.0,N,NOT RELATED,1.0,1,1.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-23,2011-06-23,,,1.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-07,2011-07-07,,,15.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,EPIGASTRIC PAINS,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-07-10,2011-07-10,2011-07-14,2011-07-14,18.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-07,2011-07-07,2011-07-27,2011-07-27,15.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,MUSCLE PAIN,Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07-28,2011-07-28,,,36.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,PERIPHERAL NEUROPATHY OF THE HANDS,Neuropathy peripheral,NERVOUS SYSTEM DISORDERS,2011-07-28,2011-07-28,,,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-18,2011-08-18,,,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-18,2011-08-18,2011-09-01,2011-09-01,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-19,2011-08-19,2011-08-21,2011-08-21,58.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-09,,,,,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,JAUNDICE,Jaundice,HEPATOBILIARY DISORDERS,2011-10-23,2011-10-23,2011-11-15,2011-11-15,123.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,DISCOLORATION OF FECES,Faeces discoloured,GASTROINTESTINAL DISORDERS,2011-10-20,2011-10-20,,,120.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,MUCOCUTANEOUS JAUNDICE,Jaundice,HEPATOBILIARY DISORDERS,2011-10-23,2011-10-23,,,123.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-09,,,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,DETERIORATION OF GENERAL CONDITION (PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA),Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-10-23,2011-10-23,2012-02-14,2012-02-14,123.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-28,2011-07-28,2011-09-28,2011-09-28,36.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-004,01007004,007,46.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-29,2011-09-29,,,99.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-30,2011-08-30,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-06,2011-09-06,2011-10-04,2011-10-04,8.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-13,2011-09-13,,,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-09,,,,,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-10,,,,,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,MUSCLE PAIN,Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01,,,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,SHOULDERS PAIN,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-24,2012-01-24,,,148.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-005,01007005,007,64.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-14,2011-11-14,,,77.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-07,2012-02-07,,,15.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,LOSS OF APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-02,,,,,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-07,2012-02-07,2012-02-15,2012-02-15,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-14,2012-02-14,2012-02,,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2012-02-14,2012-02-14,,,22.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DRYNESS OF MUCOUS MEMBRANES,Mucosal dryness,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-14,2012-02-14,,,22.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-16,2012-01-16,,,-8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-02,2012-03-02,2012-04-10,2012-04-10,39.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-28,2012-02-28,2012-03-07,2012-03-07,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-03,2012-04-03,2012-04-10,2012-04-10,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-27,2012-03-27,,,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-04-10,2012-04-10,2012-04-14,2012-04-14,78.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,PANCREATIC ADENOCARCINOMA METASTATIC,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-05-14,2012-05-14,2012-05-31,2012-05-31,112.0,Y,NOT RELATED,1.0,5,5.0,,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,LEUKOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-06,2012-03-06,2012-03-14,2012-03-14,43.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-007-006,01007006,007,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-12,,,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-02,,,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02,,,,,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-08,2012-03-08,,,8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-05-03,2012-05-03,,,64.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PROGRESSION OF MESTASTATIC PANCREATIC ADENOCARCINOMA (HYPERBILIRUBINEMIA),Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-05-24,2012-05-24,2012-06-23,2012-06-23,85.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-15,2012-03-15,,,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYPOKALIEMA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-22,2012-02-22,,,-8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-23,2012-03-23,2012-03-26,2012-03-26,23.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-007-007,01007007,007,67.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,FECALOMA,Faecaloma,GASTROINTESTINAL DISORDERS,2012-05-03,2012-05-03,2012-05-09,2012-05-09,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-09,2011-02-09,2011-02-16,2011-02-16,7.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-16,2011-02-16,2011-02-23,2011-02-23,14.0,N,DEFINITELY,4.0,1,1.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-31,2011-01-31,2011-02-09,2011-02-09,-3.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-16,2011-02-16,2011-04-06,2011-04-06,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-02-12,2011-02-12,2011-05-16,2011-05-16,10.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-02-12,2011-02-12,2011-02-16,2011-02-16,10.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-02-12,2011-02-12,2011-02-16,2011-02-16,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-02-16,2011-02-16,2011-03-02,2011-03-02,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,"EDEMA, LOWER EXTREMITIES",Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-16,2011-02-16,,,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,MOOD CHANGE,Mood altered,PSYCHIATRIC DISORDERS,2011-02-16,2011-02-16,,,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,CS-LOW WBC COUNT,White blood cell count decreased,INVESTIGATIONS,2011-02-16,2011-02-16,2011-02-23,2011-02-23,14.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,CS-SERUM LOW BICARBONATE,Blood bicarbonate decreased,INVESTIGATIONS,2011-02-16,2011-02-16,2011-03-02,2011-03-02,14.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-01-31,2011-01-31,2011-03-02,2011-03-02,-3.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2011-01-31,2011-01-31,2011-03-02,2011-03-02,-3.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-01-31,2011-01-31,,,-3.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,CS-LOW WBC COUNT,White blood cell count decreased,INVESTIGATIONS,2011-03-02,2011-03-02,2011-03-09,2011-03-09,28.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-02,2011-03-02,2011-03-16,2011-03-16,28.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-02,2011-03-02,2011-03-09,2011-03-09,28.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-03-02,2011-03-02,2011-04-20,2011-04-20,28.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-03-02,2011-03-02,2011-03-09,2011-03-09,28.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-03-09,2011-03-09,2011-03-16,2011-03-16,35.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-03-16,2011-03-16,2011-03-30,2011-03-30,42.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,"PHLEBITIS, RIGHT ARM",Phlebitis,VASCULAR DISORDERS,2011-03-16,2011-03-16,,,42.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,"TENDERNESS, RIGHT POSTERIOR LOWER LEG)",Tenderness,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-16,2011-03-16,,,42.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,25.0,CS-LOW LYMPHOCYTE COUNT,Lymphocyte count decreased,INVESTIGATIONS,2011-03-16,2011-03-16,2011-04-06,2011-04-06,42.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,26.0,CS HIGN BUN LEVELS,Blood urea increased,INVESTIGATIONS,2011-03-16,2011-03-16,2011-03-30,2011-03-30,42.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,27.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-03-30,2011-03-30,2011-04-20,2011-04-20,56.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,28.0,PAIN(LEFT UPPER QUADRANT SUPRA-UMBILICAL REGION),Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-03-30,2011-03-30,,,56.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,29.0,HYPOCALCEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-04-06,2011-04-06,2011-04-20,2011-04-20,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,30.0,NIGHT SWEATS,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-04-06,2011-04-06,2011-04-20,2011-04-20,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,31.0,SENSORY NEUROPATHY,Peripheral sensory neuropathy,NERVOUS SYSTEM DISORDERS,2011-04-06,2011-04-06,,,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,32.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-04-06,2011-04-06,,,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,33.0,ATELECTASIS,Atelectasis,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-06,2011-04-06,,,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,34.0,CS HIGH SERUM CREATININE,Blood creatinine increased,INVESTIGATIONS,2011-04-07,2011-04-07,2011-04-20,2011-04-20,64.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,35.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-11,2011-04-11,2011-04-20,2011-04-20,68.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,36.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-06,2011-04-06,2011-04-20,2011-04-20,63.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,37.0,ASCITES (WEIGHT GAIN),Ascites,GASTROINTESTINAL DISORDERS,2011-04-20,2011-04-20,,,77.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,38.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-04-20,2011-04-20,,,77.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,39.0,BILATERAL MUSCLE PAIN,Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-20,2011-04-20,,,77.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,40.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-20,2011-04-20,2011-04-27,2011-04-27,77.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,41.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-04-20,2011-04-20,,,77.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,42.0,MILD TEMPORAL MUSCLE WASTING,Muscle atrophy,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-20,2011-04-20,,,77.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,43.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-20,2011-04-20,,,77.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,44.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-27,2011-04-27,2011-04-30,2011-04-30,84.0,Y,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,45.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-27,2011-04-27,,,84.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,46.0,PANCREATIC CANCER PROGRESSION (CLINICAL SYMPTOMATIC DETERIORATION),Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-05-03,2011-05-03,,,90.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,47.0,CHRONIC CARDIAC ISCHEMIA WITH ST DEPRESSION,Myocardial ischaemia,CARDIAC DISORDERS,2011-03-02,2011-03-02,,,28.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-009-001,01009001,009,56.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,48.0,CHRONIC CARDIAC ISCHEMIA WITH ST DEPRESSION,Electrocardiogram ST segment depression,INVESTIGATIONS,2011-03-02,2011-03-02,,,28.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-16,2010-11-16,2010-11-22,2010-11-22,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-01-19,2011-01-19,2011-01-20,2011-01-20,72.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-19,2011-01-19,2011-01-20,2011-01-20,72.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-12,2011-02-12,2011-02-12,2011-02-12,96.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-05,2011-04-05,2011-04-06,2011-04-06,148.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-12,2011-04-12,2011-05-03,2011-05-03,155.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NIGHT SWEATS,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-04-26,2011-04-26,2011-05-24,2011-05-24,169.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,STOMATITIS,Stomatitis,GASTROINTESTINAL DISORDERS,2011-03-29,2011-03-29,2011-08-02,2011-08-02,141.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07-19,2011-07-19,2011-10-18,2011-10-18,253.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,PYREXIA,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-26,2011-04-26,2011-04-27,2011-04-27,169.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,PRODUCTIVE COUGH,Productive cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-06-08,2011-06-08,2011-06-27,2011-06-27,212.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,BILATERAL EAR CERUMEN,Cerumen impaction,EAR AND LABYRINTH DISORDERS,2011-12-03,2011-12-03,2011-12-05,2011-12-05,390.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-06,2011-12-06,2011-12-06,2011-12-06,393.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ARTERIAL HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-03-06,2012-03-06,,,484.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-07,2012-05-07,2012-05-20,2012-05-20,546.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-03,2012-05-03,2012-05-04,2012-05-04,542.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-22,2012-05-22,2012-05-22,2012-05-22,561.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-01,2012-06-01,2012-06-02,2012-06-02,571.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-09,2012-06-09,2012-06-09,2012-06-09,579.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-19,2012-06-19,2012-07-03,2012-07-03,589.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2012-04-11,2012-04-11,2012-04-14,2012-04-14,520.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-07-31,2012-07-31,2012-08-27,2012-08-27,631.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-07-31,2012-07-31,2012-08-14,2012-08-14,631.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-27,2012-06-27,2012-06-27,2012-06-27,597.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-001,01015001,015,76.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-09-18,2012-09-18,2012-09-25,2012-09-25,680.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-21,2010-12-21,,,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-30,2010-12-30,,,17.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,RHINORRHEA,Rhinorrhoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-12-30,2010-12-30,2011-01-25,2011-01-25,17.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-08,2011-03-08,2011-03-30,2011-03-30,85.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DYSPEPSIA,Dyspepsia,GASTROINTESTINAL DISORDERS,2011-03-14,2011-03-14,2011-03-15,2011-03-15,91.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-03-15,2011-03-15,,,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,SLIGHT EFFORT DYSPNEA,Dyspnoea exertional,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-01-20,2011-01-20,2011-01-24,2011-01-24,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-002,01015002,015,70.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PERIARTHRITIS,Periarthritis,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-05,2011-04-05,,,113.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-02-04,2011-02-04,,,9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-25,2011-02-25,2011-03-09,2011-03-09,30.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-10,2011-03-10,2011-03-29,2011-03-29,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-31,2011-03-31,,,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-015-003,01015003,015,67.0,YEARS,F,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-03,2011-02-03,,,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-29,2011-08-29,,,-8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,STOMATITIS,Stomatitis,GASTROINTESTINAL DISORDERS,2011-10-12,2011-10-12,,,37.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-015-004,01015004,015,86.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-10-21,2011-10-21,2011-11-03,2011-11-03,46.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,DIABETES MELLITUS,Diabetes mellitus,METABOLISM AND NUTRITION DISORDERS,2011-09-09,2011-09-09,,,-12.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-04,2011-10-04,2011-10-18,2011-10-18,14.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-28,2011-09-28,2011-10-18,2011-10-18,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,STOMATITIS,Stomatitis,GASTROINTESTINAL DISORDERS,2011-10-05,2011-10-05,2011-10-18,2011-10-18,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CEPHALGIA,Headache,NERVOUS SYSTEM DISORDERS,2011-10-20,2011-10-20,2011-10-25,2011-10-25,30.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-26,2011-10-26,2011-11-02,2011-11-02,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CEPHALGIA,Headache,NERVOUS SYSTEM DISORDERS,2011-10-26,2011-10-26,2011-11-20,2011-11-20,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PARESTHESIAS,Paraesthesia,NERVOUS SYSTEM DISORDERS,2011-10-23,2011-10-23,2011-10-24,2011-10-24,33.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ARM PAIN,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-21,2011-10-21,2011-10-22,2011-10-22,31.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-005,01015005,015,72.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,SEPSIS,Sepsis,INFECTIONS AND INFESTATIONS,2011-11-19,2011-11-19,2011-11-22,2011-11-22,60.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANGIOCHOLITIS,Cholangitis,HEPATOBILIARY DISORDERS,2012-01-21,2012-01-21,2012-01-30,2012-01-30,4.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-14,2012-01-14,2012-01-22,2012-01-22,-4.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-07,2012-03-07,2012-03-09,2012-03-09,50.0,Y,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-27,2012-02-27,2012-03-05,2012-03-05,41.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-015-006,01015006,015,59.0,YEARS,M,WHITE,5.0,BEL,BELGIUM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-12,2012-02-12,2012-02-26,2012-02-26,26.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-08-05,2010-08-05,2010-08-11,2010-08-11,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,UPPER LIMB EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-08-01,2010-08-01,,,-4.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CARDIAC DISORDER = REDUCTION OF VESICULAR MURMUR,Cardiac murmur,INVESTIGATIONS,2010-08-05,2010-08-05,2010-09-01,2010-09-01,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPOGLYCEMIA INCREASED,Hypoglycaemia,METABOLISM AND NUTRITION DISORDERS,2010-08-01,2010-08-01,2010-08-06,2010-08-06,-4.0,Y,NOT RELATED,1.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,METASTATIC PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-08-06,2010-08-06,2010-09-01,2010-09-01,2.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-08-08,2010-08-08,,,4.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,TUMOR PAIN,Tumour pain,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-08-20,2010-08-20,,,16.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CARDIAC INSUFFICIENSY,Cardiac failure,CARDIAC DISORDERS,2010-08-09,2010-08-09,,,5.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,RENAL DISORDER = RENAL INSUFFICIENSY,Renal failure,RENAL AND URINARY DISORDERS,2010-08-09,2010-08-09,,,5.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,GENITAL AREA EDEMA,Oedema genital,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2010-08-27,2010-08-27,,,23.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-017-001,01017001,017,79.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERKALIEMIA,Hyperkalaemia,METABOLISM AND NUTRITION DISORDERS,2010-08-19,2010-08-19,2010-08-19,2010-08-19,15.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2012-01-13,2012-01-13,2012-02-07,2012-02-07,-27.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-02,,2012-02-15,2012-02-15,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02,,2012-02-15,2012-02-15,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-02-21,2012-02-21,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-02-19,2012-02-19,7.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,2012-02-23,2012-02-23,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-14,2012-03-14,2012-03-14,2012-03-14,35.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-21,2012-03-21,2012-03-27,2012-03-27,42.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-16,2012-04-16,2012-04-20,2012-04-20,68.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-19,2012-04-19,2012-04-20,2012-04-20,71.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-22,2012-02-22,2012-02-23,2012-02-23,14.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-24,2012-02-24,2012-02-27,2012-02-27,16.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-16,2012-02-16,2012-04-19,2012-04-19,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-18,2012-02-18,2012-02-18,2012-02-18,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,DRY SKIN,Dry skin,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-02-23,2012-02-23,,,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,PEG EDEMA,Post procedural oedema,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-03-15,2012-03-15,2012-03-21,2012-03-21,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-17,2012-03-17,2012-03-20,2012-03-20,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-28,2012-03-28,2012-04-13,2012-04-13,49.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-21,2012-03-21,2012-03-21,2012-03-21,42.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-08,2012-04-08,2012-04-08,2012-04-08,60.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-14,2012-04-14,2012-04-18,2012-04-18,66.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,EDEMA,Oedema,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-13,2012-04-13,2012-05-01,2012-05-01,65.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-21,2012-04-21,2012-04-23,2012-04-23,73.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-24,2012-04-24,2012-04-29,2012-04-29,76.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-04,2012-05-04,2012-05-04,2012-05-04,86.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,FOOT EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-18,2012-05-18,2012-05-28,2012-05-28,100.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-20,2012-04-20,,,72.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-04,2012-05-04,2012-05-08,2012-05-08,86.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-09,2012-05-09,,,91.0,N,DEFINITELY,4.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-09,2012-05-09,2012-05-17,2012-05-17,91.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,31.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-18,2012-05-18,2012-05-20,2012-05-20,100.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,32.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-21,2012-05-21,2012-05-24,2012-05-24,103.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,33.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-02,2012-06-02,2012-06-06,2012-06-06,115.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,34.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,2012-06-11,2012-06-11,120.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-12,2012-06-12,2012-06-21,2012-06-21,125.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,36.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-22,2012-06-22,2012-06-24,2012-06-24,135.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,37.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-25,2012-06-25,2012-07-05,2012-07-05,138.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,38.0,CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-15,2012-06-15,,,128.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,39.0,STIFFNESS,Musculoskeletal stiffness,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-06-15,2012-06-15,,,128.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-10,2012-02-10,,,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,41.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-02-16,2012-02-16,2012-02-19,2012-02-19,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,42.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-06,2012-07-06,2012-07-08,2012-07-08,149.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,43.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-09,2012-07-09,2012-07-10,2012-07-10,152.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,44.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-11,2012-07-11,2012-07-15,2012-07-15,154.0,N,POSSIBLE/PROBABLE,3.0,4,4.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,45.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-03,2012-08-03,2012-08-05,2012-08-05,177.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,46.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-07-25,2012-07-25,2012-07-28,2012-07-28,168.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,47.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-16,2012-08-16,2012-08-30,2012-08-30,190.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,48.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-08-16,2012-08-16,2012-08-23,2012-08-23,190.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,49.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-01,2012-09-01,2012-09-04,2012-09-04,206.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,50.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-05,2012-09-05,2012-09-09,2012-09-09,210.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,51.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-08-31,2012-08-31,2012-09-05,2012-09-05,205.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,52.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-08-31,2012-08-31,2012-09-05,2012-09-05,205.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-017-002,01017002,017,74.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,53.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-10,2012-09-10,2012-09-12,2012-09-12,215.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-08,2011-02-08,2011-02-08,2011-02-08,8.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-08,2011-02-08,2011-02-22,2011-02-22,8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,MALIGNE ULCUS DUODENI,Duodenal ulcer,GASTROINTESTINAL DISORDERS,2011-02-10,2011-02-10,2011-02-18,2011-02-18,10.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-02-09,2011-02-09,2011-02-18,2011-02-18,9.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,REFLUX ESOPHAGITIS,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2011-02-10,2011-02-10,2011-02-16,2011-02-16,10.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,THROMBUS OF PORT,Thrombosis in device,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-17,2011-02-17,2011-02-17,2011-02-17,17.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-08,2011-03-08,2011-03-15,2011-03-15,36.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-10,2011-03-10,2011-03-10,2011-03-10,38.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,CLINICAL SIGNIFICANT INCREASING OF C-REACTIVE PROTEINE,C-reactive protein increased,INVESTIGATIONS,2011-03-11,2011-03-11,,,39.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-15,2011-03-15,,,43.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-22,2011-03-22,,,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,TUMOR BLEEDING,Tumour haemorrhage,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-03-27,2011-03-27,2011-03-27,2011-03-27,55.0,Y,UNLIKELY,2.0,5,5.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,GASTROINTESTINAL BLEEDING,Gastrointestinal haemorrhage,GASTROINTESTINAL DISORDERS,2011-02-09,2011-02-09,2011-02-18,2011-02-18,9.0,Y,UNLIKELY,2.0,4,4.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-27,2011-03-27,,,55.0,Y,NOT RELATED,1.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-27,2011-03-27,,,55.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,,N,Y,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-03-27,2011-03-27,,,55.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-27,2011-03-27,,,55.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,VOMITING OF BLOOD,Haematemesis,GASTROINTESTINAL DISORDERS,2011-03-27,2011-03-27,,,55.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,PAIN OF UPPER ABDOMEN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-03-27,2011-03-27,,,55.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-10,2011-03-10,2011-03-10,2011-03-10,38.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,SLEEPING DISTURBANCE,Sleep disorder,PSYCHIATRIC DISORDERS,2011-02-09,2011-02-09,,,9.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,MELENA,Melaena,GASTROINTESTINAL DISORDERS,2011-01-26,2011-01-26,,,-6.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,N
CO-101-001,CO-101-001-018-001,01018001,018,51.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,ICTERUS,Jaundice,HEPATOBILIARY DISORDERS,2011-01-30,2011-01-30,,,-2.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,RESPIRATORY INFECTION,Respiratory tract infection,INFECTIONS AND INFESTATIONS,2011-03-06,2011-03-06,2011-03-22,2011-03-22,54.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,LOW WBC CLINICAL SIGNIFICANT,White blood cell count decreased,INVESTIGATIONS,2011-04-20,2011-04-20,2011-04-27,2011-04-27,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LOW ANC CLINICAL SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2011-04-20,2011-04-20,2011-04-27,2011-04-27,99.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-14,2011-03-14,2011-03-23,2011-03-23,62.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PAIN RIGHT SHOULDER,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-13,2011-04-13,2011-04-20,2011-04-20,92.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-06,2011-03-06,2011-03-06,2011-03-06,54.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,THROMBOZYTOPENIE,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-09,2011-06-09,2011-06-15,2011-06-15,149.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,THROMBOZYTOPENIE,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-06,2011-07-06,2011-07-14,2011-07-14,176.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,LOW WBC CLINICAL SIGNIFICANT,White blood cell count decreased,INVESTIGATIONS,2011-07-06,2011-07-06,2011-07-14,2011-07-14,176.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,LOW ANC CLINICAL SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2011-07-06,2011-07-06,2011-07-14,2011-07-14,176.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,THROMBOZYTOPENIE,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-03,2011-08-03,2011-08-10,2011-08-10,204.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-001,01019001,019,65.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,LOW ANC CLINICAL SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2011-08-31,2011-08-31,2011-09-07,2011-09-07,232.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-002,01019002,019,59.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,1.0,PNEUMOTHORAX,Pneumothorax,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-01-24,2011-01-24,2011-01-31,2011-01-31,,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-019-002,01019002,019,59.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-01,2011-02-01,2011-02-04,2011-02-04,,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-019-002,01019002,019,59.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,3.0,CIRCULATORY COLAPSE,Circulatory collapse,VASCULAR DISORDERS,2011-02-01,2011-02-01,2011-02-01,2011-02-01,,Y,NOT RELATED,1.0,2,2.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,N
CO-101-001,CO-101-001-019-002,01019002,019,59.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,4.0,VENOUS THROMBOSIS OF RIGHT UPPER ARM,Venous thrombosis limb,VASCULAR DISORDERS,2011-01-26,2011-01-26,2011-02-28,2011-02-28,,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,N
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-21,2011-08-21,2011-08-21,2011-08-21,5.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-25,2011-08-25,2011-08-25,2011-08-25,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-01,2011-09-01,2011-09-01,2011-09-01,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,RESTLESSNESS,Restlessness,PSYCHIATRIC DISORDERS,2011-09-01,2011-09-01,2011-09-01,2011-09-01,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,SUPRAVENTRICULAR TACHYCARDIA,Supraventricular tachycardia,CARDIAC DISORDERS,2011-09,,2011-09-18,2011-09-18,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,INCREASED GAMMA GT CLINICAL SIGNIFICANT,Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-09-28,2011-09-28,,,43.0,N,UNLIKELY,2.0,4,4.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,LATENT CHOLANGITIS,Cholangitis,HEPATOBILIARY DISORDERS,2011-10,,,,,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,SLEEP DISTURBANCES,Sleep disorder,PSYCHIATRIC DISORDERS,2011-10,,,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,THROMBOPHLEBITIS OF LEFT THIGH,Thrombophlebitis,VASCULAR DISORDERS,2011-10-30,2011-10-30,2011-11-01,2011-11-01,75.0,Y,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-08,2011-09-08,2011-09-08,2011-09-08,23.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-23,2011-09-23,2011-09-23,2011-09-23,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-29,2011-10-29,,,74.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,INCREASED BLOOD PRESURE,Blood pressure increased,INVESTIGATIONS,2011-10,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,THROMBOPHLEBITIS OF LEFT THIGH,Thrombophlebitis,VASCULAR DISORDERS,2011-11-01,2011-11-01,2011-11-28,2011-11-28,77.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,THROMBOPHLEBITIS OF LEFT THIGH,Thrombophlebitis,VASCULAR DISORDERS,2011-10-29,2011-10-29,2011-10-30,2011-10-30,74.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10,,2011-11,,,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-004,01019004,019,66.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-10,,2011-11,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-24,2011-08-24,2011-08,,8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,THROMBOPENIE,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-31,2011-08-31,2011-09-07,2011-09-07,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,LOW ANC CLINICAL SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2011-08-31,2011-08-31,2011-09-07,2011-09-07,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,LOW WBC CLINICAL SIGNIFICANT,White blood cell count decreased,INVESTIGATIONS,2011-08-31,2011-08-31,2011-09-07,2011-09-07,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,LOSS OF APETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,LOW ANC CLINICAL SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2011-09-14,2011-09-14,2011-09-21,2011-09-21,29.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-019-005,01019005,019,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,HYPOCALEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-24,2011-08-24,2011-09-14,2011-09-14,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,GEMCITABINE EXTRAVASATE,Extravasation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-11,2011-02-11,2011-02-12,2011-02-12,1.0,N,DEFINITELY,4.0,1,1.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,RASH,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-02-15,2011-02-15,2011-03-08,2011-03-08,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-11,2011-02-11,2011-02-11,2011-02-11,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,LACK OF APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-02-12,2011-02-12,,,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,OTHER,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LEUCOPENIA/ NEUTROPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-04,2011-03-04,2011-03-11,2011-03-11,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,LEUCOPENIA/ NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-04,2011-03-04,2011-03-11,2011-03-11,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-03-09,2011-03-09,,,27.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,GASTROINTESTINAL INFECTION,Gastrointestinal infection,INFECTIONS AND INFESTATIONS,2011-03-10,2011-03-10,2011-03-10,2011-03-10,28.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-03-12,2011-03-12,,,30.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-03-20,2011-03-20,2011-03-20,2011-03-20,38.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,BRONCHOPNEUMONIA,Bronchopneumonia,INFECTIONS AND INFESTATIONS,2011-05-19,2011-05-19,2011-05-23,2011-05-23,98.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,INFECTION OF UNKNOWN ORIGEN,Infection,INFECTIONS AND INFESTATIONS,2011-04-29,2011-04-29,2011-05-04,2011-05-04,78.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,SUSPICION OF PORT INFECTION  NOT CONFIRMED,Device related infection,INFECTIONS AND INFESTATIONS,2011-05-27,2011-05-27,2011-05-30,2011-05-30,106.0,Y,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-001,01020001,020,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,INFECTION WITH UNKNOWN FOCUS,Infection,INFECTIONS AND INFESTATIONS,2011-06-03,2011-06-03,2011-06-09,2011-06-09,113.0,Y,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-14,2011-08-14,2011-08-14,2011-08-14,20.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,INCREASED SWEATING,Hyperhidrosis,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-08-23,2011-08-23,2011-08-25,2011-08-25,29.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-24,2011-08-24,,,30.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERING/RESOLVING,N,N,N,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NOCTURIA,Nocturia,RENAL AND URINARY DISORDERS,2011-07-20,2011-07-20,,,-6.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2011-08-24,2011-08-24,2011-08,,30.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,"KACHEXIA, LACK OF APETITIS",Cachexia,METABOLISM AND NUTRITION DISORDERS,2011-09-01,2011-09-01,2011-09-14,2011-09-14,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,KACHEXIA LACK OF APETITE,Cachexia,METABOLISM AND NUTRITION DISORDERS,2011-09-14,2011-09-14,,,51.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-08-25,2011-08-25,2011-08-31,2011-08-31,31.0,N,UNLIKELY,2.0,2,2.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,LUNG EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-04,2011-10-04,2011-10-14,2011-10-14,71.0,Y,UNLIKELY,2.0,4,4.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,PNEUMONIA POST LE,Pneumonia,INFECTIONS AND INFESTATIONS,2011-10-07,2011-10-07,2011-10-13,2011-10-13,74.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,DIFFUSE GI BLEEDING UNDER ANTICOAGULATION,Gastrointestinal haemorrhage,GASTROINTESTINAL DISORDERS,2011-10-11,2011-10-11,2011-10-13,2011-10-13,78.0,N,UNLIKELY,2.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,SEVERE INFECTION (MULTI RESISTANT ENTEROCOCCUS FAECALIS IN BLOOD),Enterococcal bacteraemia,INFECTIONS AND INFESTATIONS,2011-11-04,2011-11-04,2011-11-18,2011-11-18,102.0,Y,POSSIBLE/PROBABLE,3.0,4,4.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-16,2011-09-16,,,53.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,PAIN RIGHT SHOULDER,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-22,2011-09-22,,,59.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-020-003,01020003,020,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,COMMON COLD WITH COUGH,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2011-09-19,2011-09-19,2011-09-25,2011-09-25,56.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,CHOLANGIOSEPIS,Biliary sepsis,INFECTIONS AND INFESTATIONS,2011-11-06,2011-11-06,2011-12-13,2011-12-13,12.0,Y,UNLIKELY,2.0,4,4.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,THROMBOSIS RIGHT LOWER LEG,Thrombosis,VASCULAR DISORDERS,2011-11-21,2011-11-21,2011-12-05,2011-12-05,27.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-26,2011-10-26,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DISPNOE,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10,,,,,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-02,2011-11-02,,,8.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-10-29,2011-10-29,,,4.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2011-11-15,2011-11-15,2011-11-29,2011-11-29,21.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,PRURITUS,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-12-19,2011-12-19,2012-01-09,2012-01-09,55.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,TEMPERATURE MOST PROBABLY DUE TO URINARY TRACT INFECTION,Body temperature increased,INVESTIGATIONS,2011-12-17,2011-12-17,2011-12-20,2011-12-20,53.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,TEMPERATURE MOST PROBABLY DUE TO URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-12-17,2011-12-17,2011-12-20,2011-12-20,53.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,PAIN OF LOWER BACK,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-04,2012-01-04,,,71.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,PAIN OF RIGHT KNEE,Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-03,2012-01-03,2012-01-04,2012-01-04,70.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-005,01020005,020,54.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,ERYSIPELAS,Erysipelas,INFECTIONS AND INFESTATIONS,2011-11-27,2011-11-27,2011-12-02,2011-12-02,33.0,Y,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NECK TENSIONS,Muscle tightness,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-22,2011-11-22,2012-05-22,2012-05-22,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-22,2011-11-22,2012-06-03,2012-06-03,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,NIGHT SWEAT,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-22,2011-11-22,2012-05-22,2012-05-22,1.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,MALAISE,Malaise,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-30,2011-11-30,2012-05-28,2012-05-28,9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HEAD ACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-12-10,2011-12-10,2011-12-11,2011-12-11,19.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,TIREDNESS,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-21,2011-12-21,2012-04,,30.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-02,2012-04-02,,,133.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,DRY MOUTH,Dry mouth,GASTROINTESTINAL DISORDERS,2011-11-23,2011-11-23,2012-02-14,2012-02-14,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,DISPNOE,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-05,2012-03-05,2012-05-05,2012-05-05,105.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-06,2012-01-06,2012-01-06,2012-01-06,46.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,EDEMA RIGHT LOWER LEG,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-12,2012-02-12,,,83.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,HYPERKALEMIA,Hyperkalaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-05,2012-06-05,2012-06-28,2012-06-28,197.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,MALIGNANT PLEURAL EFFUSION,Malignant pleural effusion,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-06-27,2012-06-27,2012-06-29,2012-06-29,219.0,Y,UNLIKELY,2.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,CARDIAL DECOMPENSATION,Cardiac failure,CARDIAC DISORDERS,2012-03-07,2012-03-07,2012-03-14,2012-03-14,107.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,PERIPHERE VASOSPASM,Vasospasm,VASCULAR DISORDERS,2012-01-13,2012-01-13,,,53.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-11-23,2011-11-23,2011-11-24,2011-11-24,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-06,2011-12-06,2012-05-08,2012-05-08,15.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-11,2012-04-11,2012-07-11,2012-07-11,142.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,HYPERTENSIVE PULMONARY EDEMA WITH PARTIAL RESPIRATORY INSUFFICIENCY,Hypertension,VASCULAR DISORDERS,2012-03-29,2012-03-29,2012-03-31,2012-03-31,129.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,HYPERTENSIVE PULMONARY EDEMA WITH PARTIAL RESPIRATORY INSUFFICIENCY,Pulmonary oedema,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-29,2012-03-29,2012-03-31,2012-03-31,129.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,HYPERTENSIVE PULMONARY EDEMA WITH PARTIAL RESPIRATORY INSUFFICIENCY,Respiratory failure,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-29,2012-03-29,2012-03-31,2012-03-31,129.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,22.0,WORSENING OF RENAL INSUFFIECIENCY,Renal failure,RENAL AND URINARY DISORDERS,2012-05-22,2012-05-22,2012-07-20,2012-07-20,183.0,N,UNLIKELY,2.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-020-006,01020006,020,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,23.0,CARDIAL DECOMPENSATION,Cardiac failure,CARDIAC DISORDERS,2012-03-05,2012-03-05,,,105.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,EPIGASTRALGIA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-01-03,2011-01-03,2011-04-25,2011-04-25,8.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-01-03,2011-01-03,,,8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NOCTURIA,Nocturia,RENAL AND URINARY DISORDERS,2010-12-15,2010-12-15,,,-12.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PROSTATIC HYPERTROPHY,Benign prostatic hyperplasia,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011-01-10,2011-01-10,,,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,"EXTRASYSTOLE, NOT CLINICALLY SIGNIFICANT",Extrasystoles,CARDIAC DISORDERS,2011-01-24,2011-01-24,2011-01-24,2011-01-24,29.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-02-10,2011-02-10,2011-04-18,2011-04-18,46.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,IRRITABILITY,Irritability,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-31,2011-01-31,2011-04-11,2011-04-11,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,CHEILITIS,Cheilitis,GASTROINTESTINAL DISORDERS,2011-02-28,2011-02-28,2011-03-07,2011-03-07,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-28,2011-03-28,2011-04-03,2011-04-03,92.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,IKTERUS,Jaundice,HEPATOBILIARY DISORDERS,2011-03-28,2011-03-28,2011-04-14,2011-04-14,92.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,PRURITUS,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-03-28,2011-03-28,2011-04-04,2011-04-04,92.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-03-29,2011-03-29,2011-04-04,2011-04-04,93.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,CHOLANGITIS,Cholangitis,HEPATOBILIARY DISORDERS,2011-03-28,2011-03-28,2011-04-06,2011-04-06,92.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,EPIGASTRALGIA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-04-26,2011-04-26,2011-06-22,2011-06-22,121.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-04,2011-04-04,2011-06-22,2011-06-22,99.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-23,2011-06-23,,,179.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,EPIGASTRALGIA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-23,2011-06-23,,,179.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,"PLATELETS COUNT DECREASED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-01-10,2011-01-10,2011-01-17,2011-01-17,15.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,CHOLESTASE,Cholestasis,HEPATOBILIARY DISORDERS,2011-03-22,2011-03-22,2011-03-29,2011-03-29,86.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-04-05,2011-04-05,2011-05-16,2011-05-16,100.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,GGT-ELEVATED(CLINICALLY SIGNIFICANT),Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-05-17,2011-05-17,2011-05-30,2011-05-30,142.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,CHOLESTATIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-05-31,2011-05-31,,,156.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-07,2011-06-07,2011-06-23,2011-06-23,163.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-10,2011-01-10,2011-01-16,2011-01-16,15.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,URINE INCONTINENCE,Urinary incontinence,RENAL AND URINARY DISORDERS,2011-05-31,2011-05-31,,,156.0,N,NOT RELATED,1.0,,,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-29,2011-03-29,2011-03-31,2011-03-31,93.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,PRURITUS,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-04-04,2011-04-04,2011-04-26,2011-04-26,99.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-001,01021001,021,72.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-05-24,2011-05-24,,,149.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-25,2011-02-25,2011-03-13,2011-03-13,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-03-02,2011-03-02,,,7.0,N,NOT RELATED,1.0,2,2.0,,OTHER,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-14,2011-03-14,2011-06-29,2011-06-29,19.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,EPIGASTRALGIA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-03-28,2011-03-28,2011-03-31,2011-03-31,33.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,"PLATELET COUNT DECREASED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-03-03,2011-03-03,2011-03-17,2011-03-17,8.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,"PLATELET COUNT DECREASED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-05-04,2011-05-04,2011-05-18,2011-05-18,70.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,"PLATELET COUNT DECRESED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-06-01,2011-06-01,2011-06-14,2011-06-14,98.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-06-01,2011-06-01,2011-07-14,2011-07-14,98.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,"BLOOD BILIRUBIN ELEVATED, CLINICALLY SIGNIFICANT",Blood bilirubin increased,INVESTIGATIONS,2011-06-30,2011-06-30,2011-07-01,2011-07-01,127.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-25,2011-07-25,2011-08-09,2011-08-09,152.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-06-20,2011-06-20,,,117.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-29,2011-06-29,,,126.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,NOCTURIA,Nocturia,RENAL AND URINARY DISORDERS,2011-02-11,2011-02-11,2011-05-03,2011-05-03,-13.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,BILE DUCT STENOSIS,Bile duct stenosis,HEPATOBILIARY DISORDERS,2011-07-01,2011-07-01,,,128.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,"NEUTROPHILE COUNT DECREASE, CLINICALLY SIGNIFICANT",Neutrophil count decreased,INVESTIGATIONS,2011-03-17,2011-03-17,2011-03-31,2011-03-31,22.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,"PLATELET COUNT DECREASED, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-06-29,2011-06-29,2011-07-14,2011-07-14,126.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,"PLATELET COUNT DECREASED, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-07-25,2011-07-25,2011-08-01,2011-08-01,152.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07,,2011-08,,,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,HYPERGLYCAEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-10,2011-03-10,2011-06-29,2011-06-29,15.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,BILE DUCT STENOSIS,Bile duct stenosis,HEPATOBILIARY DISORDERS,2011-02-24,2011-02-24,2011-07-01,2011-07-01,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-07-14,2011-07-14,2011-08-01,2011-08-01,141.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-26,2011-07-26,2011-08-01,2011-08-01,153.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,"AST INCREASED, CLINICALLY SIGNIFICANT",Aspartate aminotransferase increased,INVESTIGATIONS,2011-02-24,2011-02-24,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,"ALT INCREASED, CLINICALLY SIGNIFICANT",Alanine aminotransferase increased,INVESTIGATIONS,2011-02-24,2011-02-24,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,SYNCOPE,Syncope,NERVOUS SYSTEM DISORDERS,2011-07,,2011-07,,,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,EDEMA LOWER LEG,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-25,2011-07-25,,,152.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-17,2011-03-17,2011-03-24,2011-03-24,22.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,HYPOCALCEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-05-18,2011-05-18,2011-05-26,2011-05-26,84.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-004,01021004,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,CREATININE INCREASED,Blood creatinine increased,INVESTIGATIONS,2011-08-01,2011-08-01,,,159.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-31,2011-03-31,2011-04-07,2011-04-07,36.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-28,2011-04-28,2011-05-05,2011-05-05,64.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,BONE PAIN,Bone pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-02-11,2011-02-11,2011-03-08,2011-03-08,-13.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,N
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-16,2011-06-16,2011-06-27,2011-06-27,113.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-30,2011-06-30,2011-07-14,2011-07-14,127.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-23,2011-06-23,2011-06-30,2011-06-30,120.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-30,2011-06-30,2011-07-04,2011-07-04,127.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-26,2011-05-26,2011-06-01,2011-06-01,92.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-27,2011-07-27,2011-07-27,2011-07-27,154.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-09,2011-06-09,,,106.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-24,2011-03-24,2011-04-14,2011-04-14,29.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-21,2011-04-21,2011-06-09,2011-06-09,57.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,"PLATELET COUNT DECREASE, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-07-21,2011-07-21,,,148.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,"PLATELET COUNT DECREASE, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-03-10,2011-03-10,2011-03-24,2011-03-24,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,"PLATELET COUNT DECREASE, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-04-07,2011-04-07,2011-04-21,2011-04-21,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,"WHITE BLOOD CELL COUNT DECREASE, CLINICALLY SIGNIFICANT",White blood cell count decreased,INVESTIGATIONS,2011-03-10,2011-03-10,2011-03-17,2011-03-17,15.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-02-24,2011-02-24,,,1.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,HYPOKALIEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-06-01,2011-06-01,2011-06-16,2011-06-16,98.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,"PLATELET COUNT DECREASE, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-06-01,2011-06-01,2011-06-09,2011-06-09,98.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-06,2011-07-06,2011-07-06,2011-07-06,133.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,WEIGHTLOSS,Weight decreased,INVESTIGATIONS,2011-02-16,2011-02-16,,,-8.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-03-17,2011-03-17,,,22.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,EDEMA ANKLE,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-21,2011-04-21,2011-05-19,2011-05-19,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03,,2011-03,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-16,2011-06-16,2011-06-16,2011-06-16,113.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-005,01021005,021,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-03,,2011-06-16,2011-06-16,,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-05-24,2011-05-24,2011-06-07,2011-06-07,1.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,FLU LIKE SYMPTOMS,Influenza like illness,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-26,2011-05-26,2011-05-27,2011-05-27,3.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-13,2011-06-13,2011-06-13,2011-06-13,21.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-06-13,2011-06-13,,,21.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PALPITATIONS,Palpitations,CARDIAC DISORDERS,2011-07-05,2011-07-05,,,43.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,DRY COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-05,2011-07-05,,,43.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,"PLATELET COUNT DECREASED, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-10-06,2011-10-06,2011-10-13,2011-10-13,136.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,2011-11-03,2011-11-03,157.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-27,2012-02-27,2012-03-05,2012-03-05,280.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-27,2012-02-27,2012-03-05,2012-03-05,280.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2012-03,,2012-03-19,2012-03-19,,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-23,2012-04-23,2012-05-02,2012-05-02,336.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-23,2012-04-23,2012-05-02,2012-05-02,336.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-16,2012-07-16,,,420.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,HYPOGLYCEMIA,Hypoglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-10-05,2012-10-05,,,501.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-10-22,2012-10-22,,,518.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-10-22,2012-10-22,,,518.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-10-22,2012-10-22,,,518.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,LYMPHOPENIA,Lymphopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-10-22,2012-10-22,,,518.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-006,01021006,021,77.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-10-22,2012-10-22,,,518.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,"PLATELET COUNT DECREASED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-08-03,2011-08-03,2011-08-08,2011-08-08,13.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,"PLATELETS COUNT DECREASED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-09-29,2011-09-29,,,70.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,"PLATELET COUNT DECREASED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-10-27,2011-10-27,2011-11-10,2011-11-10,98.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,"PLATELETS COUNT DECREASED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-11-24,2011-11-24,2011-12-01,2011-12-01,126.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,"PLATELETS COUNT DECREASED, CLINIC SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2011-12-01,2011-12-01,2011-12-07,2011-12-07,133.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,BRONCHITIS,Bronchitis,INFECTIONS AND INFESTATIONS,2012-01-25,2012-01-25,2012-01-27,2012-01-27,188.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,"PLATELET COUNT DECREASED, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2012-01-30,2012-01-30,2012-02-13,2012-02-13,193.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,"PLATELENT COUNT DECREASED, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2012-02-27,2012-02-27,2012-03-05,2012-03-05,221.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,"PLATELET COUNT DECREASED, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2012-03-05,2012-03-05,2012-03-12,2012-03-12,228.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,"PLATELET COUNT DECREASED, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2012-03-26,2012-03-26,2012-04-10,2012-04-10,249.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,"PLATELET COUNT DECREASE, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2012-04-23,2012-04-23,2012-04-30,2012-04-30,277.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-021-007,01021007,021,62.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,"PLATELET COUNT DECREASED, CLINICALLY SIGNIFICANT",Platelet count decreased,INVESTIGATIONS,2012-04-30,2012-04-30,2012-05-07,2012-05-07,284.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-19,2011-12-19,2012-01-03,2012-01-03,-15.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-03,2012-01-03,2012-01-05,2012-01-05,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-01-03,2012-01-03,2012-01-10,2012-01-10,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-21,2011-12-21,2012-01-05,2012-01-05,-13.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,INSUFFICIENT NUTRICION,Malnutrition,METABOLISM AND NUTRITION DISORDERS,2012-01-05,2012-01-05,2012-01-10,2012-01-10,3.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-05,2012-01-05,2012-01-10,2012-01-10,3.0,Y,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,"THROMBOSIS, ARM VEIN RIGHT",Venous thrombosis limb,VASCULAR DISORDERS,2012-01-05,2012-01-05,2012-01-10,2012-01-10,3.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2012-01-17,2012-01-17,2012-01-17,2012-01-17,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-19,2011-12-19,2011-12-21,2011-12-21,-15.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,"THROMBOPHLEBITIS WITH SWELLING, RIGHT ARM",Thrombophlebitis,VASCULAR DISORDERS,2012-01-03,2012-01-03,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,MALNOURISHMENT,Malnutrition,METABOLISM AND NUTRITION DISORDERS,2012-01-03,2012-01-03,2012-01-05,2012-01-05,1.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-03,2012-01-03,2012-01-04,2012-01-04,1.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-25,2012-01-25,2012-01-31,2012-01-31,23.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-07,2012-02-07,2012-02-13,2012-02-13,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-14,2012-02-14,2012-02-20,2012-02-20,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-21,2012-02-21,,,50.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-21,2012-02-21,2012-03-08,2012-03-08,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-02-21,2012-02-21,2012-02-28,2012-02-28,50.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-21,2012-02-21,,,50.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,"LUNG EMBOLISM,SUBSEGMENTAL LEFT",Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-28,2012-02-28,,,57.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,LUNG EMBOLISM RIGHT,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-28,2012-02-28,,,57.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,WEAKNESS LEGS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-03,2012-03-03,2012-03-08,2012-03-08,61.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-03-05,2012-03-05,,,63.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-16,2012-03-16,,,74.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-03,,2012-03,,,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-022-003,01022003,022,45.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,WEIGTH LOSS,Weight decreased,INVESTIGATIONS,2012-03-16,2012-03-16,,,74.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,PAIN NOS,Pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-23,2010-12-23,,,-21.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOSIS,Thrombosis,VASCULAR DISORDERS,2011-01-10,2011-01-10,,,-3.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,N
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PAIN RIGHT FOOT,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01-14,2011-01-14,,,2.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,LOW PLATLETS (CLINICALLY SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2011-01-27,2011-01-27,2011-02-03,2011-02-03,15.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-01-25,2011-01-25,,,13.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-01-25,2011-01-25,2011-01-25,2011-01-25,13.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-01-25,2011-01-25,,,13.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERING/RESOLVING,N,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,LOW HAEMAGLOBIN (CLINICALLY SIGNIFICANT),Haemoglobin decreased,INVESTIGATIONS,2011-03-11,2011-03-11,2011-03-12,2011-03-12,58.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,LOW PLATLETS (CLINICALLY SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2011-03-24,2011-03-24,,,71.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,SKIN ULCER (L) HEAL,Skin ulcer,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-03-10,2011-03-10,,,57.0,N,UNLIKELY,2.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-03-06,2011-03-06,,,53.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-03-06,2011-03-06,,,53.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,SKIN ULCER LEFT SIDE TOE,Skin ulcer,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-03-24,2011-03-24,,,71.0,N,UNLIKELY,2.0,1,1.0,,OTHER,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,STOMATITIS,Stomatitis,GASTROINTESTINAL DISORDERS,2011-03-17,2011-03-17,,,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,HYPOKAELEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-18,2011-03-18,,,65.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-03-08,2011-03-08,2011-03-12,2011-03-12,55.0,N,NOT RELATED,1.0,1,1.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,ARTERIAL THROMBOSIS (L) LEG,Arterial thrombosis limb,VASCULAR DISORDERS,2011-03-11,2011-03-11,,,58.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,PANCREATIC METASTATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-04-15,2011-04-15,2011-04-15,2011-04-15,93.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-023-001,01023001,023,61.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,N,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,OBSTRUCTIVE JAUNDICE,Jaundice cholestatic,HEPATOBILIARY DISORDERS,2011-04-13,2011-04-13,,,91.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,Y,N,Y
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,1.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-03-31,2011-03-31,,,,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,Y,N,N
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,2.0,DIC,Disseminated intravascular coagulation,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-31,2011-03-31,2011-04-11,2011-04-11,,Y,NOT RELATED,1.0,4,4.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,3.0,GASTROINTESTINAL HAEMORRAGE,Gastrointestinal haemorrhage,GASTROINTESTINAL DISORDERS,2011-04-01,2011-04-01,2011-04-11,2011-04-11,,Y,NOT RELATED,1.0,4,4.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,4.0,METASTATIC PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-04-11,2011-04-11,2011-04-11,2011-04-11,,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,N
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,5.0,TUMOUR PAIN (ABDOMINAL),Tumour pain,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-03-22,2011-03-22,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-03-24,2011-03-24,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-023-002,01023002,023,55.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Positive (High),2.0,7.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-24,2011-03-24,,,,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,CEREBROVASCULAR EVENT,Cerebrovascular accident,NERVOUS SYSTEM DISORDERS,2011-12-03,2011-12-03,,,2.0,Y,POSSIBLE/PROBABLE,3.0,4,4.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-024-004,01024004,024,64.0,YEARS,F,OTHER,99.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,METASTATIC PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-03,2011-12-03,2011-12-13,2011-12-13,2.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,HOT FLUSHES,Hot flush,VASCULAR DISORDERS,2011-01-18,2011-01-18,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-28,2011-01-28,,,11.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-025-001,01025001,025,77.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEAMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-14,2011-02-14,2011-02-21,2011-02-21,28.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,1.0,OBSTRUCTIVE JAUNDICE,Jaundice cholestatic,HEPATOBILIARY DISORDERS,2011-03-08,2011-03-08,,,8.0,Y,NOT RELATED,1.0,4,4.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,2.0,DEEP VENOUS THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-03-08,2011-03-08,,,8.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-025-002,01025002,025,73.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,PANCREATIC CARCINOMA METASATIC,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-03-27,2011-03-27,2011-03-27,2011-03-27,27.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-025-003,01025003,025,66.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,1.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-03-23,2011-03-23,2011-03-24,2011-03-24,,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-025-003,01025003,025,66.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Negative (Low),1.0,2.0,DEEP VEINOUS THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-03-23,2011-03-23,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,MUSCULOSKELETAL- STRAIN OF MUSCULUS TRAPEZIUS,Muscle strain,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2010-12-13,2010-12-13,2011-01-04,2011-01-04,-2.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,HEART MURMUR,Cardiac murmur,INVESTIGATIONS,2010-12-15,2010-12-15,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-17,2010-12-17,2010-12-19,2010-12-19,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,NIGHT SWEATS,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-12-17,2010-12-17,2010-12-19,2010-12-19,3.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-19,2010-12-19,2010-12-20,2010-12-20,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,SOAR THROAT,Oropharyngeal pain,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-12-19,2010-12-19,2010-12-21,2010-12-21,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,TRANSIENT ISCHEMIC ATTACK,Transient ischaemic attack,NERVOUS SYSTEM DISORDERS,2010-12-24,2010-12-24,2010-12-25,2010-12-25,10.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,NEUTROPHILS COUNT DECREASED CLINCIALLY SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2010-12-28,2010-12-28,2010-12-29,2010-12-29,14.0,N,DEFINITELY,4.0,4,4.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,PLATELET COUNT DECREASED CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2010-12-28,2010-12-28,2010-12-30,2010-12-30,14.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,EPISTAXIS,Epistaxis,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-12-24,2010-12-24,2010-12-24,2010-12-24,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,PAIN IN CALF  MUSCULATURE,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12-28,2010-12-28,2011-01-25,2011-01-25,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,TROMBOEMBOLIC EVENT (DEEP VEIN TROMBOSIS RIGHT LEG),Deep vein thrombosis,VASCULAR DISORDERS,2011-01-18,2011-01-18,,,35.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,NEUTROPHILS COUNT DECREASED CLINICALLY SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2010-12-29,2010-12-29,2011-01-03,2011-01-03,15.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,PLATELET COUNT DECREASED CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2010-12-30,2010-12-30,2011-01-03,2011-01-03,16.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,"SUSPECT INFECTION(NOT CONFIRMED) WITH UNKNOWN ORIGIN DUE TO INCREASED C-REACTIVE PROTEIN,WBC,FEVER AND FATIGUE",C-reactive protein increased,INVESTIGATIONS,2011-02-03,2011-02-03,2011-02-24,2011-02-24,51.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,"SUSPECT INFECTION(NOT CONFIRMED) WITH UNKNOWN ORIGIN DUE TO INCREASED C-REACTIVE PROTEIN,WBC,FEVER AND FATIGUE",Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-03,2011-02-03,2011-02-24,2011-02-24,51.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,"SUSPECT INFECTION(NOT CONFIRMED) WITH UNKNOWN ORIGIN DUE TO INCREASED C-REACTIVE PROTEIN,WBC,FEVER AND FATIGUE",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-03,2011-02-03,2011-02-24,2011-02-24,51.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,"SUSPECT INFECTION(NOT CONFIRMED) WITH UNKNOWN ORIGIN DUE TO INCREASED C-REACTIVE PROTEIN,WBC,FEVER AND FATIGUE",White blood cell count increased,INVESTIGATIONS,2011-02-03,2011-02-03,2011-02-24,2011-02-24,51.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,DYSGEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-02-08,2011-02-08,,,56.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-02-08,2011-02-08,,,56.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2010-12-30,2010-12-30,,,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,OTHER,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,WORSENED UPPER ABDOMINAL PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-02-01,2011-02-01,,,49.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,TUMOR RELATED FEVER,Tumour associated fever,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-02-24,2011-02-24,2011-03-08,2011-03-08,72.0,Y,UNLIKELY,2.0,2,2.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-029-002,01029002,029,71.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,TUMOR RELATED FEVER,Tumour associated fever,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-03-09,2011-03-09,,,85.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-29,2012-03-29,2012-03-30,2012-03-30,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,INCREASED ALAKLINE PHOSPHATATSE-CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-04-03,2012-04-03,2012-04-03,2012-04-03,7.0,N,UNLIKELY,2.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,INCREASED ALAKLINE PHOSPHATSE-CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-04-04,2012-04-04,2012-04-05,2012-04-05,8.0,Y,UNLIKELY,2.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,INCREASED ALT-CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-04-03,2012-04-03,2012-04-03,2012-04-03,7.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,INCREASED ALT - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-04-04,2012-04-04,2012-04-05,2012-04-05,8.0,Y,UNLIKELY,2.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,INCREASED AST-CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-03,2012-04-03,2012-04-03,2012-04-03,7.0,N,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-04,2012-04-04,2012-04-05,2012-04-05,8.0,Y,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,BLOOD BILIRUBIN INCREASED - CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2012-04-03,2012-04-03,2012-04-03,2012-04-03,7.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,BLOOD BILIRUBIN INCREASED - CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2012-04-04,2012-04-04,2012-04-05,2012-04-05,8.0,Y,UNLIKELY,2.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,BLOOD BILIRUBIN INCREASED - CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2012-04-10,2012-04-10,2012-06-07,2012-06-07,14.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,MALLORY-WEISS TEAR ( BLEEDING),Mallory-Weiss syndrome,GASTROINTESTINAL DISORDERS,2012-04-16,2012-04-16,2012-04-20,2012-04-20,20.0,Y,UNLIKELY,2.0,3,3.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,PYLORIC ULCER,Gastric ulcer,GASTROINTESTINAL DISORDERS,2012-04-16,2012-04-16,2012-04-20,2012-04-20,20.0,Y,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,FEVER INTERMITTENT,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-12,2012-04-12,2012-10-24,2012-10-24,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-25,2012-03-25,2012-05-09,2012-05-09,-3.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-25,2012-03-25,2012-05-09,2012-05-09,-3.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,ATRIAL FIBRILLATION,Atrial fibrillation,CARDIAC DISORDERS,2012-04-30,2012-04-30,2012-05-01,2012-05-01,34.0,Y,UNLIKELY,2.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,"SUSPECT INFECTION (NOT CONFIRMED) WITH UNKNOWN ORIGIN, DUE TO INCREASED C-REACTIVE PROTEIN AND FEVER.",C-reactive protein increased,INVESTIGATIONS,2012-04-30,2012-04-30,2012-05-03,2012-05-03,34.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,"SUSPECT INFECTION (NOT CONFIRMED) WITH UNKNOWN ORIGIN, DUE TO INCREASED C-REACTIVE PROTEIN AND FEVER.",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-30,2012-04-30,2012-05-03,2012-05-03,34.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,THROMBOPHLEBITIS RIGHT FOREARM,Thrombophlebitis,VASCULAR DISORDERS,2012-05-01,2012-05-01,2012-05-09,2012-05-09,35.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-01,2012-05-01,2012-05-03,2012-05-03,35.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,INCREASED FREQUEBCY OF MIKTION,Pollakiuria,RENAL AND URINARY DISORDERS,2012-05-03,2012-05-03,,,37.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,WORSENED WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-05-23,2012-05-23,2012-08-01,2012-08-01,57.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,PLEURAL EFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-30,2012-03-30,,,3.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,URINARY TRACT INFECTION-CYSTITIS,Cystitis,INFECTIONS AND INFESTATIONS,2012-05-23,2012-05-23,2012-05-30,2012-05-30,57.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,25.0,URINARY TRACT INFECTION-CYSTITIS,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-05-23,2012-05-23,2012-05-30,2012-05-30,57.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,26.0,PYLORIC ULCER,Gastric ulcer,GASTROINTESTINAL DISORDERS,2012-04-21,2012-04-21,2012-04-24,2012-04-24,25.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,27.0,URINARY TRACT INFECTION-CYSTITIS,Cystitis,INFECTIONS AND INFESTATIONS,2012-06-27,2012-06-27,2012-07-01,2012-07-01,92.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,28.0,URINARY TRACT INFECTION-CYSTITIS,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-06-27,2012-06-27,2012-07-01,2012-07-01,92.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,29.0,NEUTROPHIL COUNT DECREASED-CLINICALLY SIGNFICANT,Neutrophil count decreased,INVESTIGATIONS,2012-06-26,2012-06-26,2012-06-27,2012-06-27,91.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,30.0,PYELONEPHRITIS,Pyelonephritis,INFECTIONS AND INFESTATIONS,2012-07-02,2012-07-02,2012-07-02,2012-07-02,97.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,31.0,PYELONEPHRITIS,Pyelonephritis,INFECTIONS AND INFESTATIONS,2012-07-03,2012-07-03,2012-07-16,2012-07-16,98.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,32.0,WORSENING FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-07-18,2012-07-18,2012-09-19,2012-09-19,113.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,33.0,"PUNCTURE WOUND LEFT HAND.( CAUSED BY CAR KEE , THAT PATIENT WAS HOLDING IN HIS HAND WHEN HE FELL , DUE TO A VERY SHORT SEIZURE  OF VERTIGO)",Fall,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-08-07,2012-08-07,2012-08-16,2012-08-16,133.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,34.0,"PUNCTURE WOUND LEFT HAND.( CAUSED BY CAR KEE , THAT PATIENT WAS HOLDING IN HIS HAND WHEN HE FELL , DUE TO A VERY SHORT SEIZURE  OF VERTIGO)",Wound,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-08-07,2012-08-07,2012-08-16,2012-08-16,133.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,35.0,"PUNCTURE WOUND LEFT HAND.( CAUSED BY CAR KEE , THAT PATIENT WAS HOLDING IN HIS HAND WHEN HE FELL , DUE TO A VERY SHORT SEIZURE  OF VERTIGO)",Vertigo,EAR AND LABYRINTH DISORDERS,2012-08-07,2012-08-07,2012-08-16,2012-08-16,133.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,36.0,BURPING,Eructation,GASTROINTESTINAL DISORDERS,2012-08-31,2012-08-31,,,157.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,37.0,PAIN STOMACH,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-08-31,2012-08-31,2012-10-24,2012-10-24,157.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,38.0,BRUISING,Contusion,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-08-31,2012-08-31,,,157.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,39.0,INTERMITTENT DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2012-09-14,2012-09-14,,,171.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,40.0,INCREASED ALT-CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-04-06,2012-04-06,2012-04-10,2012-04-10,10.0,N,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,41.0,INCREASED AST-CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-06,2012-04-06,2012-04-10,2012-04-10,10.0,N,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,42.0,INCREASED ALAKLINE PHOSPHATSE-CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-04-06,2012-04-06,2012-04-16,2012-04-16,10.0,N,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,43.0,BLOOD BILIRUBIN INCREASED-CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2012-04-06,2012-04-06,2012-04-09,2012-04-09,10.0,N,UNLIKELY,2.0,1,1.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,44.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-10-01,2012-10-01,2012-10-02,2012-10-02,188.0,N,DEFINITELY,4.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,45.0,WORSENING (I.E MORE FREKVENT) PAROXYMAL ATRIAL FIBRILLATION,Atrial fibrillation,CARDIAC DISORDERS,2012-10-01,2012-10-01,2012-10-24,2012-10-24,188.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,46.0,WORSENING PLEURAL EFFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-10-02,2012-10-02,2012-10-07,2012-10-07,189.0,Y,UNLIKELY,2.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,47.0,WORSENING HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-10-03,2012-10-03,2012-10-24,2012-10-24,190.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,48.0,HEART FAILURE,Cardiac failure,CARDIAC DISORDERS,2012-10-02,2012-10-02,2012-10-12,2012-10-12,189.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,49.0,CREATININE INCREASED,Blood creatinine increased,INVESTIGATIONS,2012-10-01,2012-10-01,2012-10-09,2012-10-09,188.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,50.0,CREATININE INCREASED,Blood creatinine increased,INVESTIGATIONS,2012-10-10,2012-10-10,2012-10-14,2012-10-14,197.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,51.0,INFECTION ( NOT CONFIRMED) DUE TO FEVER AND ELEVATED CRP,,,2012-10-01,2012-10-01,2012-10-01,2012-10-01,188.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,52.0,INFECTION (NOT CONFIRMED) DUE TO FEVER AND ELEVATED CRP,,,2012-10-02,2012-10-02,2012-10-12,2012-10-12,189.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,53.0,INTERMITTENT ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2012-10-04,2012-10-04,,,191.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,54.0,HEART FAILURE,Cardiac failure,CARDIAC DISORDERS,2012-10-13,2012-10-13,,,200.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,55.0,WORSENING NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-10-12,2012-10-12,,,199.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,56.0,CREATININE INCREASED,Blood creatinine increased,INVESTIGATIONS,2012-10-15,2012-10-15,,,202.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-029-003,01029003,029,69.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,57.0,WORSENING FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-10-23,2012-10-23,,,210.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-12-26,2011-12-26,2012-01-09,2012-01-09,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,2.0,VENOUS THROMBOSIS,Venous thrombosis,VASCULAR DISORDERS,2012-01-03,2012-01-03,2012-01-09,2012-01-09,,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-03,2012-01-03,,,,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,4.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-09,2012-01-09,2012-01-09,2012-01-09,,Y,NOT RELATED,1.0,4,4.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,5.0,ILEUS,Ileus,GASTROINTESTINAL DISORDERS,2012-01-09,2012-01-09,2012-01-10,2012-01-10,,Y,NOT RELATED,1.0,4,4.0,,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,6.0,THROMBOEMBOLIC EVENT - PULMONARY EMBOLISM AND THROMBOSIS IN VENA CAVA INFERIOR,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-09,2012-01-09,,,,Y,NOT RELATED,1.0,4,4.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,7.0,THROMBOEMBOLIC EVENT - PULMONARY EMBOLISM AND THROMBOSIS IN VENA CAVA INFERIOR,Vena cava thrombosis,VASCULAR DISORDERS,2012-01-09,2012-01-09,,,,Y,NOT RELATED,1.0,4,4.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,8.0,POSTOPERATIVE URINARY RETENTION,Urinary retention postoperative,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-01-11,2012-01-11,2012-02-03,2012-02-03,,Y,NOT RELATED,1.0,2,2.0,,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,9.0,ANEMI,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-15,2012-01-15,2012-01-16,2012-01-16,,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,10.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2012-01-09,2012-01-09,2012-02-02,2012-02-02,,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,11.0,SUSPECTED INFECTION  NOT CONFIRMED; SYMPTOM FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-19,2012-01-19,2012-02-02,2012-02-02,,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,12.0,EDEMA LIMBS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-22,2012-01-22,2012-02-03,2012-02-03,,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-030-004,01030004,030,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,,,Positive (High),2.0,13.0,GASTRITIS,Gastritis,GASTROINTESTINAL DISORDERS,2012-01-21,2012-01-21,2012-02-03,2012-02-03,,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,N
CO-101-001,CO-101-001-031-001,01031001,031,66.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ARTRALGIA,Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-15,2011-04-15,2011-04-16,2011-04-16,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-031-001,01031001,031,66.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-27,2011-04-27,2011-05-04,2011-05-04,14.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-031-001,01031001,031,66.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DELIRIUM,Delirium,PSYCHIATRIC DISORDERS,2011-06-23,2011-06-23,2011-06-30,2011-06-30,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-05,2012-02-05,2012-02-11,2012-02-11,12.0,Y,UNLIKELY,2.0,4,4.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-01-30,2012-01-30,,,6.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-07,2012-02-07,2012-02-28,2012-02-28,14.0,N,NOT RELATED,1.0,3,3.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DYSPNOEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,SOMNOLENCE,Somnolence,NERVOUS SYSTEM DISORDERS,2012-03-07,2012-03-07,,,43.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,LOWER LIMB EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-29,2012-01-29,,,5.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-29,2012-02-29,,,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HYPERURICEMIA,Hyperuricaemia,METABOLISM AND NUTRITION DISORDERS,2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,1,1.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CREATININE INCREASED - CLINICALLY SIGNIFICANT,Blood creatinine increased,INVESTIGATIONS,2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ALKALINE PHOSPHATASE INCREASED - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,HYPOGLYCEMIA,Hypoglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,1,1.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,AST INCREASED - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-031-002,01031002,031,75.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,HYPOCALCEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2012-03-08,2012-03-08,,,44.0,N,NOT RELATED,1.0,1,1.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-29,2011-09-29,2011-10-01,2011-10-01,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,WHITE BLOOD DECREASED-CLINICALLY SIGNIFICANT,White blood cell count decreased,INVESTIGATIONS,2011-10-05,2011-10-05,2011-10-12,2011-10-12,15.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,NEUTROPHIL COUNT DECREASED-CLINICALLY SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2011-10-05,2011-10-05,2011-10-12,2011-10-12,15.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,POST OPERATIVE PAIN CICATRIX,Procedural pain,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-10-07,2011-10-07,,,17.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,WHITE BLOOD DECREASED-CLINICALLY SIGNIFICANT,White blood cell count decreased,INVESTIGATIONS,2011-10-12,2011-10-12,2011-10-19,2011-10-19,22.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,NEUTROPHIL COUNT DECREASED-CLINICALLY SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2011-10-12,2011-10-12,2011-10-19,2011-10-19,22.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-03,2011-11-03,2011-11-04,2011-11-04,44.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-11-03,2011-11-03,2011-11-05,2011-11-05,44.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,HICCUPS,Hiccups,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-24,2011-11-24,2011-11-24,2011-11-24,65.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,HICCUPS,Hiccups,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-01,2011-12-01,2011-12-01,2011-12-01,72.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,HICCUPS,Hiccups,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-22,2011-12-22,2011-12-22,2011-12-22,93.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-033-001,01033001,033,48.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-14,2012-03-14,2012-03-14,2012-03-14,176.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ILIAC VEIN THROMBOSIS,Pelvic venous thrombosis,VASCULAR DISORDERS,2011-05-02,2011-05-02,,,-7.0,Y,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,Y,Y,N
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,LUMBALGIA,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-05-04,2011-05-04,2011-06-01,2011-06-01,-5.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ACUTE DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-05-11,2011-05-11,2011-05-12,2011-05-12,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DYSPHAGIA,Dysphagia,GASTROINTESTINAL DISORDERS,2011-05-13,2011-05-13,2011-05-15,2011-05-15,5.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PHLEBITIS OF THE RIGHT UPPER,Phlebitis,VASCULAR DISORDERS,2011-07-11,2011-07-11,2011-07-25,2011-07-25,64.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-11,2011-07-11,2011-07-11,2011-07-11,64.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-23,2011-07-23,2011-09-03,2011-09-03,76.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-01,2011-08-01,2011-08-15,2011-08-15,85.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-29,2011-08-29,2011-09-12,2011-09-12,113.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-26,2011-09-26,2011-10-03,2011-10-03,141.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERTRANSAMINASEMIA,Hypertransaminasaemia,HEPATOBILIARY DISORDERS,2011-09-26,2011-09-26,,,141.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ALOPECI,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-09-27,2011-09-27,2011-10-27,2011-10-27,142.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-03,2011-10-03,,,148.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,NAUSEAS,Nausea,GASTROINTESTINAL DISORDERS,2011-10-14,2011-10-14,2011-10-24,2011-10-24,159.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-24,2011-10-24,2011-11-07,2011-11-07,169.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-10-28,2011-10-28,2011-10-31,2011-10-31,173.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-10-31,2011-10-31,,,176.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,INR INCREASED - CLINICALLY SIGNIFICANT,International normalised ratio increased,INVESTIGATIONS,2011-10-31,2011-10-31,2011-11-03,2011-11-03,176.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,THROMBOPLASTIN TIME PROLONGED - CLINICALLY SIGNIFICANT,Activated partial thromboplastin time prolonged,INVESTIGATIONS,2011-11-21,2011-11-21,2012-01-02,2012-01-02,197.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,GINGIVAL BLEEDING,Gingival bleeding,GASTROINTESTINAL DISORDERS,2011-10-30,2011-10-30,2011-11-01,2011-11-01,175.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-14,2011-11-14,,,190.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,PLATELET COUNT INCREASED,Platelet count increased,INVESTIGATIONS,2011-11-21,2011-11-21,,,197.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-11-21,2011-11-21,,,197.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,PRURITUS,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-19,2011-11-19,2011-11-25,2011-11-25,195.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,HYPERHIDROSIS,Hyperhidrosis,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-19,2011-11-19,,,195.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,MACULOPAPULAR RASH,Rash maculo-papular,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-19,2011-11-19,,,195.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,INR INCREASED - CLINICALLY SIGNIFICANT,International normalised ratio increased,INVESTIGATIONS,2011-11-14,2011-11-14,,,190.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,NAIL INFECTION,Nail infection,INFECTIONS AND INFESTATIONS,2011-11-18,2011-11-18,,,194.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,PRURITUS,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-26,2011-11-26,,,202.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-001,01034001,034,43.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,BILE DUCT STENOSIS,Bile duct stenosis,HEPATOBILIARY DISORDERS,2011-11-30,2011-11-30,2011-12-07,2011-12-07,206.0,Y,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-06,,2011-11-15,2011-11-15,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-25,2011-08-25,2011-09-08,2011-09-08,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERTRANSAMINASEMIA,Hypertransaminasaemia,HEPATOBILIARY DISORDERS,2011-09-01,2011-09-01,2011-11-24,2011-11-24,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CYSTITIS,Cystitis,INFECTIONS AND INFESTATIONS,2011-09-08,2011-09-08,2011-09-15,2011-09-15,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CYSTITIS,Cystitis,INFECTIONS AND INFESTATIONS,2011-09-16,2011-09-16,2011-10-13,2011-10-13,30.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-29,2011-09-29,2011-10-06,2011-10-06,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-06,2011-10-06,2011-11-10,2011-11-10,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2011-10-01,2011-10-01,,,45.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,2011-11-10,2011-11-10,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-11-15,2011-11-15,,,90.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-12-08,2011-12-08,2011-12-14,2011-12-14,113.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-12-14,2011-12-14,,,119.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-002,01034002,034,55.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ACNE,Acne,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-12-02,2011-12-02,,,107.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ABDOMINA PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-05,,2011-10-21,2011-10-21,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,HYPEROXIA,Hyperoxia,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-05,,2012-02-15,2012-02-15,,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-09,2011-09-09,2011-10-12,2011-10-12,9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-15,2011-09-15,2011-09-24,2011-09-24,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ALTERATION OF URINE SEDIMENT - CLINICALLY SIGNIFICANT,Urinary sediment abnormal,INVESTIGATIONS,2011-09-28,2011-09-28,2011-10-26,2011-10-26,28.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ACUTE DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-10-02,2011-10-02,2011-10-04,2011-10-04,32.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-12,2011-10-12,2012-03-08,2012-03-08,42.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-10-26,2011-10-26,2011-11-02,2011-11-02,56.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-19,2011-11-19,2011-11-21,2011-11-21,80.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,BRONCHITIS,Bronchitis,INFECTIONS AND INFESTATIONS,2011-11-21,2011-11-21,2011-11-30,2011-11-30,82.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-30,2011-11-30,2011-12-05,2011-12-05,91.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,DECREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-03-08,2012-03-08,2012-03-15,2012-03-15,190.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,INCREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count increased,INVESTIGATIONS,2012-03-15,2012-03-15,2012-03-22,2012-03-22,197.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,DECREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-03-29,2012-03-29,2012-04-12,2012-04-12,211.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-04-04,2012-04-04,2012-04-12,2012-04-12,217.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,LOWER LIMB EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-04,2012-04-04,2012-04-12,2012-04-12,217.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,INCREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count increased,INVESTIGATIONS,2012-04-12,2012-04-12,2012-04-26,2012-04-26,225.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-08,2012-03-08,2012-05-03,2012-05-03,190.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,DECREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-04-26,2012-04-26,2012-05-03,2012-05-03,239.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-01,2012-05-01,2012-05-05,2012-05-05,244.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-03,2012-05-03,2012-05-09,2012-05-09,246.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-05-01,2012-05-01,2012-05-09,2012-05-09,244.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,BRONCHITIS,Bronchitis,INFECTIONS AND INFESTATIONS,2012-05-03,2012-05-03,2012-05-09,2012-05-09,246.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,DECREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-05-03,2012-05-03,,,246.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,25.0,COMMUNITY-ACQUIRED PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2012-05-09,2012-05-09,2012-05-18,2012-05-18,252.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,26.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-05-09,2012-05-09,,,252.0,N,NOT RELATED,1.0,4,4.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,27.0,INTRACRANIAL HEMORRAGE,Haemorrhage intracranial,NERVOUS SYSTEM DISORDERS,2012-05-14,2012-05-14,2012-05-23,2012-05-23,257.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,28.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-09,2012-05-09,,,252.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,29.0,COMMUNITY ACQUIRED PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2012-05-19,2012-05-19,2012-05-23,2012-05-23,262.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-003,01034003,034,58.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,30.0,CONVLSIVE SYNDROME DUE TO INTRACRANIAL HEMORRAGE,Convulsion,NERVOUS SYSTEM DISORDERS,2012-05-18,2012-05-18,,,261.0,Y,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,INCREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count increased,INVESTIGATIONS,2012-02-22,2012-02-22,2012-02-29,2012-02-29,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-02-22,2012-02-22,,,10.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-07,2012-03-07,2012-05-21,2012-05-21,24.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DEEP VEIN THROMBOSIS OF THE RIGHT LEG,Deep vein thrombosis,VASCULAR DISORDERS,2012-03-27,2012-03-27,,,44.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-26,2012-03-26,2012-03-30,2012-03-30,43.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,GALLBLADDER STONES,Cholelithiasis,HEPATOBILIARY DISORDERS,2012-03-29,2012-03-29,,,46.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,LEUKOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-03,2012-04-03,,,51.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,URINARY INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-03-30,2012-03-30,2012-04-11,2012-04-11,47.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,INCREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count increased,INVESTIGATIONS,2012-04-03,2012-04-03,2012-04-18,2012-04-18,51.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-29,2012-02-29,2012-03-07,2012-03-07,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,DECREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-03-21,2012-03-21,2012-04-03,2012-04-03,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,FEVER AND PROFUSE SWEATING,Hyperhidrosis,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-04-23,2012-04-23,2012-05-08,2012-05-08,71.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,FEVER AND PROFUSE SWEATING,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-23,2012-04-23,2012-05-08,2012-05-08,71.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-22,2012-04-22,,,70.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,INCREASED PLATELET - CLINICALLY SIGNIFICANT,Platelet count increased,INVESTIGATIONS,2012-04-26,2012-04-26,2012-05-11,2012-05-11,74.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-034-004,01034004,034,38.0,YEARS,F,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,THRAUMATIC PNEUMOTHORAX,Pneumothorax traumatic,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-05-07,2012-05-07,2012-05-14,2012-05-14,85.0,Y,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,INAPETENCE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-05-26,2011-05-26,,,-5.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-07,2011-06-07,2011-06-14,2011-06-14,8.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DEEP VENOUS THROMBOSIS IN THE RIGHT LEG,Deep vein thrombosis,VASCULAR DISORDERS,2011-06-15,2011-06-15,,,16.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-06-19,2011-06-19,2011-06-26,2011-06-26,20.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,RESPIRATORY INSUFFICIENCY,Respiratory failure,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-04,2011-07-04,2011-07-04,2011-07-04,35.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2011-06-10,2011-06-10,,,11.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-21,2011-06-21,,,22.0,N,NOT RELATED,1.0,2,2.0,,OTHER,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,LEUKOCYTOSIS/ INFECTION WITHOUT A DEFINED FOCUS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-21,2011-06-21,,,22.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-28,2011-06-28,,,29.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,WORSEN ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-07-20,2011-07-20,2011-07-22,2011-07-22,51.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,AGITATION,Agitation,PSYCHIATRIC DISORDERS,2011-06-22,2011-06-22,2011-07-22,2011-07-22,23.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-06-23,2011-06-23,2011-07-28,2011-07-28,24.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-036-001,01036001,036,71.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-04,2011-07-04,,,35.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,,Y,N,N,Y
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,NAUSEAS,Nausea,GASTROINTESTINAL DISORDERS,2011-07-11,2011-07-11,,,-2.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,PULMONARY LYMPHANGITIS,Lymphangitis,INFECTIONS AND INFESTATIONS,2011-07-23,2011-07-23,,,11.0,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-07-23,2011-07-23,,,11.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,,N,Y,N,Y
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-27,2011-07-27,2011-08-04,2011-08-04,15.0,Y,NOT RELATED,1.0,5,5.0,DRUG INTERRUPTED,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,IMNSONIA,Insomnia,PSYCHIATRIC DISORDERS,2011-07-27,2011-07-27,2011-07-28,2011-07-28,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-07-27,2011-07-27,2011-07-29,2011-07-29,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-036-002,01036002,036,40.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-07-29,2011-07-29,2011-07-29,2011-07-29,17.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,CERVICAL PAIN,Neck pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-22,2011-10-22,,,-12.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-036-003,01036003,036,77.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,DIAHRREIA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-04,2011-11-04,2011-11-06,2011-11-06,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-08-19,2011-08-19,,,-14.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-19,2011-08-19,2011-10-01,2011-10-01,-14.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ARM HYPEREMIA,Hyperaemia,VASCULAR DISORDERS,2011-09-23,2011-09-23,2011-09-30,2011-09-30,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,THORACIC BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-30,2011-09-30,2011-10-07,2011-10-07,29.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-10-02,2011-10-02,2011-11-07,2011-11-07,31.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-10-07,2011-10-07,2011-10-31,2011-10-31,36.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-10,2011-10-10,2011-10-12,2011-10-12,39.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-19,2011-10-19,2011-10-28,2011-10-28,48.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-10-21,2011-10-21,2011-11-06,2011-11-06,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-29,2011-10-29,,,58.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-037-001,01037001,037,71.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-09-14,2011-09-14,2011-09-19,2011-09-19,13.0,Y,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-03,2011-09-03,2011-09-10,2011-09-10,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-11,2011-09-11,,,10.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-037-002,01037002,037,70.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-09-11,2011-09-11,2011-09-14,2011-09-14,10.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-23,2011-09-23,2011-09-29,2011-09-29,8.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-30,2011-09-30,2011-10-07,2011-10-07,15.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-08,2011-10-08,2011-10-13,2011-10-13,23.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-07,2011-11-07,2011-11-10,2011-11-10,53.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-08,2011-09-08,2011-11-11,2011-11-11,-8.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PLATELET COUNT DECREASED - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2011-11-25,2011-11-25,2011-12-02,2011-12-02,71.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-02,2011-12-02,2011-12-09,2011-12-09,78.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-16,2011-12-16,2011-12-23,2011-12-23,92.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PLATELET COUNT DECREASED - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2011-12-23,2011-12-23,2011-12-30,2011-12-30,99.0,N,DEFINITELY,4.0,2,2.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-23,2011-12-23,2011-12-30,2011-12-30,99.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-20,2011-12-20,2011-12-21,2011-12-21,96.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-20,2011-12-20,2011-12-21,2011-12-21,96.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-22,2011-12-22,2011-12-23,2011-12-23,98.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-06,2012-01-06,2012-01-12,2012-01-12,113.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-13,2012-01-13,2012-01-19,2012-01-19,120.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,PLATELET COUNT DECREASED - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-01-20,2012-01-20,2012-02-03,2012-02-03,127.0,N,DEFINITELY,4.0,1,1.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-27,2012-01-27,2012-02-03,2012-02-03,134.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-03,2012-02-03,2012-02-10,2012-02-10,141.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,NETROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-17,2012-02-17,2012-03-02,2012-03-02,155.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,PLATELET COUNT DECREASED - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-02-17,2012-02-17,2012-02-24,2012-02-24,155.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-24,2012-02-24,2012-03-02,2012-03-02,162.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-037-003,01037003,037,60.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,PLATELET COUNT DECREASED - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-02-24,2012-02-24,2012-03-02,2012-03-02,162.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,SHOULDER PAIN,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12-21,2010-12-21,2010-12-23,2010-12-23,-2.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,RIGHT UPPER QUADRANT PAIN ON INSPIRATION,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2010-12,,2010-12-23,2010-12-23,,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2010-12-24,2010-12-24,2011-04-12,2011-04-12,2.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2010-12-26,2010-12-26,2010-12-27,2010-12-27,4.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2010-12-30,2010-12-30,2011-01-06,2011-01-06,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,BILIARY TRACT INFECTION,Biliary tract infection,INFECTIONS AND INFESTATIONS,2011-01-15,2011-01-15,2011-01-26,2011-01-26,24.0,Y,UNLIKELY,2.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED",CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-12,2011-01-12,2011-01-15,2011-01-15,21.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-01-15,2011-01-15,2011-01-17,2011-01-17,24.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-01-15,2011-01-15,2011-02-15,2011-02-15,24.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-17,2011-01-17,2011-01-19,2011-01-19,26.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-01-18,2011-01-18,2011-02-19,2011-02-19,27.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,PYREXIA,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-15,2011-01-15,2011-01-16,2011-01-16,24.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,DRY MOUTH,Dry mouth,GASTROINTESTINAL DISORDERS,2011-02-16,2011-02-16,2011-02-23,2011-02-23,56.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-02-22,2011-02-22,2011-02-23,2011-02-23,62.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-22,2011-02-22,2011-02-23,2011-02-23,62.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-04-13,2011-04-13,2011-05-12,2011-05-12,112.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-02-23,2011-02-23,2011-03-08,2011-03-08,63.0,Y,NOT RELATED,1.0,4,4.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-03-09,2011-03-09,2011-03-15,2011-03-15,77.0,N,NOT RELATED,1.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-03-16,2011-03-16,2011-04-13,2011-04-13,84.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,PYREXIA,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-10,2011-04-10,2011-04-19,2011-04-19,109.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,GGT INCREASED (CS),Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-02-23,2011-02-23,2011-04-13,2011-04-13,63.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-14,2011-04-14,2011-04-19,2011-04-19,113.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-04-16,2011-04-16,2011-04-16,2011-04-16,115.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,GGT INCREASED (CS),Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-04-20,2011-04-20,,,119.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,25.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-27,2011-04-27,2011-05-11,2011-05-11,126.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,26.0,ALK PHOS INCREASED (CS),Blood alkaline phosphatase increased,INVESTIGATIONS,2011-04-20,2011-04-20,,,119.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,27.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-13,2011-05-13,2011-05-19,2011-05-19,142.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,28.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-05-04,2011-05-04,2011-05-04,2011-05-04,133.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,29.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-05-03,2011-05-03,2011-05-10,2011-05-10,132.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,30.0,PYREXIA,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-03,2011-05-03,2011-05-04,2011-05-04,132.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,31.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-20,2011-05-20,2011-07-19,2011-07-19,149.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,32.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-07-07,2011-07-07,2011-07-08,2011-07-08,197.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,33.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-07-13,2011-07-13,2011-07-15,2011-07-15,203.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,34.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-07-20,2011-07-20,,,210.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,35.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-29,2010-12-29,2011-04-26,2011-04-26,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,36.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-12,2011-05-12,2011-08-03,2011-08-03,141.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,37.0,HAEMATOCRIT LOW (CS),Haematocrit decreased,INVESTIGATIONS,2010-12-29,2010-12-29,2011-03-08,2011-03-08,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,38.0,ERYTHROCYTES LOW (CS),Red blood cell count decreased,INVESTIGATIONS,2010-12-29,2010-12-29,2011-08-03,2011-08-03,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,39.0,WBCS LOW (CS),White blood cell count decreased,INVESTIGATIONS,2010-12-29,2010-12-29,2011-01-25,2011-01-25,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,40.0,WBC LOW (CS),White blood cell count decreased,INVESTIGATIONS,2011-02-23,2011-02-23,2011-03-08,2011-03-08,63.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,41.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-29,2010-12-29,2011-01-11,2011-01-11,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,42.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-23,2011-02-23,2011-03-08,2011-03-08,63.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,43.0,LYMPHOCYTES LOW (CS),Lymphocyte count decreased,INVESTIGATIONS,2010-12-29,2010-12-29,2011-03-08,2011-03-08,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,44.0,LYMPHOCYTES LOW (CS),Lymphocyte count decreased,INVESTIGATIONS,2011-07-06,2011-07-06,2011-07-19,2011-07-19,196.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,45.0,HAEMATOCRIT LOW (CS),Haematocrit decreased,INVESTIGATIONS,2011-05-25,2011-05-25,2011-06-07,2011-06-07,154.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,46.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-03-16,2011-03-16,2011-03-30,2011-03-30,84.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,47.0,DRY COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-12,2011-04-12,2011-04-20,2011-04-20,111.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,48.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-02-20,2011-02-20,2011-03-23,2011-03-23,60.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-001,01039001,039,58.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,49.0,AST HIGH (CS),Aspartate aminotransferase increased,INVESTIGATIONS,2011-05-25,2011-05-25,2011-06-08,2011-06-08,154.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-22,2011-06-22,2011-07-05,2011-07-05,-7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,N
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,PYREXIA,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-03,2011-08-03,,,36.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-08,2011-08-08,,,41.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DYSPNOEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-08,2011-08-08,,,41.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-08,2011-08-08,,,41.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HERPES LABIALIS,Oral herpes,INFECTIONS AND INFESTATIONS,2011-08-10,2011-08-10,2011-08-17,2011-08-17,43.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,BILIRUBIN HIGH (CS),Blood bilirubin increased,INVESTIGATIONS,2011-07-13,2011-07-13,2011-07-27,2011-07-27,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ALP HIGH (CLINICALLY SIGNIFICANT),Blood alkaline phosphatase increased,INVESTIGATIONS,2011-07-13,2011-07-13,2011-08-09,2011-08-09,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ALT HIGH (CLINICALLY SIGNIFICANT),Alanine aminotransferase increased,INVESTIGATIONS,2011-07-13,2011-07-13,2011-07-26,2011-07-26,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,AST HIGHT (CLINICALLY SIGNIFICANT),Aspartate aminotransferase increased,INVESTIGATIONS,2011-07-13,2011-07-13,2011-07-26,2011-07-26,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,GGT HIGH (CLINICALLY SIGNIFICANT),Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-06-29,2011-06-29,,,1.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HAEMOGLOBIN LOW (CLINICALLY SIGNIFICANT),Haemoglobin decreased,INVESTIGATIONS,2011-07-13,2011-07-13,,,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,PLATELETS LOW (CLINICALLY SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2011-07-13,2011-07-13,2011-07-27,2011-07-27,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ALP HIGH (CLINICALLY SIGNIFICANT),Blood alkaline phosphatase increased,INVESTIGATIONS,2011-08-10,2011-08-10,2011-08-23,2011-08-23,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ALP HIGH (CLINICALLY SIGNIFICANT),Blood alkaline phosphatase increased,INVESTIGATIONS,2011-08-24,2011-08-24,,,57.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ALT HIGH (CLINICALLY SIGNIFICANT),Alanine aminotransferase increased,INVESTIGATIONS,2011-07-27,2011-07-27,2011-08-24,2011-08-24,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,AST HIGH (CLINICALLY SIGNIFICANT),Aspartate aminotransferase increased,INVESTIGATIONS,2011-07-27,2011-07-27,,,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,CREATININE HIGH (CLINICALLY SIGNIFICANT),Blood creatinine increased,INVESTIGATIONS,2011-07-13,2011-07-13,2011-07-27,2011-07-27,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,PLATELETS LOW (CLINICALLY SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2011-08-24,2011-08-24,2011-09-07,2011-09-07,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,HYPONATREMIA (CLINICALLY SIGNIFICANT),Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-08-10,2011-08-10,2011-08-24,2011-08-24,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,SWEATING,Hyperhidrosis,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06-29,2011-06-29,2011-06-29,2011-06-29,1.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-12,2011-07-12,2011-07-18,2011-07-18,14.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-06-29,2011-06-29,2011-07-06,2011-07-06,1.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,PEDAL OEDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-15,2011-08-15,,,48.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-08-06,2011-08-06,,,39.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,LYMPHOCYTES LOW (CLINICALLY SIGNIFICANT),Lymphocyte count decreased,INVESTIGATIONS,2011-07-13,2011-07-13,2011-07-20,2011-07-20,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,HAEMATOCRIT LOW (CLINICALLY SIGNIFICANT),Haematocrit decreased,INVESTIGATIONS,2011-07-20,2011-07-20,2011-07-27,2011-07-27,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,RED BLOOD CELLS LOW (CLINICALLY SIGNIFICANT),Red blood cell count decreased,INVESTIGATIONS,2011-07-13,2011-07-13,2011-09-07,2011-09-07,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,LDH HIGH (CLINICALLY SIGNIFICANT),Blood lactate dehydrogenase increased,INVESTIGATIONS,2011-07-13,2011-07-13,,,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30.0,RIGHT UPPER QUADRANT PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-07-06,2011-07-06,2011-07-13,2011-07-13,8.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-002,01039002,039,51.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,31.0,PLATELETS LOW (CLINICALLY SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2011-09-07,2011-09-07,,,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03,,2011-09-13,2011-09-13,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,N
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-03,,,,,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-07,,2011-09-13,2011-09-13,,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,N
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-07,,,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NASAL CONGESTION,Nasal congestion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-10,2011-09-10,,,-4.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-14,2011-09-14,,,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-039-004,01039004,039,55.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-09-14,2011-09-14,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-01-06,2012-01-06,2012-01-24,2012-01-24,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-01-25,2012-01-25,2012-01-25,2012-01-25,21.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-11,2012-01-11,,,7.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-09,2012-01-09,2012-01-15,2012-01-15,5.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-16,2012-01-16,2012-01-25,2012-01-25,12.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,MACULAR RASH,Rash macular,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-01-18,2012-01-18,2012-01-20,2012-01-20,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-18,2012-01-18,2012-01-25,2012-01-25,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-02-03,2012-02-03,2012-02-15,2012-02-15,30.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,PYREXIA,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-27,2012-01-27,2012-01-31,2012-01-31,23.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-29,2012-01-29,2012-02-08,2012-02-08,25.0,Y,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-28,2012-01-28,2012-01-28,2012-01-28,24.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-29,2012-01-29,2012-01-29,2012-01-29,25.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-29,2012-01-29,2012-02-08,2012-02-08,25.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-26,2012-01-26,,,22.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,LOW BACK PIAN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-02-15,2012-02-15,2012-02-29,2012-02-29,42.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,LOWER RESPIRATORY TRACT INFECTION,Lower respiratory tract infection,INFECTIONS AND INFESTATIONS,2012-02-15,2012-02-15,2012-02-23,2012-02-23,42.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,DIABETES MELLITIS TYPE II,Type 2 diabetes mellitus,METABOLISM AND NUTRITION DISORDERS,2012-02-15,2012-02-15,,,42.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,NIGHT SWEATS,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-02-29,2012-02-29,,,56.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-039-005,01039005,039,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,BILIARY SEPSIS,Biliary sepsis,INFECTIONS AND INFESTATIONS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,22.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-04-08,2011-04-08,2011-04-18,2011-04-18,4.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-04-06,2011-04-06,,,2.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DRY MOUTH,Dry mouth,GASTROINTESTINAL DISORDERS,2011-04-08,2011-04-08,,,4.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-12,2011-04-12,,,8.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-04-12,2011-04-12,2011-04-13,2011-04-13,8.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,RASH - UPPER CHEST,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-04-16,2011-04-16,,,12.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-04-19,2011-04-19,2011-04-26,2011-04-26,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-04-19,2011-04-19,2011-05-13,2011-05-13,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-19,2011-04-19,2011-04-26,2011-04-26,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-04-19,2011-04-19,,,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,PAIN (BACK & ABDOMINAL),Abdominal pain,GASTROINTESTINAL DISORDERS,2011-04-19,2011-04-19,,,15.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,PAIN (BACK & ABDOMINAL),Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-19,2011-04-19,,,15.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,GASTRIC OUTLET OBSTRUCTION,Obstruction gastric,GASTROINTESTINAL DISORDERS,2011-04-26,2011-04-26,2011-05-10,2011-05-10,22.0,Y,NOT RELATED,1.0,2,2.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-03-25,2011-03-25,2011-04-07,2011-04-07,-11.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-041-001,01041001,041,74.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,PANCREATIC DEFICIENCY,Pancreatic insufficiency,GASTROINTESTINAL DISORDERS,2011-04-12,2011-04-12,,,8.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,PEDAL OEDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-16,2011-05-16,,,-1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,UPPER ABDOMINAL PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-27,2011-05-27,2011-06-06,2011-06-06,11.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-05-24,2011-05-24,2011-05-28,2011-05-28,8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-24,2011-05-24,2011-06-07,2011-06-07,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-05-10,2011-05-10,2011-06-03,2011-06-03,-7.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-06-04,2011-06-04,2011-06-17,2011-06-17,19.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-05-25,2011-05-25,2011-06-06,2011-06-06,9.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-29,2011-05-29,2011-05-31,2011-05-31,13.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-21,2011-06-21,2011-06-25,2011-06-25,36.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-26,2011-06-26,2011-07-04,2011-07-04,41.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-06-26,2011-06-26,2011-06-29,2011-06-29,41.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,PYREXIA,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-28,2011-06-28,2011-07-05,2011-07-05,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-06-29,2011-06-29,2011-07-03,2011-07-03,44.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,RIGHT LOWER LIMB DEEP VENOUS THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-06-19,2011-06-19,,,34.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,ABDOMINAL SWELLING,Abdominal distension,GASTROINTESTINAL DISORDERS,2011-07-29,2011-07-29,,,74.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-25,2011-07-25,,,70.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,FECAL URGENCY,Defaecation urgency,GASTROINTESTINAL DISORDERS,2011-07-30,2011-07-30,,,75.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-07-25,2011-07-25,,,70.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-06-28,2011-06-28,2011-07-03,2011-07-03,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-07-03,2011-07-03,2011-07-29,2011-07-29,48.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,FAECAL IMPACTION,Faecaloma,GASTROINTESTINAL DISORDERS,2011-06-28,2011-06-28,,,43.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-15,2011-07-15,,,60.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,BILATERAL DEEP VENOUS THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-07-15,2011-07-15,,,60.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-06-04,2011-06-04,2011-06-17,2011-06-17,19.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-12,2011-07-12,2011-07-19,2011-07-19,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-07-30,2011-07-30,,,75.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,RAISED ALP - CS,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-07-19,2011-07-19,2011-08-01,2011-08-01,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-003,01041003,041,49.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,RAISED ALP - CS,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-08-02,2011-08-02,,,78.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-05-21,2011-05-21,2011-05-23,2011-05-23,5.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-05-24,2011-05-24,2011-08-01,2011-08-01,8.0,N,NOT RELATED,1.0,2,2.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-30,2011-05-30,2011-05-30,2011-05-30,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,LIGHTHEADED,Dizziness,NERVOUS SYSTEM DISORDERS,2011-05-30,2011-05-30,2011-05-30,2011-05-30,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-21,2011-06-21,2011-06-21,2011-06-21,36.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-19,2011-07-19,2011-07-25,2011-07-25,64.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-08-02,2011-08-02,,,78.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ORAL THRUSH,Oral candidiasis,INFECTIONS AND INFESTATIONS,2011-07-19,2011-07-19,2011-08-02,2011-08-02,64.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-12,2011-07-12,2011-07-25,2011-07-25,57.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-26,2011-07-26,,,71.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-03,,2011-08-16,2011-08-16,,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,LOWER ABDOMINAL PAIN,Abdominal pain lower,GASTROINTESTINAL DISORDERS,2011-08-10,2011-08-10,2011-08-12,2011-08-12,86.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-15,2011-08-15,2011-08-24,2011-08-24,91.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ORAL THRUSH,Oral candidiasis,INFECTIONS AND INFESTATIONS,2011-08-28,2011-08-28,,,104.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,HYPERGLYCAEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-30,2011-08-30,,,106.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ORAL THRUSH,Oral candidiasis,INFECTIONS AND INFESTATIONS,2011-08-02,2011-08-02,2011-08-02,2011-08-02,78.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-28,2011-06-28,2011-07-26,2011-07-26,43.0,N,,,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-09,,2011-09-14,2011-09-14,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,LOWER ABDOMINAL PAIN,Abdominal pain lower,GASTROINTESTINAL DISORDERS,2011-09-13,2011-09-13,2011-09-13,2011-09-13,120.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,REDUCED APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-08,2011-09-08,,,115.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-21,2011-05-21,2011-05-23,2011-05-23,5.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,ELEVATED C-REACTIVE PROTEIN (CLINICALLY SIGNIFICANT),C-reactive protein increased,INVESTIGATIONS,2011-05-21,2011-05-21,2011-05-23,2011-05-23,5.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,INFECTION (UNKNOWN SOURCE),Infection,INFECTIONS AND INFESTATIONS,2011-05-21,2011-05-21,2011-05-23,2011-05-23,5.0,Y,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,INFECTION AT PICC LINE EXIT SITE,Catheter site infection,INFECTIONS AND INFESTATIONS,2011-09-22,2011-09-22,2011-09-29,2011-09-29,129.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-17,2011-05-17,2011,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,POOR VENOUS ACCESS,Poor venous access,VASCULAR DISORDERS,2011,,,,,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-20,2011-09-20,2011-10-04,2011-10-04,127.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-05-17,2011-05-17,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-041-004,01041004,041,67.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011,,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-16,2011-10-16,2011-10-23,2011-10-23,-2.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09,,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-09,,2011-10-23,2011-10-23,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-24,2011-10-24,2011-10-25,2011-10-25,7.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-006,01041006,041,77.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-10-24,2011-10-24,2011-11-17,2011-11-17,7.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ATRIAL FIBRILLATION,Atrial fibrillation,CARDIAC DISORDERS,2012-01-03,2012-01-03,2012-01-13,2012-01-13,-7.0,Y,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,BILIARY SEPSIS,Biliary sepsis,INFECTIONS AND INFESTATIONS,2012-01-03,2012-01-03,2012-01-13,2012-01-13,-7.0,Y,NOT RELATED,1.0,4,4.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,INFECTION (SOURCE: STENT),Device related infection,INFECTIONS AND INFESTATIONS,2012-02-09,2012-02-09,2012-02-17,2012-02-17,31.0,Y,UNLIKELY,2.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-22,2012-03-22,2012-03-23,2012-03-23,73.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BILATERAL ANKLE OEDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-23,2012-03-23,,,74.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-29,2012-03-29,2012-04-06,2012-04-06,80.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-29,2012-03-29,2012-04-06,2012-04-06,80.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-03-29,2012-03-29,2012-04-06,2012-04-06,80.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,CHOLANGITIS,Cholangitis,HEPATOBILIARY DISORDERS,2012-04-19,2012-04-19,2012-04-25,2012-04-25,101.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANKLE OEDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-20,2012-04-20,,,102.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-04-26,2012-04-26,,,108.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,SWELLING OF TOE,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-17,2012-05-17,2012-07-29,2012-07-29,129.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ERYTHEMA OF TOE,Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-05-17,2012-05-17,2012-07-29,2012-07-29,129.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-05-09,2012-05-09,2012-05-17,2012-05-17,121.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,RAISED CREATININE (CLINICALLY SIGNIFICANT),Blood creatinine increased,INVESTIGATIONS,2012-05-15,2012-05-15,,,127.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,RAISED UREA (CLINICALLY SIGNIFICANT),Blood urea increased,INVESTIGATIONS,2012-05-15,2012-05-15,,,127.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,RAISED POTASSIUM (CLINICALLY SIGNIFICANT),Blood potassium increased,INVESTIGATIONS,2012-05-15,2012-05-15,,,127.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,RAISED URIC ACID (CLINICALLY SIGNIFICANT),Blood uric acid increased,INVESTIGATIONS,2012-05-15,2012-05-15,,,127.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,LOW HAEMOGLOBIN - CLINICALLY SIGNIFICANT,Haemoglobin decreased,INVESTIGATIONS,2012-05-15,2012-05-15,,,127.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,KIDNEY FAILURE,Renal failure,RENAL AND URINARY DISORDERS,2012-06-06,2012-06-06,2012-07-04,2012-07-04,149.0,Y,UNLIKELY,2.0,4,4.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,HYPERURICAEMIA,Hyperuricaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-06,2012-06-06,,,149.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-06,2012-06-06,,,149.0,Y,UNLIKELY,2.0,2,2.0,,,CONTINUOUS,,N,Y,N,Y
CO-101-001,CO-101-001-041-007,01041007,041,69.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,HAEMATURIA,Haematuria,RENAL AND URINARY DISORDERS,2012-04-03,2012-04-03,,,85.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-11,2012-01-11,,,-6.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-18,2012-01-18,2012-01-19,2012-01-19,2.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,LOW MOOD,Depressed mood,PSYCHIATRIC DISORDERS,2012-02,,,,,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-01,2012-02-01,2012-02-23,2012-02-23,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-01,2012-02-01,2012-02-01,2012-02-01,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-02-22,2012-02-22,,,37.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ALKALINE PHOSPHATASE RAISED (CLINICALLY SIGNIFICANT),Blood alkaline phosphatase increased,INVESTIGATIONS,2012-01-31,2012-01-31,,,15.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ALANINE TRANSAMINASE RAISED (CLINICALLY SIGNIFICANT),Alanine aminotransferase increased,INVESTIGATIONS,2012-01-31,2012-01-31,2012-02-20,2012-02-20,15.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,ASPARTATE AMINOTRANSFERASE RAISED (CLINICALLY SIGNIFICANT),Aspartate aminotransferase increased,INVESTIGATIONS,2012-01-31,2012-01-31,2012-03-06,2012-03-06,15.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,GLUCOSE RAISED (CLINICALLY SIGNIFICANT),Blood glucose increased,INVESTIGATIONS,2012-01-31,2012-01-31,2012-02-28,2012-02-28,15.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,GGT RAISED (CLINICALLY SIGNIFICANT),Gamma-glutamyltransferase increased,INVESTIGATIONS,2012-01-31,2012-01-31,,,15.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,BILIRUBIN RAISED (CLINICALLY SIGNIFICANT),Blood bilirubin increased,INVESTIGATIONS,2012-02-14,2012-02-14,2012-03-13,2012-03-13,29.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,MALABSORPTION,Malabsorption,GASTROINTESTINAL DISORDERS,2012,,,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-041-008,01041008,041,64.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,ALANINE TRANSAMINASE RAISED (CLINICALLY SIGNIFICANT),Alanine aminotransferase increased,INVESTIGATIONS,2012-02-21,2012-02-21,2012-02-28,2012-02-28,36.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-25,2012-01-25,2012-02-06,2012-02-06,2.0,N,DEFINITELY,4.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2012-01-25,2012-01-25,,,2.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-01-31,2012-01-31,,,8.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CLINICAL DISEASE PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-03-22,2012-03-22,2012-04-27,2012-04-27,59.0,Y,NOT RELATED,1.0,5,5.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-03,2012-03-03,2012-03-03,2012-03-03,40.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-25,2012-01-25,2012-02-06,2012-02-06,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-31,2012-01-31,2012-02-15,2012-02-15,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-02,2012-03-02,2012-03-03,2012-03-03,39.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,HYPERGLYCAEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-24,2012-01-24,2012-03-06,2012-03-06,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,LEFT LEG DEEP VEIN THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2012-01-17,2012-01-17,,,-7.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-06,2012-02-06,2012-02-15,2012-02-15,14.0,N,DEFINITELY,4.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-07,2012-03-07,2012-03-13,2012-03-13,44.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-041-009,01041009,041,63.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,LOW SODIUM (CLINICALLY SIGNIFICANT),Blood sodium decreased,INVESTIGATIONS,2012-01-31,2012-01-31,2012-02-07,2012-02-07,8.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,1.0,PELVIC RASH,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-05-17,2011-05-17,2011-05-23,2011-05-23,13.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,2.0,HIGH BLOOD PRESSURE,Hypertension,VASCULAR DISORDERS,2011-05-19,2011-05-19,2011-05-19,2011-05-19,15.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-12,2011-05-12,2011-05-26,2011-05-26,8.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-05,2011-05-05,2011-09-09,2011-09-09,1.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-10,2011-06-10,2011-07-04,2011-07-04,37.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-03,2011-06-03,2011-07-04,2011-07-04,30.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-11,2011-07-11,2011-08-05,2011-08-05,68.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-12,2011-08-12,2011-09-02,2011-09-02,100.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,9.0,THROMBOCITOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-16,2011-09-16,2011-09-22,2011-09-22,135.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-14,2011-10-14,,,163.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-16,2011-09-16,,,135.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,12.0,RIGHT HIP PAIN,Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-03,2011-10-03,,,152.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,13.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-12,2011-08-12,2011-08-23,2011-08-23,100.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,14.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-16,2011-09-16,2011-09-23,2011-09-23,135.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,15.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-23,2011-09-23,2011-09-30,2011-09-30,142.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,16.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-23,2011-09-23,2011-09-30,2011-09-30,142.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-23,2011-09-23,2011-09-30,2011-09-30,142.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-042-001,01042001,042,68.0,YEARS,M,WHITE,5.0,ARG,ARGENTINA,South America,5.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,18.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-10-21,2011-10-21,,,170.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2010-11-12,2010-11-12,,,1.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11-12,2010-11-12,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2010-11-12,2010-11-12,2010-12-10,2010-12-10,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CELLULITIS,Cellulitis,INFECTIONS AND INFESTATIONS,2010-11-28,2010-11-28,2010-12-04,2010-12-04,17.0,Y,UNLIKELY,2.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ABDOMNIAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2010-11-12,2010-11-12,2010-12-10,2010-12-10,1.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11-25,2010-11-25,2010-12-01,2010-12-01,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,EDEMA LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11-25,2010-11-25,,,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PAIN LEFT KNEE,Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-11-12,2010-11-12,2010-11-19,2010-11-19,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,PAIN LEFT SHOULDER,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2010-12-04,2010-12-04,2010-12-20,2010-12-20,23.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,REDNESS AT PORT SITE,Catheter site erythema,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-19,2010-12-19,2010-12-23,2010-12-23,38.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2010-11-12,2010-11-12,,,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,YEAST INFECTION,Fungal infection,INFECTIONS AND INFESTATIONS,2010-12-04,2010-12-04,2010-12-10,2010-12-10,23.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ELEVATED LIVER ENZYMES - CLINICALLY SIGNIFICANT,Hepatic enzyme increased,INVESTIGATIONS,2010-11-25,2010-11-25,2011-01-07,2011-01-07,14.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-12,2011-01-12,2011-02-04,2011-02-04,62.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-29,2011-04-29,2011-05-05,2011-05-05,169.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-29,2011-04-29,2011-05-01,2011-05-01,169.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,INFECTION EAR,Ear infection,INFECTIONS AND INFESTATIONS,2011-04-29,2011-04-29,2011-05-07,2011-05-07,169.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,GASTRITIS,Gastritis,GASTROINTESTINAL DISORDERS,2011-04-21,2011-04-21,,,161.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-05-14,2011-05-14,2011-05-14,2011-05-14,184.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-14,2011-05-14,2011-05-14,2011-05-14,184.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-27,2011-05-27,2011-06-17,2011-06-17,197.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,EPISTAXIS,Epistaxis,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-05-26,2011-05-26,2011-05-27,2011-05-27,196.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-05-24,2011-05-24,2011-06-25,2011-06-25,194.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,CELLULITIS,Cellulitis,INFECTIONS AND INFESTATIONS,2011-02-08,2011-02-08,2011-02-14,2011-02-14,89.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,CELLULITIS,Cellulitis,INFECTIONS AND INFESTATIONS,2011-03-07,2011-03-07,2011-03-12,2011-03-12,116.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-04-15,2011-04-15,2011-06-25,2011-06-25,155.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-05-20,2011-05-20,,,190.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,EROSIVE ESOPHAGITIS,Erosive oesophagitis,GASTROINTESTINAL DISORDERS,2011-04-18,2011-04-18,2011-04-29,2011-04-29,158.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,PLEURAL EFFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-18,2011-04-18,2011-04-29,2011-04-29,158.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,BRONCHOSPASMS,Bronchospasm,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-03-08,2011-03-08,2011-03-28,2011-03-28,117.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-01,2011-04-01,2011-04-29,2011-04-29,141.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-04-18,2011-04-18,2011-04-18,2011-04-18,158.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2011-06-02,2011-06-02,2011-06-10,2011-06-10,203.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,34.0,EDEMA BILATERAL LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-01,2011-04-01,2011-04-29,2011-04-29,141.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35.0,VIRAL UPPER RESPIRATORY TRACT INFECTION,Viral upper respiratory tract infection,INFECTIONS AND INFESTATIONS,2011-07-19,2011-07-19,2011-07-22,2011-07-22,250.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,36.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-15,2011-06-15,2011-07-15,2011-07-15,216.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,37.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-01,2011-07-01,2011-07-15,2011-07-15,232.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,38.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-12,2011-08-12,2011-08-16,2011-08-16,274.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,39.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-10,2011-08-10,2011-09-16,2011-09-16,272.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-25,2011-08-25,2011-08-25,2011-08-25,287.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,41.0,FLUID RETENTION SYNDROME,Fluid retention,METABOLISM AND NUTRITION DISORDERS,2011-08-31,2011-08-31,2011-09-08,2011-09-08,293.0,Y,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,42.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-05,2011-09-05,2011-09-06,2011-09-06,298.0,Y,NOT RELATED,1.0,2,2.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,43.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-21,2011-09-21,2011-10-13,2011-10-13,314.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,44.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-21,2011-10-21,,,344.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-044-001,01044001,044,49.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45.0,CELLULITIS BILATERAL LEGS,Cellulitis,INFECTIONS AND INFESTATIONS,2011-10-24,2011-10-24,2011-10-28,2011-10-28,347.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-01-31,2011-01-31,2011-02-01,2011-02-01,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-02-07,2011-02-07,2011-02-08,2011-02-08,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-01,2011-02-01,,,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-21,2011-02-21,,,22.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-03-28,2011-03-28,,,57.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMNIAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-01-31,2011-01-31,2011-04-03,2011-04-03,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,GORD,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2011-03-07,2011-03-07,,,36.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-04-13,2011-04-13,,,73.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-04-20,2011-04-20,,,80.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-04-04,2011-04-04,,,64.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-04-27,2011-04-27,,,87.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-044-002,01044002,044,57.0,YEARS,M,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HYPOGLYCEMIA,Hypoglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-05-01,2011-05-01,,,91.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,CELLULITIS LEFT LEG,Cellulitis,INFECTIONS AND INFESTATIONS,2011-04-18,2011-04-18,2011-05-11,2011-05-11,14.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,FLUID RETENTION,Fluid retention,METABOLISM AND NUTRITION DISORDERS,2011-04-01,2011-04-01,,,-4.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,SEPSIS,Sepsis,INFECTIONS AND INFESTATIONS,2011-04-17,2011-04-17,2011-05-11,2011-05-11,13.0,N,UNLIKELY,2.0,2,2.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-044-003,01044003,044,50.0,YEARS,F,WHITE,5.0,AUS,AUSTRALIA,Australia,4.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PORT INFECTION,Catheter site infection,INFECTIONS AND INFESTATIONS,2011-04-21,2011-04-21,2011-05-11,2011-05-11,17.0,N,UNLIKELY,2.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,DISCOMFORT IN VENOUS ACCESS,Catheter site related reaction,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-21,2011-09-21,2011-09-21,2011-09-21,1.0,N,DEFINITELY,4.0,1,1.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,DISCOMFORT IN VENOUS ACCESS,Catheter site related reaction,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-28,2011-09-28,2011-09-28,2011-09-28,8.0,N,DEFINITELY,4.0,1,1.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HEPATOTOXICITY,Hepatotoxicity,HEPATOBILIARY DISORDERS,2011-10-04,2011-10-04,2011-11-03,2011-11-03,14.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-04,2011-10-04,2011-10-13,2011-10-13,14.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,URINARY INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-09-23,2011-09-23,2011-10-07,2011-10-07,3.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,RIGHT ILIAC FOSSA PAIN,Abdominal pain lower,GASTROINTESTINAL DISORDERS,2011-11-04,2011-11-04,2011-11-15,2011-11-15,45.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,GASTRITIS,Gastritis,GASTROINTESTINAL DISORDERS,2011-11-15,2011-11-15,2011-11-19,2011-11-19,56.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,HEPATOTOXICITY,Hepatotoxicity,HEPATOBILIARY DISORDERS,2011-12-13,2011-12-13,2011-12-26,2011-12-26,84.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-10,2011-09-10,2011-11-15,2011-11-15,-11.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-045-001,01045001,045,46.0,YEARS,F,OTHER,99.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-09-20,2011-09-20,,,-1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,INFECTION BILIARY TREE,Biliary tract infection,INFECTIONS AND INFESTATIONS,2011-07-06,2011-07-06,2011-07-20,2011-07-20,7.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,OBSTRUCTION BILIARY TREE,Bile duct obstruction,HEPATOBILIARY DISORDERS,2011-07-06,2011-07-06,,,7.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-046-001,01046001,046,61.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-10,2011-07-10,,,11.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-10-25,2011-10-25,2011-11-03,2011-11-03,6.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-25,2011-10-25,2011-11-11,2011-11-11,6.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-26,2011-10-26,2012-01-02,2012-01-02,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,,,8.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-10,2011-11-10,2011-11-17,2011-11-17,22.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-04,2011-11-04,2011-11-07,2011-11-07,16.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-08,2011-11-08,2011-11-27,2011-11-27,20.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-12,2011-11-12,2011-11-14,2011-11-14,24.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-15,2011-11-15,2011-11-21,2011-11-21,27.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-19,2011-11-19,2011-11-20,2011-11-20,31.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-28,2011-11-28,2011-11-30,2011-11-30,40.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-28,2011-11-28,2011-11-29,2011-11-29,40.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-30,2011-11-30,2011-12-17,2011-12-17,42.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,ORCHIEPIDIDIMITIS BILATERAL,Orchitis noninfective,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011-11-24,2011-11-24,,,36.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-18,2011-12-18,2011-12-23,2011-12-23,60.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,LOWER LIMBS EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-21,2011-12-21,,,63.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-12-28,2011-12-28,,,70.0,N,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-09,2012-01-09,2012-01-10,2012-01-10,82.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-03,2012-01-03,,,76.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,MONILIASIS ORAL,Oral candidiasis,INFECTIONS AND INFESTATIONS,2012-01-15,2012-01-15,,,88.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-10-07,2011-10-07,2011-10-19,2011-10-19,-13.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-10-04,2011-10-04,,,-16.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-046-002,01046002,046,55.0,YEARS,M,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-10,2011-10-10,2011-10-19,2011-10-19,-10.0,N,NOT RELATED,1.0,2,2.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-09-30,2011-09-30,2011-10-06,2011-10-06,53.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-31,2011-08-31,2011-09-22,2011-09-22,23.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-22,2011-09-22,,,45.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,INFECTION WITH UNKNOWN NEUTROPHIL COUNT,Infection,INFECTIONS AND INFESTATIONS,2011-10-26,2011-10-26,2011-10-26,2011-10-26,79.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-047-001,01047001,047,65.0,YEARS,F,WHITE,5.0,BRA,BRAZIL,South America,5.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-29,2011-08-29,2011-08-31,2011-08-31,21.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,MICTION PAIN,Dysuria,RENAL AND URINARY DISORDERS,2011-02-17,2011-02-17,,,28.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02,,,,,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-01-28,2011-01-28,2011-02-22,2011-02-22,8.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERTHERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-10,2011-03-10,,,49.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-11,2011-03-11,,,50.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,HYPERCALCEMIA,Hypercalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-11,2011-03-11,2011-03-17,2011-03-17,50.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,BUCCAL MYCOSIS,Fungal infection,INFECTIONS AND INFESTATIONS,2011-03-13,2011-03-13,,,52.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-16,2011-03-16,2011-03-23,2011-03-23,55.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-03-04,2011-03-04,,,43.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,METASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-03-11,2011-03-11,2011-04-08,2011-04-08,50.0,Y,NOT RELATED,1.0,5,5.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-02-23,2011-02-23,,,34.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-03-04,2011-03-04,,,43.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,BONE PAIN,Bone pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-11,2011-03-11,,,50.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-03-11,2011-03-11,,,50.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-050-002,01050002,050,37.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,CONFUSION,Confusional state,PSYCHIATRIC DISORDERS,2011-03-14,2011-03-14,,,53.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-01-18,2011-01-18,2011-03-07,2011-03-07,-6.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-04-10,2011-04-10,,,77.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-05-27,2011-05-27,2011-05-27,2011-05-27,124.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-04,2011-04-04,,,71.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-003,01050003,050,39.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-04,2011-04-04,,,71.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-02,2012-01-02,,,-1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-10,2012-01-10,,,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2012-01-02,2012-01-02,,,-1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-07,2012-02-07,,,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-02-07,2012-02-07,,,36.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-03,2012-03-03,,,61.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,JAUNDICE,Jaundice,HEPATOBILIARY DISORDERS,2012-03-03,2012-03-03,,,61.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,MOUTH XEROSIS,Xerosis,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-03,2012-03-03,,,61.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,HYPERCALCEMIA,Hypercalcaemia,METABOLISM AND NUTRITION DISORDERS,2012-03-03,2012-03-03,2012-03-12,2012-03-12,61.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,HYPOPHOSPHOREMIA,Hypophosphataemia,METABOLISM AND NUTRITION DISORDERS,2012-03-07,2012-03-07,,,65.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,EDEMA OF LOWER LIMBS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-07,2012-03-07,,,65.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ABDOMINAL PAIN WORSENING,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-03-03,2012-03-03,2012-03-14,2012-03-14,61.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-050-005,01050005,050,68.0,YEARS,F,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,GASTROESOPHAGEAL REFLUX DISEASE,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2012-01-31,2012-01-31,,,29.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-03,2011-03-03,2011-03,,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-12,2011-04-12,2011-04-15,2011-04-15,41.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-13,2011-05-13,,,72.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-10,2011-08-10,155.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-08,2011-11-08,2011-11-15,2011-11-15,251.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,EPISTAXIS,Epistaxis,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-15,2012-02-15,2012-02-16,2012-02-16,350.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-03-30,2012-03-30,350.0,Y,POSSIBLE/PROBABLE,3.0,4,4.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-03-14,2012-03-14,350.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-07,2011-12-07,2011-12-15,2011-12-15,280.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-12,2012-01-12,2012-01-18,2012-01-18,316.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-20,2011-10-20,2012-02-14,2012-02-14,232.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-051-002,01051002,051,68.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,SUBDURAL HEMATOMA,Subdural haematoma,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-04-10,2012-04-10,2012-04-13,2012-04-13,405.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,N
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-21,2011-04-21,2011-05-04,2011-05-04,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-051-003,01051003,051,69.0,YEARS,M,OTHER,99.0,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-04,2011-05-04,2011-05-25,2011-05-25,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2011-04-03,2011-04-03,2011-04-03,2011-04-03,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-07,2011-04-07,2011-04-07,2011-04-07,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-08,2011-04-08,2011-04-08,2011-04-08,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2011-04-08,2011-04-08,2011-04-08,2011-04-08,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-15,2011-04-15,2011-04-17,2011-04-17,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2011-04-15,2011-04-15,2011-04-17,2011-04-17,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-22,2011-04-22,2011-04-22,2011-04-22,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2011-04-30,2011-04-30,2011-04-30,2011-04-30,30.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2011-05-20,2011-05-20,2011-05-20,2011-05-20,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2011-05-29,2011-05-29,2011-05-29,2011-05-29,59.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,SLEEP DISTURBANCES,Sleep disorder,PSYCHIATRIC DISORDERS,2011-06,,,,,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,PAIN SHOULDER,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08-12,2011-08-12,,,134.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-29,2011-05-29,2011-05-29,2011-05-29,59.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-052-002,01052002,052,71.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,INCREASED BODY TEMPERATURE,Body temperature increased,INVESTIGATIONS,2011-08,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-04,2011-06-04,2011-06-04,2011-06-04,4.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-08,2011-06-08,2011-06-09,2011-06-09,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-15,2011-06-15,2011-06-16,2011-06-16,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-22,2011-06-22,2011-06-24,2011-06-24,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-08,2011-07-08,2011-07-09,2011-07-09,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-04,2011-06-04,2011-06-04,2011-06-04,4.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-052-003,01052003,052,43.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NIGHTSWEAT,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06-01,2011-06-01,2011-06-07,2011-06-07,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-07-20,2011-07-20,2011-07-29,2011-07-29,-15.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,SAE TUMOUR PAIN AS A CONSEQUENCE OF PANCREATIC CANCER,Tumour pain,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-28,2011-07-28,,,-7.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,Y,Y,N
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYOPKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-01,2011-08-01,2011-08-05,2011-08-05,-3.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-052-004,01052004,052,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-28,2011-07-28,2011-07,,-7.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,POLYNEUROPATHIE,Polyneuropathy,NERVOUS SYSTEM DISORDERS,2012-03-19,2012-03-19,,,-3.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,N
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-30,2012-03-30,2012-04-03,2012-04-03,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HICCUP,Hiccups,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-06,2012-04-06,2012-04-15,2012-04-15,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,SLEEPINESS,Somnolence,NERVOUS SYSTEM DISORDERS,2012-04-13,2012-04-13,2012-04-16,2012-04-16,23.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,"NON REPORTED NASAL CONGESTION, COMMON SNIFF",Nasal congestion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-13,2012-04-13,2012-04-18,2012-04-18,23.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,HEPATOBILIARY INSUFFICIENCY CAUSE BY LIVER MTS,Metastases to liver,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-04-18,2012-04-18,,,28.0,N,UNLIKELY,2.0,2,2.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,LEUCOZYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-18,2012-04-18,2012-05-22,2012-05-22,28.0,N,UNLIKELY,2.0,2,2.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, NONE",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-052-007,01052007,052,56.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,THROMBOPENIE,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-29,2012-03-29,,,8.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA (CLINICALLY SIGNIFICANT),Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-25,2011-05-25,2011-05-30,2011-05-30,14.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOPENIA (CLINICALLY SIGNIFICANT),Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-25,2011-05-25,2011-06-06,2011-06-06,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CRP ELEVATION (CLINICALLY SIGNIFICANT),C-reactive protein increased,INVESTIGATIONS,2011-05-17,2011-05-17,2011-05-30,2011-05-30,6.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEUTROPENIA (CLINICALLY SIGNIFICANT),Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-06,2011-06-06,2011-06-08,2011-06-08,26.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-06-06,2011-06-06,2011-06-20,2011-06-20,26.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-06-08,2011-06-08,2011-06-22,2011-06-22,28.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CHOLANGITIS/ CHOLESTASE,Cholangitis,HEPATOBILIARY DISORDERS,2011-06-30,2011-06-30,2011-07-11,2011-07-11,50.0,Y,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CHOLANGITIS/ CHOLESTASE,Cholestasis,HEPATOBILIARY DISORDERS,2011-06-30,2011-06-30,2011-07-11,2011-07-11,50.0,Y,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,WORSENING OF GENERAL CONDITION,General physical health deterioration,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-18,2011-07-18,2011-07-20,2011-07-20,68.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,URINARY TRACT INFECTION WITH ECOLI,Escherichia urinary tract infection,INFECTIONS AND INFESTATIONS,2011-08-01,2011-08-01,2011-08-25,2011-08-25,82.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-08,2011-06-08,2011-06-21,2011-06-21,28.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,WORSENING OF GENERAL CONDITION,General physical health deterioration,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-29,2011-08-29,,,110.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,SPASMODIC STOMACHACHE,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-07-18,2011-07-18,2011-07-25,2011-07-25,68.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,MINOR NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-01,2011-08-01,2011-08-02,2011-08-02,82.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,LEUCOPENIA (CLINICALLY SIGNIFICANT),Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-25,2011-05-25,2011-05-30,2011-05-30,14.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,LEUCOPENIA (CLINICALLY SIGNIFICANT),Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-08,2011-08-08,85.0,N,DEFINITELY,4.0,4,4.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,CONTINUAL LOSS OF WEIGHT,Weight decreased,INVESTIGATIONS,2011-07-25,2011-07-25,,,75.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,LACK OF APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-07-25,2011-07-25,,,75.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,RENAL FAILURE,Renal failure,RENAL AND URINARY DISORDERS,2011-06-08,2011-06-08,2011-06-14,2011-06-14,28.0,N,NOT RELATED,1.0,2,2.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,THROMBOPENIA (CLINICALLY SIGNIFICANT),Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-04,2011-07-04,2011-07-11,2011-07-11,54.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,THROMBOPENIA (CLINICALLY SIGNIFICANT),Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-08,2011-08-08,85.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,NEUTROPENIA (CLINICALLY SIGNIFICANT),Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-04,2011-07-04,2011-07-18,2011-07-18,54.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,NEUTROPENIA (CLINICALLY SIGNIFICANT),Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-28,2011-07-28,2011-08-01,2011-08-01,78.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,HYPOCALIMIA (CLINICALLY SIGNIFICANT),Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-07-20,2011-07-20,2011-07-28,2011-07-28,70.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,INFARCTPNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2011-05-04,2011-05-04,2012-05-25,2012-05-25,-8.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,INCREASED CRP VALUE (CLINICAL SIGNIFICANT),C-reactive protein increased,INVESTIGATIONS,2011-06-06,2011-06-06,2011-08-23,2011-08-23,26.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,PRERENAL ACUTE RENAL FAILURE,Acute prerenal failure,RENAL AND URINARY DISORDERS,2011-08-01,2011-08-01,2011-08-25,2011-08-25,82.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,ANMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-05,2011-08-05,85.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,PANCREATIC DISFUNCTION,Pancreatic insufficiency,GASTROINTESTINAL DISORDERS,2011-08,,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,LEUCOPENIA (CLINICAL SIGNIFICANT),Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-06,2011-06-06,2011-06-08,2011-06-08,26.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,LEUCOPENIA (CLINICAL SIGNIFICANT),Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-28,2011-07-28,2011-08-04,2011-08-04,78.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,EXSICCOSIS,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-08-01,2011-08-01,2011-08-25,2011-08-25,82.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-053-001,01053001,053,69.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,ENTERITIS,Enteritis,GASTROINTESTINAL DISORDERS,2011-06-08,2011-06-08,2011-06-20,2011-06-20,28.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-14,2011-12-14,2012-01-04,2012-01-04,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-14,2011-12-14,2012-01-04,2012-01-04,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-18,2012-01-18,2012-01-25,2012-01-25,49.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,UNCLEAR INFECT NO ADDITIONAL INFO,Infection,INFECTIONS AND INFESTATIONS,2012-02-02,2012-02-02,2012-02-13,2012-02-13,64.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HYPOKALMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-25,2012-01-25,2012-02-02,2012-02-02,56.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,MILD FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2012-01-11,2012-01-11,2012-01-12,2012-01-12,42.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-053-002,01053002,053,73.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-01,2012-02-01,2012-02-02,2012-02-02,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-05,2011-01-05,2011-01-05,2011-01-05,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-05,2011-01-05,2011-01-05,2011-01-05,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SLEEP DISORDER,Sleep disorder,PSYCHIATRIC DISORDERS,2010-12-14,2010-12-14,,,-1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PLATELET COUNT INCREASED (CLINICAL SIGNIFICANT),Platelet count increased,INVESTIGATIONS,2011-01-05,2011-01-05,2011-01-12,2011-01-12,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2010-12-23,2010-12-23,2011-01-14,2011-01-14,9.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2010-12-19,2010-12-19,2011-01-08,2011-01-08,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-01-05,2011-01-05,,,22.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PLATELET COUNT DECREASED (CLINICAL SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2011-02-02,2011-02-02,,,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-26,2011-01-26,,,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-02-12,2011-02-12,2011-02-12,2011-02-12,60.0,Y,UNLIKELY,2.0,5,5.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,FATAL,Y,N,Y,Y
CO-101-001,CO-101-001-054-001,01054001,054,66.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-02-10,2011-02-10,2011-02-12,2011-02-12,58.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-22,2010-12-22,2011-01-05,2011-01-05,8.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2010-12-27,2010-12-27,2011-01-02,2011-01-02,13.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-01-03,2011-01-03,2011-01-20,2011-01-20,20.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PLATELET COUNT INCREASED CLINICAL SIGNIFICANT,Platelet count increased,INVESTIGATIONS,2011-01-05,2011-01-05,2011-01-19,2011-01-19,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2010-12-15,2010-12-15,,,1.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,TASTE ALTERATION,Dysgeusia,NERVOUS SYSTEM DISORDERS,2010-12-15,2010-12-15,2011-02-14,2011-02-14,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2010-12-15,2010-12-15,2011-02-14,2011-02-14,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-01-07,2011-01-07,2011-01-21,2011-01-21,24.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-01-20,2011-01-20,2011-01-24,2011-01-24,37.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,GASTRIC STENOSIS,Gastric stenosis,GASTROINTESTINAL DISORDERS,2011-02-16,2011-02-16,2011-02-17,2011-02-17,64.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-02,2011-02-02,2011-02-16,2011-02-16,50.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-02,2011-02-02,2011-03-09,2011-03-09,50.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-003,01054003,054,68.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,GASTRIC STENOSIS,Gastric stenosis,GASTROINTESTINAL DISORDERS,2011-02-08,2011-02-08,2011-02-15,2011-02-15,56.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-03,2011-03-03,2011-03-10,2011-03-10,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-24,2011-02-24,,,1.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,EMESIS,Vomiting,GASTROINTESTINAL DISORDERS,2011-02-24,2011-02-24,2011-03-13,2011-03-13,1.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,OBSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-02-24,2011-02-24,,,1.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,TASTE ALTERATION,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-02-24,2011-02-24,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-02-24,2011-02-24,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,"PAIN (BACK, ABDOMEN)",Abdominal pain,GASTROINTESTINAL DISORDERS,2011-02-24,2011-02-24,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,"PAIN (BACK, ABDOMEN)",Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-02-24,2011-02-24,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-054-005,01054005,054,49.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-24,2011-02-24,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,PLATELET COUNT DECREASED CLINICAL SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2011-03-14,2011-03-14,2011-03-25,2011-03-25,8.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2011-02-23,2011-02-23,2011-03-04,2011-03-04,-12.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-14,2011-03-14,2011-03-18,2011-03-18,8.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-14,2011-03-14,2011-03-18,2011-03-18,8.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-15,2011-03-15,2011-08-13,2011-08-13,9.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,OBSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-03-26,2011-03-26,2011-03-27,2011-03-27,20.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-05-09,2011-05-09,2011-07-21,2011-07-21,64.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-05-13,2011-05-13,,,68.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,PAIN CALVES,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-05-20,2011-05-20,,,75.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-04,2011-06-04,2011-08-12,2011-08-12,90.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CHILL,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-04,2011-06-04,2011-06-05,2011-06-05,90.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,HYPOFERREMIA,Iron deficiency,METABOLISM AND NUTRITION DISORDERS,2011-06-06,2011-06-06,2011-07-05,2011-07-05,92.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,HYPOCALCEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-06-06,2011-06-06,2011-07-05,2011-07-05,92.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,RASH ACNEIFORM,Dermatitis acneiform,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06-19,2011-06-19,,,105.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,EMESIS,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-13,2011-08-13,2011-08-13,2011-08-13,160.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-10,2011-07-10,,,126.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,HEARTBURN,Dyspepsia,GASTROINTESTINAL DISORDERS,2011-07-20,2011-07-20,,,136.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,PLATELET COUNT DECREASED CLINICAL SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2011-04-04,2011-04-04,2011-04-18,2011-04-18,29.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-01,2011-04-01,2011-04-04,2011-04-04,26.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-11,2011-04-11,2011-04-18,2011-04-18,36.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-23,2011-05-23,2011-05-26,2011-05-26,78.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,DECREASED PLATELET COUNT CLINICAL SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2011-05-23,2011-05-23,2011-08-02,2011-08-02,78.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,NOSE BLEED,Epistaxis,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-02-14,2011-02-14,2011-02-14,2011-02-14,-21.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-02-11,2011-02-11,2011-02-11,2011-02-11,-24.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-11,2011-02-11,2011-02-11,2011-02-11,-24.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,HEARTBURN,Dyspepsia,GASTROINTESTINAL DISORDERS,2011-02-27,2011-02-27,2011-02-27,2011-02-27,-8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-27,2011-02-27,2011-02-27,2011-02-27,-8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,ERUCTATION,Eructation,GASTROINTESTINAL DISORDERS,2011-02-27,2011-02-27,2011-02-27,2011-02-27,-8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,FEELING OF PRESSURE IN STOMACH,Abdominal discomfort,GASTROINTESTINAL DISORDERS,2011-02-27,2011-02-27,2011-02-27,2011-02-27,-8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,PAIN LOWER ABDOMEN,Abdominal pain lower,GASTROINTESTINAL DISORDERS,2011-03-16,2011-03-16,2011-03-24,2011-03-24,10.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-03-25,2011-03-25,2011-03,,19.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-11,2011-04-11,2011-04-18,2011-04-18,36.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,SPLENOMEGALY,Splenomegaly,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-18,2011-03-18,,,12.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,34.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-23,2011-05-23,2011-05-26,2011-05-26,78.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35.0,PAIN THORACIC SPINE,Spinal pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08,,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,36.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-21,2011-06-21,2011-09-06,2011-09-06,107.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,37.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-12,2011-07-12,2011-08-30,2011-08-30,128.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,38.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-28,2011-08-28,2011-08,,175.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,39.0,RED SKIN NOSE AND CHEST,Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-08,,,,,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-006,01054006,054,40.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40.0,TASTE ALTERATION,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-05-14,2011-05-14,2011-05-27,2011-05-27,69.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,"ERYTHEMA (ABDOMEN, BREAST)",Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06-30,2011-06-30,2011-10-07,2011-10-07,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-24,2011-06-24,,,8.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-08,2011-07-08,2011-07-29,2011-07-29,22.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-08,2011-07-08,2011-08-26,2011-08-26,22.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,INFECTION (URINARY TRACT),Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-06-17,2011-06-17,2011-10-07,2011-10-07,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DRY COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-12,2011-08-12,,,57.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-08-18,2011-08-18,,,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-08-20,2011-08-20,,,65.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07-29,2011-07-29,,,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NIGHT SWEATS,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-09-09,2011-09-09,,,85.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,DECREASED HEMOGLOBIN CLINICALLY SIGNIFICANT,Haemoglobin decreased,INVESTIGATIONS,2011-08-18,2011-08-18,2011-11-18,2011-11-18,63.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-06-17,2011-06-17,2011-07-15,2011-07-15,1.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,PAIN SPINE,Spinal pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-21,2011-07-21,2011-09-09,2011-09-09,35.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,FATIQUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-09,2011-09-09,2011-09-23,2011-09-23,85.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-16,2011-09-16,2011-10-07,2011-10-07,92.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,IRON DEFICIENCY,Iron deficiency,METABOLISM AND NUTRITION DISORDERS,2011-08-12,2011-08-12,2011-10-07,2011-10-07,57.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-11-02,2011-11-02,2011-11-03,2011-11-03,139.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-007,01054007,054,68.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,LUNG METASTASES OF PANCREATIC CARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-10-31,2011-10-31,2011-11-03,2011-11-03,137.0,Y,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,EXANTHEMA THORAX,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-28,2011-11-28,,,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,UNKNOWN,N,N,Y,Y
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-24,2011-11-24,2011-12-04,2011-12-04,1.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-02,2011-12-02,2011-12-04,2011-12-04,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-009,01054009,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-01,2011-12-01,2011-12-10,2011-12-10,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,UNSPECIFIED INFECTION,Infection,INFECTIONS AND INFESTATIONS,2011-12-16,2011-12-16,2011-12-22,2011-12-22,8.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-10,2011-12-10,2011-12-21,2011-12-21,2.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-10,2011-12-10,2011-12-21,2011-12-21,2.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-12-10,2011-12-10,2011-12-21,2011-12-21,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,COAGULATION TIME DECREASED,Coagulation time shortened,INVESTIGATIONS,2011-12-19,2011-12-19,2011-12-20,2011-12-20,11.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,SLEEP DISTURBANCE,Sleep disorder,PSYCHIATRIC DISORDERS,2011-12,,,,,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-12-09,2011-12-09,,,1.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-28,2011-12-28,2011-12-28,2011-12-28,20.0,Y,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,DSYPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-28,2011-12-28,2011-12-30,2011-12-30,20.0,Y,NOT RELATED,1.0,1,1.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,METEORISM,Flatulence,GASTROINTESTINAL DISORDERS,2011-12-20,2011-12-20,2011-12-20,2011-12-20,12.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,UNSPECIFIED INFECTION,Infection,INFECTIONS AND INFESTATIONS,2011-12-23,2011-12-23,,,15.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,INCREASED PAIN ABDOMEN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-12-16,2011-12-16,2011-12-22,2011-12-22,8.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,INCREASED PAIN ABDOMEN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-12-23,2011-12-23,2012-01-03,2012-01-03,15.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-01-04,2012-01-04,,,27.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-29,2011-12-29,2012-01-03,2012-01-03,21.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-12-16,2011-12-16,2011-12-22,2011-12-22,8.0,Y,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,CHOLESTASIS,Cholestasis,HEPATOBILIARY DISORDERS,2011-12-23,2011-12-23,,,15.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,ABDOMINAL CRAMPS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-12-20,2011-12-20,2011-12-20,2011-12-20,12.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-010,01054010,054,52.0,YEARS,M,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,INCREASED PAIN ABDOMEN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-01-04,2012-01-04,,,27.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-13,2012-01-13,2012-01-27,2012-01-27,29.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-13,2012-01-13,2012-01-27,2012-01-27,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-17,2012-02-17,2012-03-09,2012-03-09,64.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-17,2012-02-17,2012-03-09,2012-03-09,64.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,SKIN RASH FACE AND THORAX,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-02,,,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,BURNING SENSATION ORAL MUCOSA,Burning sensation mucosal,NERVOUS SYSTEM DISORDERS,2012-02,,2012-02,,,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-011,01054011,054,57.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02,,,,,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2012-02-03,2012-02-03,2012-02-03,2012-02-03,22.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FEELING OF PRESSURE UPPER ABDOMEN,Abdominal discomfort,GASTROINTESTINAL DISORDERS,2012-01-05,2012-01-05,2012-01-06,2012-01-06,-8.0,Y,NOT RELATED,1.0,1,1.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,N
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-05,2012-01-05,2012-01-06,2012-01-06,-8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-03,2012-02-03,,,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,FATIQUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-03,2012-02-03,,,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CARDIAC DECOMPENSATION,Cardiac failure,CARDIAC DISORDERS,2012-02-10,2012-02-10,2012-02-18,2012-02-18,29.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CARDIAC DECOMPENSATION,Cardiac failure,CARDIAC DISORDERS,2012-02-19,2012-02-19,2012-03-09,2012-03-09,38.0,Y,UNLIKELY,2.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-01-13,2012-01-13,2012-02-20,2012-02-20,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOPENIA CLINICAL SIGNIFICANT,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-27,2012-01-27,2012-02-10,2012-02-10,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DORSAL PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-27,2012-01-27,2012-02-09,2012-02-09,15.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,EDEMA LOWER LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-15,2012-02-15,,,34.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-19,2012-02-19,2012-02-24,2012-02-24,38.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,HYPOCALCEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-19,2012-02-19,2012-02-28,2012-02-28,38.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2012-02-19,2012-02-19,2012-03-09,2012-03-09,38.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,OBSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-02-19,2012-02-19,2012-02-23,2012-02-23,38.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,OBSTRUCTIVE BRONCHITIS,Bronchitis,INFECTIONS AND INFESTATIONS,2012-02-19,2012-02-19,,,38.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-054-012,01054012,054,76.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01,,2012-02-18,2012-02-18,,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,1.0,METASTASES TO SPINE WITH PARALYSIS APPEARENCE,Metastases to spine,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-03-22,2012-03-22,2012-03-28,2012-03-28,,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,N
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,2.0,METASTASES TO SPINE WITH PARALYSIS APPEARENCE,Spinal cord paralysis,NERVOUS SYSTEM DISORDERS,2012-03-22,2012-03-22,2012-03-28,2012-03-28,,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,N
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,3.0,MYELON EDEMA TO THORACIC VERTEBRA 4 AND 5 WITH PARALYSIS APPEARANCE,Spinal cord oedema,NERVOUS SYSTEM DISORDERS,2012-03-29,2012-03-29,2012-04-04,2012-04-04,,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,4.0,METASTASIS TO SPINE WITH PARALYSIS APPEARANCE,Metastases to spine,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-03-29,2012-03-29,,,,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,5.0,METASTASIS TO SPINE WITH PARALYSIS APPEARANCE,Spinal cord paralysis,NERVOUS SYSTEM DISORDERS,2012-03-29,2012-03-29,,,,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-03-27,2012-03-27,2012-04-10,2012-04-10,,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-054-015,01054015,054,69.0,YEARS,F,WHITE,5.0,DEU,GERMANY,Western Europe,2.0,N,Y,Y,N,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,,,Negative (Low),1.0,7.0,URINARY RETENTION,Urinary retention,RENAL AND URINARY DISORDERS,2012-03-26,2012-03-26,2012-04-10,2012-04-10,,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2010-07-27,2010-07-27,2010-07-27,2010-07-27,-9.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,"NAUSEA, BELCHING",Eructation,GASTROINTESTINAL DISORDERS,2010-08-05,2010-08-05,2010-08-30,2010-08-30,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,"NAUSEA, BELCHING",Nausea,GASTROINTESTINAL DISORDERS,2010-08-05,2010-08-05,2010-08-30,2010-08-30,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,INSULIN DEPENDENT DIABETES MELLITUS,Type 1 diabetes mellitus,METABOLISM AND NUTRITION DISORDERS,2010-08-19,2010-08-19,2010-08-31,2010-08-31,15.0,Y,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-09-02,2010-09-02,2010-09-09,2010-09-09,29.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-09-09,2010-09-09,2010-09-16,2010-09-16,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,PLATELET DECREASING (CLINICALLY SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2010-12-09,2010-12-09,2010-12-23,2010-12-23,127.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,CANDIDA INFECTION,Candidiasis,INFECTIONS AND INFESTATIONS,2010-10-21,2010-10-21,2010-10-28,2010-10-28,78.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,NEUTROPENIA AND LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-11,2010-11-11,2010-11-25,2010-11-25,99.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,NEUTROPENIA AND LEUCOPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-11,2010-11-11,2010-11-25,2010-11-25,99.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-01-01,2011-01-01,2011-01-02,2011-01-02,150.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01-11,2011-01-11,2011-01-12,2011-01-12,160.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-16,2011-01-16,2011-01-21,2011-01-21,165.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,GASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-01-25,2011-01-25,,,174.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-24,2011-02-24,2011-03-03,2011-03-03,204.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-03,2011-03-03,2011-03-10,2011-03-10,211.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,DYSPEPSIA,Dyspepsia,GASTROINTESTINAL DISORDERS,2011-02-24,2011-02-24,2011-03-03,2011-03-03,204.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-31,2011-03-31,2011-04-07,2011-04-07,239.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-09-02,2010-09-02,2010-09-09,2010-09-09,29.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-09-09,2010-09-09,2010-09-16,2010-09-16,36.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,ORAL APHTA,Aphthous stomatitis,GASTROINTESTINAL DISORDERS,2011-03-17,2011-03-17,2011-03-31,2011-03-31,225.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,DIABETES,Diabetes mellitus,METABOLISM AND NUTRITION DISORDERS,2010-08-31,2010-08-31,,,27.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-21,2011-04-21,2011-05-05,2011-05-05,260.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-12,2011-05-12,,,281.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,25.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-10,2011-03-10,2011-03-16,2011-03-16,218.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,26.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-05,2011-05-05,2011-05-12,2011-05-12,274.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,27.0,RESTLESSNESS,Restlessness,PSYCHIATRIC DISORDERS,2010-08-21,2010-08-21,,,17.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,28.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2010-09-09,2010-09-09,,,36.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,29.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-10-16,2010-10-16,2010-10-23,2010-10-23,73.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,30.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2010-09-16,2010-09-16,,,43.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-055-001,01055001,055,72.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,31.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-18,2010-11-18,2010-11-25,2010-11-25,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-09-05,2010-09-05,2010-09-05,2010-09-05,-4.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-09-10,2010-09-10,2010-09-12,2010-09-12,2.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-09-22,2010-09-22,,,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ALT INCREASING (CONFIRMED),Alanine aminotransferase increased,INVESTIGATIONS,2010-09-23,2010-09-23,2010-10-07,2010-10-07,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,GGT INCREASING (CONFIRMED),Gamma-glutamyltransferase increased,INVESTIGATIONS,2010-10-09,2010-10-09,,,31.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HIGH BLOOD PRESSURE,Hypertension,VASCULAR DISORDERS,2010-09-09,2010-09-09,2010-09-09,2010-09-09,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ITCH,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-09-19,2010-09-19,,,11.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,SLEEPLESSNESS,Insomnia,PSYCHIATRIC DISORDERS,2010-09-11,2010-09-11,,,3.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,COLITIS,Colitis,GASTROINTESTINAL DISORDERS,2010-09-11,2010-09-11,,,3.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,TEETH PAIN,Toothache,GASTROINTESTINAL DISORDERS,2010-10-01,2010-10-01,2010-10-02,2010-10-02,23.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,BILIRUBIN INCREASE (CLINICALLY SIGNIFICANT),Blood bilirubin increased,INVESTIGATIONS,2010-11-18,2010-11-18,,,71.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DISURIA,Dysuria,RENAL AND URINARY DISORDERS,2010-09-23,2010-09-23,2010-09-30,2010-09-30,15.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,UROBILINOGEN IN URINE INCREASE (CLINICALLY SIGNIFICANT),Urobilinogen urine increased,INVESTIGATIONS,2010-09-23,2010-09-23,2010-10-07,2010-10-07,15.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-004,01055004,055,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,HEPATOMEGALIA,Hepatomegaly,HEPATOBILIARY DISORDERS,2010-10-07,2010-10-07,,,29.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-055-005,01055005,055,37.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,COSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2010-10-07,2010-10-07,,,8.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-055-005,01055005,055,37.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2010-10-17,2010-10-17,2010-11-11,2010-11-11,18.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-005,01055005,055,37.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-18,2010-11-18,2010-11-18,2010-11-18,50.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-005,01055005,055,37.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HEPATOMEGALIA,Hepatomegaly,HEPATOBILIARY DISORDERS,2010-11-04,2010-11-04,,,36.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-055-006,01055006,055,43.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11-06,2010-11-06,2010-11-06,2010-11-06,17.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-006,01055006,055,43.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,HIGH LEVEL OF GGT (CONFIRMED),Gamma-glutamyltransferase increased,INVESTIGATIONS,2010-11-04,2010-11-04,,,15.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-055-006,01055006,055,43.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2010-10-23,2010-10-23,,,3.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-055-006,01055006,055,43.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FLU,Influenza,INFECTIONS AND INFESTATIONS,2011-01-30,2011-01-30,2011-02-02,2011-02-02,102.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-006,01055006,055,43.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-01-30,2011-01-30,2011-02-07,2011-02-07,102.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-02-08,2011-02-08,2011-02-08,2011-02-08,-9.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-20,2011-02-20,2011-02-20,2011-02-20,4.0,Y,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-05,2011-03-05,2011-03-06,2011-03-06,17.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HIGH ALP (CLINICALLY SIGNIFICANT),Blood alkaline phosphatase increased,INVESTIGATIONS,2011-03-16,2011-03-16,,,28.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HIGH GGT (CLINICALLY SIGNIFICANT),Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-03-16,2011-03-16,,,28.0,N,POSSIBLE/PROBABLE,3.0,4,4.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,RESTLESNESS,Restlessness,PSYCHIATRIC DISORDERS,2011-03-16,2011-03-16,2011-03-16,2011-03-16,28.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ALT INCREASE (CLINICALLY SIGNIFICANT),Alanine aminotransferase increased,INVESTIGATIONS,2011-03-24,2011-03-24,,,36.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-20,2011-02-20,2011-02-22,2011-02-22,4.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PROTEINE C REACTIVE INCREASED (CLINICALLY SIGNIFICANT,C-reactive protein increased,INVESTIGATIONS,2011-02-20,2011-02-20,2011-02-28,2011-02-28,4.0,Y,NOT RELATED,1.0,,,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,LEUKOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-03,2011-03-03,,,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-17,2011-02-17,,,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2011-03-24,2011-03-24,,,36.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,WATER RETENTION,Fluid retention,METABOLISM AND NUTRITION DISORDERS,2011-04-05,2011-04-05,,,48.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-02-17,2011-02-17,2011-02-26,2011-02-26,1.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-008,01055008,055,48.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-19,2011-02-19,2011-02-19,2011-02-19,3.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-26,2011-05-26,2011-06-01,2011-06-01,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,HYPERTENSIVE CRISIS,Hypertensive crisis,VASCULAR DISORDERS,2011-05-26,2011-05-26,2011-05-26,2011-05-26,15.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-16,2011-06-16,,,36.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-23,2011-06-23,2011-07-04,2011-07-04,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-055-010,01055010,055,70.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-06-30,2011-06-30,,,50.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-06,2011-05-06,2011-05-06,2011-05-06,9.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOPENY,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-11,2011-05-11,2011-05-25,2011-05-25,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-05-16,2011-05-16,2011-05-20,2011-05-20,19.0,Y,NOT RELATED,1.0,4,4.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DEEP VEIN THROMBOSIS RIGHT LEG,Deep vein thrombosis,VASCULAR DISORDERS,2011-05-16,2011-05-16,2011-05-20,2011-05-20,19.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DEEP VEIN THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-07-03,2011-07-03,2011-07-06,2011-07-06,67.0,Y,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-02,2011-05-02,2011-05-02,2011-05-02,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-08,2011-06-08,2011-06-08,2011-06-08,42.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-09,2011-06-09,2011-06-09,2011-06-09,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-15,2011-06-15,2011-06-29,2011-06-29,49.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-06-23,2011-06-23,2011-06-29,2011-06-29,57.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-30,2011-06-30,2011-06-30,2011-06-30,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-001,01056001,056,61.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HEPATIC TOXICITY,Hepatotoxicity,HEPATOBILIARY DISORDERS,2011-05-11,2011-05-11,,,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-05-25,2011-05-25,2011-06-06,2011-06-06,7.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,"OTHER, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-26,2011-05-26,,,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-05-05,2011-05-05,2011-05-19,2011-05-19,-14.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-06-15,2011-06-15,,,28.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,JAUNDICE,Jaundice,HEPATOBILIARY DISORDERS,2011-06-29,2011-06-29,2011-07-08,2011-07-08,42.0,Y,UNLIKELY,2.0,3,3.0,DRUG WITHDRAWN,,INTERMITTENT,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-056-002,01056002,056,79.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-05-26,2011-05-26,2011-05-31,2011-05-31,8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-14,2011-07-14,2011-08-12,2011-08-12,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-07-16,2011-07-16,2011-07-19,2011-07-19,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-21,2011-07-21,2011-08-18,2011-08-18,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-27,2011-07-27,2011-09-07,2011-09-07,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-03,2011-08-03,2011-08-10,2011-08-10,21.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-16,2011-08-16,2011-08-18,2011-08-18,34.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,TACHICARDIA,Tachycardia,CARDIAC DISORDERS,2011-08-27,2011-08-27,2011-08-27,2011-08-27,45.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,SWELLING AT INJECTION OF EPREX,Injection site swelling,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-31,2011-08-31,,,49.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-05,2011-09-05,2011-09-07,2011-09-07,54.0,N,UNLIKELY,2.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-056-003,01056003,056,56.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HEPATIC TOXICITY,Hepatotoxicity,HEPATOBILIARY DISORDERS,2011-07-20,2011-07-20,,,7.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,THROMBOCITOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-11,2011-11-11,2011-11-18,2011-11-18,8.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-11-11,2011-11-11,,,8.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-11,2011-11-11,2011-11-18,2011-11-18,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PULMONARY EMBOLYSM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-05,2011-12-05,,,32.0,Y,POSSIBLE/PROBABLE,3.0,4,4.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,Y,Y,Y
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-20,2011-11-20,2011-12-14,2011-12-14,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,THROMBOCITOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-30,2011-12-30,2012-01-19,2012-01-19,57.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-059-003,01059003,059,71.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-18,2011-11-18,,,15.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-29,2011-04-29,2011-05-06,2011-05-06,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-29,2011-04-29,2011-05-05,2011-05-05,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-06,2011-05-06,2011-05-13,2011-05-13,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-29,2011-04-29,2011-05-02,2011-05-02,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DERMATITIS,Dermatitis,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-04-23,2011-04-23,2011-05-13,2011-05-13,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-27,2011-05-27,2011-06-10,2011-06-10,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-27,2011-05-27,2011-06-03,2011-06-03,36.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,WBC DECREASED CLINICALLY SIGNIFICANT,White blood cell count decreased,INVESTIGATIONS,2011-04-29,2011-04-29,2011-05-06,2011-05-06,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-08,2011-07-08,2011-07-22,2011-07-22,78.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-05,2011-08-05,2011-08-26,2011-08-26,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-01,2011-07-01,2011-07-08,2011-07-08,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,BASOCELLULAR CARCINOMA RIGHT LEG,Basal cell carcinoma,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-01,2011-07-01,2011-07-01,2011-07-01,71.0,N,NOT RELATED,1.0,1,1.0,,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-22,2011-07-22,2011-08-18,2011-08-18,92.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-19,2011-08-19,2011-09-02,2011-09-02,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-22,2011-07-22,2011-07-23,2011-07-23,92.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-28,2011-10-28,2012-01-18,2012-01-18,190.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-28,2011-10-28,2012-01-18,2012-01-18,190.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-002,01060002,060,77.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-28,2011-10-28,2012-01-18,2012-01-18,190.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-20,2011-05-20,,,16.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,MILD TACHCARDIA,Tachycardia,CARDIAC DISORDERS,2011-05-05,2011-05-05,,,1.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,LIPOTIMIC EPISODE,Syncope,NERVOUS SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-06-22,2011-06-22,49.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-06-23,2011-06-23,49.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-003,01060003,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-23,2011-06-23,2011-07-01,2011-07-01,50.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-18,2011-07-18,2011-07-18,2011-07-18,5.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-005,01060005,060,66.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-29,2011-07-29,2011-08-05,2011-08-05,16.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-10,2011-10-10,2011-10-18,2011-10-18,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-02,2011-11-02,2011-11-09,2011-11-09,31.0,N,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-04,2012-01-04,2012-01-11,2012-01-11,94.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PULMONARY EMBOLISM ASYMPTOMATIC,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-06,2011-09-06,,,-27.0,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,N
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HEMORRAGIC SHOCK,Shock haemorrhagic,VASCULAR DISORDERS,2011-09-06,2011-09-06,2011-09-07,2011-09-07,-27.0,Y,NOT RELATED,1.0,4,4.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-060-007,01060007,060,69.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CLINICAL DETERIORATION,General physical health deterioration,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-24,2012-02-24,,,145.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-060-008,01060008,060,73.0,YEARS,M,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,PERITONITIS,Peritonitis,INFECTIONS AND INFESTATIONS,2011-10-29,2011-10-29,2011-10-30,2011-10-30,9.0,Y,UNLIKELY,2.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-22,2012-02-22,2012-03-16,2012-03-16,8.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,RIGHT LEG OEDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-23,2012-03-23,,,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-060-009,01060009,060,77.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-24,2012-03-24,2012-03-25,2012-03-25,39.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-04-03,2012-04-03,2012-04-10,2012-04-10,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-10,2012-04-10,2012-04-30,2012-04-30,36.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-01,2012-05-01,2012-05-09,2012-05-09,57.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-16,2012-05-16,2012-06-06,2012-06-06,72.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-060-010,01060010,060,82.0,YEARS,F,WHITE,5.0,ITA,ITALY,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PORTAL VEIN THROMBOSIS,Portal vein thrombosis,HEPATOBILIARY DISORDERS,2012-04-24,2012-04-24,,,50.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,LOWER TORSO PAIN,Pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-09,2011-05-09,,,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-05-04,2011-05-04,2011-05-09,2011-05-09,-5.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-05-09,2011-05-09,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-05-04,2011-05-04,2011-05-08,2011-05-08,-5.0,Y,NOT RELATED,1.0,4,4.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,BILIARY SEPSIS,Biliary sepsis,INFECTIONS AND INFESTATIONS,2011-05-13,2011-05-13,2011-05-24,2011-05-24,5.0,Y,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-05-09,2011-05-09,,,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-05-13,2011-05-13,2011-05-18,2011-05-18,5.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-04-20,2011-04-20,,,-19.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-05-13,2011-05-13,2011-05-29,2011-05-29,5.0,Y,UNLIKELY,2.0,5,5.0,,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-05-13,2011-05-13,2011-05-24,2011-05-24,5.0,Y,UNLIKELY,2.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,ALKALINE PHOSPHATASE ELEVATED - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-04-20,2011-04-20,,,-19.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-10,2011-05-10,,,2.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-05-13,2011-05-13,2011-05-15,2011-05-15,5.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-001,01062001,062,71.0,YEARS,F,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-05-13,2011-05-13,2011-05-24,2011-05-24,5.0,Y,UNLIKELY,2.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED","CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-13,2011-08-13,2011-08-14,2011-08-14,-10.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-08,2011-08-08,2011-08-12,2011-08-12,-15.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-15,2011-08-15,2011-09-12,2011-09-12,-8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-24,2011-08-24,2011-09-05,2011-09-05,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,PELVIC PAIN,Pelvic pain,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2011-08-20,2011-08-20,2011-09-12,2011-09-12,-3.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,FEET EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-24,2011-08-24,,,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-05,2011-09-05,2011-09-12,2011-09-12,14.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-09-01,2011-09-01,2011-09-07,2011-09-07,10.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-09,2011-09-09,,,18.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,PETECHIAL LEFT LEG RASH,Petechiae,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-09-11,2011-09-11,,,20.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-09-09,2011-09-09,,,18.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-30,2011-08-30,2011-09-19,2011-09-19,8.0,N,DEFINITELY,4.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-10-05,2011-10-05,,,44.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-09-05,2011-09-05,2011-10-04,2011-10-04,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-12,2011-09-12,2011-09-19,2011-09-19,21.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,BILIARY SEPSIS,Biliary sepsis,INFECTIONS AND INFESTATIONS,2011-09-25,2011-09-25,2011-10-13,2011-10-13,34.0,Y,NOT RELATED,1.0,2,2.0,"DRUG INTERRUPTED, DRUG WITHDRAWN","CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-09-27,2011-09-27,2011-10-12,2011-10-12,36.0,N,UNLIKELY,2.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-26,2011-09-26,2011-09-28,2011-09-28,35.0,N,UNLIKELY,2.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-29,2011-09-29,,,38.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,HAND CRAMPING,Muscle spasms,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08-23,2011-08-23,2011-08-30,2011-08-30,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-003,01062003,062,78.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,WORSENING OF METASTATIC ADENOCARCINOMA OF PANCREAS,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-09-27,2011-09-27,,,36.0,N,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,"HEAD, ABDOMINAL AND LOWER BACK PAIN",Abdominal pain,GASTROINTESTINAL DISORDERS,2011-11-09,2011-11-09,,,1.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,"HEAD, ABDOMINAL AND LOWER BACK PAIN",Headache,NERVOUS SYSTEM DISORDERS,2011-11-09,2011-11-09,,,1.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,"HEAD, ABDOMINAL AND LOWER BACK PAIN",Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-09,2011-11-09,,,1.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-16,2011-11-16,2011-11-22,2011-11-22,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPOMAGNESEMIA,Hypomagnesaemia,METABOLISM AND NUTRITION DISORDERS,2011-11-16,2011-11-16,2011-11-22,2011-11-22,8.0,N,UNLIKELY,2.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-04,2011-12-04,2011-12-05,2011-12-05,26.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-10,2011-12-10,2011-12-11,2011-12-11,32.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-14,2011-12-14,2011-12-22,2011-12-22,36.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,THROMBOSIS OF LEFT COMMON FEMORAL VEIN,Deep vein thrombosis,VASCULAR DISORDERS,2011-12-14,2011-12-14,,,36.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CELLULITIS OF LEFT LOWER LEG,Cellulitis,INFECTIONS AND INFESTATIONS,2012-01-25,2012-01-25,2012-02-04,2012-02-04,78.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-25,2012-01-25,2012-02-02,2012-02-02,78.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-22,2012-01-22,2012-01-25,2012-01-25,75.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,DIARRHEOA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-15,2012-02-15,2012-02-22,2012-02-22,99.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-09,2012-02-09,2012-02-10,2012-02-10,93.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-01-25,2012-01-25,2012-02-15,2012-02-15,78.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-02-16,2012-02-16,2012-03-01,2012-03-01,100.0,N,UNLIKELY,2.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,EAR INFECTION,Ear infection,INFECTIONS AND INFESTATIONS,2012-02-08,2012-02-08,2012-02-22,2012-02-22,92.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-03-07,2012-03-07,,,120.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-03-07,2012-03-07,,,120.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2012-03-07,2012-03-07,,,120.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-07,2012-03-07,,,120.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,RIGHT LOWER LEG PAIN,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-15,2012-01-15,2012-02-04,2012-02-04,68.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,CLINICAL WORSENING OF METASTATIC ADENOCARCINOMA OF PANCREAS,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-03-07,2012-03-07,2012-04-13,2012-04-13,120.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-03-04,2012-03-04,,,117.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-004,01062004,062,59.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,GASTIC OUTLET OBSTRUCTION,Obstruction gastric,GASTROINTESTINAL DISORDERS,2011-10-21,2011-10-21,2011-10-28,2011-10-28,-19.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-21,2011-11-21,2011-11-28,2011-11-28,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-11-22,2011-11-22,2011-11-25,2011-11-25,2.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-11-22,2011-11-22,2011-11-24,2011-11-24,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DRY MOUTH,Dry mouth,GASTROINTESTINAL DISORDERS,2011-11-22,2011-11-22,2011-12-12,2011-12-12,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ELEVATED ALKALINE PHOPHATASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-11-28,2011-11-28,,,8.0,N,POSSIBLE/PROBABLE,3.0,4,4.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ELEVATED ASPARTATE TRANSAMINASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-11-28,2011-11-28,2011-12-05,2011-12-05,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-11-28,2011-11-28,2011-12-02,2011-12-02,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-12-02,2011-12-02,2011-12-05,2011-12-05,12.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2011-12-26,2011-12-26,2011-12-31,2011-12-31,36.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-16,2012-01-16,2012-01-17,2012-01-17,57.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-23,2012-01-23,2012-01-30,2012-01-30,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2012-01-16,2012-01-16,2012-01-18,2012-01-18,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,SKIN IRRITATION AT SITE OF CANNULATION,Catheter site inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-30,2012-01-30,2012-02-16,2012-02-16,71.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,BLOCKED STENT (RAISED BILIRUBIN),Blood bilirubin increased,INVESTIGATIONS,2012-02-19,2012-02-19,2012-02-27,2012-02-27,91.0,Y,UNLIKELY,2.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,BLOCKED STENT (RAISED BILIRUBIN),Device occlusion,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-19,2012-02-19,2012-02-27,2012-02-27,91.0,Y,UNLIKELY,2.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-27,2012-02-27,2012-03-19,2012-03-19,99.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-13,2012-03-13,,,114.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,BILATERAL LEG OEDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-13,2012-03-13,,,114.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2012-01-24,2012-01-24,2012-01-26,2012-01-26,65.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,HOARSENESS,Dysphonia,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-20,2012-03-20,2012-03-29,2012-03-29,121.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,SPRAINED RIGHT ANKLE,Ligament sprain,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-03-22,2012-03-22,2012-04-18,2012-04-18,123.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-04-18,2012-04-18,,,150.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-04-23,2012-04-23,2012-04-25,2012-04-25,155.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,DRY PAINFUL EYES,Dry eye,EYE DISORDERS,2012-05-04,2012-05-04,2012-05-08,2012-05-08,166.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,25.0,DRY PAINFUL EYES,Eye pain,EYE DISORDERS,2012-05-04,2012-05-04,2012-05-08,2012-05-08,166.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,26.0,RIGHT UPPER LEG PAIN,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-05-12,2012-05-12,,,174.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,27.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-05,2011-12-05,,,15.0,N,UNLIKELY,2.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,28.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-07-17,2012-07-17,2012-07-20,2012-07-20,240.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,29.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-08-05,2012-08-05,2012-08-06,2012-08-06,259.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,30.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-08-06,2012-08-06,,,260.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,31.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-08-08,2012-08-08,,,262.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,32.0,STOMACH PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-09-10,2012-09-10,,,295.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,33.0,PAIN IN FINGERTIPS AND TOES,,,2012-09-24,2012-09-24,2012-10-08,2012-10-08,309.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-005,01062005,062,75.0,YEARS,F,OTHER,99.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,34.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-10-08,2012-10-08,2012-10-09,2012-10-09,323.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-30,2011-11-30,2011-12-05,2011-12-05,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,CHEST INFECTION,Lower respiratory tract infection,INFECTIONS AND INFESTATIONS,2011-11-29,2011-11-29,2011-12-12,2011-12-12,2.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-12,2011-12-12,2012-01-03,2012-01-03,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ELEVATED ASPARTATE AMINOTRANSFERASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-12,2011-12-12,,,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ELEVATED ALANINE AMINOTRANSFERASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-12-05,2011-12-05,,,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-19,2011-12-19,2012-01-03,2012-01-03,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,DIZZINESS CAUSED BY INNER EAR INFECTION,Labyrinthitis,INFECTIONS AND INFESTATIONS,2012-01-03,2012-01-03,2012-02-06,2012-02-06,37.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-03,2012-02-03,2012-02-04,2012-02-04,68.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-27,2012-02-27,2012-03-25,2012-03-25,92.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2012-03-05,2012-03-05,,,99.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2012-03-07,2012-03-07,2012-03-08,2012-03-08,101.0,Y,UNLIKELY,2.0,2,2.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-15,2012-03-15,2012-05-28,2012-05-28,109.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-15,2012-03-15,2012-03-16,2012-03-16,109.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-15,2012-03-15,2012-03-16,2012-03-16,109.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-27,2012-03-27,,,121.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-02,2012-04-02,2012-04-23,2012-04-23,127.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-02,2012-04-02,2012-04-23,2012-04-23,127.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-04-21,2012-04-21,2012-04-22,2012-04-22,146.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-04-21,2012-04-21,2012-04-22,2012-04-22,146.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-13,2012-04-13,2012-04-14,2012-04-14,138.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-21,2012-04-21,2012-04-22,2012-04-22,146.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-04-02,2012-04-02,2012-05-20,2012-05-20,127.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-04-23,2012-04-23,2012-05-21,2012-05-21,148.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,CHEST INFECTION,Lower respiratory tract infection,INFECTIONS AND INFESTATIONS,2012-04-24,2012-04-24,2012-05-01,2012-05-01,149.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,25.0,DYSPNOEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-24,2012-04-24,2012-05-01,2012-05-01,149.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,26.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-24,2012-04-24,2012-05-01,2012-05-01,149.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,27.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-05-01,2012-05-01,2012-05-09,2012-05-09,156.0,Y,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,28.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-05-21,2012-05-21,,,176.0,Y,UNLIKELY,2.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,29.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-28,2012-05-28,,,183.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,30.0,ELEVATED BLOOD BILIRUBIN - CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2012-05-28,2012-05-28,,,183.0,N,UNLIKELY,2.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,31.0,GEMCITABINE-INDUCED PULMONARY FIBROSIS,Pulmonary fibrosis,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-05-29,2012-05-29,2012-07-02,2012-07-02,184.0,Y,DEFINITELY,4.0,5,5.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,32.0,INNER EAR INFECTION,Labyrinthitis,INFECTIONS AND INFESTATIONS,2011-12-26,2011-12-26,2012-02-06,2012-02-06,29.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,33.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-23,2012-01-23,2012-02-05,2012-02-05,57.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,34.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-30,2012-01-30,2012-02-05,2012-02-05,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,35.0,INDIGESTION,Dyspepsia,GASTROINTESTINAL DISORDERS,2012-01-30,2012-01-30,2012-02-19,2012-02-19,64.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,36.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-05-28,2012-05-28,,,183.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,37.0,PROGRESSION OF METASTATIC ADENOCARCINOMA OF PANCREAS,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-05-29,2012-05-29,2012-07-02,2012-07-02,184.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-062-006,01062006,062,41.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,38.0,BILIARY OBSTRUCTION,Bile duct obstruction,HEPATOBILIARY DISORDERS,2012-05-29,2012-05-29,2012-06-02,2012-06-02,184.0,Y,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-13,2012-01-13,2012-01-14,2012-01-14,-3.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-13,2012-01-13,,,-3.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DYSPNOEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-16,2012-01-16,,,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-007,01062007,062,69.0,YEARS,F,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DIARRHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-13,2012-01-13,2012-01-14,2012-01-14,-3.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-01,2012-02-01,2012-02-03,2012-02-03,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-14,2012-02-14,2012-02-27,2012-02-27,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,WIND,Flatulence,GASTROINTESTINAL DISORDERS,2012-02-27,2012-02-27,,,27.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,SENSORY NEUROPATHY - TINGLINESS IN RIGHT FINGERS,Peripheral sensory neuropathy,NERVOUS SYSTEM DISORDERS,2012-03-03,2012-03-03,2012-03-26,2012-03-26,32.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-08,2012-05-08,2012-05-21,2012-05-21,98.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-08,2012-05-08,2012-05-21,2012-05-21,98.0,N,POSSIBLE/PROBABLE,3.0,4,4.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-05-02,2012-05-02,2012-05-06,2012-05-06,92.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-12,2012-03-12,2012-03-15,2012-03-15,41.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-04-03,2012-04-03,2012-05-21,2012-05-21,63.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-05-21,2012-05-21,,,111.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-02,2012-07-02,,,153.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-28,2012-05-28,2012-06-04,2012-06-04,118.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-03,2012-03-03,2012-07-20,2012-07-20,32.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-009,01062009,062,55.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-10,2012-07-10,2012-07-23,2012-07-23,161.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,INFUSION-RELATED REACTION,Infusion related reaction,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-02-08,2012-02-08,2012-02-12,2012-02-12,1.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-15,2012-02-15,,,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DRY MOUTH,Dry mouth,GASTROINTESTINAL DISORDERS,2012-02-15,2012-02-15,,,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-08,2012-02-08,2012-02-12,2012-02-12,1.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,INFUSION-RELATED REACTION,Infusion related reaction,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-02-15,2012-02-15,2012-02-17,2012-02-17,8.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-06,2012-03-06,,,28.0,N,UNLIKELY,2.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,INFUSION-RELATED REACTION,Infusion related reaction,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-03-07,2012-03-07,2012-03-09,2012-03-09,29.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-062-010,01062010,062,63.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-08,2012-02-08,2012-02-09,2012-02-09,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-03-05,2012-03-05,2012-03-26,2012-03-26,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,LEFT QUADRANT PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-03-03,2012-03-03,2012-03-26,2012-03-26,6.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-05,2012-03-05,2012-03-12,2012-03-12,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-03-05,2012-03-05,2012-03-26,2012-03-26,8.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,RASH ON ARMS,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-03-26,2012-03-26,2012-04-02,2012-04-02,29.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-04-02,2012-04-02,2012-04-11,2012-04-11,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-04-11,2012-04-11,2012-04-23,2012-04-23,45.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DIARRHEOA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-04-25,2012-04-25,2012-07-26,2012-07-26,59.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-04-30,2012-04-30,2012-06-06,2012-06-06,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-05-21,2012-05-21,2012-05-28,2012-05-28,85.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-30,2012-03-30,2012-06-29,2012-06-29,33.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,DYSPNOEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-05-21,2012-05-21,2012-05-28,2012-05-28,85.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-21,2012-05-21,2012-08-12,2012-08-12,85.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-06-01,2012-06-01,2012-06-02,2012-06-02,96.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,BILATERAL ANKLE OEDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-01,2012-06-01,,,96.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-06-25,2012-06-25,,,120.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,HYPOMAGNESEMIA,Hypomagnesaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-29,2012-06-29,,,124.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-07-16,2012-07-16,,,141.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-07-16,2012-07-16,,,141.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-07-17,2012-07-17,2012-07-18,2012-07-18,142.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2012-07-19,2012-07-19,2012-09-10,2012-09-10,144.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,DYSNOEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-07-19,2012-07-19,2012-07-30,2012-07-30,144.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-08-13,2012-08-13,,,169.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,MUSCLE WEAKNESS,Muscular weakness,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-08-13,2012-08-13,,,169.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,DYSNOEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-08-13,2012-08-13,,,169.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-062-012,01062012,062,60.0,YEARS,M,ASIAN,2.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2012-08-13,2012-08-13,,,169.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-29,2012-02-29,2012-03-07,2012-03-07,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2012-02-29,2012-02-29,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CEREBREAL VASCULAR EVENT,Cerebrovascular accident,NERVOUS SYSTEM DISORDERS,2012-03-17,2012-03-17,2012-03-26,2012-03-26,18.0,Y,UNLIKELY,2.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2012-03-17,2012-03-17,2012-03-26,2012-03-26,18.0,Y,UNLIKELY,2.0,5,5.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,VOMTING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-06,2012-03-06,2012-03-07,2012-03-07,7.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-17,2012-03-17,2012-03-18,2012-03-18,18.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HICCUPS,Hiccups,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-18,2012-03-18,2012-03-19,2012-03-19,19.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,TACHYCARDIC SECONDARY TO DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2012-03-18,2012-03-18,,,19.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,TACHYCARDIC SECONDARY TO DEHYDRATION,Tachycardia,CARDIAC DISORDERS,2012-03-18,2012-03-18,,,19.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-062-013,01062013,062,68.0,YEARS,M,WHITE,5.0,GBR,UNITED KINGDOM,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DYSARTHRIA,Dysarthria,NERVOUS SYSTEM DISORDERS,2012-03-17,2012-03-17,,,18.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,DISTAL BILE DUCT STRICTURE,Bile duct stenosis,HEPATOBILIARY DISORDERS,2011-06-04,2011-06-04,2011-06-10,2011-06-10,3.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-16,2011-06-16,,,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-16,2011-06-16,,,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,OTHER,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-02,2011-06-02,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BLOATING,Abdominal distension,GASTROINTESTINAL DISORDERS,2011-07-12,2011-07-12,,,41.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-06-16,2011-06-16,,,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-063-002,01063002,063,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,METASTATIC PANCREATIC ADENOCARCINOMA SYMPTOMATIC DETERIORATION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-29,2011-07-29,,,58.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,DECREASED PLATELETS (THROMBOCYTOPENIA) - CLINICALLY SIGNIFICANT,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-16,2011-12-16,2011-12-22,2011-12-22,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,DECREASED HEMOGLOBIN (ANEMIA) - CLINICALLY SIGNIFICANT,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-22,2011-12-22,,,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DECREASED HEMATOCRIT - CLINCALLY SIGNIFICANT,Haematocrit decreased,INVESTIGATIONS,2011-12-22,2011-12-22,,,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,INCREASED WBC - CLINICALLY SIGNIFICANT,White blood cell count increased,INVESTIGATIONS,2011-12-22,2011-12-22,2011-12-27,2011-12-27,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,INCREASED ANC - CLINICALLY SIGNIFICANT,Neutrophil count increased,INVESTIGATIONS,2011-12-22,2011-12-22,,,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,MALIGNANT PLEURAL EFFUSION,Malignant pleural effusion,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-09,2011-12-09,2011-12-10,2011-12-10,1.0,Y,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-24,2011-12-24,2012-01-10,2012-01-10,16.0,Y,NOT RELATED,1.0,4,4.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ELEVATED NEUTROPHILS - CLINICALLY SIGNIFICANT,Neutrophil count increased,INVESTIGATIONS,2011-12-22,2011-12-22,,,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ELEVATED LYMPHOCYTES - CLINICALLY SIGNIFICANT,Lymphocyte count increased,INVESTIGATIONS,2011-12-22,2011-12-22,,,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,ELEVATED MONOCYTES - CLINICALLY SIGNIFICANT,Monocyte count increased,INVESTIGATIONS,2011-12-22,2011-12-22,,,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,ELEVATED EOSINOPHILS - CLINICALY SIGNIFICANT,Eosinophil count increased,INVESTIGATIONS,2011-12-22,2011-12-22,,,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-12-13,2011-12-13,2012-01-04,2012-01-04,5.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,CLINICAL PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-01-14,2012-01-14,2012-01-14,2012-01-14,37.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,MALIGNANT PLEURAL EFFUSION,Malignant pleural effusion,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-10,2011-12-10,2011-12-12,2011-12-12,2.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,MALIGNANT PLEURAL EFFUSION,Malignant pleural effusion,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-12,2011-12-12,2011-12-18,2011-12-18,4.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,MALIGNANT PLEURAL EFFUSION,Malignant pleural effusion,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-18,2011-12-18,,,10.0,N,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,PULMONARY EMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-10,2012-01-10,,,33.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-063-003,01063003,063,69.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,CLINICAL PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-01-12,2012-01-12,2012-01-14,2012-01-14,35.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-09-22,2010-09-22,2010-09-29,2010-09-29,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,PAIN-HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2010-09-22,2010-09-22,2010-09-22,2010-09-22,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-10-05,2010-10-05,2010-12-08,2010-12-08,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-10-08,2010-10-08,,,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2010-11-24,2010-11-24,2011-06-22,2011-06-22,65.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2010-12-15,2010-12-15,2011-01-01,2011-01-01,86.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,LOCALIZED EDEMA-BILATERAL ANKLES,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-15,2010-12-15,2010-12-16,2010-12-16,86.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,PAIN-RIGHT UPPER EXTREMITY,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-02-03,2011-02-03,2011-02-06,2011-02-06,136.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-10-05,2010-10-05,2010-10-12,2010-10-12,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DIVERTICULITIS,Diverticulitis,INFECTIONS AND INFESTATIONS,2011-03,,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-07,2010-12-07,2010-12-14,2010-12-14,78.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-28,2010-12-28,2011-01-11,2011-01-11,99.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-25,2011-01-25,2011-02-08,2011-02-08,127.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-22,2011-02-22,2011-03-08,2011-03-08,155.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-22,2011-03-22,2011-04-05,2011-04-05,183.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-19,2011-04-19,2011-05-03,2011-05-03,211.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-17,2011-05-17,2011-06-14,2011-06-14,239.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-28,2011-04-28,2011-05-02,2011-05-02,220.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-30,2011-04-30,2011-05-02,2011-05-02,222.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-05-03,2011-05-03,2011-08-04,2011-08-04,225.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,ITCHING EYES,Eye pruritus,EYE DISORDERS,2011-05-30,2011-05-30,2011-06-14,2011-06-14,252.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-05-18,2011-05-18,2011-08-15,2011-08-15,240.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-07,2011-06-07,2011-06-14,2011-06-14,260.0,N,UNLIKELY,2.0,1,1.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-14,2011-06-14,2011-06-21,2011-06-21,267.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-14,2011-06-14,2011-06-28,2011-06-28,267.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,ANKLE EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-14,2011-06-14,2011-06-21,2011-06-21,267.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-14,2011-06-14,2012-07-26,2012-07-26,267.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-02,2011-08-02,2011-08-23,2011-08-23,316.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,EDEMA AROUND EYE,Periorbital oedema,EYE DISORDERS,2011-07-21,2011-07-21,2011-08-09,2011-08-09,304.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-04,2011-08-04,2011-09-27,2011-09-27,318.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-04,2011-08-04,2011-08-18,2011-08-18,318.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,FATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2011-02-16,2011-02-16,2011-08-03,2011-08-03,149.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,A-FIB,Atrial fibrillation,CARDIAC DISORDERS,2011-08-26,2011-08-26,2011-08-27,2011-08-27,340.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,34.0,COPD EXACERBATION,Chronic obstructive pulmonary disease,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-26,2011-08-26,2011-08-27,2011-08-27,340.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35.0,A-FIB,Atrial fibrillation,CARDIAC DISORDERS,2011-06-17,2011-06-17,2011-08-26,2011-08-26,270.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,36.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-23,2011-09-23,2011-09-29,2011-09-29,368.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,37.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-12,2011-09-12,2011-09-23,2011-09-23,357.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,38.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-06,2011-09-06,2011-09-20,2011-09-20,351.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,39.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-27,2011-09-27,2011-10-11,2011-10-11,372.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40.0,FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2011-08-04,2011-08-04,,,318.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,41.0,A-FIB,Atrial fibrillation,CARDIAC DISORDERS,2011-08-28,2011-08-28,,,342.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,42.0,EDEMA FACE,Face oedema,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-15,2011-09-15,2011-09-27,2011-09-27,360.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,43.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-23,2011-09-23,2011-10-20,2011-10-20,368.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,44.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-04,2011-10-04,2011-10-11,2011-10-11,379.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45.0,HYPERALKALINEPHOSPHATEMIA,Hyperphosphataemia,METABOLISM AND NUTRITION DISORDERS,2011-10-04,2011-10-04,,,379.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,46.0,"TRANSAMINITIS ( ELEVATED ALT, AST, T BILI",Transaminases increased,INVESTIGATIONS,2011-10-04,2011-10-04,,,379.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,47.0,DIARRRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-09-27,2011-09-27,2011-10-06,2011-10-06,372.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,48.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-27,2011-09-27,2011-10-05,2011-10-05,372.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,49.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-29,2011-09-29,2011-10-20,2011-10-20,374.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,50.0,PLEURAL EFFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-27,2011-09-27,2011-10-04,2011-10-04,372.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,51.0,PLUERAL EFFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-04,2011-10-04,2011-10-11,2011-10-11,379.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,52.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-10-06,2011-10-06,2011-10-10,2011-10-10,381.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,53.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-05,2011-10-05,2011-10-14,2011-10-14,380.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,54.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-14,2011-10-14,2011-11-03,2011-11-03,389.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,55.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-01,2011-11-01,2011-11-15,2011-11-15,407.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,56.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-03,2011-11-03,,,409.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,57.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-04,2011-11-04,2011-11-08,2011-11-08,410.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,58.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-15,2011-11-15,2011-11-21,2011-11-21,421.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,59.0,THROMCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-08,2011-11-08,2011-11-15,2011-11-15,414.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,60.0,DYSPENIA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-10,2011-11-10,2012-01-06,2012-01-06,416.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,61.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-29,2011-11-29,,,435.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,62.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-22,2011-11-22,,,428.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,63.0,EDEMA TO ANKLES AND FEET BILATERAL,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-29,2011-11-29,2012-01-07,2012-01-07,435.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,64.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-07,2012-01-07,,,474.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,65.0,GENERALIZED MUSCLE WEAKNESS,Muscular weakness,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-06,2011-12-06,2012-01-07,2012-01-07,442.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,66.0,GENERALIZED MUSCLE WEAKNESS,Muscular weakness,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-07,2012-01-07,,,474.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,67.0,EDEMA TO ANKLES AND FEET,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-08,2012-01-08,,,475.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,68.0,PLEURAL EFFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-07,2011-12-07,2011-12-07,2011-12-07,443.0,Y,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,69.0,EXACERABATION OF COPD,Chronic obstructive pulmonary disease,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-07,2011-12-07,2011-12-09,2011-12-09,443.0,Y,NOT RELATED,1.0,1,1.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,70.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-10-25,2011-10-25,,,400.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,71.0,THRUSH,Candidiasis,INFECTIONS AND INFESTATIONS,2012-01-06,2012-01-06,,,473.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,72.0,ACUTE KIDNEY INJURY,Renal failure acute,RENAL AND URINARY DISORDERS,2012-01-21,2012-01-21,,,488.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,73.0,PNEMONITIS,Pneumonitis,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-21,2012-01-21,,,488.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,UNKNOWN,N,Y,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,74.0,DIGOXIN TOXICITY,Toxicity to various agents,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-01-25,2012-01-25,,,492.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,75.0,PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2012-01-21,2012-01-21,2012-01-31,2012-01-31,488.0,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,76.0,WORSENING COPD,Chronic obstructive pulmonary disease,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-31,2012-01-31,2012-02-13,2012-02-13,498.0,Y,NOT RELATED,1.0,5,5.0,,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,77.0,ACUTE KIDNEY INJURY,Renal failure acute,RENAL AND URINARY DISORDERS,2012-01-31,2012-01-31,,,498.0,Y,NOT RELATED,1.0,5,5.0,,,CONTINUOUS,,Y,Y,N,Y
CO-101-001,CO-101-001-064-001,01064001,064,76.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,78.0,ATRIAL FIB,Atrial fibrillation,CARDIAC DISORDERS,2012-01-31,2012-01-31,,,498.0,Y,NOT RELATED,1.0,5,5.0,,,CONTINUOUS,,Y,Y,N,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11-08,2010-11-08,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,CS ELEVATED ALKLINE PHOSPHATASE,Blood alkaline phosphatase increased,INVESTIGATIONS,2010-12-06,2010-12-06,,,29.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CS ELEVATED ALT,Alanine aminotransferase increased,INVESTIGATIONS,2010-12-06,2010-12-06,,,29.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CS INCREASED AST,Aspartate aminotransferase increased,INVESTIGATIONS,2010-12-06,2010-12-06,2010-12-22,2010-12-22,29.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,BILIARY OBSTRUCTION,Bile duct obstruction,HEPATOBILIARY DISORDERS,2010-12-06,2010-12-06,2010-12-10,2010-12-10,29.0,N,NOT RELATED,1.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED",OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DEEP VEIN THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-02-05,2011-02-05,2011-02-07,2011-02-07,90.0,Y,NOT RELATED,1.0,3,3.0,,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HEADACHES,Headache,NERVOUS SYSTEM DISORDERS,2010-11-15,2010-11-15,2011-02-18,2011-02-18,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,FLUSHING,Flushing,VASCULAR DISORDERS,2010-11-15,2010-11-15,2011-02-18,2011-02-18,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,NIGHT SWEAT,Night sweats,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-11-22,2010-11-22,2011-02-18,2011-02-18,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-003,01064003,064,60.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,RT AXILLA TENDERNESS,Axillary pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-11,2011-02-11,2011-02-16,2011-02-16,96.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-17,2010-12-17,2011-02-23,2011-02-23,25.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,DERMATOLOGY-ERYTHEMA TO BILATERAL ARMS,Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-12-17,2010-12-17,2010-12-22,2010-12-22,25.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DERMATOLOGY_ECCHYMOSES TO RIGHT HAND,Ecchymosis,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-12-17,2010-12-17,2010-12-22,2010-12-22,25.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-12-30,2010-12-30,,,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,EDEMA-LEFT LEG,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-06,2011-01-06,2011-03-31,2011-03-31,45.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PAIN-LEFT LOWER LEG,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-01-06,2011-01-06,2011-01-26,2011-01-26,45.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-06,2011-01-06,2011-01-20,2011-01-20,45.0,N,DEFINITELY,4.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2010-12-03,2010-12-03,2010-12-16,2010-12-16,11.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2010-12-17,2010-12-17,2010-12-17,2010-12-17,25.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-30,2010-12-30,,,38.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ITCH,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2010-11-21,2010-11-21,2010-12-04,2010-12-04,-2.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,CS DECREASED WBC,White blood cell count decreased,INVESTIGATIONS,2010-12-09,2010-12-09,2010-12-30,2010-12-30,17.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,CS DECREASED WBC,White blood cell count decreased,INVESTIGATIONS,2011-01-06,2011-01-06,2011-01-12,2011-01-12,45.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,CS DECREASED WBC,White blood cell count decreased,INVESTIGATIONS,2011-01-13,2011-01-13,2011-01-19,2011-01-19,52.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-24,2011-02-24,,,94.0,N,UNLIKELY,2.0,2,2.0,"DOSE REDUCED, DRUG INTERRUPTED",OTHER,CONTINUOUS,RECOVERING/RESOLVING,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,CS REDUCED RBC,Red blood cell count decreased,INVESTIGATIONS,2011-03-03,2011-03-03,,,101.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,CS REDUCED HEMATOCRIT,Haematocrit decreased,INVESTIGATIONS,2011-03-03,2011-03-03,,,101.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,CS REDUCED ANC,Neutrophil count decreased,INVESTIGATIONS,2010-12-09,2010-12-09,,,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-28,2011-01-28,2011-02-01,2011-02-01,67.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-04-26,2011-04-26,2011-04-30,2011-04-30,155.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,N,Y,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,CANCER RELATED PAIN,Cancer pain,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-04-26,2011-04-26,,,155.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-26,2011-04-26,,,155.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,AGITATION,Agitation,PSYCHIATRIC DISORDERS,2011-04-26,2011-04-26,,,155.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-064-004,01064004,064,80.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,PAIN TO LOWER EXT,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-02-11,2011-02-11,,,81.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-30,2011-06-30,2011-07-31,2011-07-31,24.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,DYSGEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-07-11,2011-07-11,2011-08-08,2011-08-08,35.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,FATIQUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-01,2011-08-01,,,56.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-005,01064005,064,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,BELCHING,Eructation,GASTROINTESTINAL DISORDERS,2011-08-14,2011-08-14,,,69.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-07-29,2011-07-29,2011-08-13,2011-08-13,-17.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-28,2011-07-28,2011-08-02,2011-08-02,-18.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ERCP INDUCED PANCREATITIS,Pancreatitis,GASTROINTESTINAL DISORDERS,2011-08-02,2011-08-02,2011-08-11,2011-08-11,-13.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08-11,2011-08-11,2011-08-18,2011-08-18,-4.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,THRUSH,Candidiasis,INFECTIONS AND INFESTATIONS,2011-08-08,2011-08-08,2011-08-18,2011-08-18,-7.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-03,2011-08-03,2011-08-06,2011-08-06,-12.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-03,2011-08-03,2011-08-06,2011-08-06,-12.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-18,2011-08-18,2011-08-18,2011-08-18,4.0,Y,NOT RELATED,1.0,1,1.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-18,2011-08-18,2011-08-19,2011-08-19,4.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-18,2011-08-18,2011-08-19,2011-08-19,4.0,Y,NOT RELATED,1.0,2,2.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2011-09-08,2011-09-08,,,25.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-09-07,2011-09-07,2011-10-04,2011-10-04,24.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-02,2011-08-02,2011-08-11,2011-08-11,-13.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,GASTROINTESTINAL PAIN,Gastrointestinal pain,GASTROINTESTINAL DISORDERS,2011-08-12,2011-08-12,2011-09-08,2011-09-08,-3.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-23,2011-08-23,2011-08-25,2011-08-25,9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,RASH,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-08-26,2011-08-26,2011-09-08,2011-09-08,12.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-10-04,2011-10-04,,,51.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-03,2011-08-03,2011-08-06,2011-08-06,-12.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-09-06,2011-09-06,,,23.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,INTERMITTENT CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-20,2011-08-20,,,6.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,ABDOMEN SPASMS,Abdominal rigidity,GASTROINTESTINAL DISORDERS,2011-10-24,2011-10-24,2012-01-06,2012-01-06,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-12,2011-12-12,2011-12-16,2011-12-16,120.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-19,2011-12-19,,,127.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,GASTROESOPHAGEAL REFLUX,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2011-12-27,2011-12-27,2011-12-31,2011-12-31,135.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,DUODENAL STRICTURE,Duodenal stenosis,GASTROINTESTINAL DISORDERS,2012-01-02,2012-01-02,2012-01-06,2012-01-06,141.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,PYLORIC STRICTURE,Pyloric stenosis,"CONGENITAL, FAMILIAL AND GENETIC DISORDERS",2012-01-02,2012-01-02,2012-01-06,2012-01-06,141.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,GE REFLUX,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2012-01-01,2012-01-01,2012-01-06,2012-01-06,140.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,GE REFLUX,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2012-01-06,2012-01-06,,,145.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-01-28,2012-01-28,,,167.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30.0,OBSTRUCTION GASTRIC,Obstruction gastric,GASTROINTESTINAL DISORDERS,2012-01-06,2012-01-06,,,145.0,N,NOT RELATED,1.0,2,2.0,,"NONE, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,31.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-30,2012-01-30,,,169.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-064-006,01064006,064,53.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,32.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-06,2012-01-06,,,145.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-065-002,01065002,065,59.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-05-20,2011-05-20,2011-05-22,2011-05-22,23.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-10,2011-07-10,,,39.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-21,2011-07-21,2011-08-02,2011-08-02,50.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,LEUCOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-21,2011-07-21,,,50.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,LIVER ABSCESS,Liver abscess,INFECTIONS AND INFESTATIONS,2011-07-25,2011-07-25,,,54.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-065-003,01065003,065,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-03,2011-08-03,,,63.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-02,2011-12-02,2011-12-04,2011-12-04,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2011-12-06,2011-12-06,2011-12-07,2011-12-07,7.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CLINICAL SIGNIFICANT PLATELET  COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2011-12-06,2011-12-06,2011-12-14,2011-12-14,7.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,CLINICAL SIGNIFICANT NEUTROPHILL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2011-12-13,2011-12-13,2011-12-14,2011-12-14,14.0,N,DEFINITELY,4.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2011-12-14,2011-12-14,2011-12-20,2011-12-20,15.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2011-12-20,2011-12-20,2011-12-21,2011-12-21,21.0,N,DEFINITELY,4.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,CLINICAL SIGNIFICANT PLATELETL COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2011-12-20,2011-12-20,2012-01-04,2012-01-04,21.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2011-12-21,2011-12-21,2011-12-27,2011-12-27,22.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-22,2011-12-22,2011-12-26,2011-12-26,23.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-01-10,2012-01-10,2012-01-24,2012-01-24,42.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,CLINICAL SIGNIFICANT ALANINE AMINOTRANSFERASE INCREASED,Alanine aminotransferase increased,INVESTIGATIONS,2012-01-11,2012-01-11,2012-01-18,2012-01-18,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,CLINICAL SIGNIFICANT ASPARTATE AMINOTRANSFERASE INCREASED,Aspartate aminotransferase increased,INVESTIGATIONS,2012-01-11,2012-01-11,2012-02-08,2012-02-08,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,CLINICAL SIGNIFICANT ALANINE AMINOTRANSFERASE INCREASED,Alanine aminotransferase increased,INVESTIGATIONS,2012-01-18,2012-01-18,2012-01-24,2012-01-24,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,CLINICAL SIGNIFICANT NENTROPHIL COUNT DECEASED,Neutrophil count decreased,INVESTIGATIONS,2012-01-18,2012-01-18,2012-01-24,2012-01-24,50.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-02-07,2012-02-07,2012-02-22,2012-02-22,70.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-14,2012-02-14,2012-02-22,2012-02-22,77.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT  DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-02-29,2012-02-29,2012-03-14,2012-03-14,92.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-03-07,2012-03-07,2012-03-22,2012-03-22,99.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-16,2012-03-16,2012-03-18,2012-03-18,108.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-03-29,2012-03-29,2012-04-05,2012-04-05,121.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-04-05,2012-04-05,2012-04-12,2012-04-12,128.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,CLINICAL SIGNIFICANT PLATELETL COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-04-05,2012-04-05,2012-04-19,2012-04-19,128.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,CLINICAL SIGNIFICANT ASPARTATE AMINOTRANSFERASE INCREASED,Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-05,2012-04-05,2012-04-19,2012-04-19,128.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-04-05,2012-04-05,2012-04-25,2012-04-25,128.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-04-12,2012-04-12,2012-04-19,2012-04-19,135.0,N,DEFINITELY,4.0,4,4.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-04-26,2012-04-26,2012-05-02,2012-05-02,149.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-04-26,2012-04-26,2012-05-30,2012-05-30,149.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-05-03,2012-05-03,2012-05-05,2012-05-05,156.0,N,DEFINITELY,4.0,4,4.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-03,2012-05-03,2012-05-30,2012-05-30,156.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,CLINICAL SIGNIFICANT PLATELETL COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-05-03,2012-05-03,2012-05-05,2012-05-05,156.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-05-05,2012-05-05,2012-05-11,2012-05-11,158.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-05-11,2012-05-11,2012-05-17,2012-05-17,164.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,PLEURAL EFFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-05-14,2012-05-14,,,167.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,34.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-05-24,2012-05-24,2012-06-04,2012-06-04,177.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-05-31,2012-05-31,,,184.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,36.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-31,2012-05-31,2012-06-08,2012-06-08,184.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,37.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-05-31,2012-05-31,2012-06-03,2012-06-03,184.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,38.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-04,2012-06-04,2012-06-07,2012-06-07,188.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,39.0,EDEMA LIMBS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-04,2012-06-04,2012-06-11,2012-06-11,188.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,40.0,CLINICAL SIGNIFICANT BLOOD BILIRUBIN INCREASED,Blood bilirubin increased,INVESTIGATIONS,2012-06-04,2012-06-04,2012-06-08,2012-06-08,188.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,41.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-06-04,2012-06-04,2012-06-06,2012-06-06,188.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,42.0,CLINICAL SIGNIFICANT ASPARTATE AMINOTRANSFERASE INCREASED,Aspartate aminotransferase increased,INVESTIGATIONS,2012-06-04,2012-06-04,2012-06-08,2012-06-08,188.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,43.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-08,2012-06-08,2012-06-11,2012-06-11,192.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,44.0,CLINICAL SIGNIFICANT BLOOD BILIRUBIN INCREASED,Blood bilirubin increased,INVESTIGATIONS,2012-06-08,2012-06-08,2012-06-09,2012-06-09,192.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,45.0,CLINICAL SIGNIFICANT BLOOD BILIRUBIN INCREASED,Blood bilirubin increased,INVESTIGATIONS,2012-06-09,2012-06-09,2012-06-11,2012-06-11,193.0,Y,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,46.0,CLINICAL SIGNIFICANT ASPARTATE AMINOTRANSFERAS INCREASED,Aspartate aminotransferase increased,INVESTIGATIONS,2012-06-09,2012-06-09,2012-07-04,2012-07-04,193.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,47.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-08,2012-06-08,2012-06-08,2012-06-08,192.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,48.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-09,2012-06-09,,,193.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,49.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-09,2012-06-09,2012-06-09,2012-06-09,193.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,50.0,EDEMA LIMBS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-12,2012-06-12,,,196.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,51.0,CLINICAL SIGNIFICANT BLOOD BILIRUBIN INCREASED,Blood bilirubin increased,INVESTIGATIONS,2012-06-12,2012-06-12,2012-06-13,2012-06-13,196.0,Y,DEFINITELY,4.0,4,4.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,52.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-12,2012-06-12,,,196.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,53.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-12,2012-06-12,2012-06-13,2012-06-13,196.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,54.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-06-12,2012-06-12,2012-06-12,2012-06-12,196.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,55.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-06-13,2012-06-13,2012-06-13,2012-06-13,197.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,56.0,CLINICAL SIGNIFICANT ALANINE AMINOTRANSFERASE INCREASED,Alanine aminotransferase increased,INVESTIGATIONS,2012-06-13,2012-06-13,2012-06-18,2012-06-18,197.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,57.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-14,2012-06-14,2012-06-18,2012-06-18,198.0,N,POSSIBLE/PROBABLE,3.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,58.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-06-14,2012-06-14,2012-06-15,2012-06-15,198.0,N,DEFINITELY,4.0,4,4.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,59.0,CLINICAL SIGNIFICANT BLOOD BILIRUBIN INCREASED,Blood bilirubin increased,INVESTIGATIONS,2012-06-14,2012-06-14,2012-06-22,2012-06-22,198.0,Y,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,60.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-06-16,2012-06-16,2012-06-19,2012-06-19,200.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,61.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-15,2012-06-15,2012-06-17,2012-06-17,199.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,62.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-18,2012-06-18,,,202.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,63.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-19,2012-06-19,,,203.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,64.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-06-20,2012-06-20,2012-06-21,2012-06-21,204.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,65.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-07-04,2012-07-04,,,218.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,66.0,CLINICAL SIGNIFICANT NEUTROPHIL COUNT DECREASED,Neutrophil count decreased,INVESTIGATIONS,2012-07-04,2012-07-04,,,218.0,N,NOT RELATED,1.0,4,4.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,67.0,CLINICAL SIGNIFICANT BLOOD BILIRUBIN INCREASED,Blood bilirubin increased,INVESTIGATIONS,2012-06-22,2012-06-22,,,206.0,N,DEFINITELY,4.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,68.0,CLINICAL SIGNIFICANT PLATELET COUNT DECREASED,Platelet count decreased,INVESTIGATIONS,2012-06-22,2012-06-22,2012-07-03,2012-07-03,206.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,69.0,PERICARDIAL EFFUSION,Pericardial effusion,CARDIAC DISORDERS,2012-07-04,2012-07-04,,,218.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-065-004,01065004,065,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,70.0,ACSITES,Ascites,GASTROINTESTINAL DISORDERS,2012-07-04,2012-07-04,,,218.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,INCREASE OF GGT (CLINICALLY SIGNIFICANT),Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-01-11,2011-01-11,,,16.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-02-02,2011-02-02,,,38.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,OEDEMA OF LOWER LEGS AND FOOTS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-18,2011-02-18,,,54.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-066-003,01066003,066,65.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-17,2011-02-17,,,53.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-22,2011-09-22,2011-09-29,2011-09-29,92.0,N,DEFINITELY,4.0,1,1.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,GGT INCREASE CLINICALLY SIGNIFICANT,Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-09-29,2011-09-29,,,99.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,FATIQUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-10,2011-10-10,,,110.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,2011-11-03,2011-11-03,127.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-005,01066005,066,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,PAIN IN THE RIGHT SIDE OF RIBS,Musculoskeletal chest pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-03,2011-12-03,,,164.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-02,2011-09-02,2011-09-06,2011-09-06,2.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-03,2011-09-03,2011-09-09,2011-09-09,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,EDEMA OF THE FEET,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-07,2011-09-07,2011-10-22,2011-10-22,7.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PNEUMOTHORAX,Pneumothorax,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-09,2011-09-09,2011-09-15,2011-09-15,9.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,EDEMA OF THE LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-23,2011-10-23,2011-11-02,2011-11-02,53.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-22,2011-10-22,2011-10-25,2011-10-25,52.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,FATIQUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-03,2011-11-03,,,64.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,EDEMA OF THE LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-03,2011-11-03,,,64.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,PAIN IN THE RIGHT ILLIAC AREA,Abdominal pain lower,GASTROINTESTINAL DISORDERS,2011-11-14,2011-11-14,,,75.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,HYPOGLICEMIA,Hypoglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-11-24,2011-11-24,,,85.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-11-24,2011-11-24,,,85.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-006,01066006,066,39.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,DYSPNOE,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-14,2011-11-14,,,75.0,N,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-09-21,2011-09-21,,,15.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-21,2011-09-21,2011-09-28,2011-09-28,15.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PAIN IN THE RIGHT SIDE OF ABDOMEN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-10-01,2011-10-01,2011-10-24,2011-10-24,25.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,OBSTRUCTIVE JAUNDICE,Jaundice cholestatic,HEPATOBILIARY DISORDERS,2011-10-07,2011-10-07,2011-10-14,2011-10-14,31.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,APPETITE LOSS,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-10-01,2011-10-01,,,25.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,GGT INCREASE CLINICAL SIGNIFICANT,Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-09-21,2011-09-21,,,15.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,OBSTRUCTIVE JAUNDICE,Jaundice cholestatic,HEPATOBILIARY DISORDERS,2011-10-14,2011-10-14,,,38.0,N,UNLIKELY,2.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,EROSIVE GASTRITIS,Gastritis erosive,GASTROINTESTINAL DISORDERS,2011-10-24,2011-10-24,,,48.0,N,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-066-007,01066007,066,62.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PAIN IN THE RIGHT SIDE OF ABDOMEN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-10-25,2011-10-25,,,49.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-28,2012-02-28,2012-03-13,2012-03-13,8.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-008,01066008,066,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-03,2012-04-03,2012-04-10,2012-04-10,43.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-20,2012-03-20,2012-03-27,2012-03-27,22.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,EDEMA OF LEG,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-14,2012-05-14,2012-06-17,2012-06-17,77.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-009,01066009,066,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CHRONIC PROSTATITIS,Prostatitis,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2012-02-22,2012-02-22,,,-6.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-21,2012-03-21,2012-03-28,2012-03-28,15.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-21,2012-03-21,2012-03-28,2012-03-28,15.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-13,2012-06-13,2012-06-27,2012-06-27,99.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-16,2012-05-16,2012-05-30,2012-05-30,71.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-06-22,2012-06-22,2012-07-09,2012-07-09,108.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL DISTENSION,Abdominal distension,GASTROINTESTINAL DISORDERS,2012-06-22,2012-06-22,2012-07-09,2012-07-09,108.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-06-24,2012-06-24,2012-07-09,2012-07-09,110.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-06-29,2012-06-29,2012-07-01,2012-07-01,115.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-07-03,2012-07-03,2012-07-09,2012-07-09,119.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,FUNCTIONAL INTESTINAL OBSTRUCTION,Intestinal obstruction,GASTROINTESTINAL DISORDERS,2012-07-09,2012-07-09,2012-07-17,2012-07-17,125.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-08,2012-05-08,2012-07-17,2012-07-17,63.0,N,UNLIKELY,2.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-066-010,01066010,066,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,"METASTATIC PANCREATIC ADENOCARCINOMA, PROGRESSION DISEASE",Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-07-17,2012-07-17,2012-07-17,2012-07-17,133.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-03,2012-04-03,2012-05-10,2012-05-10,8.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,EDEMA OF LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-08,2012-05-08,2012-05-23,2012-05-23,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-06,2012-06-06,2012-06-20,2012-06-20,72.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-04,2012-07-04,2012-07-18,2012-07-18,100.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-01,2012-08-01,2012-08-15,2012-08-15,128.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-29,2012-08-29,2012-09-12,2012-09-12,156.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,INCREASE URIC-ACID - CLINICALLY SIGNIFICANT,Blood uric acid increased,INVESTIGATIONS,2012-08-01,2012-08-01,2012-08-15,2012-08-15,128.0,N,NOT RELATED,1.0,4,4.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-26,2012-09-26,2012-10-10,2012-10-10,184.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-066-011,01066011,066,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2012-10-10,2012-10-10,,,198.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-02,2010-11-02,2011-01-21,2011-01-21,7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,TROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-24,2010-11-24,2010-12-08,2010-12-08,29.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,TROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-08,2010-12-08,2010-12-15,2010-12-15,43.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-001,01067001,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,TROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-21,2010-12-21,2011-01-21,2011-01-21,56.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-02-05,2011-02-05,,,75.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,SCIN METASTASIS,Metastases to skin,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-02-08,2011-02-08,,,78.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-002,01067002,067,26.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,BODY WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-02-17,2011-02-17,,,87.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-06,2010-12-06,2010-12-13,2010-12-13,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,VENA PORTALIS TROMBUS,Portal vein thrombosis,HEPATOBILIARY DISORDERS,2011-01-25,2011-01-25,,,58.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-01,2011-03-01,2011-03-15,2011-03-15,93.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-09,2011-03-09,2011-03-15,2011-03-15,101.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-22,2011-03-22,2011-04-12,2011-04-12,114.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-05,2011-04-05,2011-04-12,2011-04-12,128.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-19,2011-04-19,2011-05-10,2011-05-10,142.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-03,2011-05-03,2011-05-10,2011-05-10,156.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-17,2011-05-17,,,170.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-003,01067003,067,63.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-13,2011-05-13,,,166.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2010-12-24,2010-12-24,2010-12-24,2010-12-24,11.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2010-12-30,2010-12-30,2010-12-30,2010-12-30,17.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PNEUMONITIS,Pneumonitis,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-02-07,2011-02-07,2011-04-04,2011-04-04,56.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,RHINITIS,Rhinitis,INFECTIONS AND INFESTATIONS,2011-03-07,2011-03-07,2011-03-15,2011-03-15,84.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-07,2011-03-07,2011-03-18,2011-03-18,84.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-07,2011-03-07,2011-03-15,2011-03-15,84.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,"PAIN IN MUSCLES,BONE,HEAD",Bone pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-07,2011-03-07,2011-03-15,2011-03-15,84.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,"PAIN IN MUSCLES,BONE,HEAD",Headache,NERVOUS SYSTEM DISORDERS,2011-03-07,2011-03-07,2011-03-15,2011-03-15,84.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,"PAIN IN MUSCLES,BONE,HEAD",Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-07,2011-03-07,2011-03-15,2011-03-15,84.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,RHINITIS,Rhinitis,INFECTIONS AND INFESTATIONS,2011-03-15,2011-03-15,2011-03-18,2011-03-18,92.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-15,2011-03-15,2011-03-18,2011-03-18,92.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,"PAIN IN MUSCLES,BONE,HEAD",Bone pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-15,2011-03-15,2011-03-18,2011-03-18,92.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,"PAIN IN MUSCLES,BONE,HEAD",Headache,NERVOUS SYSTEM DISORDERS,2011-03-15,2011-03-15,2011-03-18,2011-03-18,92.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,"PAIN IN MUSCLES,BONE,HEAD",Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-15,2011-03-15,2011-03-18,2011-03-18,92.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-05,2011-04-05,2011-04-12,2011-04-12,113.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-28,2010-12-28,2011-01-05,2011-01-05,15.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-31,2011-05-31,2011-06-07,2011-06-07,169.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-004,01067004,067,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-28,2011-06-28,,,197.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,INFECTION WITH UNKNOWN ANC(ACUTE RESPIRATORY DISEASE),Respiratory tract infection,INFECTIONS AND INFESTATIONS,2011-01-02,2011-01-02,2011-01-08,2011-01-08,20.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2010-12-17,2010-12-17,2010-12-17,2010-12-17,4.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-22,2011-03-22,2011-03-29,2011-03-29,99.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-19,2011-04-19,2011-04-26,2011-04-26,127.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-31,2011-05-31,2011-06-07,2011-06-07,169.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-005,01067005,067,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-27,2011-05-27,,,165.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-01-27,2011-01-27,2011-02-09,2011-02-09,37.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-20,2011-01-20,2011-02-09,2011-02-09,30.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-01-13,2011-01-13,2011-01-13,2011-01-13,23.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-007,01067007,067,73.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,METASTATIC PANCREATIC CANCER PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-02-09,2011-02-09,2011-02-09,2011-02-09,50.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,PAIN IN LEFT SUBCOSTAL AREA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2010-12-24,2010-12-24,2010-12-27,2010-12-27,-12.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-11,2011-01-11,2011-01-18,2011-01-18,7.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ASCITE,Ascites,GASTROINTESTINAL DISORDERS,2011-01-11,2011-01-11,2011-01-12,2011-01-12,7.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-008,01067008,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PROGRESSION OF PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-01-20,2011-01-20,2011-01-20,2011-01-20,16.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-01,2011-03-01,2011-03-09,2011-03-09,9.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-009,01067009,067,47.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-15,2011-03-15,2011-04-23,2011-04-23,23.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,BILIRUBIN (HYPERBILIRUBINEMIA),Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-04-26,2011-04-26,2011-05-11,2011-05-11,9.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ALT(SERUM GLUTAMIC PYRUVIC TRANSAMINASE) INCREASED  CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-04-26,2011-04-26,2011-05-11,2011-05-11,9.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-010,01067010,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-05-11,2011-05-11,2011-05-11,2011-05-11,24.0,Y,UNLIKELY,2.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-22,2011-11-22,2011-11-29,2011-11-29,212.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-29,2011-11-29,2011-12-05,2011-12-05,219.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-05,2011-12-05,2011-12-13,2011-12-13,225.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,CREATININE INCREASED CLINICALLY SIGNIFICANT,Blood creatinine increased,INVESTIGATIONS,2011-12-05,2011-12-05,,,225.0,N,DEFINITELY,4.0,2,2.0,"DOSE REDUCED, DRUG WITHDRAWN",CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,EROSIVE ESOPHAGITIS,Erosive oesophagitis,GASTROINTESTINAL DISORDERS,2011-12-05,2011-12-05,,,225.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-011,01067011,067,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-13,2011-12-13,,,233.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ALCALINE PHOSPHATASE INCREASED CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-05-12,2011-05-12,2011-06-09,2011-06-09,15.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2011-04-14,2011-04-14,2011-04-26,2011-04-26,-14.0,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-26,2011-05-26,2011-06-09,2011-06-09,29.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ALCALINE PHOSPHATASE INCREASED CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-06-09,2011-06-09,2011-07-26,2011-07-26,43.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,"CALCIUM,SERUM-LOW(HYPOCALCEMIA)",Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-06-23,2011-06-23,2011-07-26,2011-07-26,57.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,"ALT,SGPT(SERUM GLUTAMIC PYRUVIC TRANSAMINASE)INCREASED CLINICALLY SIGNIFICANT",Alanine aminotransferase increased,INVESTIGATIONS,2011-06-23,2011-06-23,2011-07-07,2011-07-07,57.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-23,2011-06-23,2011-06-30,2011-06-30,57.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,GGT(Y-GLUTAMYL TRANSPEPTIDASE)INCREASED CLINICALLY SIGNIFICANT,Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-06-23,2011-06-23,2011-07-21,2011-07-21,57.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,"ALT,SGPT(SERUM GLUTAMIC PYRUVIC TRANSAMINASE) INCREASED CLINICALLY SIGNIFICANT",Alanine aminotransferase increased,INVESTIGATIONS,2011-07-07,2011-07-07,2011-07-21,2011-07-21,71.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,GGT(Y-GLUTAMYL TRANSPEPTIDASE) CLINICALLY SIGNIFICANT INCREASED,Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-07-21,2011-07-21,2011-07-26,2011-07-26,85.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-012,01067012,067,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,PANCREATIC ADENOCARCINOMA CANCER PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-07-26,2011-07-26,2011-07-26,2011-07-26,90.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-067-013,01067013,067,57.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-29,2012-03-29,2012-04-05,2012-04-05,323.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ALCALINE PHOSPHATASE INCREASED CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-05-03,2011-05-03,2011-05-26,2011-05-26,-9.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,N
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,GGT (Y-GLYTAMYL TRANSPEPTIDASE INCREASED CLINICALLY SIGNIFICANT,Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-05-03,2011-05-03,,,-9.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LDH (LACTAT DEHYDROGENASE)INCREASED  - CLINICALLY SIGNIFICANT,Blood lactate dehydrogenase increased,INVESTIGATIONS,2011-05-03,2011-05-03,,,-9.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-19,2011-05-19,2011-05-26,2011-05-26,8.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,"AST,SGOT(SERUM GLUTAMIC OXALOACETIC TRANSAMINASE) INCREASED - CLINICALLY SIGNIFICANT",Aspartate aminotransferase increased,INVESTIGATIONS,2011-05-19,2011-05-19,2011-05-26,2011-05-26,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-14,2011-05-14,,,3.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,PROTEIN DECREASE - CLINICALLY SIGNIFICANT,Protein total decreased,INVESTIGATIONS,2011-05-19,2011-05-19,,,8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,BILIRUBIN (HYPERBILIRUBINEMIA) - CLINICALLY SIGNIFICANT,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-05-12,2011-05-12,,,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCITOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-26,2011-05-26,,,15.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ALCALINE PHOSPHATASE INCREASED CCLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-05-26,2011-05-26,,,15.0,N,NOT RELATED,1.0,2,2.0,,OTHER,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,"AST,SGOT(SERUM GLUTAMIC OXALOACETIC TRANSAMINASE) INCREASE - CLINICALLY SIGNIFICANT",Aspartate aminotransferase increased,INVESTIGATIONS,2011-05-26,2011-05-26,,,15.0,N,NOT RELATED,1.0,3,3.0,,OTHER,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,FAILING APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-05-16,2011-05-16,,,5.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,EDEMA LOWER EXTREMITY,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-17,2011-05-17,,,6.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-014,01067014,067,69.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,PULMONARY ARTERY THROMBOEMBOLISM,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-05-30,2011-05-30,2011-05-30,2011-05-30,19.0,Y,UNLIKELY,2.0,5,5.0,DRUG INTERRUPTED,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-28,2011-06-28,2011-07-13,2011-07-13,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-13,2011-07-13,2011-07-19,2011-07-19,30.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-26,2011-07-26,2011-08-02,2011-08-02,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,"ALT,INCREASED CLINICALLY SIGNIFICANT",Alanine aminotransferase increased,INVESTIGATIONS,2011-08-23,2011-08-23,2011-09-06,2011-09-06,71.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,"ALT,INCREASED  CLINICALLY SIGNIFICANT",Alanine aminotransferase increased,INVESTIGATIONS,2011-09-06,2011-09-06,2011-09-20,2011-09-20,85.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-22,2011-09-22,2011-09-29,2011-09-29,101.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ASCITIS,Ascites,GASTROINTESTINAL DISORDERS,2011-09-27,2011-09-27,2011-09-29,2011-09-29,106.0,Y,UNLIKELY,2.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ASCITIS,Ascites,GASTROINTESTINAL DISORDERS,2011-09-22,2011-09-22,2011-09-27,2011-09-27,101.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ASCITIS,Ascites,GASTROINTESTINAL DISORDERS,2011-09-30,2011-09-30,2011-10-18,2011-10-18,109.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,PAIN IN EPIGASTRIC AREA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-09-30,2011-09-30,2011-10-18,2011-10-18,109.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-30,2011-09-30,2011-10-18,2011-10-18,109.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-015,01067015,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,PROGRESSION METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-10-18,2011-10-18,2011-10-18,2011-10-18,127.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-05,2011-07-05,2011-07-13,2011-07-13,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-13,2011-07-13,2011-07-26,2011-07-26,23.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PORTAL VEIN THROMBOSIS,Portal vein thrombosis,HEPATOBILIARY DISORDERS,2011-08-12,2011-08-12,,,53.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,EDEMA LOWER EXTREMITY,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-01,2011-12-01,,,164.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ASCITIS,Ascites,GASTROINTESTINAL DISORDERS,2011-12-01,2011-12-01,,,164.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PAIN IN  RIGHT RIGHT RIB,Musculoskeletal chest pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-01,2011-12-01,,,164.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-016,01067016,067,62.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,PAIN IN LEFT EPIGASTRIC AREA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-12-01,2011-12-01,,,164.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-09,2011-08-09,2011-08-16,2011-08-16,8.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-30,2011-08-30,2011-09-06,2011-09-06,29.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-11,2011-10-11,2011-10-18,2011-10-18,71.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-11,2011-10-11,2011-10-18,2011-10-18,71.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LIMPHOCYTOPENIA,Lymphopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-11,2011-10-11,2011-10-18,2011-10-18,71.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-01,2011-11-01,2011-11-08,2011-11-08,92.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,EPIGASTRIC PAIN AND  A REFERRED PAIN TO THE AREA UNDER THE RIGHT RIB,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-10-29,2011-10-29,2011-11-03,2011-11-03,89.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,STOMATITIS,Stomatitis,GASTROINTESTINAL DISORDERS,2011-10-29,2011-10-29,2011-11-05,2011-11-05,89.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,EDEMA LOWER EXTREMITY,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-29,2011-10-29,2011-11-05,2011-11-05,89.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-08,2011-11-08,,,99.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,STOMATITIS,Stomatitis,GASTROINTESTINAL DISORDERS,2011-11-05,2011-11-05,,,96.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,EPIGASTRIC PAIN AND  A REFERRED PAIN TO THE AREA UNDER THE RIGHT RIB,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-11-03,2011-11-03,,,94.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ASCITIS,Ascites,GASTROINTESTINAL DISORDERS,2011-11-05,2011-11-05,,,96.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,EDEMA LOWER EXTREMITY,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-05,2011-11-05,,,96.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,ALKALINE PHOSPHOTASE INCREASED - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-11-08,2011-11-08,,,99.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,CREATININE INCREASED - CLINICALLY SIGNIFICANT,Blood creatinine increased,INVESTIGATIONS,2011-11-08,2011-11-08,,,99.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-11-08,2011-11-08,,,99.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-019,01067019,067,56.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-11-10,2011-11-10,2011-11-10,2011-11-10,101.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-06,2011-09-06,2011-09-13,2011-09-13,8.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-15,2011-11-15,2011-11-21,2011-11-21,78.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,CHOLELITHIASIS,Cholelithiasis,HEPATOBILIARY DISORDERS,2011-08-24,2011-08-24,,,-6.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-067-020,01067020,067,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PULMONARY EMPHYSEMA,Emphysema,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-24,2011-08-24,,,-6.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-15,2011-09-15,2011-09-22,2011-09-22,15.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,HYDROPERICARD,Pericardial effusion,CARDIAC DISORDERS,2012-02-13,2012-02-13,2012-04-11,2012-04-11,166.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,MINIR TWO SIDED HYDROTHORAX,Hydrothorax,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-13,2012-02-13,2012-04-11,2012-04-11,166.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-021,01067021,067,55.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,INTERSTITIAL PULMONARY EDEMA,Pulmonary oedema,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-13,2012-02-13,2012-04-11,2012-04-11,166.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-29,2011-09-29,2011-10-13,2011-10-13,8.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-13,2011-10-13,2011-11-03,2011-11-03,22.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-03,2011-11-03,2011-11-17,2011-11-17,43.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-24,2011-11-24,2011-12-01,2011-12-01,64.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-01,2011-12-01,,,71.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-08,2011-12-08,2011-12-15,2011-12-15,78.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-022,01067022,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-04,2012-01-04,2012-01-12,2012-01-12,105.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-02,2012-02-02,2012-02-22,2012-02-22,50.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-02,2012-02-02,2012-02-09,2012-02-09,50.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-02,2012-02-02,2012-02-09,2012-02-09,50.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERCREATININEMIA,Hypercreatininaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-22,2012-02-22,2012-03-07,2012-03-07,70.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-023,01067023,067,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-07,2012-03-07,2012-03-15,2012-03-15,84.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-024,01067024,067,54.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,"SUDDEN DEATH, CAUSE UNKNOWN",Sudden death,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-03,2012-01-03,2012-01-03,2012-01-03,9.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-07,2012-02-07,2012-03-06,2012-03-06,23.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-07,2012-02-07,2012-02-14,2012-02-14,23.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-07,2012-02-07,2012-02-14,2012-02-14,23.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2012-03-10,2012-03-10,,,55.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,LEFT EXOPHTHALMOS,Exophthalmos,EYE DISORDERS,2012-03-10,2012-03-10,,,55.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,CEPHALGII,Headache,NERVOUS SYSTEM DISORDERS,2012-03-14,2012-03-14,,,59.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-026,01067026,067,55.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-28,2012-06-28,2012-07-12,2012-07-12,165.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-19,2012-01-19,2012-01-24,2012-01-24,-11.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-07,2012-02-07,2012-02-14,2012-02-14,9.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-14,2012-02-14,2012-02-21,2012-02-21,16.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-14,2012-02-14,2012-02-21,2012-02-21,16.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-21,2012-02-21,,,23.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-30,2012-01-30,,,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-067-027,01067027,067,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-02-24,2012-02-24,2012-02-24,2012-02-24,26.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-31,2011-01-31,2011-02-07,2011-02-07,15.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-068-001,01068001,068,69.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,PAIN IN ABDOMEN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-03-28,2011-03-28,,,71.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-31,2011-01-31,2011-02-07,2011-02-07,15.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,TOXICAL HEPATITIS,Hepatitis toxic,HEPATOBILIARY DISORDERS,2011-03-07,2011-03-07,2011-04-11,2011-04-11,50.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,TOXICAL HEPATITIS,Hepatitis toxic,HEPATOBILIARY DISORDERS,2011-04-18,2011-04-18,2011-05-10,2011-05-10,92.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-27,2011-06-27,2011-07-04,2011-07-04,162.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-27,2011-06-27,2011-07-18,2011-07-18,162.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-068-002,01068002,068,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,PAIN IN ABDOMEN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-07-06,2011-07-06,,,171.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-30,2011-03-30,2011-04-05,2011-04-05,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,PERIODICAL DISCOMFORT IN RIGHT MESOGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-03-11,2011-03-11,,,24.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-09,2011-05-09,2011-05-10,2011-05-10,83.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-06,2011-06-06,2011-06-07,2011-06-07,111.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PERIODICAL PAIN IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-11,2011-06-11,2011-08-06,2011-08-06,116.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,PERIODICAL PAIN IN SUBSCAPULARIS AREA AND LUMBALIS AREA,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07-03,2011-07-03,,,138.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,PERIODICAL PAIN IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-08-07,2011-08-07,,,173.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-07,2011-08-07,2011-08-24,2011-08-24,173.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-25,2011-08-25,,,191.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-25,2011-08-25,,,191.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-25,2011-08-25,,,191.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-25,2011-08-25,,,191.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-069-001,01069001,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,LEFT HYDROTHORAX,Hydrothorax,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-02,2011-08-02,,,168.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-05-07,2011-05-07,,,11.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,PAIN IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-15,2011-05-15,,,19.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-069-003,01069003,069,52.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-15,2011-05-15,,,19.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,STENOSIS OF GASTROENTERO-ANASTOMOSIS,Intestinal anastomosis complication,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-08-08,2011-08-08,2011-08-26,2011-08-26,27.0,Y,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,STENOSIS OF GASTROENTEROANASTOMOSIS,Intestinal anastomosis complication,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-08-27,2011-08-27,2011-09-06,2011-09-06,46.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,STENOSIS OF GASTROENTEROANASTOMOSIS,Intestinal anastomosis complication,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-09-07,2011-09-07,2011-09-28,2011-09-28,57.0,Y,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HEAVINESS IN EPIGASTRIUM,Epigastric discomfort,GASTROINTESTINAL DISORDERS,2011-08-06,2011-08-06,,,25.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,DIATHERMIC ULCER,Ulcer,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-15,2011-08-15,,,34.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,PAIN IN MESOGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-09-04,2011-09-04,,,54.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-02,2011-09-02,,,52.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-069-004,01069004,069,51.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,VOMETING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-02,2011-09-02,,,52.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-06,2011-09-06,2011-09-19,2011-09-19,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,PERIODICAL PAIN IN LUMBOSAKRALIS AREA,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-07,2011-09-07,,,9.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-20,2011-09-20,2011-09-26,2011-09-26,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-15,2011-09-15,2011-09-22,2011-09-22,17.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-27,2011-09-27,,,29.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-069-005,01069005,069,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,GASTROINTESTINAL HEMORRAGGE,Gastrointestinal haemorrhage,GASTROINTESTINAL DISORDERS,2011-10-02,2011-10-02,2011-10-03,2011-10-03,34.0,Y,POSSIBLE/PROBABLE,3.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-10,2011-02-10,2011-02-14,2011-02-14,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-11,2011-02-11,2011-02-15,2011-02-15,3.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-11,2011-02-11,2011-02-14,2011-02-14,3.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-17,2011-02-17,2011-02-19,2011-02-19,9.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-18,2011-02-18,2011-02-18,2011-02-18,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-02-25,2011-02-25,2011-02-28,2011-02-28,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-11,2011-03-11,2011-03-13,2011-03-13,31.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-18,2011-03-18,2011-03-21,2011-03-21,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-18,2011-03-18,2011-03-19,2011-03-19,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-25,2011-03-25,2011-03-28,2011-03-28,45.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-08,2011-04-08,2011-04-11,2011-04-11,59.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-08,2011-04-08,2011-04-12,2011-04-12,59.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-15,2011-04-15,,,66.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-15,2011-04-15,2011-04-17,2011-04-17,66.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,GENERAL BODY PAIN,Pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-22,2011-04-22,2011-05-04,2011-05-04,73.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-070-003,01070003,070,68.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,GENERAL BODY PAIN,Pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-05,2011-05-05,,,86.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-07,2011-02-07,2011-02-09,2011-02-09,1.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-02-15,2011-02-15,,,9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-15,2011-02-15,2011-02-19,2011-02-19,9.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-15,2011-02-15,2011-02-18,2011-02-18,9.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-19,2011-02-19,2011-03-24,2011-03-24,13.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DYSGEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-02-16,2011-02-16,,,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-02-28,2011-02-28,2011-03-03,2011-03-03,22.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-28,2011-02-28,2011-03-02,2011-03-02,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-25,2011-03-25,,,47.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-03-25,2011-03-25,,,47.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-004,01070004,070,58.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ICTERUS,Jaundice,HEPATOBILIARY DISORDERS,2011-03-23,2011-03-23,,,45.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-16,2011-02-16,,,2.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-23,2011-02-23,2011-02-27,2011-02-27,9.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-03,2011-03-03,2011-03-06,2011-03-06,17.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-20,2011-04-20,2011-05-03,2011-05-03,65.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-20,2011-04-20,2011-04-26,2011-04-26,65.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-27,2011-04-27,2011-05-03,2011-05-03,72.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,TROMBOPHLEBITIS,Thrombophlebitis,VASCULAR DISORDERS,2011-05-01,2011-05-01,,,76.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-04,2011-05-04,2011-05-10,2011-05-10,79.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-11,2011-05-11,,,86.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-27,2011-04-27,2011-05-11,2011-05-11,72.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-04,2011-05-04,2011-05-11,2011-05-11,79.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-18,2011-05-18,2011-06-01,2011-06-01,93.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,LEUKOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-18,2011-05-18,,,93.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,EDEMA LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-22,2011-05-22,,,97.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-25,2011-05-25,2011-06-01,2011-06-01,100.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-06-29,2011-06-29,128.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-18,2011-05-18,2011-05-20,2011-05-20,93.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-07,2011-07-07,2011-07-08,2011-07-08,143.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-20,2011-07-20,2011-07-27,2011-07-27,156.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-16,2011-08-16,2011-08-30,2011-08-30,183.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-09-13,2011-09-13,2011-09-14,2011-09-14,211.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-27,2011-09-27,,,225.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-006,01070006,070,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-09-20,2011-09-20,,,218.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-24,2011-02-24,2011-03-17,2011-03-17,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-03-25,2011-03-25,,,37.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-31,2011-03-31,2011-04-07,2011-04-07,43.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-28,2011-04-28,2011-05-12,2011-05-12,71.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-04-25,2011-04-25,,,68.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-28,2011-04-28,2011-05-12,2011-05-12,71.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-26,2011-05-26,2011-06-09,2011-06-09,99.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-16,2011-06-16,2011-06-22,2011-06-22,120.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-23,2011-06-23,2011-06-30,2011-06-30,127.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-14,2011-07-14,2011-07-21,2011-07-21,148.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,EDEMA LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-26,2011-07-26,,,160.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,PAIN IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-07-28,2011-07-28,,,162.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-07-28,2011-07-28,,,162.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-007,01070007,070,72.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-07-29,2011-07-29,,,163.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ICTERIC SCLERA,Ocular icterus,EYE DISORDERS,2011-04-20,2011-04-20,,,27.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,INCREASE OF TOTAL BILIRUBIN-CLINICALY SIGNIFICANT.,Blood bilirubin increased,INVESTIGATIONS,2011-04-22,2011-04-22,,,29.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ICTERITIOUSNESS OF SKIN,Jaundice,HEPATOBILIARY DISORDERS,2011-04-26,2011-04-26,2011-05-09,2011-05-09,33.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ICTERITIOUSNESS OF SKIN,Jaundice,HEPATOBILIARY DISORDERS,2011-05-10,2011-05-10,,,47.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-15,2011-05-15,,,52.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,EDEMA OF LOWER EXTREMITIES,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-15,2011-05-15,,,52.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-05-15,2011-05-15,,,52.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-01,2011-04-01,2011-04-07,2011-04-07,8.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-011,01070011,070,48.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-08,2011-04-08,2011-04-15,2011-04-15,15.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-27,2011-04-27,,,7.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,HYPOTENSOIN,Hypotension,VASCULAR DISORDERS,2011-04-27,2011-04-27,,,7.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,EDEMA OF LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-01,2011-05-01,,,11.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-012,01070012,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-05-17,2011-05-17,2011-05-17,2011-05-17,27.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-070-014,01070014,070,32.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-30,2011-05-30,,,33.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-014,01070014,070,32.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-08,2011-07-08,2011-07-09,2011-07-09,72.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-014,01070014,070,32.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PAIN IN LUMBAR AREA,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-02,2011-12-02,,,219.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-25,2011-07-25,2011-07-25,2011-07-25,88.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,CHILL,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-30,2011-07-30,2011-08-01,2011-08-01,93.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-30,2011-07-30,2011-08-01,2011-08-01,93.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-05,2011-08-05,2011-08-12,2011-08-12,99.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-06,2011-08-06,2011-08-08,2011-08-08,100.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-26,2011-08-26,2011-09-09,2011-09-09,120.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-02,2011-09-02,2011-09-16,2011-09-16,127.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,EDEMA OF LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-28,2011-08-28,2011-09-11,2011-09-11,122.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-09-12,2011-09-12,,,137.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,EDEMA OF LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-12,2011-09-12,2011-09-21,2011-09-21,137.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-28,2011-08-28,2011-09-11,2011-09-11,122.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,WORSENING WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-12,2011-09-12,2011-09-24,2011-09-24,137.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-25,2011-09-25,2011-10-18,2011-10-18,150.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,WORSENING WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-19,2011-10-19,,,174.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-09-30,2011-09-30,,,155.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-20,2011-10-20,,,175.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-015,01070015,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,TACHYCARDIA,Tachycardia,CARDIAC DISORDERS,2011-10-20,2011-10-20,,,175.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-13,2011-05-13,2011-05-20,2011-05-20,15.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-05-13,2011-05-13,2011-05-15,2011-05-15,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-25,2011-05-25,2011-07-10,2011-07-10,27.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-08,2011-07-08,2011-07-15,2011-07-15,71.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-017,01070017,070,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-05,2011-08-05,2011-08-12,2011-08-12,99.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-06-20,2011-06-20,,,4.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,BONE PAIN,Bone pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-20,2011-06-20,,,4.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-07-03,2011-07-03,,,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-08,2011-07-08,,,22.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ICTERUS,Jaundice,HEPATOBILIARY DISORDERS,2011-07-12,2011-07-12,2011-07-18,2011-07-18,26.0,N,NOT RELATED,1.0,1,1.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,EDEMA OF LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-12,2011-07-12,,,26.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-19,2011-07-19,,,33.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,INCREASE OF ALT-CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-07-15,2011-07-15,,,29.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,INCREASE OF AST-CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-07-15,2011-07-15,,,29.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,INCREASE OF ALKALINE PHOSPHATASE-CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-07-15,2011-07-15,,,29.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,INCREASE OF TOYAL BILIRUBIN-CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2011-07-15,2011-07-15,,,29.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-021,01070021,070,74.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ICTERUS,Jaundice,HEPATOBILIARY DISORDERS,2011-07-19,2011-07-19,,,33.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-21,2011-06-21,2011-06-26,2011-06-26,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-22,2011-06-22,2011-06-22,2011-06-22,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-22,2011-06-22,2011-06-26,2011-06-26,3.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,MYALGIA,Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-23,2011-06-23,2011-06-25,2011-06-25,4.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ARTHRALGIA,Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-23,2011-06-23,2011-06-25,2011-06-25,4.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-27,2011-06-27,2011-07-04,2011-07-04,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,RASH,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06-23,2011-06-23,2011-06-25,2011-06-25,4.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-022,01070022,070,52.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-05,2011-07-05,2011-07-07,2011-07-07,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,URTICARIA,Urticaria,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06-18,2011-06-18,2011-06-20,2011-06-20,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,URTICARIA,Urticaria,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-06-26,2011-06-26,2011-06-27,2011-06-27,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-02,2011-07-02,2011-11-23,2011-11-23,16.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ARTHRALGIA,Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07-23,2011-07-23,2011-07-24,2011-07-24,37.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,MYALGIA,Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07-23,2011-07-23,2011-07-24,2011-07-24,37.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-06,2011-08-06,,,51.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-26,2011-08-26,2011-09-02,2011-09-02,71.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-19,2011-07-19,2011-08-12,2011-08-12,33.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,EDEMA LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-17,2011-09-17,,,93.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-07-03,2011-07-03,2011-09-09,2011-09-09,17.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-09-10,2011-09-10,2011-10-14,2011-10-14,86.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-24,2011-11-24,,,161.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,COLITIS,Colitis,GASTROINTESTINAL DISORDERS,2011-11-07,2011-11-07,,,144.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-023,01070023,070,50.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-21,2011-11-21,2011-11-28,2011-11-28,158.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-24,2011-08-24,2011-08-25,2011-08-25,3.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-23,2011-08-23,2011-08-25,2011-08-25,2.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-29,2011-08-29,2011-09-12,2011-09-12,8.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-27,2011-09-27,2011-10-12,2011-10-12,37.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-27,2011-09-27,2011-09-30,2011-09-30,37.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-28,2011-09-28,2011-10-12,2011-10-12,38.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-03,2011-10-03,2011-10-11,2011-10-11,43.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-02,2011-11-02,2011-11-03,2011-11-03,73.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-31,2011-10-31,2011-11-28,2011-11-28,71.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,FLU-LIKE SYNDROM,Influenza like illness,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-13,2011-11-13,2011-11-26,2011-11-26,84.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-28,2011-11-28,2011-11-30,2011-11-30,99.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,WORSENING WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-28,2011-11-28,,,99.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-28,2011-11-28,,,99.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-11-28,2011-11-28,2011-12-01,2011-12-01,99.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-05,2011-12-05,2011-12-26,2011-12-26,106.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-024,01070024,070,78.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-10,2011-08-10,2011-09-03,2011-09-03,-12.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,PAIN IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-08-27,2011-08-27,,,4.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,WEGHT LOSS,Weight decreased,INVESTIGATIONS,2011-09-14,2011-09-14,2011-09-14,2011-09-14,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-10-20,2011-10-20,,,58.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ICTERUS,Jaundice,HEPATOBILIARY DISORDERS,2011-12-10,2011-12-10,,,109.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-12-07,2011-12-07,,,106.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,"INCREASE OF AST, CS",Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-07,2011-12-07,,,106.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-025,01070025,070,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,"INCREASE OF ALT, CS",Alanine aminotransferase increased,INVESTIGATIONS,2011-12-07,2011-12-07,,,106.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-19,2011-09-19,2011-09-27,2011-09-27,14.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-28,2011-09-28,,,23.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-01,2011-10-01,,,26.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,GENERAL BODY PAIN,Pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-25,2011-10-25,,,50.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-026,01070026,070,64.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-25,2011-10-25,,,50.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-21,2011-09-21,2011-09-25,2011-09-25,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-29,2011-09-29,2012-01-09,2012-01-09,9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-027,01070027,070,78.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,EDEMA LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-12,2011-11-12,2012-01-09,2012-01-09,53.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-25,2011-11-25,2011-11-28,2011-11-28,1.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-11-26,2011-11-26,,,2.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-04,2011-12-04,2011-12-12,2011-12-12,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-09,2011-12-09,2011-12-12,2011-12-12,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-18,2011-12-18,,,24.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-06,2012-01-06,2012-01-20,2012-01-20,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-12,2012-01-12,,,49.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-029,01070029,070,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-01-09,2012-01-09,,,46.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-09,2011-12-09,,,3.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-12-08,2011-12-08,,,2.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-07,2011-12-07,2011-12-09,2011-12-09,1.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-14,2011-12-14,2011-12-16,2011-12-16,8.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-030,01070030,070,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-16,2011-12-16,2011-12-16,2011-12-16,10.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-033,01070033,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-14,2012-01-14,2012-01-16,2012-01-16,2.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-033,01070033,070,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-11-02,2012-11-02,,,295.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,WORSENING EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-02-29,2012-02-29,,,9.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-07,2012-03-07,2012-03-09,2012-03-09,16.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPEREMIA OF THE SKIN OF LOWER EXTREMITIES,Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-03-08,2012-03-08,2012-03-24,2012-03-24,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPEREMIA OF THE SKIN OF LOWER EXTREMITIES,Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-03-25,2012-03-25,,,34.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,DRY SKIN OF LOWER EXTREMITIES,Dry skin,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-03-08,2012-03-08,2012-03-24,2012-03-24,17.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-070-035,01070035,070,46.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ITCH SKIN OF LOWER EXTREMITIES,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-03-08,2012-03-08,2012-03-24,2012-03-24,17.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,GRANULOMA OF POSTOPERATIVE SCAR,Granuloma,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11-02,2010-11-02,,,-13.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ALT INCREASE (CLINICALLY SIGNIFICANT),Alanine aminotransferase increased,INVESTIGATIONS,2010-11-29,2010-11-29,2010-12-13,2010-12-13,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,AST INCREASE (CLINICALLY SIGNIFICANT),Aspartate aminotransferase increased,INVESTIGATIONS,2010-11-29,2010-11-29,2010-12-13,2010-12-13,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-20,2010-12-20,2011-01-05,2011-01-05,36.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,EDEMA OF LOWER EXTREMITIES,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-20,2011-02-20,,,98.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,"FATIGUE, GRADE 2",Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-27,2011-02-27,,,105.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CYST OF RIGHT OVARIUM,Ovarian cyst,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2010-11-02,2010-11-02,,,-13.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-071-001,01071001,071,51.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYDROPERICARDIUM,Pericardial effusion,CARDIAC DISORDERS,2010-11-02,2010-11-02,,,-13.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-071-002,01071002,071,59.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,AST INCREASE (CLINICALLY SIGNIFICANT),Aspartate aminotransferase increased,INVESTIGATIONS,2010-12-01,2010-12-01,2010-12-15,2010-12-15,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-071-003,01071003,071,50.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,CYST OF LEFT KIDNEY,Renal cyst,RENAL AND URINARY DISORDERS,2010-12-06,2010-12-06,,,-11.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-02-25,2011-02-25,2011-04-07,2011-04-07,39.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-02-24,2011-02-24,2011-02-25,2011-02-25,38.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-073-001,01073001,073,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HYPOTONIA,Hypotonia,NERVOUS SYSTEM DISORDERS,2011-02-24,2011-02-24,2011-03-03,2011-03-03,38.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-20,2011-06-20,2011-06-27,2011-06-27,145.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-073-002,01073002,073,66.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,STENOSIS OF DUODENUM,Duodenal stenosis,GASTROINTESTINAL DISORDERS,2011-06-24,2011-06-24,2011-06-27,2011-06-27,149.0,Y,NOT RELATED,1.0,4,4.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,JAUNDICE,Jaundice,HEPATOBILIARY DISORDERS,2011-03-23,2011-03-23,2011-04-03,2011-04-03,7.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-004,01073004,073,64.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-26,2011-05-26,2011-07-24,2011-07-24,71.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-14,2011-04-14,2011-04-21,2011-04-21,15.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-21,2011-04-21,2011-04-28,2011-04-28,22.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-30,2011-06-30,2011-07-07,2011-07-07,92.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-11,2011-08-11,127.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-18,2011-08-18,,,141.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-01,2011-09-01,2011-09-08,2011-09-08,155.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-005,01073005,073,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-01,2011-09-01,2011-09-08,2011-09-08,155.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-008,01073008,073,63.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,GASTRORRHAGIA,Gastric haemorrhage,GASTROINTESTINAL DISORDERS,2011-06-12,2011-06-12,2011-06-13,2011-06-13,4.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-02,2012-02-02,2012-02-09,2012-02-09,8.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-011,01073011,073,61.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-16,2012-02-16,2012-02-22,2012-02-22,22.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-02-20,2012-02-20,2012-02-22,2012-02-22,-4.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-07,2012-03-07,2012-03-15,2012-03-15,13.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-03-14,2012-03-14,2012-03-16,2012-03-16,20.0,Y,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-20,2012-03-20,2012-03-23,2012-03-23,26.0,Y,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-20,2012-03-20,2012-03-22,2012-03-22,26.0,Y,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,PAIN IN THE EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-02-26,2012-02-26,2012-03-27,2012-03-27,3.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-03-12,2012-03-12,2012-03-13,2012-03-13,18.0,N,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ASTENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-22,2012-03-22,2012-03-27,2012-03-27,28.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-073-012,01073012,073,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-26,2012-03-26,2012-03-27,2012-03-27,32.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-09,2011-03-09,2011-03-10,2011-03-10,14.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-17,2011-03-17,2011-04-21,2011-04-21,22.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-09,2011-03-09,2011-03-10,2011-03-10,14.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-04,2011-05-04,2011-05-12,2011-05-12,70.0,N,DEFINITELY,4.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED",CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-07,2011-04-07,2011-04-14,2011-04-14,43.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-07,2011-04-07,2011-04-14,2011-04-14,43.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-05,2011-05-05,2011-05-26,2011-05-26,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-19,2011-05-19,2011-06-02,2011-06-02,85.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-19,2011-05-19,2011-05-23,2011-05-23,85.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-02,2011-06-02,,,99.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-02,2011-06-02,,,99.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-06-02,2011-06-02,,,99.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-075-002,01075002,075,53.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,INDISPOSITION (ASTHENIA),Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-02,2011-06-02,,,99.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-27,2011-08-27,,,3.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-003,01075003,075,42.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,HEMATURIA,Haematuria,RENAL AND URINARY DISORDERS,2011-09-08,2011-09-08,2011-09-15,2011-09-15,15.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,LIVER IMPAIRMENT,Hepatic function abnormal,HEPATOBILIARY DISORDERS,2011-10-13,2011-10-13,2011-10-17,2011-10-17,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-03,2011-11-03,2011-11-24,2011-11-24,43.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-10,2011-11-10,2011-11-17,2011-11-17,50.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,TROMBPCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-08,2011-12-08,2011-12-15,2011-12-15,78.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-28,2011-12-28,2012-01-05,2012-01-05,98.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-28,2011-12-28,2012-01-05,2012-01-05,98.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,TROMBPCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,2012-03-01,2012-03-01,155.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ACUTE CARDIOVASCULAR FAILURE,Cardiac failure acute,CARDIAC DISORDERS,2012-04-03,2012-04-03,2012-04-04,2012-04-04,195.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-04,2012-04-04,,,196.0,Y,DEFINITELY,4.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-04,2012-04-04,,,196.0,Y,DEFINITELY,4.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-04,2012-04-04,,,196.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-28,2012-02-28,,,160.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ACUTE DESTRUCTIVE PANCREATITIS,Pancreatitis acute,GASTROINTESTINAL DISORDERS,2012-03-11,2012-03-11,,,172.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,127.0,N,DEFINITELY,4.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,127.0,N,DEFINITELY,4.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-29,2012-03-29,,,190.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,2012-03-01,2012-03-01,155.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-004,01075004,075,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-28,2012-02-28,,,160.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-075-005,01075005,075,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,HEPATOTOXITY,Hepatotoxicity,HEPATOBILIARY DISORDERS,2012-02-16,2012-02-16,2012-04-19,2012-04-19,15.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-005,01075005,075,49.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,TROMBOCITOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-15,2012-03-15,2012-04-19,2012-04-19,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-10,2012-03-10,2012-03-12,2012-03-12,2.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-22,2012-03-22,2012-03-29,2012-03-29,14.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-12,2012-04-12,2012-04-19,2012-04-19,35.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-17,2012-05-17,2012-05-24,2012-05-24,70.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,2012-06-14,2012-06-14,91.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,2012-06-14,2012-06-14,91.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-21,2012-06-21,2012-06-28,2012-06-28,105.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-12,2012-07-12,2012-07-19,2012-07-19,126.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-02,2012-08-02,,,147.0,N,DEFINITELY,4.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-16,2012-03-16,2012-03-18,2012-03-18,8.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-23,2012-08-23,2012-09-06,2012-09-06,168.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-10-04,2012-10-04,,,210.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-075-007,01075007,075,61.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-10-04,2012-10-04,,,210.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,DVT OF RIGHT LEG,Deep vein thrombosis,VASCULAR DISORDERS,2011-06-30,2011-06-30,2011-07-18,2011-07-18,8.0,Y,NOT RELATED,1.0,1,1.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,BILLIOTHORAX-BILE IN THE RIGHT PLEURAL CAVITI,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-12,2011-07-12,2011-07-18,2011-07-18,20.0,N,NOT RELATED,1.0,3,3.0,"DOSE REDUCED, DRUG WITHDRAWN","CONCOMITANT MEDICATION REQUIRED, OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PNEUMONIA S-VI IN THE RIGHT,Pneumonia,INFECTIONS AND INFESTATIONS,2011-07-06,2011-07-06,,,14.0,N,NOT RELATED,1.0,2,2.0,"DOSE REDUCED, DRUG WITHDRAWN","CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-076-001,01076001,076,57.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PANCREATIC METASTATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-06-30,2011-06-30,2011-07-26,2011-07-26,8.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,AGRANULOCYTOSIS,Agranulocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-12,2012-03-12,2012-03-19,2012-03-19,13.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-076-002,01076002,076,60.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-12,2012-03-12,2012-03-19,2012-03-19,13.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-20,2010-12-20,2010-12-22,2010-12-22,-3.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-02,2011-02-02,2011-02-11,2011-02-11,42.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-078-001,01078001,078,53.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-12-30,2010-12-30,2011-01-03,2011-01-03,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-078-003,01078003,078,70.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,CEREBRAL STROKE,Cerebrovascular accident,NERVOUS SYSTEM DISORDERS,2011-03-07,2011-03-07,,,8.0,N,UNLIKELY,2.0,1,1.0,"DOSE REDUCED, DRUG INTERRUPTED, DRUG WITHDRAWN",PROCEDURE TREATMENT REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,HYPERCREATINEMIA,Hypercreatinaemia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-20,2011-04-20,2011-04-27,2011-04-27,-22.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-05-27,2011-05-27,,,16.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-078-004,01078004,078,49.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,METASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-06-02,2011-06-02,2011-06-02,2011-06-02,22.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,FATAL,Y,N,Y,Y
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-08,2011-08-08,,,97.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,COMMON COLD,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2011-08-31,2011-08-31,2011-09-05,2011-09-05,120.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-12,2011-10-12,2011-10-19,2011-10-19,162.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-078-005,01078005,078,56.0,YEARS,F,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-19,2011-10-19,,,169.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,RINITIS,Rhinitis,INFECTIONS AND INFESTATIONS,2012-01-02,2012-01-02,2012-01-08,2012-01-08,34.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,FOCAL PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2012-01-25,2012-01-25,2012-02-01,2012-02-01,57.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,THROMBOSIS OF FOOTED VENAS,Venous thrombosis,VASCULAR DISORDERS,2012-05-14,2012-05-14,,,167.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,RINITIS,Rhinitis,INFECTIONS AND INFESTATIONS,2012-06-05,2012-06-05,2012-06-14,2012-06-14,189.0,N,NOT RELATED,1.0,1,1.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-28,2012-06-28,2012-07-17,2012-07-17,212.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-25,2012-07-25,2012-08-16,2012-08-16,239.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-23,2012-08-23,,,268.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-25,2012-07-25,2012-08-16,2012-08-16,239.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-078-011,01078011,078,71.0,YEARS,M,WHITE,5.0,RUS,RUSSIA,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ASCITIS,Ascites,GASTROINTESTINAL DISORDERS,2012-09-17,2012-09-17,,,293.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-10-21,2010-10-21,2010-10-28,2010-10-28,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,HYPERGLICEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-01-04,2011-01-04,,,83.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,METASTATIC PANCREATIC CARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-02-02,2011-02-02,2011-02-02,2011-02-02,112.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-10-28,2010-10-28,2010-11-04,2010-11-04,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-10-21,2010-10-21,2010-11-04,2010-11-04,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-001,01079001,079,77.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-10-28,2010-10-28,2010-11-04,2010-11-04,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-09,2010-12-09,2010-12-11,2010-12-11,50.0,N,DEFINITELY,4.0,4,4.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-11,2010-12-11,2010-12-16,2010-12-16,52.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,SWELLING OF THE LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-04,2011-01-04,,,76.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,'METASTATIC PANCREATIC CARCINOMA',Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-02-04,2011-02-04,2011-02-04,2011-02-04,107.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,TROMBOCYTOPENY,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-29,2010-12-29,2011-01-04,2011-01-04,70.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,TROMBOCYTOPENY,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-04,2011-01-04,2011-01-13,2011-01-13,76.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-04,2011-01-04,2011-01-13,2011-01-13,76.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-04,2011-01-04,2011-01-13,2011-01-13,76.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-002,01079002,079,70.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-13,2011-01-13,2011-01-20,2011-01-20,85.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-05-28,2011-05-28,,,214.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-079-006,01079006,079,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-28,2011-05-28,,,214.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-23,2011-06-23,2011-06-30,2011-06-30,239.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-21,2011-07-21,2011-07-28,2011-07-28,267.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-16,2011-06-16,,,232.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-03,2011-11-03,2011-11-10,2011-11-10,372.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,GGT INCREASED (ACCORDING TO THE CENTRAL LAB)- CLINICALLY SIGNIFICANT,Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-11-24,2011-11-24,2012-01-28,2012-01-28,393.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-009,01079009,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-10,2011-12-10,2012-01-28,2012-01-28,409.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-010,01079010,079,68.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,'METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2010-12-02,2010-12-02,2010-12-02,2010-12-02,24.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-28,2011-07-28,2011-08-04,2011-08-04,183.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-18,2011-08-18,2011-09-01,2011-09-01,204.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-01,2011-09-01,2011-09-08,2011-09-08,218.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-15,2011-09-15,,,232.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-079-012,01079012,079,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DEATH DUE TO THE METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-09-17,2011-09-17,2011-09-17,2011-09-17,234.0,Y,NOT RELATED,1.0,5,5.0,DRUG INTERRUPTED,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-01,2011-03-01,2011-03-09,2011-03-09,8.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-05-22,2011-05-22,,,90.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-29,2011-06-29,2011-07-13,2011-07-13,128.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-013,01079013,079,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ACUTE CHOLANGITIS,Cholangitis acute,HEPATOBILIARY DISORDERS,2011-09-12,2011-09-12,2011-09-22,2011-09-22,203.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-20,2011-04-20,2011-05-18,2011-05-18,7.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-20,2011-04-20,2011-04-27,2011-04-27,7.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-28,2011-05-28,,,45.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-014,01079014,079,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PAIN IN HYPOGASTRIUM,Abdominal pain lower,GASTROINTESTINAL DISORDERS,2011-05-28,2011-05-28,,,45.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-26,2011-05-26,2011-06-02,2011-06-02,8.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-26,2011-05-26,2011-06-02,2011-06-02,8.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-30,2011-06-30,2011-07-07,2011-07-07,43.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-07,2011-07-07,2011-07-28,2011-07-28,50.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ALT INCREASE - CLINICALLY SIGNIFICANT (ACCORDING TO THE CENTRAL LAB),Alanine aminotransferase increased,INVESTIGATIONS,2011-06-16,2011-06-16,2011-07-28,2011-07-28,29.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-28,2011-07-28,2011-08-04,2011-08-04,71.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-11,2011-08-11,2011-08-18,2011-08-18,85.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-18,2011-08-18,2011-08-25,2011-08-25,92.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-25,2011-08-25,2011-10-20,2011-10-20,99.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,AST INCREASE - CLINICALLY SIGNIFICANT (ACCORDING TO THE CENTRAL LAB),Aspartate aminotransferase increased,INVESTIGATIONS,2011-06-16,2011-06-16,2011-07-28,2011-07-28,29.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,GGT INCREASED (ACCORDING TO THE CENTRAL LAB RESULTS),Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-08-25,2011-08-25,2011-09-08,2011-09-08,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,GGT INCREASED (ACCORDING TO THE CENTRAL LAB RESULTS),Gamma-glutamyltransferase increased,INVESTIGATIONS,2011-09-08,2011-09-08,2012-06-25,2012-06-25,113.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-20,2011-10-20,2011-10-27,2011-10-27,155.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,LOSS APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-27,2011-09-27,2012-06-25,2012-06-25,132.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,2011-12-15,2011-12-15,162.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-08-25,2011-08-25,2011-12-15,2011-12-15,99.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-08-25,2011-08-25,2011-12-15,2011-12-15,99.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-22,2011-12-22,2012-02-23,2012-02-23,218.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-02-02,2012-02-02,2012-02-09,2012-02-09,260.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,2012-03-01,2012-03-01,281.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-01,2012-03-01,2012-04-26,2012-04-26,288.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-03-15,2012-03-15,2012-03-22,2012-03-22,302.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-03-29,2012-03-29,2012-04-19,2012-04-19,316.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-03-29,2012-03-29,2012-04-05,2012-04-05,316.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-05,2012-04-05,2012-04-19,2012-04-19,323.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-26,2012-04-26,2012-05-03,2012-05-03,344.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,2012-06-25,2012-06-25,358.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-05-17,2012-05-17,2012-05-24,2012-05-24,365.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-016,01079016,079,57.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-10,2012-06-10,2012-06-25,2012-06-25,389.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-18,2011-08-18,2011-08-23,2011-08-23,22.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-18,2011-08-18,2011-08-23,2011-08-23,22.0,Y,POSSIBLE/PROBABLE,3.0,4,4.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-018,01079018,079,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-02-29,2012-02-29,203.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-11-03,2011-11-03,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-03,2011-11-03,2011-11-10,2011-11-10,106.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-10,2011-11-10,2011-12-22,2011-12-22,113.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-05,2011-12-05,2011-12-29,2011-12-29,138.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-22,2011-12-22,2012-02-02,2012-02-02,155.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-29,2011-12-29,2012-01-25,2012-01-25,162.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-25,2012-01-25,2012-06-22,2012-06-22,189.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-20,2012-04-20,2012-04-26,2012-04-26,275.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,2012-06-22,2012-06-22,295.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,2012-06-22,2012-06-22,323.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-019,01079019,079,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,DEATH DUE TO THE PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-06-22,2012-06-22,2012-06-22,2012-06-22,338.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,"INCREASE OF ALP - CLINICALLY SIGNIFICANT""",Blood alkaline phosphatase increased,INVESTIGATIONS,2011-10-25,2011-10-25,2011-10-26,2011-10-26,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,INCREASE OF BILLIRUBINE - CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2011-10-25,2011-10-25,2011-10-26,2011-10-26,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-23,2011-10-23,2011-10-26,2011-10-26,13.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PLATTELET COUNT DECREASE (ACCORDING TO THE CENTRAL LAB RESULTS),Platelet count decreased,INVESTIGATIONS,2011-10-25,2011-10-25,2011-10-26,2011-10-26,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-020,01079020,079,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DEATH DUE TO THE PROGRESSION OF THE METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-10-26,2011-10-26,2011-10-26,2011-10-26,16.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-20,2011-11-20,,,19.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-021,01079021,079,64.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,DEATH DUE TO THE PROGRESSION OF THE METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-01-19,2012-01-19,2012-01-19,2012-01-19,79.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-11-21,2011-11-21,2011-12-19,2011-12-19,21.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-11-21,2011-11-21,2011-12-05,2011-12-05,21.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-12-05,2011-12-05,2011-12-12,2011-12-12,35.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-11-29,2011-11-29,2011-12-05,2011-12-05,29.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-12-05,2011-12-05,2011-12-12,2011-12-12,35.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-12-12,2011-12-12,2011-12-19,2011-12-19,42.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,BILIRUBIN INCREASE - CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2012-01-31,2012-01-31,2012-02-21,2012-02-21,92.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-02-07,2012-02-07,2012-02-20,2012-02-20,99.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,SCLERAL ICTERUS,Ocular icterus,EYE DISORDERS,2012-02-07,2012-02-07,2012-02-21,2012-02-21,99.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-20,2012-02-20,2012-02-21,2012-02-21,112.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,ISCHEMIC STROKE,Ischaemic stroke,NERVOUS SYSTEM DISORDERS,2012-02-16,2012-02-16,,,108.0,Y,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ACUTE MYOCARDIAL INFARCTION,Acute myocardial infarction,CARDIAC DISORDERS,2012-02-17,2012-02-17,,,109.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-079-022,01079022,079,59.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,PANCREATIC CARCINOMA METASTATIC,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-02-21,2012-02-21,2012-02-21,2012-02-21,113.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ABDOMINAL DISTENTION,Abdominal distension,GASTROINTESTINAL DISORDERS,2011-11-02,2011-11-02,2011-11-09,2011-11-09,1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-16,2011-11-16,2011-11-23,2011-11-23,15.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-16,2011-11-16,2011-11-23,2011-11-23,15.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-02-11,2012-02-11,2012-02-15,2012-02-15,102.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-02-15,2012-02-15,2012-02-22,2012-02-22,106.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-03-07,2012-03-07,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-02-29,2012-02-29,2012-04-10,2012-04-10,120.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-03-07,2012-03-07,2012-03-21,2012-03-21,127.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-04,2012-04-04,2012-04-10,2012-04-10,155.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-04-04,2012-04-04,2012-04-25,2012-04-25,155.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-18,2012-04-18,2012-04-25,2012-04-25,169.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-14,2011-12-14,2012-02-01,2012-02-01,43.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-03,2012-05-03,2012-05-16,2012-05-16,184.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-03,2012-05-03,2012-05-07,2012-05-07,184.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-05-03,2012-05-03,2012-05-16,2012-05-16,184.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-05-03,2012-05-03,2012-05-16,2012-05-16,184.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-05-03,2012-05-03,2012-05-07,2012-05-07,184.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,OBSTRUCTIVE JAUNDICE,Jaundice cholestatic,HEPATOBILIARY DISORDERS,2012-05-14,2012-05-14,2012-05-23,2012-05-23,195.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-04-18,2012-04-18,2012-05-23,2012-05-23,169.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-05-07,2012-05-07,2012-05-10,2012-05-10,188.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-16,2012-05-16,2012-05-23,2012-05-23,197.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-23,2012-05-23,2012-08-02,2012-08-02,204.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-05-10,2012-05-10,2012-05-16,2012-05-16,191.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-05-16,2012-05-16,2012-05-23,2012-05-23,197.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,THROMBOCYTOPENI,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-04,2012-07-04,2012-07-11,2012-07-11,246.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,ALT INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-08-02,2012-08-02,2012-08-08,2012-08-08,275.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,ALKALINE PHOSPHATASE INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-07-25,2012-07-25,2012-08-08,2012-08-08,267.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-12,2012-09-12,,,316.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-22,2012-08-22,2012-08-29,2012-08-29,295.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,GGT INCREASE - CLINICALLY SIGNIFICANT,Gamma-glutamyltransferase increased,INVESTIGATIONS,2012-08-22,2012-08-22,,,295.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-09-19,2012-09-19,2012-10-03,2012-10-03,323.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-023,01079023,079,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-10-17,2012-10-17,,,351.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-23,2011-11-23,2011-12-01,2011-12-01,7.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-08,2011-12-08,2011-12-15,2011-12-15,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-08,2011-12-08,2011-12-15,2011-12-15,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-22,2011-12-22,2012-01-12,2012-01-12,36.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-22,2011-12-22,2011-12-29,2011-12-29,36.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-29,2011-12-29,2012-01-05,2012-01-05,43.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-29,2011-12-29,2012-01-05,2012-01-05,43.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-29,2011-12-29,2012-01-05,2012-01-05,43.0,N,DEFINITELY,4.0,1,1.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-19,2012-01-19,2012-01-26,2012-01-26,64.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-19,2012-01-19,2012-02-09,2012-02-09,64.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-19,2012-01-19,2012-02-09,2012-02-09,64.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,71.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-02,2012-02-02,2012-02-09,2012-02-09,78.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-16,2012-02-16,2012-03-15,2012-03-15,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-16,2012-02-16,2012-02-23,2012-02-23,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-23,2011-11-23,2011-12-08,2011-12-08,7.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,2012-03-07,2012-03-07,99.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,2012-03-07,2012-03-07,99.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-22,2012-03-22,2012-04-05,2012-04-05,127.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-22,2012-03-22,2012-04-05,2012-04-05,127.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-22,2012-03-22,2012-05-17,2012-05-17,127.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-22,2012-03-22,2012-04-05,2012-04-05,127.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,LYMPHOPENIA,Lymphopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-29,2012-03-29,2012-04-05,2012-04-05,134.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,AST INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-03-29,2012-03-29,2012-04-05,2012-04-05,134.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-12,2012-04-12,2012-04-19,2012-04-19,148.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-12,2012-04-12,2012-05-03,2012-05-03,148.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-19,2012-04-19,2012-05-03,2012-05-03,155.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-19,2012-04-19,2012-04-26,2012-04-26,155.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,LYMPHOPENIA,Lymphopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-19,2012-04-19,2012-04-26,2012-04-26,155.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-26,2012-04-26,2012-05-03,2012-05-03,162.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,LYMPHOPENIA,Lymphopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-26,2012-04-26,2012-05-03,2012-05-03,162.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,LYMPHOPENIA,Lymphopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,2012-05-24,2012-05-24,176.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,2012-05-17,2012-05-17,176.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,34.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,2012-05-17,2012-05-17,176.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-17,2012-05-17,2012-05-31,2012-05-31,183.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,36.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-24,2012-05-24,2012-07-06,2012-07-06,190.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-024,01079024,079,34.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,37.0,DEATH DUE TO THE METASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-07-06,2012-07-06,2012-07-06,2012-07-06,233.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-23,2011-12-23,2012-01-04,2012-01-04,25.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,PAIN IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-12-23,2011-12-23,2012-01-04,2012-01-04,25.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-025,01079025,079,47.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DEATH DUE TO THE PROGRESSION OF THE METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-01-04,2012-01-04,2012-01-04,2012-01-04,37.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-13,2011-12-13,,,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-20,2011-12-20,2011-12-24,2011-12-24,8.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-026,01079026,079,61.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,METASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-24,2011-12-24,2011-12-24,2011-12-24,12.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-01-26,2012-01-26,2012-02-29,2012-02-29,15.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-16,2012-02-16,2012-02-29,2012-02-29,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-15,2012-03-15,2012-04-05,2012-04-05,64.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-12,2012-04-12,2012-04-19,2012-04-19,92.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-26,2012-04-26,2012-05-03,2012-05-03,106.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,2012-06-14,2012-06-14,120.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-05-24,2012-05-24,2012-05-31,2012-05-31,134.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-05-31,2012-05-31,2012-06-22,2012-06-22,141.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-029,01079029,079,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,DEATH DUE TO THE METHASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-06-22,2012-06-22,2012-06-22,2012-06-22,163.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,GGT INCREASE - CLINICALLY SIGNIFICANT (ACCORDING TO THE CENTRAL LAB),Gamma-glutamyltransferase increased,INVESTIGATIONS,2012-01-26,2012-01-26,2012-03-10,2012-03-10,1.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-09,2012-02-09,2012-02-16,2012-02-16,15.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,2012-03-10,2012-03-10,29.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ALP INCREASE - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-02-23,2012-02-23,2012-03-10,2012-03-10,29.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,GENERAL WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-26,2012-02-26,,,32.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,LOSS APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-02-27,2012-02-27,2012-03-10,2012-03-10,33.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DEEP VENOUS THROMBOSIS OF RIGHT CRUS,Deep vein thrombosis,VASCULAR DISORDERS,2012-02-27,2012-02-27,2012-03-10,2012-03-10,33.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-079-030,01079030,079,56.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DEATH DUE TO METASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-03-10,2012-03-10,2012-03-10,2012-03-10,45.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,PAIN IN RIGHT LOWER EXTREMITY,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-15,2011-04-15,,,187.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,"L3-S1 OSTEOCHONDROSIS WITH PROTRUSION OF VERTEBRAL DISK L3-L4, L4-L5",Intervertebral disc protrusion,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-26,2011-04-26,,,198.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,"L3-S1 OSTEOCHONDROSIS WITH PROTRUSION OF VERTEBRAL DISK L3-L4, L4-L5",Osteochondrosis,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-26,2011-04-26,,,198.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,L5-S1 HERNIA,Intervertebral disc protrusion,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-15,2011-04-15,2011-08-15,2011-08-15,187.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-05,2011-06-05,2011-06-07,2011-06-07,238.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-11,2011-07-11,2011-07-18,2011-07-18,274.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,L5-S1 HERNIA,Intervertebral disc protrusion,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08-15,2011-08-15,,,309.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-24,2011-10-24,2011-10-31,2011-10-31,379.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-05,2011-12-05,2011-12-12,2011-12-12,421.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-19,2011-12-19,2012-01-10,2012-01-10,435.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-26,2011-12-26,2012-01-10,2012-01-10,442.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-001,01080001,080,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-23,2012-01-23,2012-02-06,2012-02-06,470.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,'INCREASED ALT LEVEL (CONFIRMED AE),Alanine aminotransferase increased,INVESTIGATIONS,2010-11-11,2010-11-11,2010-12-09,2010-12-09,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2010-12-20,2010-12-20,2010-12-20,2010-12-20,54.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,GENERAL FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-01-20,2011-01-20,2011-01-22,2011-01-22,85.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,GENERAL FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-02-26,2011-02-26,2011-03-04,2011-03-04,122.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-02-26,2011-02-26,2011-03-04,2011-03-04,122.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,SECONDARY DIABETES MELLITUS,Diabetes mellitus,METABOLISM AND NUTRITION DISORDERS,2011-02-26,2011-02-26,,,122.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,"PAIN IN ABDOMINAL, LUMBAR AND ILIAC AREAS",Abdominal pain lower,GASTROINTESTINAL DISORDERS,2011-04-11,2011-04-11,,,166.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,"PAIN IN ABDOMINAL, LUMBAR AND ILIAC AREAS",Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-04-11,2011-04-11,,,166.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-005,01080005,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,"PAIN IN ABDOMINAL, LUMBAR AND ILIAC AREAS",Abdominal pain,GASTROINTESTINAL DISORDERS,2011-04-11,2011-04-11,,,166.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ATRIOVENTRICULAR HEART BLOCK,Atrioventricular block,CARDIAC DISORDERS,2011-01-26,2011-01-26,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-09,2011-02-09,2011-02-16,2011-02-16,15.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-25,2011-03-25,2011-03-25,2011-03-25,59.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HEMATURIA,Haematuria,RENAL AND URINARY DISORDERS,2011-04-20,2011-04-20,2011-05-04,2011-05-04,85.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HEMATURIA,Haematuria,RENAL AND URINARY DISORDERS,2011-06-15,2011-06-15,2011-06-22,2011-06-22,141.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,NEPHROPATHY,Nephropathy,RENAL AND URINARY DISORDERS,2011-06-22,2011-06-22,,,148.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-06,2011-07-06,2011-07-19,2011-07-19,162.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-07-06,2011-07-06,2011-07-13,2011-07-13,162.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,PLEURAL EFFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-07-06,2011-07-06,,,162.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-07-13,2011-07-13,2011-07-19,2011-07-19,169.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-19,2011-07-19,2011-07-27,2011-07-27,175.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-27,2011-07-27,2011-08-31,2011-08-31,183.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-22,2011-07-22,2011-07-22,2011-07-22,178.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-25,2011-08-25,2011-09-07,2011-09-07,212.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-31,2011-08-31,2011-09-07,2011-09-07,218.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-08-31,2011-08-31,2011-09-07,2011-09-07,218.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-09-07,2011-09-07,,,225.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-009,01080009,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-07,2011-09-07,,,225.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-09,2011-03-09,2011-03-16,2011-03-16,29.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-20,2011-04-20,2011-05-04,2011-05-04,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-11,2011-05-11,2011-05-25,2011-05-25,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-01,2011-06-01,2011-06-08,2011-06-08,113.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-06-08,2011-06-08,2011-06-12,2011-06-12,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-15,2011-06-15,2011-07-27,2011-07-27,127.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-03,2011-08-03,2011-08-17,2011-08-17,176.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-07,2011-09-07,2011-09-21,2011-09-21,211.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-28,2011-09-28,2011-10-19,2011-10-19,232.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-26,2011-10-26,2011-11-02,2011-11-02,260.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-011,01080011,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-09,2011-11-09,2011-11-16,2011-11-16,274.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-21,2011-03-21,2011-03-28,2011-03-28,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-21,2011-03-21,2011-03-28,2011-03-28,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-18,2011-04-18,2011-04-26,2011-04-26,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-10,2011-05-10,2011-06-20,2011-06-20,72.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-11,2011-07-11,2011-07-18,2011-07-18,134.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-25,2011-07-25,2011-08-22,2011-08-22,148.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-08,2011-08-08,2011-08-16,2011-08-16,162.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-29,2011-08-29,2011-09-05,2011-09-05,183.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-29,2011-08-29,2011-09-05,2011-09-05,183.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-02,2011-09-02,2011-09-04,2011-09-04,187.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-05,2011-09-05,2011-09-06,2011-09-06,190.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-02,2011-09-02,2011-09-04,2011-09-04,187.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-05,2011-09-05,2011-09-06,2011-09-06,190.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-09,2011-09-09,2011-09-11,2011-09-11,194.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-09,2011-09-09,,,194.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-013,01080013,080,48.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-12,2011-09-12,,,197.0,Y,POSSIBLE/PROBABLE,3.0,4,4.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-12,2011-05-12,2011-06-09,2011-06-09,15.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-19,2011-05-19,2011-05-26,2011-05-26,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-15,2011-06-15,2011-07-19,2011-07-19,49.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-27,2011-07-27,2011-08-17,2011-08-17,91.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,PAIN SYNDROME IN LUMBAR AREA,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07-22,2011-07-22,2011-08-06,2011-08-06,86.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-07,2011-09-07,2011-09-14,2011-09-14,133.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,WORSENING OF PAIN SYNDROME IN LUMBAR AREA,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-27,2011-09-27,2011-10-10,2011-10-10,153.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-09-28,2011-09-28,2011-10-12,2011-10-12,154.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-05,2011-10-05,2011-11-15,2011-11-15,161.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-06,2011-10-06,2011-10-13,2011-10-13,162.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,CO-1.01 MEDICATION ERROR,Medication error,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-05-19,2011-05-19,2011-05-19,2011-05-19,22.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-26,2011-10-26,2011-11-02,2011-11-02,182.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,PAIN SYNDROME IN LUMBAR AREA & RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-10-24,2011-10-24,2011-10-25,2011-10-25,180.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,PAIN SYNDROME IN LUMBAR AREA & RIGHT HYPOCHONDRIUM,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-24,2011-10-24,2011-10-25,2011-10-25,180.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,PAIN SYNDROME IN LUMBAR AREA & RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-10-25,2011-10-25,2011-10-31,2011-10-31,181.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,PAIN SYNDROME IN LUMBAR AREA & RIGHT HYPOCHONDRIUM,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-25,2011-10-25,2011-10-31,2011-10-31,181.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-24,2011-10-24,2011-10-27,2011-10-27,180.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,PAIN SYNDROME IN LUMBAR AREA & RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-10-31,2011-10-31,,,187.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,PAIN SYNDROME IN LUMBAR AREA & RIGHT HYPOCHONDRIUM,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-31,2011-10-31,,,187.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-11-02,2011-11-02,,,189.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-014,01080014,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-15,2011-11-15,,,202.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-06,2011-06-06,2011-06-09,2011-06-09,19.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,PROTEINURIA,Proteinuria,RENAL AND URINARY DISORDERS,2011-06-08,2011-06-08,2011-06-16,2011-06-16,21.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-09,2011-06-09,2011-07-21,2011-07-21,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,PROTEINURIA,Proteinuria,RENAL AND URINARY DISORDERS,2011-06-16,2011-06-16,2011-07-14,2011-07-14,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,VARICOSITY DESEASE OF LOWER EXTREMITIES GR II,Varicose vein,VASCULAR DISORDERS,2011-07-18,2011-07-18,2011-08-04,2011-08-04,61.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-28,2011-07-28,2011-08-11,2011-08-11,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,VARICOSITY DESEASE OF LOWER EXTREMITIES,Varicose vein,VASCULAR DISORDERS,2011-08-04,2011-08-04,2011-08-11,2011-08-11,78.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-18,2011-08-18,2011-09-01,2011-09-01,92.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-15,2011-09-15,2011-09-22,2011-09-22,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-22,2011-09-22,2011-09-29,2011-09-29,127.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-20,2011-10-20,2011-10-27,2011-10-27,155.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-16,2011-11-16,2011-12-07,2011-12-07,182.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-07,2011-12-07,2011-12-14,2011-12-14,203.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-04,2012-01-04,2012-01-12,2012-01-12,231.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-18,2012-01-18,2012-01-25,2012-01-25,245.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-01,2012-02-01,2012-02-08,2012-02-08,259.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-02-22,2012-02-22,273.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-14,2012-03-14,2012-03-21,2012-03-21,301.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-14,2012-03-14,2012-03-21,2012-03-21,301.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-04,2012-04-04,2012-04-11,2012-04-11,322.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-04,2012-04-04,2012-04-11,2012-04-11,322.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-23,2012-05-23,2012-05-30,2012-05-30,371.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-23,2012-05-23,2012-06-13,2012-06-13,371.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-06,2012-06-06,2012-06-13,2012-06-13,385.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-27,2012-06-27,2012-07-11,2012-07-11,406.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-07-11,2012-07-11,2012-07-11,2012-07-11,420.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-015,01080015,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-25,2012-07-25,2012-08-08,2012-08-08,434.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-09,2011-06-09,2011-06-16,2011-06-16,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-09,2011-06-09,2011-06-16,2011-06-16,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,AGGRAVATION OF CENTRAL PAIN SYNDROME,Central pain syndrome,NERVOUS SYSTEM DISORDERS,2011-06-13,2011-06-13,2011-06-17,2011-06-17,19.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,APPETITE DECREASE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-06-13,2011-06-13,2011-06-17,2011-06-17,19.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-06-16,2011-06-16,2011-06-17,2011-06-17,22.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-016,01080016,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-16,2011-06-16,,,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-24,2011-05-24,2011-06-30,2011-06-30,-9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-30,2011-06-30,2011-07-07,2011-07-07,29.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,SUPRAVENTRICULAR EXTRASYSTOLE,Supraventricular extrasystoles,CARDIAC DISORDERS,2011-06-30,2011-06-30,,,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-07,2011-07-07,2011-07-14,2011-07-14,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-06-30,2011-06-30,2011-07-07,2011-07-07,29.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-07-07,2011-07-07,2011-07-14,2011-07-14,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-14,2011-07-14,2011-08-04,2011-08-04,43.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-07-14,2011-07-14,2011-08-04,2011-08-04,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-28,2011-07-28,2011-08-04,2011-08-04,57.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-11,2011-08-11,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,LEUKOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-11,2011-08-11,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-04,2011-08-04,2011-08-11,2011-08-11,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-11,2011-08-11,2011-09-01,2011-09-01,71.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-11,2011-08-11,,,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,PAIN IN LOWER PART OF ABDOMEN,Abdominal pain lower,GASTROINTESTINAL DISORDERS,2011-08-17,2011-08-17,2011-08-18,2011-08-18,77.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-25,2011-08-25,2011-09-01,2011-09-01,85.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-01,2011-09-01,2011-09-08,2011-09-08,92.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-27,2011-08-27,,,87.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-08,2011-09-08,,,99.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-25,2011-08-25,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-019,01080019,080,82.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-01,2011-09-01,,,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-12,2011-08-12,2011-08-14,2011-08-14,25.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-18,2011-08-18,2011-08-22,2011-08-22,31.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-20,2011-08-20,2011-08-21,2011-08-21,33.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-26,2011-08-26,2011-08-27,2011-08-27,39.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-26,2011-08-26,,,39.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-020,01080020,080,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-28,2011-08-28,2011-08-29,2011-08-29,41.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,PAIN SYNDROME IN ABDOMEN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-10-15,2011-10-15,2011-10-22,2011-10-22,34.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-24,2011-10-24,2011-11-21,2011-11-21,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-10-31,2011-10-31,2011-11-07,2011-11-07,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PAIN WORSENING IN LEFT AND RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-11-04,2011-11-04,2011-12-18,2011-12-18,54.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-21,2011-11-21,2011-12-12,2011-12-12,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-12,2011-12-12,2011-12-19,2011-12-19,92.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-19,2011-12-19,,,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-022,01080022,080,54.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,PAIN WORSENING IN LEFT AND RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-12-18,2011-12-18,,,98.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,OSTEOARTROSIS,Osteoarthritis,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-20,2011-10-20,,,39.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,SUBCARTILAGINOUS OSTEOSCLEROSIS OF GLENOID SURFACE,Osteosclerosis,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-20,2011-10-20,,,39.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FROZEN SHOULDER,Periarthritis,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-25,2011-10-25,2011-11-01,2011-11-01,44.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-25,2011-10-25,2011-11-08,2011-11-08,44.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,FROZEN SHOULDER,Periarthritis,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-01,2011-11-01,,,51.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,HYPERPROTEINEMIA,Hyperproteinaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-07,2012-02-07,2012-02-15,2012-02-15,149.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-023,01080023,080,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-28,2012-02-28,,,170.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,VENTRICULAR PREMATURE BEATS,Ventricular extrasystoles,CARDIAC DISORDERS,2011-09-05,2011-09-05,,,-10.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-22,2012-02-22,2012-03-01,2012-03-01,161.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-21,2012-03-21,,,189.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-03-28,2012-03-28,2012-04-04,2012-04-04,196.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-04-04,2012-04-04,,,203.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-024,01080024,080,59.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-04-04,2012-04-04,,,203.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-09-15,2011-09-15,2011-09-29,2011-09-29,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-22,2011-09-22,2011-09-29,2011-09-29,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-09-22,2011-09-22,2011-10-13,2011-10-13,8.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-09-22,2011-09-22,2011-09-29,2011-09-29,8.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-29,2011-09-29,2011-10-06,2011-10-06,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-09-29,2011-09-29,2011-10-06,2011-10-06,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-09-29,2011-09-29,2011-10-06,2011-10-06,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-06,2011-10-06,2011-11-03,2011-11-03,22.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-10-06,2011-10-06,2011-11-17,2011-11-17,22.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-10-06,2011-10-06,2011-10-13,2011-10-13,22.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,2011-11-03,2011-11-03,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-03,2011-11-03,2011-11-10,2011-11-10,50.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-10,2011-11-10,2011-11-17,2011-11-17,57.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-17,2011-11-17,2011-12-08,2011-12-08,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-11-17,2011-11-17,,,64.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-11-17,2011-11-17,2011-11-24,2011-11-24,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-11-17,2011-11-17,2011-11-24,2011-11-24,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-24,2011-11-24,2011-12-08,2011-12-08,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-08,2011-12-08,2011-12-15,2011-12-15,85.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-025,01080025,080,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,TROMBOEMBOLISM OF RIGHT PULMONARY ARTERY BRONCH,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-15,2011-12-15,2011-12-19,2011-12-19,92.0,Y,NOT RELATED,1.0,5,5.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-10-03,2011-10-03,2011-10-10,2011-10-10,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-10,2011-10-10,,,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-07,2011-10-07,,,19.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-026,01080026,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-07,2011-10-07,,,19.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-06,2011-10-06,2011-10-07,2011-10-07,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-10,2011-11-10,2012-01-26,2012-01-26,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,PLEURISY,Pleurisy,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-17,2011-11-17,2012-01-12,2012-01-12,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PAIN SYNDROME IN RIGHT HYPOCHONDRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-12-19,2011-12-19,2011-12-23,2011-12-23,82.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-02,2012-02-02,2012-02-23,2012-02-23,127.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,2012-03-01,2012-03-01,148.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-027,01080027,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,"ANEMIA, GRADE 1",Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-01,2012-03-01,,,155.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-11-17,2011-11-17,2011-11-24,2011-11-24,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-11-24,2011-11-24,2011-12-08,2011-12-08,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-11-24,2011-11-24,2011-12-01,2011-12-01,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-01,2011-12-01,2011-12-08,2011-12-08,57.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-08,2011-12-08,2011-12-22,2011-12-22,64.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,INCREASED ALT  -CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-12-15,2011-12-15,2011-12-29,2011-12-29,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-22,2011-12-22,2011-12-29,2011-12-29,78.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-01-05,2012-01-05,2012-01-26,2012-01-26,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,INCREASED ALT - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-01-05,2012-01-05,2012-01-12,2012-01-12,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,INCREASED ALT - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-01-12,2012-01-12,2012-01-26,2012-01-26,99.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-01-19,2012-01-19,2012-01-26,2012-01-26,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,INCREASED ALT - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-01-26,2012-01-26,2012-02-16,2012-02-16,113.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,113.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,HIPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-02-02,2012-02-02,2012-02-16,2012-02-16,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,AST LEVEL INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-02-02,2012-02-02,2012-02-16,2012-02-16,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-028,01080028,080,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-02-16,2012-02-16,,,134.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-19,2011-10-19,2011-10-21,2011-10-21,7.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-19,2011-10-19,2011-10-21,2011-10-21,7.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,2011-11-03,2011-11-03,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-10-27,2011-10-27,2011-11-10,2011-11-10,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-10-27,2011-10-27,2011-11-17,2011-11-17,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-03,2011-11-03,2011-12-01,2011-12-01,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-11-10,2011-11-10,2011-11-24,2011-11-24,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-11-17,2011-11-17,2011-11-24,2011-11-24,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-11-24,2011-11-24,,,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-11-24,2011-11-24,,,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-12-01,2011-12-01,,,50.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-01,2011-12-01,2011-12-02,2011-12-02,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-01,2011-12-01,2011-12-02,2011-12-02,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,OBSTRUCTIVE JAUNDICE,Jaundice cholestatic,HEPATOBILIARY DISORDERS,2011-12-11,2011-12-11,2011-12-15,2011-12-15,60.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-030,01080030,080,36.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-16,2011-12-16,2012-01-17,2012-01-17,65.0,Y,NOT RELATED,1.0,5,5.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-24,2011-11-24,2011-12-22,2011-12-22,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-11-24,2011-11-24,2011-12-08,2011-12-08,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-11-24,2011-11-24,2011-12-01,2011-12-01,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-08,2011-12-08,2011-12-15,2011-12-15,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-22,2011-12-22,2011-12-29,2011-12-29,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-29,2011-12-29,2012-01-12,2012-01-12,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-01-05,2012-01-05,2012-01-12,2012-01-12,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,INCREASED ALT - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-01-05,2012-01-05,2012-01-12,2012-01-12,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,WORSENING CENTRAL PAIN SYNDROME,Central pain syndrome,NERVOUS SYSTEM DISORDERS,2012-01-19,2012-01-19,2012-01-20,2012-01-20,64.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-01,2011-12-01,2011-12-08,2011-12-08,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-16,2012-02-16,2012-02-27,2012-02-27,92.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,PHLEBITIS,Phlebitis,VASCULAR DISORDERS,2012-02-11,2012-02-11,2012-02-23,2012-02-23,87.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,,,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-02-23,2012-02-23,2012-02-27,2012-02-27,99.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-02-23,2012-02-23,,,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-23,2012-02-23,2012-02-27,2012-02-27,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-031,01080031,080,48.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-27,2012-02-27,,,103.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-06,2011-12-06,2011-12-13,2011-12-13,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-06,2011-12-06,2011-12-13,2011-12-13,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ARTERIAL HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-12-06,2011-12-06,2011-12-07,2011-12-07,15.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-13,2011-12-13,2011-12-20,2011-12-20,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-20,2011-12-20,,,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PAIN SYNDROME IN EPIGASTRIUM,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-12-24,2011-12-24,,,33.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-24,2011-12-24,,,33.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-032,01080032,080,58.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-12-24,2011-12-24,,,33.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ALT LEVEL INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-01-12,2012-01-12,2012-01-26,2012-01-26,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,AST LEVEL INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-01-19,2012-01-19,2012-01-26,2012-01-26,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ALT LEVEL INCREASED - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-02-09,2012-02-09,2012-02-23,2012-02-23,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-15,2012-03-15,2012-03-22,2012-03-22,106.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2012-03-15,2012-03-15,2012-03-22,2012-03-22,106.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ALT LEVEL INCREASED - CLINICALLY SIGNIFICNAT,Alanine aminotransferase increased,INVESTIGATIONS,2012-03-29,2012-03-29,2012-04-05,2012-04-05,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,AST LEVEL INCREASED - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-03-29,2012-03-29,2012-04-05,2012-04-05,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-05,2012-04-05,2012-04-12,2012-04-12,127.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,2012-05-17,2012-05-17,162.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,BODY WEIGHT DECREASE,Weight decreased,INVESTIGATIONS,2012-05-17,2012-05-17,,,169.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,,,190.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,2012-06-14,2012-06-14,190.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,2012-06-14,2012-06-14,190.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-07,2012-06-07,,,190.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,LOWER EXTREMITIES EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-07,2012-06-07,,,190.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-033,01080033,080,61.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,LEFT FOREARM EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-07,2012-06-07,,,190.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-034,01080034,080,52.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,INTOXICATION SYNDROME DUE TO PANCREATIC METASTATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-01-07,2012-01-07,2012-01-10,2012-01-10,3.0,Y,NOT RELATED,1.0,5,5.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,N,Y,Y
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-21,2011-12-21,2012-01-19,2012-01-19,-8.0,N,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,INCREASED ALT - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-01-12,2012-01-12,2012-01-19,2012-01-19,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-01-12,2012-01-12,2012-01-25,2012-01-25,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-19,2012-01-19,2012-01-25,2012-01-25,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-25,2012-01-25,2012-01-26,2012-01-26,28.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-26,2012-01-26,,,29.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-01-25,2012-01-25,2012-01-26,2012-01-26,28.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-01-26,2012-01-26,,,29.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-035,01080035,080,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,INCREASED AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-01-26,2012-01-26,,,29.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-06,2012-02-06,2012-02-20,2012-02-20,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-27,2012-02-27,,,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ALT LEVEL INCREASE - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-03-12,2012-03-12,2012-03-19,2012-03-19,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-036,01080036,080,65.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,AST LEVEL INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-03-12,2012-03-12,2012-03-19,2012-03-19,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-07,2012-03-07,2012-03-14,2012-03-14,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-07,2012-03-07,2012-03-14,2012-03-14,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-14,2012-03-14,2012-03-21,2012-03-21,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-21,2012-03-21,2012-03-29,2012-03-29,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-21,2012-03-21,2012-04-04,2012-04-04,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-21,2012-03-21,2012-04-04,2012-04-04,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-18,2012-04-18,2012-04-25,2012-04-25,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,WORSENING OF PAIN SYNDROME IN UPPER ABDOMINAL PART,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-04-24,2012-04-24,2012-04-25,2012-04-25,56.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-06,2012-06-06,2012-06-13,2012-06-13,99.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-06,2012-06-06,2012-06-13,2012-06-13,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-037,01080037,080,60.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERGLUCOSEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-06,2012-06-06,2012-06-13,2012-06-13,99.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-26,2012-03-26,2012-04-02,2012-04-02,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-23,2012-04-23,2012-05-03,2012-05-03,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LEUKOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-07,2012-05-07,,,57.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-080-038,01080038,080,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ARTERIAL THROMBOSIS OF FEMORAL SEGMENT ON THE RIGHT LOWER EXTREMITY,Arterial thrombosis limb,VASCULAR DISORDERS,2012-05-10,2012-05-10,2012-05-18,2012-05-18,60.0,Y,UNLIKELY,2.0,3,3.0,"DRUG INTERRUPTED, DRUG WITHDRAWN",,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-04-11,2012-04-11,2012-04-18,2012-04-18,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-11,2012-04-11,2012-04-18,2012-04-18,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-11,2012-04-11,2012-04-18,2012-04-18,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-18,2012-04-18,2012-04-25,2012-04-25,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-18,2012-04-18,2012-04-25,2012-04-25,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-08,2012-05-08,2012-05-16,2012-05-16,35.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-05-30,2012-05-30,,,57.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,INCREASED ALP LEVEL - CLINICALLY SIGNIFICANT,Blood alkaline phosphatase increased,INVESTIGATIONS,2012-06-06,2012-06-06,,,64.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,INCREASED AST LEVEL - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-06-06,2012-06-06,,,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-06-13,2012-06-13,2012-06-20,2012-06-20,71.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-13,2012-06-13,2012-07-02,2012-07-02,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-039,01080039,080,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-06-30,2012-06-30,2012-07-04,2012-07-04,88.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-12,2012-04-12,2012-04-19,2012-04-19,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-27,2012-06-27,2012-07-05,2012-07-05,84.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-05,2012-07-05,2012-07-19,2012-07-19,92.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ALT LEVEL INCREASED - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-07-19,2012-07-19,2012-07-26,2012-07-26,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,AST LEVLE INCREASE - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2012-07-19,2012-07-19,2012-07-26,2012-07-26,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,HYPERBILIRUBEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-07-19,2012-07-19,2012-08-02,2012-08-02,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,INCREASED ALT LEVEL - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2012-08-02,2012-08-02,2012-08-09,2012-08-09,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-02,2012-08-02,2012-09-06,2012-09-06,120.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-08-23,2012-08-23,2012-09-07,2012-09-07,141.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2012-08-30,2012-08-30,2012-09-06,2012-09-06,148.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-06,2012-09-06,2012-09-07,2012-09-07,155.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2012-09-06,2012-09-06,,,155.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2012-09-07,2012-09-07,,,156.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-080-040,01080040,080,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-07,2012-09-07,,,156.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-30,2010-11-30,2010-12-14,2010-12-14,22.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,UROLITHIASIS,Calculus urinary,RENAL AND URINARY DISORDERS,2010-12-02,2010-12-02,,,24.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-07,2010-12-07,2010-12-14,2010-12-14,29.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-07,2010-12-07,,,29.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2010-11-09,2010-11-09,2010-11-10,2010-11-10,1.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,RENAL COLIC,Renal colic,RENAL AND URINARY DISORDERS,2010-12-02,2010-12-02,2010-12-05,2010-12-05,24.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2010-12-14,2010-12-14,2010-12-28,2010-12-28,36.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,"TOXIC REACTION OF LOCAL ANESTHETIC (DIZZINESS, NUMBNESS OF TONGUE AND HANDS)",Dizziness,NERVOUS SYSTEM DISORDERS,2010-12-24,2010-12-24,2010-12-28,2010-12-28,46.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,"TOXIC REACTION OF LOCAL ANESTHETIC (DIZZINESS, NUMBNESS OF TONGUE AND HANDS)",Hypoaesthesia,NERVOUS SYSTEM DISORDERS,2010-12-24,2010-12-24,2010-12-28,2010-12-28,46.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,"TOXIC REACTION OF LOCAL ANESTHETIC (DIZZINESS, NUMBNESS OF TONGUE AND HANDS)",Hypoaesthesia oral,GASTROINTESTINAL DISORDERS,2010-12-24,2010-12-24,2010-12-28,2010-12-28,46.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2011-01-10,2011-01-10,,,63.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-001,01081001,081,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ARTERIAL HYPERTENSION WORSENING,Hypertension,VASCULAR DISORDERS,2010-11-09,2010-11-09,2010-11-09,2010-11-09,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-20,2010-12-20,2010-12-27,2010-12-27,8.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-20,2010-12-20,2010-12-27,2010-12-27,8.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-20,2010-12-20,2010-12-24,2010-12-24,8.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2010-12-20,2010-12-20,2010-12-27,2010-12-27,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-30,2010-12-30,2011-01-10,2011-01-10,18.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-24,2010-12-24,2010-12-27,2010-12-27,12.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-24,2011-01-24,2011-02-03,2011-02-03,43.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-24,2011-01-24,2011-02-03,2011-02-03,43.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-31,2011-01-31,2011-02-05,2011-02-05,50.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,BILATERAL LOW LOBES PNEUMONIA,Lobar pneumonia,INFECTIONS AND INFESTATIONS,2011-02-04,2011-02-04,2011-02-06,2011-02-06,54.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,BILATERAL LOW LOBES PNEUMONIA,Lobar pneumonia,INFECTIONS AND INFESTATIONS,2011-02-06,2011-02-06,2011-02-14,2011-02-14,56.0,Y,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-02-14,2011-02-14,2011-02-21,2011-02-21,64.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-28,2011-02-28,2011-03-14,2011-03-14,78.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-28,2011-02-28,2011-03-07,2011-03-07,78.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-09,2011-03-09,2011-03-14,2011-03-14,87.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-28,2011-03-28,2011-04-04,2011-04-04,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-28,2011-03-28,,,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-28,2011-03-28,2011-04-04,2011-04-04,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-21,2011-02-21,2011-02-27,2011-02-27,71.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-04,2011-04-04,,,113.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-04,2011-04-04,,,113.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-081-004,01081004,081,68.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-04,2011-04-04,,,113.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-01,2011-03-01,2011-03-09,2011-03-09,22.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-16,2011-03-16,2011-03-23,2011-03-23,37.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-03-16,2011-03-16,,,37.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,SOMNOLENTION,Somnolence,NERVOUS SYSTEM DISORDERS,2011-03-21,2011-03-21,,,42.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-30,2011-03-30,2011-04-06,2011-04-06,51.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-17,2011-01-17,2011-02-22,2011-02-22,-22.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-01,2011-03-01,2011-03-09,2011-03-09,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-16,2011-03-16,2011-03-30,2011-03-30,37.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-06,2011-04-06,2011-04-20,2011-04-20,58.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-04,2011-05-04,2011-05-18,2011-05-18,86.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-01,2011-06-01,2011-06-15,2011-06-15,114.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-06-29,2011-06-29,135.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-06-29,2011-06-29,135.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-06-29,2011-06-29,135.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,TROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-29,2011-06-29,2011-07-13,2011-07-13,142.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-13,2011-07-13,2011-07-20,2011-07-20,156.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-13,2011-07-13,2011-07-20,2011-07-20,156.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,TROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-27,2011-07-27,2011-08-10,2011-08-10,170.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,ARTERIAL HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-08-04,2011-08-04,2011-08-22,2011-08-22,178.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-14,2011-09-14,,,219.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,TROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-14,2011-09-14,,,219.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-08-04,2011-08-04,2011-08-22,2011-08-22,178.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-31,2011-08-31,2011-09-07,2011-09-07,205.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-14,2011-09-14,2011-09-21,2011-09-21,219.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-005,01081005,081,67.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-09-14,2011-09-14,,,219.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,CHOLEMIA,Cholaemia,HEPATOBILIARY DISORDERS,2011-03-03,2011-03-03,2011-03-31,2011-03-31,1.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-06,2011-03-06,2011-03-10,2011-03-10,4.0,N,UNLIKELY,2.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-03,2011-03-03,2011-03-17,2011-03-17,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-10,2011-03-10,2011-03-31,2011-03-31,8.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-02-25,2011-02-25,,,-6.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-24,2011-03-24,2011-03-31,2011-03-31,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-24,2011-03-24,2011-03-31,2011-03-31,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPOPROTEINEMIA,Hypoproteinaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-24,2011-03-24,,,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,CHOLEMIA,Cholaemia,HEPATOBILIARY DISORDERS,2011-03-31,2011-03-31,,,29.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-04,2011-04-04,,,33.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,HYPERGLICEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-10,2011-03-10,2011-03-17,2011-03-17,8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,HYPERGLICEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-17,2011-03-17,2011-03-24,2011-03-24,15.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,HYPERGLICEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-03-24,2011-03-24,,,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,DYSPNOE,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-03-17,2011-03-17,2011-03-17,2011-03-17,15.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-006,01081006,081,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-04-13,2011-04-13,2011-04-13,2011-04-13,42.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,HYPERGLICEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-15,2011-08-15,2011-08-29,2011-08-29,15.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,HYPERGLICEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-29,2011-08-29,2011-10-24,2011-10-24,29.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HYPERGLICEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-10-24,2011-10-24,2011-10-31,2011-10-31,85.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERGLICEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-10-31,2011-10-31,,,92.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-081-010,01081010,081,46.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DISEASE PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-11-19,2011-11-19,2011-11-19,2011-11-19,111.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-26,2011-12-26,2012-01-03,2012-01-03,29.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-011,01081011,081,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,HIGH LEVEL OF ALP - CLINICALLY SIGNIFICANT.,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-11-16,2011-11-16,,,-12.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-18,2012-01-18,2012-02-01,2012-02-01,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-18,2012-01-18,2012-02-01,2012-02-01,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,LOW LEVEL OF CALCIUM - CLINICALLY SIGNIFICANT,Blood calcium decreased,INVESTIGATIONS,2012-01-18,2012-01-18,2012-01-25,2012-01-25,15.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,LOW LEVEL OF CALCIUM - CLINICALLY SIGNIFICANT.,Blood calcium decreased,INVESTIGATIONS,2012-01-25,2012-01-25,2012-02-08,2012-02-08,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,TROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-01,2012-02-01,2012-02-15,2012-02-15,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-08,2012-02-08,2012-02-15,2012-02-15,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-08,2012-02-08,2012-02-22,2012-02-22,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-02-22,2012-02-22,43.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-22,2012-02-22,2012-02-29,2012-02-29,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-22,2012-02-22,2012-02-29,2012-02-29,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,LOW LEVEL OF CALCIUM - CLINICALLY SIGNIFICANT,Blood calcium decreased,INVESTIGATIONS,2012-02-29,2012-02-29,2012-03-07,2012-03-07,57.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-07,2012-03-07,2012-03-14,2012-03-14,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-14,2012-03-14,2012-03-21,2012-03-21,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,LEUCOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-14,2012-03-14,2012-03-21,2012-03-21,71.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-14,2012-03-14,2012-03-21,2012-03-21,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-14,2012-03-14,2012-03-21,2012-03-21,71.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,ACUTE RESPIRATORY INFECTION,Respiratory tract infection,INFECTIONS AND INFESTATIONS,2012-03-28,2012-03-28,2012-04-04,2012-04-04,85.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-18,2012-04-18,2012-05-03,2012-05-03,106.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,MIALGIA,Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-05-24,2012-05-24,2012-07-02,2012-07-02,142.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,2012-06-14,2012-06-14,156.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-07,2012-06-07,2012-06-21,2012-06-21,156.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-10,2012-05-10,2012-05-17,2012-05-17,128.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-21,2012-06-21,2012-07-02,2012-07-02,170.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,LOW LEVEL OF PLATELATES (CLINICAL SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2012-06-21,2012-06-21,2012-07-02,2012-07-02,170.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-13,2012-08-13,2012-08-27,2012-08-27,223.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-13,2012-08-13,2012-08-20,2012-08-20,223.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,HIGH LEVEL OF PLATELETS (CLINICAL SIGNIFICANT),Platelet count increased,INVESTIGATIONS,2012-09-03,2012-09-03,2012-09-10,2012-09-10,244.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,AMENORHEA,Amenorrhoea,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2012-08-27,2012-08-27,,,237.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,LEUKOPENY,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-21,2012-06-21,2012-07-02,2012-07-02,170.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30.0,LOW LEVEL OF PLATELETS (CLINICAL SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2012-07-23,2012-07-23,2012-07-30,2012-07-30,202.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,31.0,HEMATURIA,Haematuria,RENAL AND URINARY DISORDERS,2012-07-30,2012-07-30,,,209.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,32.0,EDEMA OF RIGHT ANKLE JOINT,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-08-27,2012-08-27,2012-09-03,2012-09-03,237.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,33.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-03,2012-09-03,,,244.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,34.0,HIGH LEVEL OF BILIRUBIN (CLINICAL SIGNIFICANT),Blood bilirubin increased,INVESTIGATIONS,2012-09-10,2012-09-10,,,251.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35.0,OSALGIA,Bone pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-09-11,2012-09-11,,,252.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,36.0,EDEMA OF KNEES,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-09-11,2012-09-11,,,252.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,37.0,FACE EDEMA,Face oedema,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-09-11,2012-09-11,,,252.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,38.0,DYSPNOE,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-09-21,2012-09-21,,,262.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-081-012,01081012,081,39.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,39.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-09-21,2012-09-21,,,262.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NEUTROPENIE,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-22,2010-11-22,2010-11-30,2010-11-30,21.0,Y,DEFINITELY,4.0,4,4.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-22,2010-11-22,2010-12-06,2010-12-06,21.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-16,2010-11-16,2010-11-25,2010-11-25,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,PLATELET COUNT DECREASED (CLINICALLY,Platelet count decreased,INVESTIGATIONS,2010-11-15,2010-11-15,2011-11-22,2011-11-22,14.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NEUTROPHILE COUNT DECREASED (CLINICALLY SIGNIFICANT),Neutrophil count decreased,INVESTIGATIONS,2010-11-16,2010-11-16,2010-11-22,2010-11-22,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-15,2010-11-15,2010-11-22,2010-11-22,14.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-20,2010-12-20,2010-12-27,2010-12-27,49.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NEUTROPHILE COUNT DECREASED (CLINICALLY SIGNIFICANT),Neutrophil count decreased,INVESTIGATIONS,2010-12-20,2010-12-20,2010-12-27,2010-12-27,49.0,N,DEFINITELY,4.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PLATELET COUNT DECREASED (CLINICALLY SIGNIFICANT),Platelet count decreased,INVESTIGATIONS,2010-11-22,2010-11-22,2010-11-30,2010-11-30,21.0,Y,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-082-001,01082001,082,54.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-13,2010-12-13,2011-01-11,2011-01-11,42.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-02,2011-02-02,,,-5.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-02,2011-02-02,2011-02-14,2011-02-14,-5.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,LEUKOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-02,2011-02-02,,,-5.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ALKALINE PHOSPHATASE INCREASED (CLINICALLY SIGNIFICANT),Blood alkaline phosphatase increased,INVESTIGATIONS,2011-02-02,2011-02-02,2011-02-14,2011-02-14,-5.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ALKALINE PHOSPHATASE INCREASED (CLINICALLY SIGNIFICANT),,,2011-02-14,2011-02-14,,,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HYPERKALIEMIA,Hyperkalaemia,METABOLISM AND NUTRITION DISORDERS,2011-02-21,2011-02-21,,,15.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-09,2011-03-09,,,31.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-082-002,01082002,082,65.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,METASTATIC PANCREATIC CANSER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-03-16,2011-03-16,2011-03-16,2011-03-16,38.0,Y,NOT RELATED,1.0,5,5.0,DRUG INTERRUPTED,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-082-004,01082004,082,69.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,PLATELET COUNT DECREASED (CLINICALLY,Platelet count decreased,INVESTIGATIONS,2011-03-28,2011-03-28,,,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-082-004,01082004,082,69.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,GASTRORRHAGIA,Gastric haemorrhage,GASTROINTESTINAL DISORDERS,2011-05-02,2011-05-02,2011-05-06,2011-05-06,50.0,Y,POSSIBLE/PROBABLE,3.0,4,4.0,"DOSE REDUCED, DRUG INTERRUPTED, DRUG WITHDRAWN",,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,VENTRICULAR EXTRASYSTOLE,Ventricular extrasystoles,CARDIAC DISORDERS,2011-03-09,2011-03-09,2011-03-09,2011-03-09,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,TROMBOPHLEBITIS OF LEFT LEG'S VEINS,Thrombophlebitis,VASCULAR DISORDERS,2011-03-09,2011-03-09,2011-03-17,2011-03-17,1.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-17,2011-03-17,2011-03-19,2011-03-19,9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TROMBOSIS OF RIGHT LEG'S VEINS,Thrombosis,VASCULAR DISORDERS,2011-03-17,2011-03-17,2011-04-19,2011-04-19,9.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,QTC PROLONGATION,Electrocardiogram QT prolonged,INVESTIGATIONS,2011-04-06,2011-04-06,,,29.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,BONE PAIN,Bone pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-03-20,2011-03-20,2011-04-27,2011-04-27,12.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HIGH LEVEL OF ALT (CLINICALLY SIGNIFICANT),Alanine aminotransferase increased,INVESTIGATIONS,2011-03-23,2011-03-23,2011-04-05,2011-04-05,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HIGH LEVEL OF AST (CLINICALLY SIGNIFICANT),Aspartate aminotransferase increased,INVESTIGATIONS,2011-03-23,2011-03-23,2011-04-05,2011-04-05,15.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,HIGH LEVEL OF BILIRUBIN (CLINICALLY SIGNIFICANT),Blood bilirubin increased,INVESTIGATIONS,2011-04-05,2011-04-05,2011-04-06,2011-04-06,28.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-03-30,2011-03-30,2011-04-28,2011-04-28,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-03-30,2011-03-30,2011-04-10,2011-04-10,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-03-30,2011-03-30,2011-04-28,2011-04-28,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-10,2011-04-10,2011-04-27,2011-04-27,33.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-27,2011-04-27,,,50.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,CHEST PAIN NON-CARDIAC,Non-cardiac chest pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-01,2011-05-01,,,54.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,CARDIOMYOPATHY CYTOTOXIC,Cytotoxic cardiomyopathy,CARDIAC DISORDERS,2011-04-14,2011-04-14,,,37.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-083-001,01083001,083,72.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,CYSTITIS,Cystitis,INFECTIONS AND INFESTATIONS,2011-05-03,2011-05-03,2011-05-10,2011-05-10,56.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-27,2011-04-27,2011-05-04,2011-05-04,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,BILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-04-27,2011-04-27,2011-05-25,2011-05-25,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-01,2011-05-01,2011-05-31,2011-05-31,19.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HIGH LEVEL OF BILIRUBIN (CLINICALLY SIGNIFICANT),Blood bilirubin increased,INVESTIGATIONS,2011-05-25,2011-05-25,,,43.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-083-002,01083002,083,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-21,2011-05-21,,,39.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,TROMBOSIS OF LEFT POPLITEAL VEIN,Deep vein thrombosis,VASCULAR DISORDERS,2011-09-10,2011-09-10,,,32.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-18,2011-10-18,2011-10-26,2011-10-26,70.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-11,2011-10-11,2011-10-11,2011-10-11,63.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-18,2011-10-18,2011-10-18,2011-10-18,70.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-20,2011-10-20,2011-10-21,2011-10-21,72.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-26,2011-10-26,2011-10-28,2011-10-28,78.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-30,2011-10-30,2011-10-30,2011-10-30,82.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-01,2011-11-01,2011-11-01,2011-11-01,84.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-08,2011-11-08,2011-11-08,2011-11-08,91.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-15,2011-11-15,2011-11-15,2011-11-15,98.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-005,01083005,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,DEEP VEIN TROMBOSIS OF RIGHT LEG,Deep vein thrombosis,VASCULAR DISORDERS,2011-08-07,2011-08-07,,,-3.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,EDEMA OF BOTH FOOT,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-01,2011-10-01,2011-10-15,2011-10-15,12.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,EDEMA OF LEFT LEG,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-16,2011-10-16,2011-11-24,2011-11-24,27.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DEEP VENOUS THROMBOSIS OF RIGHT LEG,Deep vein thrombosis,VASCULAR DISORDERS,2011-10-16,2011-10-16,2011-10-21,2011-10-21,27.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-25,2011-10-25,2011-11-24,2011-11-24,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DEEP VENOUS THROMBOSIS OF RIGHT LEG,Deep vein thrombosis,VASCULAR DISORDERS,2011-10-21,2011-10-21,2011-11-24,2011-11-24,32.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-12,2011-11-12,2011-11-24,2011-11-24,54.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-006,01083006,083,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,METASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-11-24,2011-11-24,2011-11-24,2011-11-24,66.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-28,2011-11-28,2011-11-28,2011-11-28,7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-30,2011-11-30,2011-11-30,2011-11-30,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-04,2011-12-04,2011-12-05,2011-12-05,13.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-12,2011-12-12,2011-12-12,2011-12-12,21.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-12,2011-12-12,2011-12-31,2011-12-31,21.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-13,2011-12-13,2011-12-15,2011-12-15,22.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DUODENAL STENOSIS,Duodenal stenosis,GASTROINTESTINAL DISORDERS,2011-12-13,2011-12-13,2011-12-15,2011-12-15,22.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-01,2012-01-01,2012-01-06,2012-01-06,41.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PROSTATE ADENOMA,Prostatic adenoma,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-28,2011-12-28,,,37.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-008,01083008,083,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-07,2012-01-07,,,47.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-29,2011-11-29,2011-12-06,2011-12-06,-14.0,Y,NOT RELATED,1.0,4,4.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,N
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,SINUS TACHYCARDIA,Sinus tachycardia,CARDIAC DISORDERS,2011-12-13,2011-12-13,2011-12-13,2011-12-13,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-22,2011-11-22,,,-21.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-06,2011-12-06,,,-7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-14,2011-12-14,2011-12-14,2011-12-14,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-14,2011-12-14,2011-12-15,2011-12-15,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-21,2011-12-21,2011-12-21,2011-12-21,9.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-21,2011-12-21,2011-12-21,2011-12-21,9.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-09,2012-01-09,2012-01-10,2012-01-10,28.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,SUBCOMPENSATED STOMACH STENOSIS,Gastric stenosis,GASTROINTESTINAL DISORDERS,2012-01-10,2012-01-10,,,29.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-27,2011-12-27,2011-12-27,2011-12-27,15.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,TROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-24,2012-01-24,2012-01-31,2012-01-31,43.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-02,2012-02-02,2012-02-03,2012-02-03,52.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-04,2012-02-04,,,54.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-02,2012-02-02,2012-02-03,2012-02-03,52.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-010,01083010,083,53.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,TROMBOSIS OF LEFT FEMORAL VEIN,Deep vein thrombosis,VASCULAR DISORDERS,2012-02-14,2012-02-14,,,64.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-10,2011-12-10,2011-12-10,2011-12-10,12.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,HIGH LEVEL OF ALT AND AST - CLINICALLY SIGNIFICANT,Alanine aminotransferase increased,INVESTIGATIONS,2011-12-13,2011-12-13,2011-12-27,2011-12-27,15.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,HIGH LEVEL OF ALT AND AST - CLINICALLY SIGNIFICANT,Aspartate aminotransferase increased,INVESTIGATIONS,2011-12-13,2011-12-13,2011-12-27,2011-12-27,15.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TROMBOSIS OF DEEP VEINS,Deep vein thrombosis,VASCULAR DISORDERS,2011-12-13,2011-12-13,,,15.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,TROMBOSIS OF VENA CAVA POSTERIOR,Vena cava thrombosis,VASCULAR DISORDERS,2011-12-13,2011-12-13,,,15.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,TROMBOSIS OF LEFT MEDIAL SURRAL VEINS,Venous thrombosis limb,VASCULAR DISORDERS,2011-12-29,2011-12-29,,,31.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,TELA- TROMBOEMBOLISM OF LUNG ARTERIA,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-27,2011-12-27,,,29.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-19,2012-01-19,2012-01-20,2012-01-20,52.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,AGGRAVATION OF HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-01-19,2012-01-19,2012-01-25,2012-01-25,52.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-19,2012-01-19,2012-01-24,2012-01-24,52.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-19,2012-01-19,2012-01-24,2012-01-24,52.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,HIGH LEVEL OF BILIRUBIN - CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2012-01-24,2012-01-24,2012-01-24,2012-01-24,57.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-011,01083011,083,67.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,PROGRESSIVE OF PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-01-17,2012-01-17,2012-02-04,2012-02-04,50.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,SECRETORY DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-28,2011-11-28,2011-12-05,2011-12-05,-15.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,AGGRAVATION OF HYPERTENSION DISEASE,Hypertension,VASCULAR DISORDERS,2011-12-05,2011-12-05,2011-12-05,2011-12-05,-8.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-12-21,2011-12-21,2011-12-22,2011-12-22,9.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-21,2011-12-21,2011-12-22,2011-12-22,9.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,HIGH LEVEL OF BLOOD PRESSURE-CLINICAL SIGNIFICANT,Hypertension,VASCULAR DISORDERS,2011-12-21,2011-12-21,2011-12-21,2011-12-21,9.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-27,2011-12-27,2012-01-10,2012-01-10,15.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,INFLUENZA,Influenza,INFECTIONS AND INFESTATIONS,2011-12-28,2011-12-28,2012-01-05,2012-01-05,16.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-10,2012-01-10,2012-01-12,2012-01-12,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-21,2012-01-21,2012-01-22,2012-01-22,40.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,ABDOMEN PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-02-11,2012-02-11,2012-02-13,2012-02-13,61.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,ABDOMEN PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-02-17,2012-02-17,2012-02-23,2012-02-23,67.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ABDOMEN PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-03-08,2012-03-08,2012-03-13,2012-03-13,87.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-20,2012-03-20,2012-04-03,2012-04-03,99.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,LEFT BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-03-30,2012-03-30,2012-03-31,2012-03-31,109.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,HIGH LEVEL OF AST (CLINICAL SIGNIFICANT),Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-17,2012-04-17,2012-05-03,2012-05-03,127.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-013,01083013,083,66.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,ABDOMEN PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-05-08,2012-05-08,2012-05-08,2012-05-08,148.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-02,2012-02-02,,,8.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-27,2012-01-27,2012-01-27,2012-01-27,2.0,N,DEFINITELY,4.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-02,2012-02-02,2012-02-02,2012-02-02,8.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-05,2012-02-05,2012-02-05,2012-02-05,11.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-05,2012-02-05,2012-02-05,2012-02-05,11.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-015,01083015,083,73.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-02-06,2012-02-06,2012-02-21,2012-02-21,12.0,Y,NOT RELATED,1.0,5,5.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,N,Y,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-29,2012-02-29,2012-03-01,2012-03-01,2.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-13,2012-03-13,2012-03-14,2012-03-14,15.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-13,2012-03-13,2012-03-13,2012-03-13,15.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-27,2012-03-27,2012-03-30,2012-03-30,29.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,PAIN IN THE SPINE,Spinal pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-01,2012-04-01,2012-04-01,2012-04-01,34.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,HIGH LEVEL OF ALT (CLINICAL SIGNIFICANT),Alanine aminotransferase increased,INVESTIGATIONS,2012-04-10,2012-04-10,,,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,PAIN IN SPINE,Spinal pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-08,2012-04-08,2012-04-08,2012-04-08,41.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-04-04,2012-04-04,2012-04-06,2012-04-06,37.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ABDOMEN PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-04-22,2012-04-22,2012-04-22,2012-04-22,55.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-017,01083017,083,40.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-04-10,2012-04-10,2012-04-13,2012-04-13,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,DEEP VENOUS THROMBOSIS OF BOTH LEGS,Deep vein thrombosis,VASCULAR DISORDERS,2012-02-21,2012-02-21,2012-04-18,2012-04-18,-7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-28,2012-02-28,2012-02-28,2012-02-28,1.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,MEDIAL SURAL VENOUS THROMBOSIS OF BOTH LEGS,Venous thrombosis limb,VASCULAR DISORDERS,2012-03-30,2012-03-30,2012-04-18,2012-04-18,32.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-03-27,2012-03-27,,,29.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-09,2012-04-09,2012-04-09,2012-04-09,42.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-04-10,2012-04-10,2012-04-14,2012-04-14,43.0,N,DEFINITELY,4.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,HIGH LEVEL OF AST (CLINICAL SIGNIFICANT),Aspartate aminotransferase increased,INVESTIGATIONS,2012-04-10,2012-04-10,2012-04-24,2012-04-24,43.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,ABDOMEN PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-04-23,2012-04-23,2012-04-25,2012-04-25,56.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-17,2012-04-17,2012-04-19,2012-04-19,50.0,N,DEFINITELY,4.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,HYPERTERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-24,2012-04-24,2012-05-05,2012-05-05,57.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-25,2012-04-25,2012-05-05,2012-05-05,58.0,N,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-06,2012-05-06,2012-05-15,2012-05-15,69.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,OEDEMA OF BOTH LEGS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-08,2012-05-08,,,71.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-12,2012-06-12,2012-06-26,2012-06-26,106.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,ABDOMEN PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-04-26,2012-04-26,2012-06-20,2012-06-20,59.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,ACUTE BRONCHITIS,Bronchitis,INFECTIONS AND INFESTATIONS,2012-06-12,2012-06-12,2012-06-24,2012-06-24,106.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-19,2012-06-19,,,113.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,HYPOCALCEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2012-06-19,2012-06-19,2012-06-26,2012-06-26,113.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-07-05,2012-07-05,,,129.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-083-018,01083018,083,58.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-10,2012-07-10,,,134.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-06,2011-05-06,2011-05-20,2011-05-20,30.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-13,2011-07-13,2011-07-27,2011-07-27,98.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-03,2011-08-03,2011-08-23,2011-08-23,119.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-31,2011-08-31,2011-09-21,2011-09-21,147.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-28,2011-09-28,2011-10-19,2011-10-19,175.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-26,2011-10-26,2011-11-16,2011-11-16,203.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-23,2011-11-23,2011-11-30,2011-11-30,231.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-30,2011-11-30,2011-12-14,2011-12-14,238.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-28,2011-12-28,2012-01-04,2012-01-04,266.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-04,2012-01-04,2012-01-11,2012-01-11,273.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-15,2012-02-15,2012-02-29,2012-02-29,315.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-22,2012-02-22,2012-02-29,2012-02-29,322.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-29,2012-02-29,2012-03-07,2012-03-07,329.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-07,2012-03-07,2012-03-28,2012-03-28,336.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-28,2012-03-28,2012-04-05,2012-04-05,357.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-05,2012-04-05,2012-04-11,2012-04-11,365.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-05,2012-04-05,2012-04-25,2012-04-25,365.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-18,2012-04-18,,,378.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,PLEURISY,Pleurisy,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-06,2012-03-06,2012-04-27,2012-04-27,335.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-25,2012-04-25,,,385.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-25,2012-04-25,,,385.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-001,01084001,084,45.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-25,2012-04-25,,,385.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-002,01084002,084,51.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,PAIN IN THE THORACIC SPINE,Spinal pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-10,2011-07-10,,,54.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-17,2011-08-17,2011-08-23,2011-08-23,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-31,2011-08-31,,,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-004,01084004,084,57.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-09-04,2011-09-04,2011-09-04,2011-09-04,54.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-01-22,2012-01-22,2012-03-02,2012-03-02,110.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-22,2012-01-22,2012-03-02,2012-03-02,110.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-03-02,2012-03-02,,,150.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-005,01084005,084,44.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-02,2012-03-02,,,150.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-06,2011-12-06,2012-04-04,2012-04-04,-15.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,N
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-04,2012-04-04,2012-04-11,2012-04-11,106.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-11,2012-04-11,2012-07-18,2012-07-18,113.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-30,2012-05-30,2012-06-06,2012-06-06,162.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-13,2012-06-13,2012-06-27,2012-06-27,176.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-007,01084007,084,75.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-07-25,2012-07-25,,,218.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,UNKNOWN,N,N,N,Y
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-20,2011-12-20,2012-01-11,2012-01-11,-1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,N
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-04,2012-01-04,2012-01-11,2012-01-11,15.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-11,2012-01-11,2012-01-25,2012-01-25,22.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-11,2012-01-11,2012-02-01,2012-02-01,22.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-25,2012-01-25,2012-02-01,2012-02-01,36.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-25,2012-01-25,,,36.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-02-05,2012-02-05,,,47.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-084-008,01084008,084,73.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-05,2012-02-05,,,47.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,1.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-11,2012-01-11,2012-01-18,2012-01-18,15.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-04,2012-04-04,,,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-010,01084010,084,55.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,N,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,N/A,3.0,3.0,UROLITHIASIS,Calculus urinary,RENAL AND URINARY DISORDERS,2012-04-09,2012-04-09,,,104.0,N,NOT RELATED,1.0,3,3.0,"DRUG INTERRUPTED, DRUG WITHDRAWN",CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,EDEMA OF LOWER LIMBS,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-11,2012-04-11,,,78.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-01,2012-08-01,2012-08-08,2012-08-08,190.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-01,2012-08-01,2012-08-08,2012-08-08,190.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-011,01084011,084,64.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-15,2012-08-15,2012-08-22,2012-08-22,204.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-084-012,01084012,084,62.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,BLOOD BILIRUBIN INCREASED - CLINICALLY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2012-03-20,2012-03-20,,,14.0,N,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-02,2011-03-02,2011-04-04,2011-04-04,-47.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-04-18,2011-04-18,2011-05-04,2011-05-04,1.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,WORSENING OF ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-04,2011-05-04,2011-05-10,2011-05-10,17.0,Y,UNLIKELY,2.0,3,3.0,DRUG INTERRUPTED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-05-10,2011-05-10,2011-06-13,2011-06-13,23.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-13,2011-06-13,2011-06-21,2011-06-21,57.0,N,UNLIKELY,2.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-21,2011-06-21,2011-07-06,2011-07-06,65.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-06,2011-07-06,2011-07-13,2011-07-13,80.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-13,2011-07-13,2011-08-03,2011-08-03,87.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-085-001,01085001,085,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-03,2011-08-03,,,108.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-085-002,01085002,085,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,"HIGH ALKALINE PHOSPHATASE,CLINICALLY SIGNIFICANT",Blood alkaline phosphatase increased,INVESTIGATIONS,2012-07-11,2012-07-11,2012-08-03,2012-08-03,428.0,N,NOT RELATED,1.0,2,2.0,,"NONE, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-085-002,01085002,085,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,"LOW HBG, CLINICALLY SIGNIFICANT",Haemoglobin decreased,INVESTIGATIONS,2012-06-13,2012-06-13,2012-07-18,2012-07-18,400.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-085-002,01085002,085,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,"HIGH AST, CLINICALLY SIGNIFICANT",Aspartate aminotransferase increased,INVESTIGATIONS,2012-07-18,2012-07-18,2012-08-03,2012-08-03,435.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-085-002,01085002,085,52.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-08-01,2012-08-01,2012-08-03,2012-08-03,449.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-086-003,01086003,086,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,VOMMITING,Vomiting,GASTROINTESTINAL DISORDERS,2010-12-23,2010-12-23,,,29.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-086-003,01086003,086,63.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,CACHEXIA AS UNDERLYING SIGN OF SIGN OF METASTATIC PANCREATC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-01-14,2011-01-14,2011-02-25,2011-02-25,51.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-086-004,01086004,086,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,BLOOD BILIRUBIN INCREASED CLINICALY SIGNIFICANT,Blood bilirubin increased,INVESTIGATIONS,2011-03-24,2011-03-24,,,8.0,Y,NOT RELATED,1.0,4,4.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-086-004,01086004,086,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,EPIGASTRICAL PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-03-16,2011-03-16,,,-1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-086-004,01086004,086,50.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,PANCREATIC METASTATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-03-27,2011-03-27,2011-03-27,2011-03-27,11.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-086-006,01086006,086,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,BILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-05-10,2011-05-10,,,22.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-086-006,01086006,086,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,PROGRESSION OF PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-05-30,2011-05-30,2011-05-31,2011-05-31,42.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-086-006,01086006,086,63.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,SEVERE ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-05-17,2011-05-17,,,29.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-086-007,01086007,086,74.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-05,2011-07-05,2011-07-19,2011-07-19,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-086-007,01086007,086,74.0,YEARS,F,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-19,2011-07-19,2011-08-02,2011-08-02,50.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-12,2011-07-12,2011-07-19,2011-07-19,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ANAEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-19,2011-07-19,2011-08-23,2011-08-23,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-23,2011-08-23,2011-08-30,2011-08-30,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-30,2011-08-30,2011-09-13,2011-09-13,50.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-13,2011-09-13,2011-09-27,2011-09-27,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-27,2011-09-27,2011-10-11,2011-10-11,78.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-11,2011-10-11,2011-10-18,2011-10-18,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-086-008,01086008,086,49.0,YEARS,M,WHITE,5.0,UKR,UKRAINE,Eastern Europe,3.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-18,2011-10-18,,,99.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-10,2011-06-10,2011-06-14,2011-06-14,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-16,2011-06-16,2011-06-17,2011-06-17,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-06-27,2011-06-27,2011-06-27,2011-06-27,19.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-23,2011-06-23,2011-06-26,2011-06-26,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-06,2011-07-06,2011-07-06,2011-07-06,28.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2011-07-07,2011-07-07,2011-07-07,2011-07-07,29.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,DYSGUEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-06-23,2011-06-23,2011-07-06,2011-07-06,15.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-04,2011-08-04,2011-08-07,2011-08-07,57.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PARESTHESIAS,Paraesthesia,NERVOUS SYSTEM DISORDERS,2011-08-04,2011-08-04,2011-08-04,2011-08-04,57.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-002,01088002,088,70.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-12,2011-07-12,2011-07-21,2011-07-21,34.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-01,2011-06-01,2011-06-15,2011-06-15,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-02,2011-06-02,2011-06-03,2011-06-03,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-06-02,2011-06-02,2011-06-06,2011-06-06,3.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-06-08,2011-06-08,2011-06-09,2011-06-09,9.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,RIGHT CALF'S PAIN,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-08,2011-06-08,2011-06-12,2011-06-12,9.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-16,2011-06-16,2011-07-11,2011-07-11,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-15,2011-06-15,2011-06-17,2011-06-17,16.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-17,2011-06-17,2011-06-27,2011-06-27,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-06-15,2011-06-15,2011-07-11,2011-07-11,16.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,EPIGASTRALGIA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-06-22,2011-06-22,2011-07-26,2011-07-26,23.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-01,2011-07-01,2011-08-03,2011-08-03,32.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-13,2011-07-13,2011-07-25,2011-07-25,44.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07-28,2011-07-28,2011-07-28,2011-07-28,59.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,SHIVER,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-28,2011-07-28,2011-07-28,2011-07-28,59.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-27,2011-07-27,2011-08-10,2011-08-10,58.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-04,2011-08-04,2011-08-04,2011-08-04,66.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-03,2011-08-03,2011-08-17,2011-08-17,65.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-10,2011-08-10,2011-08-25,2011-08-25,72.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-17,2011-08-17,,,79.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-25,2011-08-25,2011-09-26,2011-09-26,87.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-07-27,2011-07-27,2011-08-03,2011-08-03,58.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,22.0,ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-03,2011-08-03,2011-08-30,2011-08-30,65.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,23.0,ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-30,2011-08-30,2011-09-13,2011-09-13,92.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,24.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-09-26,2011-09-26,2011-09-28,2011-09-28,119.0,N,UNLIKELY,2.0,2,2.0,DRUG INTERRUPTED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,25.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-09-28,2011-09-28,,,121.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,26.0,VESPERAL FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-01,2011-09-01,2011-09-15,2011-09-15,94.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,27.0,"ALT,SGPT INCREASE CLINICALLY SIGNIFICANT",Alanine aminotransferase increased,INVESTIGATIONS,2011-09-26,2011-09-26,2011-09-28,2011-09-28,119.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,28.0,"AST, SGOT INCREASE CLINICALLY SIGNIFICANT",Aspartate aminotransferase increased,INVESTIGATIONS,2011-09-26,2011-09-26,2011-09-28,2011-09-28,119.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,29.0,CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-01,2011-09-01,2011-09-06,2011-09-06,94.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,30.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-15,2011-09-15,,,108.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,31.0,ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-09-13,2011-09-13,,,106.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,32.0,EPIGASTRALGIAS,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-09-15,2011-09-15,2011-09-25,2011-09-25,108.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-003,01088003,088,71.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,33.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-09-20,2011-09-20,,,113.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,COLITIS,Colitis,GASTROINTESTINAL DISORDERS,2011-06-26,2011-06-26,,,17.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,Y,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,SEPSIS,Sepsis,INFECTIONS AND INFESTATIONS,2011-07-03,2011-07-03,2011-07-05,2011-07-05,24.0,Y,NOT RELATED,1.0,5,5.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-12,2011-06-12,2011-06-13,2011-06-13,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-11,2011-06-11,2011-06-11,2011-06-11,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-14,2011-06-14,,,5.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-14,2011-06-14,2011-06-14,2011-06-14,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-23,2011-06-23,2011-06-23,2011-06-23,14.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-24,2011-06-24,2011-06-28,2011-06-28,15.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-28,2011-06-28,2011-06-28,2011-06-28,19.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,OROPHARYNGEAL CANDIDIASIS,Oropharyngeal candidiasis,INFECTIONS AND INFESTATIONS,2011-06-30,2011-06-30,2011-07-03,2011-07-03,21.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-25,2011-06-25,2011-06-26,2011-06-26,16.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-27,2011-06-27,2011-06-27,2011-06-27,18.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-04,2011-07-04,,,25.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-004,01088004,088,68.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-06-25,2011-06-25,2011-06-27,2011-06-27,16.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-19,2011-07-19,2011-07-21,2011-07-21,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07-19,2011-07-19,2011-07-21,2011-07-21,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-07-19,2011-07-19,2011-09,,9.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-26,2011-07-26,2011-07-31,2011-07-31,16.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-17,2011-08-17,2011-08-17,2011-08-17,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,EDEMA (ON LOWER LIMBS),Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-20,2011-08-20,2011-09-05,2011-09-05,41.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-29,2011-08-29,2011-09,,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-29,2011-08-29,2011-08-30,2011-08-30,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,EDEMA (ON LOWER LIMBS),Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-05,2011-09-05,,,57.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-31,2011-08-31,2011-09-06,2011-09-06,52.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-09-06,2011-09-06,2011-09-07,2011-09-07,58.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-09-14,2011-09-14,2011-09-14,2011-09-14,66.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,COLICS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-09-14,2011-09-14,2011-09-14,2011-09-14,66.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ANEMIA CLINICALLY SIGNIFICANT,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-16,2011-09-16,,,68.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-09-30,2011-09-30,2011-10-04,2011-10-04,82.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,LOWER GENIAN HEMATOMA,Haematoma,VASCULAR DISORDERS,2011-10-14,2011-10-14,2011-10-31,2011-10-31,96.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,DYSGUEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-10-20,2011-10-20,2011-10-20,2011-10-20,102.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-11-09,2011-11-09,2011-11-21,2011-11-21,122.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,ABDOMINAL SPASMS,Abdominal rigidity,GASTROINTESTINAL DISORDERS,2011-11-13,2011-11-13,2011-11-15,2011-11-15,126.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-14,2011-11-14,,,127.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,LOWER LIMB'S INFLAMMATION,Inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-14,2011-11-14,2011-12-19,2011-12-19,127.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-29,2011-11-29,2011-11-29,2011-11-29,142.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-29,2011-11-29,2011-11-30,2011-11-30,142.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,ANXIO-DEPRESSIVE SYNDROME,Depression,PSYCHIATRIC DISORDERS,2011-12-05,2011-12-05,,,148.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-12-14,2011-12-14,2011-12-14,2011-12-14,157.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-005,01088005,088,82.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,IRON DEFICIENCY ANEMIA,Iron deficiency anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-30,2011-08-30,2011-09-06,2011-09-06,51.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,XEROSTOMIA,Dry mouth,GASTROINTESTINAL DISORDERS,2011-07-14,2011-07-14,2011-07-25,2011-07-25,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,VAGINAL MYCOSIS,Vulvovaginal mycotic infection,INFECTIONS AND INFESTATIONS,2011-07-14,2011-07-14,2011-07-31,2011-07-31,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-14,2011-07-14,,,2.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,RASH (ON KNEES),Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-07-14,2011-07-14,2011-07-25,2011-07-25,2.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-20,2011-07-20,2011-07-20,2011-07-20,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,DYSGUEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-08-03,2011-08-03,2011-08-27,2011-08-27,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,DYSPHAGIA,Dysphagia,GASTROINTESTINAL DISORDERS,2011-08-08,2011-08-08,2011-08-10,2011-08-10,27.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-09,2011-08-09,2011-10-05,2011-10-05,28.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-09,2011-08-09,2011-08-17,2011-08-17,28.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,EPIGASTRALGIAS,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-09-08,2011-09-08,2011-09-08,2011-09-08,58.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-21,2011-09-21,2011-09-30,2011-09-30,71.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,RHINOPHARYNGITIS,Nasopharyngitis,INFECTIONS AND INFESTATIONS,2011-10-09,2011-10-09,2011-10-29,2011-10-29,89.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,DYSPHAGIA,Dysphagia,GASTROINTESTINAL DISORDERS,2011-10-10,2011-10-10,2011-10-15,2011-10-15,90.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-10-17,2011-10-17,2011-10-26,2011-10-26,97.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,COLICS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-10-17,2011-10-17,,,97.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-10-20,2011-10-20,,,100.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,ACUTE CYSTITIS,Cystitis,INFECTIONS AND INFESTATIONS,2011-10-19,2011-10-19,2011-10-27,2011-10-27,99.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,URINARY INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-10-21,2011-10-21,2011-10-27,2011-10-27,101.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-03,2011-11-03,2011-11-04,2011-11-04,114.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-03,2011-11-03,2011-11-04,2011-11-04,114.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,"PARESTHESIAS (HANDS, MOUTH)",Paraesthesia,NERVOUS SYSTEM DISORDERS,2011-11-03,2011-11-03,,,114.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,"PARESTHESIAS (HANDS, MOUTH)",Paraesthesia oral,GASTROINTESTINAL DISORDERS,2011-11-03,2011-11-03,,,114.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-006,01088006,088,65.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-07-10,2011-07-10,2011-08-15,2011-08-15,-3.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-24,2011-07-24,2011-07-24,2011-07-24,12.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,LEFT CALF PAINS,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07-25,2011-07-25,2011-08-11,2011-08-11,13.0,N,UNLIKELY,2.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,LEFT CALF SUPERFICIAL VENOUS THROMBOSIS,Thrombophlebitis superficial,VASCULAR DISORDERS,2011-07-28,2011-07-28,2011-08-25,2011-08-25,16.0,N,UNLIKELY,2.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-30,2011-07-30,2011-08-01,2011-08-01,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-31,2011-07-31,2011-07-31,2011-07-31,19.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,EPIGASTRALGIAS,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-08-03,2011-08-03,2011-08-03,2011-08-03,22.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-04,2011-08-04,2011-08-09,2011-08-09,23.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ABDOMINAL DISTENSION,Abdominal distension,GASTROINTESTINAL DISORDERS,2011-08-11,2011-08-11,2011-08-18,2011-08-18,30.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-12,2011-08-12,,,31.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,LEFT CALF EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-18,2011-08-18,2011-08-25,2011-08-25,37.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-21,2011-08-21,2011-08-22,2011-08-22,40.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-21,2011-08-21,2011-08-22,2011-08-22,40.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,DYSGUEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-08-19,2011-08-19,,,38.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,EPIGASTRALGIA,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-08-15,2011-08-15,2011-08-22,2011-08-22,34.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-25,2011-08-25,2011-08-25,2011-08-25,44.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08,,2011-08-18,2011-08-18,,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,ASYMPTOMATIC PULMONARY EMBOLISM (RIGHT LOWER LOBE),Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-01,2011-09-01,,,51.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-09-05,2011-09-05,2011-09-06,2011-09-06,55.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-09-26,2011-09-26,2011-09-26,2011-09-26,76.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,ABDOMINAL + DORSAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-09-25,2011-09-25,,,75.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,ABDOMINAL + DORSAL PAINS,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-25,2011-09-25,,,75.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-30,2011-09-30,2011-10-19,2011-10-19,80.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-30,2011-09-30,2011-10-10,2011-10-10,80.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-30,2011-09-30,,,80.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-10-03,2011-10-03,2011-10-20,2011-10-20,83.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,DYSURIA,Dysuria,RENAL AND URINARY DISORDERS,2011-10-05,2011-10-05,2011-10-06,2011-10-06,85.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-21,2011-10-21,2011-10-23,2011-10-23,101.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-10-21,2011-10-21,2011-11-17,2011-11-17,101.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-11-10,2011-11-10,,,121.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-10,2011-11-10,2011-12-29,2011-12-29,121.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-06,2011-11-06,2011-12-29,2011-12-29,117.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-30,2011-11-30,2011-12-29,2011-12-29,141.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-007,01088007,088,71.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,PARESTHESIAS,Paraesthesia,NERVOUS SYSTEM DISORDERS,2011-12-02,2011-12-02,,,143.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,CONFUSION,Confusional state,PSYCHIATRIC DISORDERS,2011-09-07,2011-09-07,2011-09-12,2011-09-12,-9.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-07,2011-09-07,2011-09-09,2011-09-09,-9.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ARTERIAL HYPERTENSION,Hypertension,VASCULAR DISORDERS,2011-09-08,2011-09-08,2011-09-09,2011-09-09,-8.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-09-11,2011-09-11,2011-09-11,2011-09-11,-5.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,VAGAL MALAISE,Malaise,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-12,2011-09-12,2011-09-12,2011-09-12,-4.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,SOMNOLENCE,Somnolence,NERVOUS SYSTEM DISORDERS,2011-09-07,2011-09-07,2011-09-11,2011-09-11,-9.0,Y,NOT RELATED,1.0,3,3.0,,OTHER,INTERMITTENT,RECOVERED/RESOLVED,N,Y,N,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-09-09,2011-09-09,2011-09-28,2011-09-28,-7.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPOKALIEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-13,2011-09-13,2011-09-14,2011-09-14,-3.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-28,2011-09-28,2011-10-01,2011-10-01,13.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-28,2011-09-28,2011-10-16,2011-10-16,13.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-16,2011-10-16,,,31.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-19,2011-10-19,2011-10-21,2011-10-21,34.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,THROMBOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-21,2011-10-21,2011-10-25,2011-10-25,36.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,DYSPHONIA,Dysphonia,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-18,2011-09-18,,,3.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,URINARY INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-10-03,2011-10-03,,,18.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-19,2011-10-19,2011-10-20,2011-10-20,34.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,AGITATION,Agitation,PSYCHIATRIC DISORDERS,2011-09-08,2011-09-08,2011-09-11,2011-09-11,-8.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,AGITATION,Agitation,PSYCHIATRIC DISORDERS,2011-10-18,2011-10-18,,,33.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,CONFUSION,Confusional state,PSYCHIATRIC DISORDERS,2011-10-18,2011-10-18,,,33.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-088-008,01088008,088,67.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,SINUS TACHYCARDIA,Sinus tachycardia,CARDIAC DISORDERS,2011-09-16,2011-09-16,2011-10-28,2011-10-28,1.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,DRY MOUTH,Dry mouth,GASTROINTESTINAL DISORDERS,2011-11-11,2011-11-11,,,2.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-11-11,2011-11-11,2011-11-12,2011-11-12,2.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-14,2011-11-14,2011-12-15,2011-12-15,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-13,2011-11-13,,,4.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-12-14,2011-12-14,2012-01-05,2012-01-05,35.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-08,2011-12-08,2011-12-22,2011-12-22,29.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROAT DISCOMFORT WITH COLLECTION OF PHLEGM,Increased upper airway secretion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12,,2012-01-05,2012-01-05,,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,EDEMA OF RIGHT ARM,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-12,2011-12-12,2011-12-19,2011-12-19,33.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,THROMBOSIS OF RIGHT SUBCLAVIAN VEIN,Subclavian vein thrombosis,VASCULAR DISORDERS,2011-12-12,2011-12-12,,,33.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-009,01088009,088,57.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,PRURITUS (ABDOMEN AND BACK),Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-12-29,2011-12-29,,,50.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-27,2011-12-27,,,6.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-27,2011-12-27,2011-12-29,2011-12-29,6.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ABDOMINAL PAINS (HYPOCHONDRIUM),Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-12-23,2011-12-23,2012-02-10,2012-02-10,2.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DORSAL PAINS,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-07,2012-01-07,,,17.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,GASTROESOPHAGEAL REFLUX,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2012-01-13,2012-01-13,2012-02-01,2012-02-01,23.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,SHIVERS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-01,2012-02-01,2012-02-01,2012-02-01,42.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-02-22,2012-02-22,2012-05-29,2012-05-29,63.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,GASTROESOPHAGEAL REFLUX,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2012-03-02,2012-03-02,2012-05-15,2012-05-15,72.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,HEMORRHOIDS,Haemorrhoids,GASTROINTESTINAL DISORDERS,2012-03-07,2012-03-07,2012-04-24,2012-04-24,77.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,SHIVER,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04,,2012-04,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-010,01088010,088,64.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,POST-PRANDIAL EPIGASTRIC PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-06-08,2012-06-08,,,170.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,SMALL INTESTINE OCCLUSION (ILEUS),Ileus,GASTROINTESTINAL DISORDERS,2012-01-12,2012-01-12,2012-01-16,2012-01-16,-5.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ACUTE ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-01-11,2012-01-11,2012-01-16,2012-01-16,-6.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-12,2012-01-12,2012-01-12,2012-01-12,-5.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-19,2012-01-19,2012-01-20,2012-01-20,3.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-25,2012-01-25,2012-01-26,2012-01-26,9.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-17,2012-01-17,2012-01-28,2012-01-28,1.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-05,2012-03-05,2012-03-05,2012-03-05,49.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-25,2012-01-25,2012-01-28,2012-01-28,9.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-20,2012-01-20,,,4.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-15,2012-01-15,2012-01-24,2012-01-24,-2.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-25,2012-01-25,2012-01-29,2012-01-29,9.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,EYE REDNESS,Ocular hyperaemia,EYE DISORDERS,2012-01-26,2012-01-26,2012-02-02,2012-02-02,10.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-088-011,01088011,088,69.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-01-16,2012-01-16,,,-1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,THROAT PRURITUS,Throat irritation,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-04-06,2011-04-06,2011-04-28,2011-04-28,78.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-21,2011-04-21,2011-04-22,2011-04-22,93.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,STROKE,Cerebrovascular accident,NERVOUS SYSTEM DISORDERS,2011-06-23,2011-06-23,2011-07-05,2011-07-05,156.0,Y,UNLIKELY,2.0,3,3.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-06-30,2011-06-30,,,163.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-07-01,2011-07-01,,,164.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CERVICODYNIA,Neck pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-24,2011-06-24,2011-06-25,2011-06-25,157.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,HYPERTHERMIA,Hyperthermia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-28,2011-06-28,2011-06-28,2011-06-28,161.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,VOMIT,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-23,2011-06-23,2011-06-23,2011-06-23,156.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-24,2011-06-24,2011-06-24,2011-06-24,157.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2011-06-25,2011-06-25,2011-06-25,2011-06-25,158.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-001,01089001,089,69.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,RIGHT SHOULDER PAIN,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-25,2011-06-25,2011-07-03,2011-07-03,158.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-22,2011-06-22,2011-06-23,2011-06-23,1.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,DYSGUEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-06-22,2011-06-22,2011-07-06,2011-07-06,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-27,2011-06-27,2011-07-01,2011-07-01,6.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-06-22,2011-06-22,,,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-07-09,2011-07-09,2011-07-20,2011-07-20,18.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-13,2011-07-13,2011-07-16,2011-07-16,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-26,2011-07-26,2011-07-28,2011-07-28,35.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-15,2011-06-15,2011-06-27,2011-06-27,-7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ASTHENIA,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-17,2011-08-17,,,57.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-089-002,01089002,089,61.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-01,2011-07-01,,,10.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-06-29,2011-06-29,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-01,2011-07-01,2011-07-01,2011-07-01,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-06,2011-07-06,2011-07-11,2011-07-11,8.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,DIARHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-08,2011-07-08,2011-07-08,2011-07-08,10.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DIARHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-13,2011-07-13,2011-07-13,2011-07-13,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,DIARHOEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-07-19,2011-07-19,2011-07-19,2011-07-19,21.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-26,2011-07-26,2011-08-10,2011-08-10,28.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07-26,2011-07-26,2011-07-28,2011-07-28,28.0,N,DEFINITELY,4.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,THROMBOSIS,Thrombosis,VASCULAR DISORDERS,2011-08-18,2011-08-18,,,51.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-089-003,01089003,089,45.0,YEARS,F,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-03,2011-08-03,2011-08-05,2011-08-05,36.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-28,2012-01-28,2012-01-31,2012-01-31,11.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-30,2012-01-30,2012-01-30,2012-01-30,13.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-08,2012-02-08,,,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-10,2012-02-10,2012-02-14,2012-02-14,24.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-28,2012-01-28,,,11.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2012-02-15,2012-02-15,,,29.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-08,2012-02-08,,,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-25,2012-01-25,2012-01-27,2012-01-27,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-14,2012-03-14,2012-03-14,2012-03-14,57.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-14,2012-03-14,2012-03-14,2012-03-14,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-14,2012-03-14,2012-03-17,2012-03-17,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,ORAL MUCOSITIS,Stomatitis,GASTROINTESTINAL DISORDERS,2012-03-22,2012-03-22,,,65.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,VASCULAR PUPURA,Vascular purpura,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-04-04,2012-04-04,,,78.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,ABDOMINAL PAINS,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-02-15,2012-02-15,,,29.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-089-004,01089004,089,74.0,YEARS,M,,,FRA,FRANCE,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,GAMMAGT INCREASED-CLINICALLY SIGNIFICANT,Gamma-glutamyltransferase increased,INVESTIGATIONS,2012-03-14,2012-03-14,,,57.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,STROKE,Cerebrovascular accident,NERVOUS SYSTEM DISORDERS,2010-12-26,2010-12-26,2011-01-14,2011-01-14,12.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,"NERVOUS SYSTEM DISORDERS, SPASTICITY",Muscle spasticity,NERVOUS SYSTEM DISORDERS,2010-12-26,2010-12-26,2010-12-26,2010-12-26,12.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,GASTROINTESTINAL PAIN,Gastrointestinal pain,GASTROINTESTINAL DISORDERS,2011-03-23,2011-03-23,2011-07-15,2011-07-15,99.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-04-06,2011-04-06,,,113.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PERIPHERAL MOTOR NEUROPATHY,Peripheral motor neuropathy,NERVOUS SYSTEM DISORDERS,2011-04-23,2011-04-23,2011-07-26,2011-07-26,130.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-28,2011-06-28,2011-07-05,2011-07-05,196.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,GASTROINTESTINAL - MELAENA,Melaena,GASTROINTESTINAL DISORDERS,2011-07-15,2011-07-15,2011-07-16,2011-07-16,213.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,WORSENING OF ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-07-16,2011-07-16,2011-07-17,2011-07-17,214.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-10,2011-08-10,2011-09-14,2011-09-14,239.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-11,2011-08-11,2011-09-14,2011-09-14,240.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-001,01090001,090,62.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,STROKE,Cerebrovascular accident,NERVOUS SYSTEM DISORDERS,2011-01-15,2011-01-15,2011-01-20,2011-01-20,32.0,Y,UNLIKELY,2.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-04-10,2011-04-10,2011-04-10,2011-04-10,25.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-04-14,2011-04-14,2011-04-14,2011-04-14,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-04-14,2011-04-14,2011-04-14,2011-04-14,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,UPPER RESPIRATORY INFECTION,Upper respiratory tract infection,INFECTIONS AND INFESTATIONS,2011-05-24,2011-05-24,2011-05-31,2011-05-31,69.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ALOPECIA,Alopecia,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-05-27,2011-05-27,,,72.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-090-002,01090002,090,63.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06,,2011-06,,,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-003,01090003,090,55.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,DEEP VEIN THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-05-03,2011-05-03,,,23.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-090-003,01090003,090,55.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-05-17,2011-05-17,,,37.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-090-003,01090003,090,55.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-05-17,2011-05-17,,,37.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-090-003,01090003,090,55.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-05-17,2011-05-17,,,37.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,BILIARY TRACT INFECTION,Biliary tract infection,INFECTIONS AND INFESTATIONS,2011-05-16,2011-05-16,2011-05-17,2011-05-17,-15.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-20,2011-07-20,2011-07-27,2011-07-27,51.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-31,2011-08-31,2011-11-15,2011-11-15,93.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-31,2011-08-31,,,93.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,GASTROINTESTINAL - CHOLESTASIS DUE TO DYSFUNCTION OF STENT,Cholestasis,HEPATOBILIARY DISORDERS,2011-11-14,2011-11-14,2011-11-24,2011-11-24,168.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,GASTROINTESTINAL - CHOLESTASIS DUE TO DYSFUNCTION OF STENT,Stent malfunction,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-14,2011-11-14,2011-11-24,2011-11-24,168.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-11-15,2011-11-15,,,169.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-13,2012-02-13,,,259.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,SKIN INFECTION,Skin infection,INFECTIONS AND INFESTATIONS,2012-02-27,2012-02-27,,,273.0,N,UNLIKELY,2.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2012-03-14,2012-03-14,,,289.0,N,UNLIKELY,2.0,2,2.0,,OTHER,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,BILIARY TRACT INFECTION,Biliary tract infection,INFECTIONS AND INFESTATIONS,2011-05-18,2011-05-18,,,-13.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-090-004,01090004,090,68.0,YEARS,M,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,SUDDEN HEART DEATH,Sudden cardiac death,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-21,2012-05-21,2012-05-21,2012-05-21,357.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,OTHER,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06,,2011-08-08,2011-08-08,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,2.0,MUCOSITIS,Mucosal inflammation,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06,,,,,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2011-06-28,2011-06-28,,,28.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2011-07,,,,,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-090-005,01090005,090,76.0,YEARS,F,WHITE,5.0,SWE,SWEDEN,Western Europe,2.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-06-15,2011-06-15,,,15.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2010-11-16,2010-11-16,,,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,POOR GLUCOSE CONTROL (NOT SPECIFIED),Diabetes mellitus inadequate control,METABOLISM AND NUTRITION DISORDERS,2010-11-10,2010-11-10,,,-5.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2010-11-15,2010-11-15,,,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2010-11-15,2010-11-15,,,1.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,NASAL DRAINAGE,Rhinorrhoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-12-07,2010-12-07,2010-12-14,2010-12-14,23.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,SORE THROAT,Oropharyngeal pain,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2010-12-07,2010-12-07,2010-12-14,2010-12-14,23.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,BILATERAL TYMPANIC EFFUSIONS,Middle ear effusion,EAR AND LABYRINTH DISORDERS,2010-12-10,2010-12-10,2010-12-14,2010-12-14,26.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2010-12-15,2010-12-15,2010-12-21,2010-12-21,31.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2010-12-15,2010-12-15,2010-12-21,2010-12-21,31.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2010-12-15,2010-12-15,2010-12-21,2010-12-21,31.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2010-12-21,2010-12-21,2010-12-28,2010-12-28,37.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ACID REFLUX,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2011-03-20,2011-03-20,,,126.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-15,2011-02-15,2011-02-22,2011-02-22,93.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,LEUKOCYTOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-11-23,2010-11-23,2010-12-14,2010-12-14,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,LEUKOCYTOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2010-12-28,2010-12-28,2011-01-13,2011-01-13,44.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,LEUKOCYTOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-01-18,2011-01-18,2011-02-01,2011-02-01,65.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,LEUKOCYTOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-02-01,2011-02-01,2011-03-01,2011-03-01,79.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,LEUKOCYTOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-15,2011-03-15,2011-03-22,2011-03-22,121.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,LEUKOCYTOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-03-22,2011-03-22,,,128.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,PERIORBITAL EDEMA,Periorbital oedema,EYE DISORDERS,2011-07-15,2011-07-15,2012-04-03,2012-04-03,243.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,PRURITIS,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-07-15,2011-07-15,,,243.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,UPPER RESPIRATORY INFECTION,Upper respiratory tract infection,INFECTIONS AND INFESTATIONS,2011-10-03,2011-10-03,2011-10-07,2011-10-07,323.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-22,2011-11-22,,,373.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-22,2011-11-22,,,373.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,SINUSITIS,Sinusitis,INFECTIONS AND INFESTATIONS,2011-12-19,2011-12-19,2012-01-03,2012-01-03,400.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,UPPER RESPIRATORY INFECTION,Upper respiratory tract infection,INFECTIONS AND INFESTATIONS,2011-12-19,2011-12-19,2012-01-03,2012-01-03,400.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,SQUAMOUS CELL CARCINOMA,Squamous cell carcinoma,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-01-09,2012-01-09,2012-01-09,2012-01-09,421.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,FEVER BLISTER (LIP),Oral herpes,INFECTIONS AND INFESTATIONS,2012-01-25,2012-01-25,,,437.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-04-27,2011-04-27,2011-05-03,2011-05-03,164.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-05-03,2011-05-03,,,170.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,31.0,DRY EYES,Dry eye,EYE DISORDERS,2012-04-03,2012-04-03,,,506.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,32.0,ERYTHEMA AROUND EYES,Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-04-03,2012-04-03,2012-04-12,2012-04-12,506.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,33.0,PERIORBITAL EDEMA,Periorbital oedema,EYE DISORDERS,2012-04-03,2012-04-03,2012-04-12,2012-04-12,506.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,34.0,ERYTHEMA AROUND EYES,Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-04-14,2012-04-14,,,517.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35.0,PERIORBITAL EDEMA,Periorbital oedema,EYE DISORDERS,2012-04-14,2012-04-14,2012-06-26,2012-06-26,517.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,36.0,NASAL CONGESTION/SINUSITIS,Sinusitis,INFECTIONS AND INFESTATIONS,2012-06-08,2012-06-08,2012-06-19,2012-06-19,572.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,37.0,PERIPHERAL NEUROPATHY,Neuropathy peripheral,NERVOUS SYSTEM DISORDERS,2012-06-26,2012-06-26,,,590.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,38.0,PERIORBITAL EDEMA,Periorbital oedema,EYE DISORDERS,2012-08-21,2012-08-21,,,646.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-002,01092002,092,66.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,39.0,SKIN RASH ON SCALP & NECK,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-10-17,2012-10-17,,,703.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,RASH,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-08-15,2011-08-15,2011-09-06,2011-09-06,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-16,2011-08-16,,,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-06,2011-09-06,,,30.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-31,2011-08-31,2011-09-03,2011-09-03,24.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-31,2011-08-31,2011-09-03,2011-09-03,24.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,INCREASED FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-31,2011-08-31,2011-09-03,2011-09-03,24.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2011-08-31,2011-08-31,2011-09-03,2011-09-03,24.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,RIGHT LOWER EXTREMITY CELLULITIS,Cellulitis,INFECTIONS AND INFESTATIONS,2011-09-15,2011-09-15,2011-09-19,2011-09-19,39.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,EPIGASTRIC PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-09-06,2011-09-06,,,30.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-22,2011-08-22,2011-08-29,2011-08-29,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-17,2011-10-17,,,71.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,GASTROESOPHAGEAL REFLUX,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2011-10-10,2011-10-10,,,64.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-07,2011-11-07,,,92.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-003,01092003,092,76.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,PLATELET COUNT DECREASE-CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-01-10,2012-01-10,,,156.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-03,2012-02-03,,,-7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-09,2012-02-09,,,-1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2012-02-09,2012-02-09,,,-1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2012-02-12,2012-02-12,2012-02-13,2012-02-13,3.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2012-02-22,2012-02-22,2012-02-22,2012-02-22,13.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-22,2012-02-22,2012-02-23,2012-02-23,13.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,CHEST PAIN W/O HYPOXIA (NON CARDIAC),Non-cardiac chest pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-22,2012-02-22,2012-02-23,2012-02-23,13.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-22,2012-02-22,,,13.0,N,DEFINITELY,4.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,WORSENING ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2012-03-02,2012-03-02,2012-03-02,2012-03-02,22.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2012-03-22,2012-03-22,,,42.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,GASTROESOPHAGEAL REFLUX DISEASE/EARLY SATIETY,Early satiety,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-22,2012-03-22,,,42.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,GASTROESOPHAGEAL REFLUX DISEASE/EARLY SATIETY,Gastrooesophageal reflux disease,GASTROINTESTINAL DISORDERS,2012-03-22,2012-03-22,,,42.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2012-03-22,2012-03-22,2012-03-22,2012-03-22,42.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-04-03,2012-04-03,2012-04-04,2012-04-04,54.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,MALIGNANT ASCITES,Malignant ascites,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-04-03,2012-04-03,2012-04-04,2012-04-04,54.0,Y,NOT RELATED,1.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-04-03,2012-04-03,2012-04-04,2012-04-04,54.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,URINARY RETENTION,Urinary retention,RENAL AND URINARY DISORDERS,2012-04-05,2012-04-05,2012-04-07,2012-04-07,56.0,N,NOT RELATED,1.0,2,2.0,,"NONE, OTHER",INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-04-05,2012-04-05,2012-04-07,2012-04-07,56.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,PROTEIN MALNUTRITION,Malnutrition,METABOLISM AND NUTRITION DISORDERS,2012-04-05,2012-04-05,2012-04-07,2012-04-07,56.0,N,NOT RELATED,1.0,2,2.0,,,INTERMITTENT,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-04-03,2012-04-03,2012-04-04,2012-04-04,54.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2012-04-03,2012-04-03,2012-04-04,2012-04-04,54.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,ACUTE RENAL FAILURE,Renal failure acute,RENAL AND URINARY DISORDERS,2012-04-03,2012-04-03,2012-04-04,2012-04-04,54.0,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,PERITONEAL CARINOMATOSIS,Metastases to peritoneum,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-04-03,2012-04-03,2012-04-04,2012-04-04,54.0,Y,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,N,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,INCREASED ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-03-06,2012-03-06,,,26.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-007,01092007,092,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-22,2012-02-22,2012-02-24,2012-02-24,13.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-20,2012-02-20,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,WEIGHT LOSS/LOSS OF APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-02-20,2012-02-20,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,WEIGHT LOSS/LOSS OF APPETITE,Weight decreased,INVESTIGATIONS,2012-02-20,2012-02-20,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-27,2012-02-27,2012-03-05,2012-03-05,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-05,2012-03-05,,,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,DEEP VEIN THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2012-03-05,2012-03-05,,,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-05,2012-03-05,2012-03-09,2012-03-09,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-05,2012-03-05,,,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERING/RESOLVING,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PEDAL EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-05,2012-03-05,,,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,PANCREATIC ENZYME DEFICIENCY,Pancreatic enzymes decreased,INVESTIGATIONS,2012-02-28,2012-02-28,,,9.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2012-03-06,2012-03-06,2012-03-06,2012-03-06,16.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,"RASH ON TRUNK, CHEST & BACK",Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-03-08,2012-03-08,,,18.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,ITCHING FROM RASH,Rash pruritic,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-03-08,2012-03-08,,,18.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,BILATERAL EXTREMITIES BRUISING,Contusion,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-03-08,2012-03-08,,,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,LOWER EXTREMITY EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-05,2012-03-05,,,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-12,2012-03-12,,,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2012-03-12,2012-03-12,,,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,PERIORBITAL EDEMA,Periorbital oedema,EYE DISORDERS,2012-03-16,2012-03-16,,,26.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,ERYTHEMA,Erythema,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-03-16,2012-03-16,,,26.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-27,2012-02-27,,,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,THROMBOCYTOSIS,Thrombocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-12,2012-03-12,,,22.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-008,01092008,092,74.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,LEUKOCYTOSIS,Leukocytosis,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-16,2012-03-16,,,26.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-21,2012-03-21,,,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-22,2012-03-22,2012-03-22,2012-03-22,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FLU LIKE SYMPTOMS,Influenza like illness,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-21,2012-03-21,2012-03-22,2012-03-22,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ORAL-BROKEN TOOTH/CROWN,Tooth fracture,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-04-12,2012-04-12,2012-04-13,2012-04-13,24.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,DYSPEPSIA,Dyspepsia,GASTROINTESTINAL DISORDERS,2012-04-25,2012-04-25,,,37.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,PLATELETS DECREASED - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-05-02,2012-05-02,,,44.0,N,NOT RELATED,1.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-05-02,2012-05-02,,,44.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-05-23,2012-05-23,,,65.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ADENOCARCINOMA PANCREAS,Adenocarcinoma pancreas,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-07-21,2012-07-21,2012-07-24,2012-07-24,124.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-07-21,2012-07-21,2012-07-24,2012-07-24,124.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-07-21,2012-07-21,2012-07-24,2012-07-24,124.0,Y,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-07-21,2012-07-21,2012-07-24,2012-07-24,124.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-07-21,2012-07-21,2012-07-24,2012-07-24,124.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-07-21,2012-07-21,2012-07-24,2012-07-24,124.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-092-010,01092010,092,57.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,DIVERTICULITIS,Diverticulitis,INFECTIONS AND INFESTATIONS,2012-07-21,2012-07-21,2012-07-24,2012-07-24,124.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-29,2011-06-29,2011-06-30,2011-06-30,3.0,Y,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-06-29,2011-06-29,2011-06-30,2011-06-30,3.0,Y,DEFINITELY,4.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED",CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-06-28,2011-06-28,2011-06-28,2011-06-28,2.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-06-28,2011-06-28,2011-06-28,2011-06-28,2.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-06-22,2011-06-22,,,-5.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,N
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-06-28,2011-06-28,2011-06-29,2011-06-29,2.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-06-24,2011-06-24,,,-3.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,NAUSEA (INTERMITTENT),Nausea,GASTROINTESTINAL DISORDERS,2011-06-30,2011-06-30,2011-07-15,2011-07-15,4.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-29,2011-06-29,,,3.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,WORSENING EDEMA LIMB,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-06-30,2011-06-30,,,4.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,INFUSION RELATED REACTION (BURING AT IV SITE),Infusion site pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-11,2011-07-11,2011-07-11,2011-07-11,15.0,N,DEFINITELY,4.0,2,2.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-15,2011-07-15,2011-07-18,2011-07-18,19.0,Y,DEFINITELY,4.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07-15,2011-07-15,2011-07-18,2011-07-18,19.0,Y,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-18,2011-07-18,2011-07-19,2011-07-19,22.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-07-14,2011-07-14,2011-07-14,2011-07-14,18.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-07-15,2011-07-15,2011-07-18,2011-07-18,19.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-07-15,2011-07-15,2011-07-16,2011-07-16,19.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,HYPOMAGNESEMIA,Hypomagnesaemia,METABOLISM AND NUTRITION DISORDERS,2011-07-16,2011-07-16,2011-07-17,2011-07-17,20.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,ANAL HEMORRHAGE,Anal haemorrhage,GASTROINTESTINAL DISORDERS,2011-07-17,2011-07-17,2011-07-18,2011-07-18,21.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-093-001,01093001,093,74.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,RASH MACULO-PAPULAR,Rash maculo-papular,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-07-17,2011-07-17,,,21.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,THROMBOCYOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-08,2011-08-08,2011-08-22,2011-08-22,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,THROMBOCYOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-22,2011-08-22,2011-09-06,2011-09-06,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-22,2011-08-22,2011-09-06,2011-09-06,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,STOMACH CRAMPING (PAIN),Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-09-08,2011-09-08,2011-09-12,2011-09-12,32.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-09-09,2011-09-09,2011-09-12,2011-09-12,33.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-11,2011-09-11,2011-09-12,2011-09-12,35.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,THROMBOCYOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-19,2011-09-19,2011-10-03,2011-10-03,43.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-19,2011-09-19,2011-10-03,2011-10-03,43.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,EDEMA(RIGHT ANKLE/CALF),Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-14,2011-09-14,2011-10-03,2011-10-03,38.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-17,2011-10-17,2011-10-31,2011-10-31,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,LOWER EXTREMITY EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-11,2011-10-11,,,65.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-03,2011-10-03,2011-10-05,2011-10-05,57.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,WORSENING OF ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-29,2011-08-29,2011-10-31,2011-10-31,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,INTERMITTENT DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-28,2011-10-28,,,82.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,ENDOCRINE DISORDER/LOW TESTOSTERONE,Blood testosterone decreased,INVESTIGATIONS,2011-10-05,2011-10-05,,,59.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-07,2011-11-07,2011-12-05,2011-12-05,92.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-14,2011-11-14,2011-11-21,2011-11-21,99.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,THROMBOCYOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-14,2011-11-14,2011-11-28,2011-11-28,99.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-17,2011-11-17,2011-11-17,2011-11-17,102.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,LOW HEMOGLOBIN(ANEMIA),Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-05,2011-12-05,2012-01-23,2012-01-23,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-12,2011-12-12,2011-12-19,2011-12-19,127.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-16,2011-12-16,2011-12-18,2011-12-18,131.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-17,2011-12-17,2011-12-18,2011-12-18,132.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,STOMACH BLOATING,Abdominal distension,GASTROINTESTINAL DISORDERS,2011-12-17,2011-12-17,2011-12-18,2011-12-18,132.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-19,2011-12-19,2011-12-27,2011-12-27,134.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,INTERMITTENT STOMACH CRAMPING,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-12-26,2011-12-26,,,141.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,INTERMITTENT DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-26,2011-12-26,2012-01-26,2012-01-26,141.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,INTERMITTENT EYE BURNING,Eye irritation,EYE DISORDERS,2011-12-01,2011-12-01,,,116.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-09,2012-01-09,2012-01-16,2012-01-16,155.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30.0,ABDOMINAL/PELVIC ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-01-16,2012-01-16,,,162.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,31.0,RIGHT PLEURAL EFFUSION,Pleural effusion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-16,2012-01-16,,,162.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,32.0,THROMBOCYOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-16,2012-01-16,2012-01-23,2012-01-23,162.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,33.0,MILD NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-19,2012-01-19,2012-01-21,2012-01-21,165.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,34.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-23,2012-01-23,2012-01-23,2012-01-23,169.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-01-25,2012-01-25,2012-01-27,2012-01-27,171.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,36.0,HEMATURIA,Haematuria,RENAL AND URINARY DISORDERS,2012-01-30,2012-01-30,,,176.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,37.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-30,2012-01-30,,,176.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,38.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-01-30,2012-01-30,2012-02-20,2012-02-20,176.0,N,UNLIKELY,2.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,39.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-13,2012-02-13,2012-02-20,2012-02-20,190.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,40.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-13,2012-02-13,2012-02-20,2012-02-20,190.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,41.0,INTERMITTENT HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-02-20,2012-02-20,2012-02-26,2012-02-26,197.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,42.0,INTERMITTENT HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-02-27,2012-02-27,,,204.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,43.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-06,2012-03-06,2012-03-06,2012-03-06,212.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,44.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-06,2012-03-06,,,212.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,45.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-05,2012-03-05,2012-03-13,2012-03-13,211.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,46.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-12,2012-03-12,2012-03-19,2012-03-19,218.0,N,DEFINITELY,4.0,3,3.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,47.0,GASTROINTESTIONAL PAIN IN STERUM,Gastrointestinal pain,GASTROINTESTINAL DISORDERS,2012-03-06,2012-03-06,,,212.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,48.0,INCREASED FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-13,2012-03-13,,,219.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,49.0,INCREASED SIGHT LOSS MACULAR DEGENERATION,Macular degeneration,EYE DISORDERS,2012-03-06,2012-03-06,,,212.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,50.0,CLINICALLY SIGNIFICANT LOW ALBUMIN,Blood albumin decreased,INVESTIGATIONS,2012-03-19,2012-03-19,,,225.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,51.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-05,2012-03-05,2012-03-12,2012-03-12,211.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-001,01094001,094,84.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,52.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-12,2012-03-12,2012-03-19,2012-03-19,218.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,LEFT LEG DEEP VEIN THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-10-07,2011-10-07,2011-10-19,2011-10-19,-6.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,N
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,BILATERAL DEEP VEIN THROMBOSIS,Deep vein thrombosis,VASCULAR DISORDERS,2011-10-20,2011-10-20,,,8.0,Y,NOT RELATED,1.0,4,4.0,,OTHER,CONTINUOUS,,N,Y,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,BILATERAL PULMONARY EMBOLI,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-20,2011-10-20,,,8.0,Y,NOT RELATED,1.0,4,4.0,,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,HYPERSOMNIA,Hypersomnia,NERVOUS SYSTEM DISORDERS,2011-10-18,2011-10-18,,,6.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,PAIN BONE/BODY,Bone pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-10-18,2011-10-18,2011-10-21,2011-10-21,6.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,INTERMITTENT DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-10-19,2011-10-19,,,7.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,INTERMITTENT IRRITABILITY,Irritability,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-18,2011-10-18,,,6.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-20,2011-10-20,2011-10-27,2011-10-27,8.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ABNORMAL EKG(T-WAVE INVERSION),Electrocardiogram T wave inversion,INVESTIGATIONS,2011-10-13,2011-10-13,,,1.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,HYPOTENSION,Hypotension,VASCULAR DISORDERS,2011-10-20,2011-10-20,,,8.0,N,NOT RELATED,1.0,2,2.0,,OTHER,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,,,15.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-22,2011-10-22,2011-10-23,2011-10-23,10.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,INTERMITTENT VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-28,2011-10-28,,,16.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,CONFUSION,Confusional state,PSYCHIATRIC DISORDERS,2011-11-01,2011-11-01,2011-11-03,2011-11-03,20.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-01,2011-11-01,,,20.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,ORAL THRUSH,Oral candidiasis,INFECTIONS AND INFESTATIONS,2011-11-03,2011-11-03,,,22.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,GENERAL BODY WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-01,2011-11-01,,,20.0,N,UNLIKELY,2.0,3,3.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-11-10,2011-11-10,2011-11-10,2011-11-10,29.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-094-002,01094002,094,64.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-05,2011-10-05,2011-10-05,2011-10-05,-8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-07,2012-01-07,,,3.0,N,UNLIKELY,2.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-12,2012-01-12,2012-01-12,2012-01-12,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,INTERMITTENT NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-06,2012-01-06,2012-03-22,2012-03-22,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-11,2012-02-11,2012-02-11,2012-02-11,38.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-11,2012-02-11,2012-02-23,2012-02-23,38.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-02-11,2012-02-11,2012-02-11,2012-02-11,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-15,2012-02-15,2012-02-15,2012-02-15,42.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,INTERMITTENT HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-02-16,2012-02-16,2012-02-16,2012-02-16,43.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-09,2012-02-09,2012-03-15,2012-03-15,36.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-07,2012-03-07,2012-03-07,2012-03-07,63.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-03-01,2012-03-01,2012-03-15,2012-03-15,57.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,INCREASED ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-03-02,2012-03-02,,,58.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,INCREASED FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2012-03-02,2012-03-02,,,58.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,INTERMITTENT CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-12,2012-03-12,2012-03-12,2012-03-12,68.0,N,UNLIKELY,2.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-10,2012-03-10,2012-03-13,2012-03-13,66.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-15,2012-03-15,2012-03-22,2012-03-22,71.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,GENERALIZED WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-12,2012-03-12,,,68.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-16,2012-02-16,2012-02-23,2012-02-23,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-15,2012-03-15,2012-03-22,2012-03-22,71.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,LOWER BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-03-01,2012-03-01,,,57.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,INTERMITTENT VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-01,2012-03-01,,,57.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,22.0,INTERMITTENT DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-23,2012-03-23,,,79.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,23.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-01,2012-03-01,,,57.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,24.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-03-29,2012-03-29,,,85.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,25.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-03-29,2012-03-29,,,85.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,26.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-03-29,2012-03-29,2012-04-02,2012-04-02,85.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,27.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2012-04-02,2012-04-02,,,89.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,28.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-04-02,2012-04-02,2012-04-02,2012-04-02,89.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,29.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-11,2012-02-11,2012-02-23,2012-02-23,38.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,30.0,CANDIDA (MOUTH),Oral candidiasis,INFECTIONS AND INFESTATIONS,2012-04-05,2012-04-05,2012-04-12,2012-04-12,92.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,31.0,EAR PAIN,Ear pain,EAR AND LABYRINTH DISORDERS,2012-03-29,2012-03-29,,,85.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,32.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-12,2012-04-12,,,99.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,33.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2012-04-02,2012-04-02,,,89.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,34.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-04-02,2012-04-02,2012-04-02,2012-04-02,89.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,35.0,PROGRESSIVE PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-04-02,2012-04-02,2012-04-05,2012-04-05,89.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,36.0,PROGRESSIVE PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-04-05,2012-04-05,,,92.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-003,01094003,094,63.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,37.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-04-02,2012-04-02,2012-04-05,2012-04-05,89.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,INCREASED FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-06,2012-02-06,,,-2.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,INCREASED STOMACH PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-02-07,2012-02-07,2012-02-07,2012-02-07,-1.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,URINARY RETENTION,Urinary retention,RENAL AND URINARY DISORDERS,2012-02-13,2012-02-13,2012-02-14,2012-02-14,6.0,Y,NOT RELATED,1.0,2,2.0,DRUG INTERRUPTED,"NONE, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ACUTE MYOCARDIAL INFARCTION,Acute myocardial infarction,CARDIAC DISORDERS,2012-02-13,2012-02-13,2012-02-23,2012-02-23,6.0,Y,UNLIKELY,2.0,3,3.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,INCREASED STOMACH PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2012-02-13,2012-02-13,,,6.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-13,2012-02-13,,,6.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-02-06,2012-02-06,,,-2.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,SINUS TACHYCARDIA,Sinus tachycardia,CARDIAC DISORDERS,2012-02-15,2012-02-15,,,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,PREMATURE VENTRICULAR CONTRACTIONS,Ventricular extrasystoles,CARDIAC DISORDERS,2012-02-15,2012-02-15,,,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-15,2012-02-15,2012-02-15,2012-02-15,8.0,N,UNLIKELY,2.0,1,1.0,,"NONE, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,HYPOCALCEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-15,2012-02-15,,,8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,ATRIAL FLUTTER,Atrial flutter,CARDIAC DISORDERS,2012-02-16,2012-02-16,2012-03-18,2012-03-18,9.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,PITTING EDEMA(BILATERAL LOWER EXTREMITIES),Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-16,2012-02-16,,,9.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-02-15,2012-02-15,2012-02-19,2012-02-19,8.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,COUGHING,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-02-21,2012-02-21,2012-02-21,2012-02-21,14.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,ANAL INCONTINENCE,Faecal incontinence,GASTROINTESTINAL DISORDERS,2012-02-22,2012-02-22,2012-02-22,2012-02-22,15.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,PATIENT FALL,Fall,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-02-22,2012-02-22,2012-02-22,2012-02-22,15.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,MUCOSAL INFECTION,Mucosal infection,INFECTIONS AND INFESTATIONS,2012-02-22,2012-02-22,,,15.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2012-02-22,2012-02-22,,,15.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,PAPULAR RASH(UPPER BACK AND FACE),Rash papular,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-02-21,2012-02-21,,,14.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-094-004,01094004,094,80.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,UNKNOWN ACUTECARDIOVASCULAR EVENT,Cardiovascular disorder,CARDIAC DISORDERS,2012-02-29,2012-02-29,2012-02-29,2012-02-29,22.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,PANCYTOPENIA,Pancytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-09,2011-09-09,,,16.0,N,DEFINITELY,4.0,2,2.0,"DOSE REDUCED, DRUG INTERRUPTED",CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,STOMACH PAIN,Abdominal pain upper,GASTROINTESTINAL DISORDERS,2011-09-10,2011-09-10,2011-09-22,2011-09-22,17.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-08,2011-09-08,2011-09-29,2011-09-29,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,TINGLING AT IV SITE,Infusion site paraesthesia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-09,2011-09-09,2011-09-09,2011-09-09,16.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-22,2011-09-22,,,29.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,HEARTBURN,Dyspepsia,GASTROINTESTINAL DISORDERS,2011-10-05,2011-10-05,2011-10-05,2011-10-05,42.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-19,2011-11-19,2012-02-09,2012-02-09,87.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-05,2012-01-05,2012-01-12,2012-01-12,134.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-09,2012-02-09,2012-02-28,2012-02-28,169.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-09,2012-02-09,2012-02-09,2012-02-09,169.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-20,2012-02-20,2012-02-21,2012-02-21,180.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-002,01095002,095,82.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,GASTRIC OUTLET OBSTRUCTION,Obstruction gastric,GASTROINTESTINAL DISORDERS,2012-01-31,2012-01-31,2012-02-13,2012-02-13,160.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,PYURIA,Pyuria,RENAL AND URINARY DISORDERS,2011-08-17,2011-08-17,2011-09-01,2011-09-01,3.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-15,2011-08-15,,,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-01,2011-09-01,2011-09-02,2011-09-02,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-29,2011-08-29,,,15.0,N,DEFINITELY,4.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-29,2011-08-29,,,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,PANCYTOPENIA,Pancytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-29,2011-08-29,,,15.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,LETHARGY,Lethargy,NERVOUS SYSTEM DISORDERS,2011-08-31,2011-08-31,2011-09-06,2011-09-06,17.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-09-01,2011-09-01,2011-09-06,2011-09-06,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,CONTUSION ON BACK FROM FALL,Contusion,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-08-26,2011-08-26,2011-09-06,2011-09-06,12.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,CONTUSION ON BACK FROM FALL,Fall,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-08-26,2011-08-26,2011-09-06,2011-09-06,12.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-25,2011-09-25,2011-09-25,2011-09-25,42.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,VOMITTING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-25,2011-09-25,2011-09-25,2011-09-25,42.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,SCLERAL ICTERUS,Ocular icterus,EYE DISORDERS,2011-10-03,2011-10-03,,,50.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-10-05,2011-10-05,,,52.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-25,2011-09-25,,,42.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-05,2011-10-05,,,52.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,METASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-10-03,2011-10-03,2011-10-08,2011-10-08,50.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2011-08-11,2011-08-11,2011-10-08,2011-10-08,-4.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-095-003,01095003,095,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-10-03,2011-10-03,2011-10-08,2011-10-08,50.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,CHOLANGITIS,Cholangitis,HEPATOBILIARY DISORDERS,2012-02-20,2012-02-20,2012-02-20,2012-02-20,13.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, NONE, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,GOUT EXACERBATION,Gout,METABOLISM AND NUTRITION DISORDERS,2012-02-20,2012-02-20,,,13.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,BILATERAL LEG EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-28,2012-02-28,,,21.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,LIVER ABCESS,Liver abscess,INFECTIONS AND INFESTATIONS,2012-04-11,2012-04-11,,,64.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,"NONE, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-23,2012-05-23,,,106.0,N,DEFINITELY,4.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-23,2012-05-23,,,106.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,SERIOUS CHOLANGITIS,Cholangitis,HEPATOBILIARY DISORDERS,2012-02-21,2012-02-21,2012-02-25,2012-02-25,14.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,NON SERIOUS CHOLANGITIS,Cholangitis,HEPATOBILIARY DISORDERS,2012-02-26,2012-02-26,2012-02-28,2012-02-28,19.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2012-02-21,2012-02-21,2012-02-25,2012-02-25,14.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2012-02-21,2012-02-21,,,14.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-20,2012-02-20,2012-02-25,2012-02-25,13.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-21,2012-02-21,2012-02-25,2012-02-25,14.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,INTRACTABLE PAIN,Pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-20,2012-02-20,2012-02-25,2012-02-25,13.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,"LOOSE STOOLS, GRADE 1",Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-28,2012-02-28,,,21.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,ACHING JOINTS,Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-02-15,2012-02-15,,,8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-16,2012-02-16,2012-02-16,2012-02-16,9.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,SUPERFICIAL THROMBUS RIGHT LEG,Thrombophlebitis superficial,VASCULAR DISORDERS,2012-02-25,2012-02-25,,,18.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-005,01095005,095,84.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,C DIFFICILE COLITIS,Clostridium difficile colitis,INFECTIONS AND INFESTATIONS,2012-06-08,2012-06-08,,,122.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-27,2012-03-27,2012-04-10,2012-04-10,37.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-01,2012-05-01,,,72.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-01,2012-05-01,2012-05-15,2012-05-15,72.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,THROMBOPCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-29,2012-05-29,2012-06-13,2012-06-13,100.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,THUMB LACERATION,Laceration,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-05-28,2012-05-28,2012-06-11,2012-06-11,99.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-21,2012-08-21,2012-09-04,2012-09-04,184.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-26,2012-06-26,2012-07-17,2012-07-17,128.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-08-01,2012-08-01,2012-08-07,2012-08-07,164.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-006,01095006,095,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,N,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-09-18,2012-09-18,,,212.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-04-19,2012-04-19,2012-04-21,2012-04-21,11.0,Y,NOT RELATED,1.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED","CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,PROGRESSION OF METASTATIC PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-05-19,2012-05-19,2012-06-06,2012-06-06,41.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-05-10,2012-05-10,2012-05-17,2012-05-17,32.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,FRACTURED RIBS,Rib fracture,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-04-09,2012-04-09,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-18,2012-04-18,2012-04-18,2012-04-18,10.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-095-007,01095007,095,78.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-05-14,2012-05-14,,,36.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,DECREASED PLATELETS - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2011-12-27,2011-12-27,2012-01-03,2012-01-03,15.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,NONE,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,DECREASED PLATELETS - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-01-03,2012-01-03,2012-01-10,2012-01-10,22.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2012-01-10,2012-01-10,,,29.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,WORSENING PAIN ABDOMINAL AREA,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-01-10,2012-01-10,,,29.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-01-17,2012-01-17,2012-03-13,2012-03-13,36.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,WORSENING CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-24,2012-01-24,,,43.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-24,2012-01-24,2012-01-31,2012-01-31,43.0,N,DEFINITELY,4.0,3,3.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-03-13,2012-03-13,2012-03-27,2012-03-27,92.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,DECREASE PLATELETS - CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2012-02-21,2012-02-21,2012-02-28,2012-02-28,71.0,N,DEFINITELY,4.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-21,2012-02-21,2012-02-28,2012-02-28,71.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,"DOSE REDUCED, DRUG INTERRUPTED",,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,HYPERPIGMENTATION - HANDS,Skin hyperpigmentation,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-02-28,2012-02-28,,,78.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-06,2012-03-06,2012-03-13,2012-03-13,85.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,DECREASE HEMOGLOBIN-CLINICALLY SIGNIFICANT,Haemoglobin decreased,INVESTIGATIONS,2012-03-13,2012-03-13,2012-03-27,2012-03-27,92.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,URINARY TRACT INFECTION,Urinary tract infection,INFECTIONS AND INFESTATIONS,2012-04-15,2012-04-15,,,125.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,ELEVATED HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-04-15,2012-04-15,2012-04-18,2012-04-18,125.0,Y,UNLIKELY,2.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,GENERALIZED WEAKNESS,Asthenia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-15,2012-04-15,2012-04-18,2012-04-18,125.0,Y,UNLIKELY,2.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-096-002,01096002,096,67.0,YEARS,M,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,DECREASE ANC - CLINICALLY SIGNIFICANT,Neutrophil count decreased,INVESTIGATIONS,2012-03-20,2012-03-20,2012-03-27,2012-03-27,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,1.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-10-01,2011-10-01,2011-10-03,2011-10-03,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,2.0,FLU-LIKE SYMPTOMS,Influenza like illness,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-01,2011-10-01,2011-10-03,2011-10-03,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,FATIGUE (WORSENING),Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-02,2011-10-02,2011-10-04,2011-10-04,11.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,FATIGUE (WORSENING),Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-07,2011-10-07,2011-10-08,2011-10-08,16.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,FATIGUE (WORSENING),Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-10-14,2011-10-14,2011-10-18,2011-10-18,23.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-10-15,2011-10-15,2011-10-16,2011-10-16,24.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,SCALP SENSITIVITY,Pain of skin,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-10-29,2011-10-29,,,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,COLD SORE,Oral herpes,INFECTIONS AND INFESTATIONS,2011-11-29,2011-11-29,2011-12-10,2011-12-10,69.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,9.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-12-02,2011-12-02,2012-03-21,2012-03-21,72.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,10.0,"SWOLLEN ANKLES, BILATERAL",Joint swelling,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-09,2011-12-09,2011-12-26,2011-12-26,79.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-17,2011-12-17,2011-12-18,2011-12-18,87.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,12.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-19,2011-12-19,2011-12-20,2011-12-20,89.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-17,2011-12-17,2011-12-18,2011-12-18,87.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-19,2011-12-19,2011-12-20,2011-12-20,89.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,15.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-02,2012-01-02,2012-01-03,2012-01-03,103.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,16.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-02,2012-01-02,2012-01-03,2012-01-03,103.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,17.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-04,2012-01-04,2012-01-05,2012-01-05,105.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,18.0,HYPERKALEMIA,Hyperkalaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-19,2012-01-19,2012-01-20,2012-01-20,120.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,19.0,PRURITUS TO FACE,Pruritus,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-01-04,2012-01-04,2012-01-05,2012-01-05,105.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,20.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-02,2012-02-02,2012-02-03,2012-02-03,134.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,21.0,LOW HEMOGLOBIN - CLINICALLY SIGNIFICANT,Haemoglobin decreased,INVESTIGATIONS,2012-02-15,2012-02-15,2012-02-22,2012-02-22,147.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,22.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2012-03-14,2012-03-14,2012-04-25,2012-04-25,175.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,23.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-01,2011-12-01,2012-04-26,2012-04-26,71.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,24.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-03-22,2012-03-22,2012-06-05,2012-06-05,183.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,25.0,FATIGUE (WORSENING),Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-05,2012-04-05,2012-06-05,2012-06-05,197.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,26.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2012-04-26,2012-04-26,2012-06-05,2012-06-05,218.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,27.0,DECREASED HEMOGLOBIN (CLINICALLY SIGNFICANT),Haemoglobin decreased,INVESTIGATIONS,2012-05-02,2012-05-02,2012-05-09,2012-05-09,224.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,28.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-27,2012-04-27,2012-05-03,2012-05-03,219.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,29.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-05-04,2012-05-04,,,226.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,30.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2012-06-06,2012-06-06,,,259.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,31.0,HEADACHES,Headache,NERVOUS SYSTEM DISORDERS,2012-06-06,2012-06-06,,,259.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,32.0,PULMONARY EMBOLI,Pulmonary embolism,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-05-17,2012-05-17,,,239.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,33.0,FATIGUE (WORSENING),Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-06-06,2012-06-06,,,259.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,34.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-06-06,2012-06-06,,,259.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,35.0,"PAIN, RIGHT ABDOMEN (WORSENING)",Abdominal pain,GASTROINTESTINAL DISORDERS,2012-06-06,2012-06-06,,,259.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-097-001,01097001,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,36.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-06-06,2012-06-06,,,259.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,TENDER THROAT,Oropharyngeal pain,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-30,2011-09-30,2011-10-09,2011-10-09,-7.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-07,2011-10-07,2011-10-08,2011-10-08,1.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-07,2011-10-07,2011-10-08,2011-10-08,1.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-10-08,2011-10-08,2011-10-09,2011-10-09,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-10-13,2011-10-13,2011-10-14,2011-10-14,7.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,"BLISTER, LEFT LOWER QUADRANT",Blister,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-10-12,2011-10-12,2011-10-29,2011-10-29,6.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-21,2011-10-21,2011-10-23,2011-10-23,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-21,2011-10-21,2011-10-23,2011-10-23,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,2011-11-03,2011-11-03,21.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-31,2011-10-31,2011-11-01,2011-11-01,25.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-03,2011-11-03,2011-11-07,2011-11-07,28.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-10-31,2011-10-31,2011-11-01,2011-11-01,25.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-03,2011-11-03,2011-11-07,2011-11-07,28.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,"RASH, FACE",Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-10-23,2011-10-23,2011-10-30,2011-10-30,17.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,"INFECTION, UPPER RESPIRATORY",Upper respiratory tract infection,INFECTIONS AND INFESTATIONS,2011-11-01,2011-11-01,2011-11-11,2011-11-11,26.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,PRESYNCOPE,Presyncope,NERVOUS SYSTEM DISORDERS,2011-10-29,2011-10-29,2011-10-29,2011-10-29,23.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-12,2011-11-12,2011-11-15,2011-11-15,37.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-17,2011-11-17,2011-11-19,2011-11-19,42.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-12,2011-11-12,2011-11-15,2011-11-15,37.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-17,2011-11-17,,,42.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-13,2011-11-13,2011-11-14,2011-11-14,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,22.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-20,2011-11-20,2011-11-21,2011-11-21,45.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,23.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-22,2011-11-22,,,47.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,24.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-01,2011-12-01,,,56.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,25.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-30,2011-11-30,2011-12-01,2011-12-01,55.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,26.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-27,2011-11-27,,,52.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,27.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-27,2011-11-27,,,52.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-097-002,01097002,097,52.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,28.0,SORE THROAT,Oropharyngeal pain,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-27,2011-11-27,,,52.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,"RASH, BACK",Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-01,2011-11-01,2011-11-05,2011-11-05,6.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-04,2011-11-04,2011-11-05,2011-11-05,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-10,2011-11-10,2011-11-11,2011-11-11,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-04,2011-11-04,2011-11-05,2011-11-05,9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-10,2011-11-10,2011-11-11,2011-11-11,15.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-11-12,2011-11-12,,,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,"RASH, BACK",Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-05,2011-11-05,2011-11-12,2011-11-12,10.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,"RASH, LEGS",Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-05,2011-11-05,2011-11-12,2011-11-12,10.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,"RASH, CHEST",Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-06,2011-11-06,2011-11-12,2011-11-12,11.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,"RASH, BACK",Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-11-13,2011-11-13,2011-11-18,2011-11-18,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2011-11-19,2011-11-19,2011-11-23,2011-11-23,24.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,GATRIC OUTLET OBSTRUCTION,Obstruction gastric,GASTROINTESTINAL DISORDERS,2011-11-19,2011-11-19,2011-11-22,2011-11-22,24.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-19,2011-11-19,2011-11-23,2011-11-23,24.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,LOW HEMOGLOBIN - CLINICALLY SIGNIFICANT,Haemoglobin decreased,INVESTIGATIONS,2011-12-07,2011-12-07,2011-12-14,2011-12-14,42.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,DRY RIGHT EYE,Dry eye,EYE DISORDERS,2011-12-05,2011-12-05,,,40.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,"NEUROPATHY, HANDS - NOT COLD RELATED (RIGHT MIDDLE FINGER)",Neuropathy peripheral,NERVOUS SYSTEM DISORDERS,2011-12-13,2011-12-13,,,48.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,BILATERAL ANKLE SWELLING,Joint swelling,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-05,2011-12-05,,,40.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,SWOLLEN ABDOMEN,Abdominal distension,GASTROINTESTINAL DISORDERS,2011-12-10,2011-12-10,,,45.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,VASOVAGAL SYNCOPE,Syncope,NERVOUS SYSTEM DISORDERS,2011-12-17,2011-12-17,2011-12-18,2011-12-18,52.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,SUBACUTE BACTERIAL PERITONITIS,Peritonitis bacterial,INFECTIONS AND INFESTATIONS,2011-12-18,2011-12-18,,,53.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,Y,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-19,2011-11-19,2011-11-23,2011-11-23,24.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,HYPOGLYCEMIA,Hypoglycaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-12,2012-01-12,2012-01-12,2012-01-12,78.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-097-004,01097004,097,67.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,DISEASE PROGRESSION OF METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-12-17,2011-12-17,2012-01-17,2012-01-17,52.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-14,2011-11-14,2011-11-15,2011-11-15,5.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-16,2011-11-16,2011-11-17,2011-11-17,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-14,2011-11-14,2011-11-15,2011-11-15,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,WORSENING FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-12,2011-11-12,2011-11-15,2011-11-15,3.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-10,2011-11-10,2011-11-11,2011-11-11,1.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,WORSENING ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-11-10,2011-11-10,2011-11-10,2011-11-10,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,WORSENING ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-11-14,2011-11-14,2011-11-14,2011-11-14,5.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,WORSENING ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-11-14,2011-11-14,2011-11-15,2011-11-15,5.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-19,2011-11-19,2011-11-20,2011-11-20,10.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-18,2011-11-18,2011-11-19,2011-11-19,9.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,LOWER BACK MUSCLE SPASMS,Muscle spasms,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-16,2011-11-16,2011-12-02,2011-12-02,7.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,TASTE ALTERATION,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-11-18,2011-11-18,2012-05-02,2012-05-02,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-11-26,2011-11-26,2011-11-27,2011-11-27,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-11-26,2011-11-26,2011-11-27,2011-11-27,17.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-25,2011-11-25,2011-11-26,2011-11-26,16.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,CALF SWELLING,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-28,2011-11-28,,,19.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,BLURRY VISION,Vision blurred,EYE DISORDERS,2011-12-03,2011-12-03,2011-12-15,2011-12-15,24.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,"DVT, RIGHT LEG",Deep vein thrombosis,VASCULAR DISORDERS,2011-12-01,2011-12-01,,,22.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,LOWER BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-02,2011-12-02,2012-03-01,2012-03-01,23.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-10,2011-12-10,2011-12-11,2011-12-11,31.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-10,2011-12-10,2011-12-11,2011-12-11,31.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,22.0,"MUSCLE SPASMS, LOWER BACK",Muscle spasms,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-14,2011-12-14,2012-02-24,2012-02-24,35.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,23.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-17,2011-12-17,2011-12-18,2011-12-18,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,24.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-17,2011-12-17,2011-12-18,2011-12-18,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,25.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-25,2011-12-25,2011-12-26,2011-12-26,46.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,26.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-16,2011-12-16,2011-12-17,2011-12-17,37.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,27.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-22,2011-12-22,2011-12-23,2011-12-23,43.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,28.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-07,2012-01-07,2012-01-08,2012-01-08,59.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,29.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-14,2012-01-14,2012-01-15,2012-01-15,66.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,30.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-23,2012-01-23,2012-01-24,2012-01-24,75.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,31.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-19,2012-01-19,2012-01-20,2012-01-20,71.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,32.0,"PAIN, MID RIB CAGE, RIGHT SIDE",Musculoskeletal chest pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-30,2012-01-30,2012-02-01,2012-02-01,82.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,33.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-04,2012-02-04,2012-02-05,2012-02-05,87.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,34.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-06,2012-02-06,2012-02-06,2012-02-06,89.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,35.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-03,2012-02-03,2012-02-04,2012-02-04,86.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,36.0,CHEST TIGHTNESS,Chest discomfort,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-03,2012-02-03,2012-02-09,2012-02-09,86.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,37.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-09,2012-02-09,2012-02-09,2012-02-09,92.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,38.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-17,2012-02-17,2012-02-18,2012-02-18,100.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,39.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-17,2012-02-17,2012-02-18,2012-02-18,100.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,40.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-26,2012-02-26,2012-02-27,2012-02-27,109.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,41.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-28,2012-02-28,2012-02-29,2012-02-29,111.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,42.0,CHEST INFECTION,Lower respiratory tract infection,INFECTIONS AND INFESTATIONS,2012-02-26,2012-02-26,2012-03-03,2012-03-03,109.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,43.0,CHEST TIGHTNESS,Chest discomfort,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-26,2012-02-26,,,109.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,44.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-09,2012-02-09,2012-02-10,2012-02-10,92.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,45.0,DRY COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-03-04,2012-03-04,,,116.0,N,NOT RELATED,1.0,1,1.0,DRUG INTERRUPTED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,46.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-16,2012-03-16,2012-03-18,2012-03-18,128.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,47.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-17,2012-03-17,2012-03-18,2012-03-18,129.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,48.0,"MUSCLE SPASMS, BACK",Muscle spasms,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-03-16,2012-03-16,,,128.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,49.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-30,2012-03-30,2012-03-30,2012-03-30,142.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,50.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-31,2012-03-31,2012-03-31,2012-03-31,143.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,51.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-30,2012-03-30,2012-04-01,2012-04-01,142.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,52.0,PITTING EDEMA,Oedema,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-05,2012-04-05,2012-04-05,2012-04-05,148.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,53.0,EPIDIDYMITIS,Epididymitis,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2012-03-28,2012-03-28,2012-04-02,2012-04-02,140.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,54.0,EPIDIDYMITIS,Epididymitis,REPRODUCTIVE SYSTEM AND BREAST DISORDERS,2012-04-03,2012-04-03,2012-04-13,2012-04-13,146.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,55.0,GROIN PAIN,Groin pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-03-29,2012-03-29,2012-04-03,2012-04-03,141.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,56.0,GROIN PAIN,Groin pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-04-04,2012-04-04,2012-04-08,2012-04-08,147.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,57.0,RIB PAIN,Musculoskeletal chest pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-04-10,2012-04-10,2012-04-17,2012-04-17,153.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,58.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-04-13,2012-04-13,2012-04-16,2012-04-16,156.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,59.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-04-14,2012-04-14,2012-04-14,2012-04-14,157.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,60.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-13,2012-04-13,2012-04-16,2012-04-16,156.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,61.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-25,2012-04-25,2012-04-26,2012-04-26,168.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,62.0,COMMUNITY-ACQUIRED PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2012-04-27,2012-04-27,2012-05-04,2012-05-04,170.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,63.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-05-09,2012-05-09,2012-05-09,2012-05-09,182.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,64.0,BILATERAL RIB PAIN,Musculoskeletal chest pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-04-27,2012-04-27,,,170.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,65.0,LEFT SHOULDER PAIN,Musculoskeletal pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-04-26,2012-04-26,,,169.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,66.0,CHILLS,Chills,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-25,2012-04-25,2012-04-25,2012-04-25,168.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,67.0,COMMUNIT-ACQUIRED PNEUMONIA,Pneumonia,INFECTIONS AND INFESTATIONS,2012-05-05,2012-05-05,2012-05-11,2012-05-11,178.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-006,01097006,097,54.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,68.0,SHORTNESS OF BREATH,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-02,2011-11-02,,,-8.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-21,2011-12-21,2011-12-28,2011-12-28,-9.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-29,2011-12-29,2011-12-29,2011-12-29,-1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-30,2011-12-30,2011-12-31,2011-12-31,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-01,2012-01-01,,,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-24,2011-12-24,2011-12-29,2011-12-29,-6.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-12-30,2011-12-30,2012-01-02,2012-01-02,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-03,2012-01-03,2012-01-04,2012-01-04,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-06,2012-01-06,2012-01-09,2012-01-09,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-10,2012-01-10,2012-01-11,2012-01-11,12.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-13,2012-01-13,2012-01-14,2012-01-14,15.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-16,2012-01-16,2012-01-17,2012-01-17,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,12.0,WORSENING FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-30,2011-12-30,2012-01-02,2012-01-02,1.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,13.0,WORSENING FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-04,2012-01-04,2012-01-06,2012-01-06,6.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,14.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-24,2011-12-24,2011-12-26,2011-12-26,-6.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,15.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-12-30,2011-12-30,2012-01-04,2012-01-04,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,16.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-12-27,2011-12-27,2011-12-28,2011-12-28,-3.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,17.0,"FEVER, NO INFECTION",Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-30,2011-12-30,2011-12-31,2011-12-31,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,18.0,WORSENING ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-12-30,2011-12-30,2012-01-02,2012-01-02,1.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,19.0,REDNESS TO SCLERA,Scleral discolouration,EYE DISORDERS,2011-12-31,2011-12-31,2012-01-06,2012-01-06,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,20.0,BLURRY VISION,Vision blurred,EYE DISORDERS,2011-12-31,2011-12-31,2012-01-06,2012-01-06,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,21.0,WORSENING ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-12-22,2011-12-22,2011-12-31,2011-12-31,-8.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,22.0,WORSENING ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-01-02,2012-01-02,2012-01-02,2012-01-02,4.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,23.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-07,2012-01-07,2012-01-08,2012-01-08,9.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,24.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-20,2012-01-20,2012-01-23,2012-01-23,22.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,25.0,RASH TO NECK,Rash,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-01-04,2012-01-04,2012-01-15,2012-01-15,6.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,26.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2012-01-04,2012-01-04,,,6.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,27.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-01-26,2012-01-26,2012-01-29,2012-01-29,28.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,28.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-28,2012-01-28,2012-01-30,2012-01-30,30.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,29.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2012-01-26,2012-01-26,2012-01-29,2012-01-29,28.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,30.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-02,2012-02-02,2012-02-03,2012-02-03,35.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,31.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-05,2012-02-05,2012-02-06,2012-02-06,38.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,32.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-02-02,2012-02-02,2012-02-04,2012-02-04,35.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,33.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-09,2012-02-09,2012-02-10,2012-02-10,42.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,34.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-12,2012-02-12,2012-02-13,2012-02-13,45.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,35.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-02-12,2012-02-12,2012-02-13,2012-02-13,45.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,36.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-17,2012-02-17,2012-02-18,2012-02-18,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,37.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-19,2012-02-19,2012-02-20,2012-02-20,52.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,38.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-23,2012-02-23,2012-02-25,2012-02-25,56.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,39.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-02-24,2012-02-24,2012-02-26,2012-02-26,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,40.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-29,2012-02-29,2012-03-20,2012-03-20,62.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,41.0,ANOREXIA (WORSENING),Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-03-06,2012-03-06,,,68.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,42.0,ABDOMINAL PAIN (WORSENING),Abdominal pain,GASTROINTESTINAL DISORDERS,2012-03-09,2012-03-09,,,71.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,43.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-04-05,2012-04-05,2012-04-06,2012-04-06,98.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,44.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-04-12,2012-04-12,2012-04-13,2012-04-13,105.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,45.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-04-17,2012-04-17,,,110.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-008,01097008,097,68.0,YEARS,F,ASIAN,2.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,46.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-04-11,2012-04-11,2012-04-12,2012-04-12,104.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-02-18,2012-02-18,2012-02-19,2012-02-19,4.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-02-18,2012-02-18,2012-02-19,2012-02-19,4.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-15,2012-02-15,2012-02-16,2012-02-16,1.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-21,2012-02-21,2012-02-28,2012-02-28,7.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-21,2012-02-21,2012-02-29,2012-02-29,7.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-06,2012-03-06,2012-03-12,2012-03-12,21.0,N,DEFINITELY,4.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,FLASHES OF LIGHT,Photopsia,EYE DISORDERS,2012-02-16,2012-02-16,2012-03-14,2012-03-14,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,8.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-01,2012-03-01,2012-03-27,2012-03-27,16.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,9.0,ANOREXIA (WORSENING),Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-03-02,2012-03-02,,,17.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,10.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-13,2012-03-13,2012-03-20,2012-03-20,28.0,N,DEFINITELY,4.0,4,4.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,11.0,LOW WHITE BLOOD COUNT - CLINICALLY SIGNIFICANT,White blood cell count decreased,INVESTIGATIONS,2012-03-13,2012-03-13,2012-03-20,2012-03-20,28.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,12.0,STOMATITIS,Stomatitis,GASTROINTESTINAL DISORDERS,2012-03-08,2012-03-08,2012-03-15,2012-03-15,23.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,13.0,NEUTROPENIA - CLINICALLY SIGNIFICANT,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-03-27,2012-03-27,2012-04-03,2012-04-03,42.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,14.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-03-28,2012-03-28,2012-04-11,2012-04-11,43.0,N,DEFINITELY,4.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,15.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-04-12,2012-04-12,,,58.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,16.0,PRODUCTIVE COUGH,Productive cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-06,2012-04-06,2012-04-14,2012-04-14,52.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,17.0,PRODUCTIVE COUGH,Productive cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-15,2012-04-15,2012-04-21,2012-04-21,61.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,18.0,SORE THROAT,Oropharyngeal pain,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-06,2012-04-06,2012-04-21,2012-04-21,52.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,19.0,SNEEZING,Sneezing,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-06,2012-04-06,2012-04-14,2012-04-14,52.0,N,NOT RELATED,1.0,2,2.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,20.0,SNEEZING,Sneezing,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-15,2012-04-15,2012-04-21,2012-04-21,61.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,21.0,SHORTNESS OF BREATH WHEN COUGHING,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-06,2012-04-06,2012-04-21,2012-04-21,52.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,22.0,RIGHT RIB PAIN,Musculoskeletal chest pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-04-25,2012-04-25,2012-05-02,2012-05-02,71.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,23.0,RUNNY NOSE,Rhinorrhoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-05-06,2012-05-06,2012-05-10,2012-05-10,82.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,24.0,BURNING EYES,Eye irritation,EYE DISORDERS,2012-05-06,2012-05-06,2012-05-10,2012-05-10,82.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,25.0,INCREASED FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2012-05-02,2012-05-02,2012-05-16,2012-05-16,78.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,26.0,BURNING SENSATION TO BACK,Burning sensation,NERVOUS SYSTEM DISORDERS,2012-05-02,2012-05-02,2012-06-11,2012-06-11,78.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,27.0,NEUTROPENIA (CLINICALLY SIGNIFICANT),Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-06-12,2012-06-12,2012-06-19,2012-06-19,119.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,28.0,BURNING SENSATION TO BACK AND ABDOMEN,Burning sensation,NERVOUS SYSTEM DISORDERS,2012-06-12,2012-06-12,,,119.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,29.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2012-07-10,2012-07-10,2012-07-11,2012-07-11,147.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,30.0,HEADACHE,Headache,NERVOUS SYSTEM DISORDERS,2012-07-18,2012-07-18,2012-08-29,2012-08-29,155.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,31.0,PRODUCTIVE COUGH,Productive cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-07-29,2012-07-29,2012-08-15,2012-08-15,166.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,32.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-08-22,2012-08-22,2012-08-22,2012-08-22,190.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,33.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-08-22,2012-08-22,2012-08-22,2012-08-22,190.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,34.0,"PAIN, LOWER BACK",Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-08-22,2012-08-22,2012-08-23,2012-08-23,190.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-010,01097010,097,56.0,YEARS,M,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,35.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-10-16,2012-10-16,,,245.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,FLASHES OF LIGHT,Photopsia,EYE DISORDERS,2012-03-09,2012-03-09,2012-04-10,2012-04-10,-18.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,"MUSCULAR PAIN, RIGHT CALF",Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-03-24,2012-03-24,2012-05-01,2012-05-01,-3.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,"MUSCULAR PAIN, LEFT CALF",Myalgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-03-27,2012-03-27,2012-05-01,2012-05-01,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-04-03,2012-04-03,2012-04-30,2012-04-30,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-04-04,2012-04-04,2012-04-04,2012-04-04,9.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-03-23,2012-03-23,2012-04-15,2012-04-15,-4.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,FLATULENCE,Flatulence,GASTROINTESTINAL DISORDERS,2012-04-03,2012-04-03,2012-04-04,2012-04-04,8.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-28,2012-03-28,2012-04-17,2012-04-17,2.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,ABDOMINAL PAIN (WORSENING),Abdominal pain,GASTROINTESTINAL DISORDERS,2012-04-09,2012-04-09,,,14.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,ANOREXIA (WORSENING),Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2012-04-11,2012-04-11,,,16.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,COLD SORE,Oral herpes,INFECTIONS AND INFESTATIONS,2012-04-15,2012-04-15,2012-05-07,2012-05-07,20.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-05-01,2012-05-01,2012-05-05,2012-05-05,36.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-05-01,2012-05-01,2012-05-02,2012-05-02,36.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-05-04,2012-05-04,2012-05-05,2012-05-05,39.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,FATIGUE (WORSENING),Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-01,2012-05-01,2012-05-04,2012-05-04,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-05,2012-05-05,,,40.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-05-26,2012-05-26,,,61.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-097-011,01097011,097,59.0,YEARS,F,WHITE,5.0,CAN,CANADA,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,DUODENAL OBSTRUCTION,Duodenal obstruction,GASTROINTESTINAL DISORDERS,2012-05-01,2012-05-01,2012-05-07,2012-05-07,36.0,Y,NOT RELATED,1.0,4,4.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,INTERMITTENT NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-06,2011-07-06,,,16.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,INTERMITTENT ABDOMINAL DISCOMFORT,Abdominal discomfort,GASTROINTESTINAL DISORDERS,2011-07-06,2011-07-06,,,16.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-06-28,2011-06-28,2011-07-01,2011-07-01,8.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-05,2011-07-05,2011-07-12,2011-07-12,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-15,2011-07-15,,,25.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-19,2011-07-19,2011-07-26,2011-07-26,29.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INTERMITTENT DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-08-01,2011-08-01,,,42.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,THROMBOCYTPOENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-09,2011-08-09,2011-08-16,2011-08-16,50.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,INTERMITTENT LOWER ESTREMITY EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-16,2011-08-16,,,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-27,2011-09-27,2011-10-11,2011-10-11,99.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-18,2011-10-18,2011-10-21,2011-10-21,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-18,2011-10-18,2011-10-21,2011-10-21,120.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DRUG INTERRUPTED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-10-28,2011-10-28,2011-11-01,2011-11-01,130.0,N,NOT RELATED,1.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-22,2011-11-22,2011-12-06,2011-12-06,155.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,RIGHT LOWER QUADRANT HERNIA,Abdominal hernia,GASTROINTESTINAL DISORDERS,2011-09-21,2011-09-21,,,93.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,DYSPNEA WITH EXCERTION,Dyspnoea exertional,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-08-30,2011-08-30,,,71.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,ILIOTIBIAL BAND STRAIN,Iliotibial band syndrome,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-10-11,2011-10-11,,,113.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,STUFFY NOSE/POST NASAL DROP,Nasal congestion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-21,2011-11-21,2011-11-29,2011-11-29,154.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-002,01098002,098,75.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,STUFFY NOSE/POST NASAL DROP,Upper-airway cough syndrome,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-21,2011-11-21,2011-11-29,2011-11-29,154.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,BILIARY SEPSIS,Biliary sepsis,INFECTIONS AND INFESTATIONS,2011-07-20,2011-07-20,2011-07-24,2011-07-24,21.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,BILE DUCT STENOSIS,Bile duct stenosis,HEPATOBILIARY DISORDERS,2011-07-20,2011-07-20,2011-07-22,2011-07-22,21.0,Y,UNLIKELY,2.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-08-11,2011-08-11,2011-08-18,2011-08-18,43.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,PANCREATITIS,Pancreatitis,GASTROINTESTINAL DISORDERS,2011-09-03,2011-09-03,2011-09-05,2011-09-05,66.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-03,2011-09-03,2011-09-04,2011-09-04,66.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-27,2011-10-27,2011-11-11,2011-11-11,120.0,N,DEFINITELY,4.0,3,3.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-17,2011-11-17,,,141.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-10-06,2011-10-06,2011-10-20,2011-10-20,99.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,INTERMITTENT NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-30,2011-07-30,,,31.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,INTERMITTENT FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-18,2011-08-18,,,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-04,2012-01-04,2012-01-08,2012-01-08,189.0,Y,POSSIBLE/PROBABLE,3.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-01-26,2012-01-26,2012-01-30,2012-01-30,211.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-01-30,2012-01-30,,,215.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2012-01-30,2012-01-30,2012-01-30,2012-01-30,215.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-02,2012-02-02,2012-02-09,2012-02-09,218.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,BILATERAL LOWER EXTREMITY PAIN,Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-02-02,2012-02-02,,,218.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,PERIPHERAL NEUROPATHY -FEET,Neuropathy peripheral,NERVOUS SYSTEM DISORDERS,2012-02-03,2012-02-03,,,219.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,ABDOMINAL ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2012-02-06,2012-02-06,,,222.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,SCALP LACERATION DUE TO FALL,Fall,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-02-12,2012-02-12,2012-02-23,2012-02-23,228.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,SCALP LACERATION DUE TO FALL,Laceration,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-02-12,2012-02-12,2012-02-23,2012-02-23,228.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-09,2012-02-09,,,225.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,WEIGHT GAIN,Weight increased,INVESTIGATIONS,2011-11-17,2011-11-17,,,141.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,DYSGEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-07-14,2011-07-14,2011-07-14,2011-07-14,15.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,24.0,ALLERGIC REACTION TO IV CONTRAST,Contrast media reaction,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2011-08-11,2011-08-11,2011-08-11,2011-08-11,43.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,25.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-26,2011-09-26,2011-10-11,2011-10-11,89.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,26.0,NEUTROPENIA,Neutropenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,,,239.0,N,DEFINITELY,4.0,4,4.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,27.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2012-02-23,2012-02-23,,,239.0,N,DEFINITELY,4.0,2,2.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,28.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-01-08,2012-01-08,,,193.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,29.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-11-03,2011-11-03,2011-11-17,2011-11-17,127.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,30.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-22,2011-12-22,2011-12-29,2011-12-29,176.0,N,DEFINITELY,4.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,31.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-01,2011-12-01,2011-12-05,2011-12-05,155.0,N,DEFINITELY,4.0,2,2.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,32.0,THROMBOCYTOPENIA,Thrombocytopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-08,2011-09-08,2011-09-15,2011-09-15,71.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,33.0,METASTATIC PANCREATIC ADENOCARCINOMA,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-02-27,2012-02-27,2012-02-27,2012-02-27,243.0,Y,NOT RELATED,1.0,5,5.0,,NONE,CONTINUOUS,FATAL,Y,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,34.0,LEUKOPENIA,Leukopenia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-07-14,2011-07-14,2011-07-28,2011-07-28,15.0,N,DEFINITELY,4.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,35.0,INCREASED ALKALINE PHOSPHATASE CS,Blood alkaline phosphatase increased,INVESTIGATIONS,2011-07-14,2011-07-14,,,15.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-003,01098003,098,70.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,36.0,INCREASED CREATININE CS,Blood creatinine increased,INVESTIGATIONS,2012-02-23,2012-02-23,2012-02-27,2012-02-27,239.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-21,2011-07-21,2011-07-22,2011-07-22,-7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07-21,2011-07-21,2011-07-22,2011-07-22,-7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,DECREASED APPETITE,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-07-21,2011-07-21,2011-08-09,2011-08-09,-7.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-29,2011-07-29,,,2.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-07-29,2011-07-29,2011-08-09,2011-08-09,2.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-07-21,2011-07-21,2011-08-09,2011-08-09,-7.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,INTERMITTENT DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-07-22,2011-07-22,,,-6.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-07-23,2011-07-23,2011-08-09,2011-08-09,-5.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-07-29,2011-07-29,,,2.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-08-01,2011-08-01,2011-08-09,2011-08-09,5.0,N,NOT RELATED,1.0,3,3.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,BILE DUCT OBSTRUCTION,Bile duct obstruction,HEPATOBILIARY DISORDERS,2011-08-02,2011-08-02,2011-08-03,2011-08-03,6.0,N,NOT RELATED,1.0,3,3.0,,OTHER,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,FREQUENT BELCHING,Eructation,GASTROINTESTINAL DISORDERS,2011-08-12,2011-08-12,,,16.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-07-23,2011-07-23,2011-08-09,2011-08-09,-5.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,HYPERBILIRUBINEMIA,Hyperbilirubinaemia,HEPATOBILIARY DISORDERS,2011-08-10,2011-08-10,,,14.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,15.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-09,2011-08-09,,,13.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,16.0,INTERMITTENT VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-14,2011-08-14,2011-08-18,2011-08-18,18.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,17.0,PEDAL EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-08-17,2011-08-17,,,21.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,18.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-19,2011-08-19,,,23.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,19.0,INTERMITTENT VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-19,2011-08-19,,,23.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,20.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-08-24,2011-08-24,,,28.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,21.0,SHINGLES,Herpes zoster,INFECTIONS AND INFESTATIONS,2011-08-24,2011-08-24,,,28.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,22.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-08-24,2011-08-24,,,28.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-006,01098006,098,50.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,23.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2011-08-24,2011-08-24,,,28.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,DISTAL COMMON BILE DUCT BILIARY OBSTRUCTION,Bile duct obstruction,HEPATOBILIARY DISORDERS,2012-01-27,2012-01-27,2012-01-29,2012-01-29,-4.0,Y,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,N
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,PANCREATITIS,Pancreatitis,GASTROINTESTINAL DISORDERS,2012-01-27,2012-01-27,,,-4.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-31,2012-01-31,,,1.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-01-27,2012-01-27,2012-01-31,2012-01-31,-4.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2012-03-10,2012-03-10,,,40.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-03-10,2012-03-10,2012-05-16,2012-05-16,40.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2012-03-10,2012-03-10,,,40.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,RIGHT LOWER EXTREMITY EDEMA,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-20,2012-03-20,,,50.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2012-02-26,2012-02-26,,,27.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,10.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2012-05-17,2012-05-17,2012-05-20,2012-05-20,108.0,Y,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-098-012,01098012,098,54.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,11.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-05-17,2012-05-17,2012-05-20,2012-05-20,108.0,Y,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-03,2011-09-03,2011-11-18,2011-11-18,31.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-01,2011-08-01,2011-08-11,2011-08-11,-3.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-02,2011-08-02,,,-2.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,N
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,HYPERGLYCEMIA,Hyperglycaemia,METABOLISM AND NUTRITION DISORDERS,2011-08-01,2011-08-01,2011-08-09,2011-08-09,-3.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-08-10,2011-08-10,2011-08-31,2011-08-31,7.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-07-29,2011-07-29,,,-6.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,,N,N,N,N
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-08-25,2011-08-25,2011-09-08,2011-09-08,22.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,8.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-11,2011-09-11,2011-09-12,2011-09-12,39.0,N,UNLIKELY,2.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,9.0,PAIN- KNEE,Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-11,2011-09-11,2011-09-19,2011-09-19,39.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,10.0,PAIN - ABDOMINAL AND BACK,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-09-19,2011-09-19,,,47.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,11.0,PAIN - ABDOMINAL AND BACK,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-19,2011-09-19,,,47.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,12.0,ASCITES,Ascites,GASTROINTESTINAL DISORDERS,2011-09-19,2011-09-19,,,47.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,13.0,LOCALIZED EDEMA - KNEES,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-19,2011-09-19,2011-09-29,2011-09-29,47.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,14.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-19,2011-09-19,2011-09-28,2011-09-28,47.0,N,NOT RELATED,1.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,15.0,GENERALIZED MUSCLE WEAKNESS,Muscular weakness,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-09-22,2011-09-22,,,50.0,N,UNLIKELY,2.0,3,3.0,,OTHER,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,16.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-25,2011-09-25,2011-09-26,2011-09-26,53.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,17.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-09-29,2011-09-29,2011-11-18,2011-11-18,57.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,18.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-29,2011-09-29,2011-10-03,2011-10-03,57.0,Y,NOT RELATED,1.0,2,2.0,,,INTERMITTENT,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,19.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-09-29,2011-09-29,2011-10-03,2011-10-03,57.0,N,NOT RELATED,1.0,3,3.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,20.0,PHLEBITIS INFECTIVE,Phlebitis infective,INFECTIONS AND INFESTATIONS,2011-08-12,2011-08-12,2011-08-18,2011-08-18,9.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,21.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-09-03,2011-09-03,2011-09-08,2011-09-08,31.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,22.0,LOW PLATELET COUNT / CLINICALLY SIGNIFICANT,Platelet count decreased,INVESTIGATIONS,2011-08-18,2011-08-18,2011-08-28,2011-08-28,15.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,DOSE REDUCED,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,23.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-09-29,2011-09-29,2011-11-04,2011-11-04,57.0,Y,NOT RELATED,1.0,3,3.0,,,INTERMITTENT,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,24.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-09-29,2011-09-29,2011-10-03,2011-10-03,57.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,25.0,METASTATIC PANCREATIC ADENOCARCINOMA PAIN,Cancer pain,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-09-29,2011-09-29,2011-10-03,2011-10-03,57.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,26.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-29,2011-09-29,2011-10-03,2011-10-03,57.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,27.0,DYSPNEA,Dyspnoea,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-09-29,2011-09-29,2011-10-03,2011-10-03,57.0,Y,NOT RELATED,1.0,2,2.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,28.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-07,2011-08-07,2011-08-10,2011-08-10,4.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,29.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-07,2011-08-07,2011-08-10,2011-08-10,4.0,Y,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,30.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-07,2011-08-07,2011-08-10,2011-08-10,4.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,31.0,DEHYDRATION,Dehydration,METABOLISM AND NUTRITION DISORDERS,2011-08-07,2011-08-07,2011-08-10,2011-08-10,4.0,Y,NOT RELATED,1.0,3,3.0,,,CONTINUOUS,RECOVERED/RESOLVED,N,Y,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,32.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-08-07,2011-08-07,2011-08-10,2011-08-10,4.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,33.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-10,2011-08-10,,,7.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,34.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-11,2011-08-11,2011-09-29,2011-09-29,8.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,35.0,LOW BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08-26,2011-08-26,2011-09-03,2011-09-03,23.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,36.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-08-25,2011-08-25,2011-09-01,2011-09-01,22.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-100-001,01100001,100,67.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,37.0,VOMITING,Vomiting,GASTROINTESTINAL DISORDERS,2011-08-25,2011-08-25,2011-09-01,2011-09-01,22.0,Y,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,ABDOMINAL PAIN,Abdominal pain,GASTROINTESTINAL DISORDERS,2011-08-18,2011-08-18,,,-1.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,N
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,PAIN IN EXTREMITY (LEFT UPPER LEG AND HIP),Arthralgia,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08-25,2011-08-25,2011-09-01,2011-09-01,7.0,N,UNLIKELY,2.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,PAIN IN EXTREMITY (LEFT UPPER LEG AND HIP),Pain in extremity,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-08-25,2011-08-25,2011-09-01,2011-09-01,7.0,N,UNLIKELY,2.0,1,1.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-08,2011-09-08,,,21.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,DYSGEUSIA,Dysgeusia,NERVOUS SYSTEM DISORDERS,2011-08-25,2011-08-25,,,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-09-01,2011-09-01,,,14.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,LOCALIZED EDEMA (BILATERAL ANKLE),Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-09-01,2011-09-01,,,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,THROMBOEMBOLITIC EVENT,Embolism,VASCULAR DISORDERS,2011-09-08,2011-09-08,,,21.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,HYPOCALCEMIA,Hypocalcaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-08,2011-09-08,2011-10-14,2011-10-14,21.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,10.0,HYPOALBUMINEMIA,Hypoalbuminaemia,METABOLISM AND NUTRITION DISORDERS,2011-09-08,2011-09-08,2011-10-14,2011-10-14,21.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,11.0,HYPONATREMIA,Hyponatraemia,METABOLISM AND NUTRITION DISORDERS,2011-09-08,2011-09-08,2011-10-14,2011-10-14,21.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,12.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2011-08-25,2011-08-25,,,7.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERING/RESOLVING,N,N,Y,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,13.0,ANXIETY,Anxiety,PSYCHIATRIC DISORDERS,2011-09-22,2011-09-22,,,35.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-100-002,01100002,100,82.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,14.0,ORAL PAIN,Oral pain,GASTROINTESTINAL DISORDERS,2011-08-25,2011-08-25,2011-10-06,2011-10-06,7.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-11,2011-11-11,2012-01-04,2012-01-04,3.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2011-11-22,2011-11-22,2011-11-22,2011-11-22,14.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-101-002,01101002,101,73.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,ANEMIA,Anaemia,BLOOD AND LYMPHATIC SYSTEM DISORDERS,2011-12-14,2011-12-14,2011-12-28,2011-12-28,36.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,1.0,BURNING BACK PAIN,Pain,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-03-28,2012-03-28,,,1.0,N,NOT RELATED,1.0,2,2.0,,NONE,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,2.0,METASTATIC PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-07-20,2012-07-20,2012-07-20,2012-07-20,115.0,Y,UNLIKELY,2.0,5,5.0,"DOSE REDUCED, DRUG INTERRUPTED, DRUG WITHDRAWN",,CONTINUOUS,FATAL,Y,Y,N,Y
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,3.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-07-11,2012-07-11,,,106.0,N,NOT RELATED,1.0,3,3.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,4.0,WORSENING PNEUMOTHORAX,Pneumothorax,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-06-22,2012-06-22,2012-06-29,2012-06-29,87.0,Y,POSSIBLE/PROBABLE,3.0,2,2.0,"DOSE REDUCED, DRUG INTERRUPTED",PROCEDURE TREATMENT REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,5.0,CONSTIPATION,Constipation,GASTROINTESTINAL DISORDERS,2012-06-29,2012-06-29,,,94.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,6.0,HYPERTENSION,Hypertension,VASCULAR DISORDERS,2012-06-29,2012-06-29,,,94.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-104-001,01104001,104,70.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Negative (Low),1.0,7.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-07-18,2012-07-18,2012-10-20,2012-10-20,113.0,N,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,1.0,RASH MACULO-PAPULAR,Rash maculo-papular,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2011-07-16,2011-07-16,2011-08-02,2011-08-02,5.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,2.0,"PLATELET COUNT DECREASED -""CS""",Platelet count decreased,INVESTIGATIONS,2011-07-26,2011-07-26,2011-08-02,2011-08-02,15.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,3.0,DUODENAL OBSTRUCTION,Duodenal obstruction,GASTROINTESTINAL DISORDERS,2011-08-06,2011-08-06,2011-08-15,2011-08-15,26.0,Y,NOT RELATED,1.0,3,3.0,DRUG INTERRUPTED,"OTHER, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,4.0,"PLATELET COUNT DECREASED ""CS""",Platelet count decreased,INVESTIGATIONS,2011-08-24,2011-08-24,2011-08-31,2011-08-31,44.0,N,DEFINITELY,4.0,1,1.0,DOSE REDUCED,,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,5.0,ANOREXIA,Decreased appetite,METABOLISM AND NUTRITION DISORDERS,2011-08-05,2011-08-05,,,25.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,6.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2011-08-02,2011-08-02,2011-08-09,2011-08-09,22.0,N,NOT RELATED,1.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-105-001,01105001,105,65.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Negative (Low),1.0,7.0,FREQUENT URINATION,Pollakiuria,RENAL AND URINARY DISORDERS,2011-10-05,2011-10-05,,,86.0,N,NOT RELATED,1.0,1,1.0,,OTHER,INTERMITTENT,,N,N,N,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-10-11,2011-10-11,,,8.0,N,POSSIBLE/PROBABLE,3.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, OTHER",INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,2.0,PERITONEAL CARCINOMATOSIS,Metastases to peritoneum,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2011-11-07,2011-11-07,2011-12-21,2011-12-21,35.0,Y,NOT RELATED,1.0,3,3.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,3.0,FUNCTIONAL BOWEL OBSTRUCTION,Intestinal obstruction,GASTROINTESTINAL DISORDERS,2011-11-07,2011-11-07,2011-12-21,2011-12-21,35.0,Y,NOT RELATED,1.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,Y,Y,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,4.0,HYPERKALEMIA,Hyperkalaemia,METABOLISM AND NUTRITION DISORDERS,2011-10-13,2011-10-13,2011-10-17,2011-10-17,10.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,5.0,ADRENAL INSUFFICIENCY,Adrenal insufficiency,ENDOCRINE DISORDERS,2011-11-01,2011-11-01,,,29.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,6.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2011-10-28,2011-10-28,,,25.0,N,UNLIKELY,2.0,2,2.0,DOSE REDUCED,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,7.0,BILAT LE DVT,Deep vein thrombosis,VASCULAR DISORDERS,2011-11-14,2011-11-14,,,42.0,N,UNLIKELY,2.0,2,2.0,,PROCEDURE TREATMENT REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,8.0,ACUTE KIDNEY INJURY,Renal failure acute,RENAL AND URINARY DISORDERS,2011-11-27,2011-11-27,2011-12-21,2011-12-21,55.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-105-002,01105002,105,55.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,Y,Gemcitabine Elaidate,Gemcitabine Elaidate,1.0,Gemcitabine Elaidate,1.0,Positive (High),2.0,9.0,PERITONEAL INFECTION,Infectious peritonitis,INFECTIONS AND INFESTATIONS,2011-11-15,2011-11-15,2011-11-25,2011-11-25,43.0,N,NOT RELATED,1.0,3,3.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-03-06,2012-03-06,2012-03-27,2012-03-27,57.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,PRODUCTIVE COUGH,Productive cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2012-04-03,2012-04-03,2012-04-10,2012-04-10,85.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-105-003,01105003,105,55.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,METASTATIC PANCREATIC ADENOCARCINOMA PROGRESSION,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-05-22,2012-05-22,,,134.0,N,NOT RELATED,1.0,2,2.0,DRUG WITHDRAWN,,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,1.0,INDIGESTION,Dyspepsia,GASTROINTESTINAL DISORDERS,2011-11-10,2011-11-10,2011-11-15,2011-11-15,3.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,2.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-11-10,2011-11-10,2011-11-15,2011-11-15,3.0,N,UNLIKELY,2.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,3.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-15,2011-11-15,2011-12-06,2011-12-06,8.0,N,UNLIKELY,2.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED WITH SEQUELAE,N,N,Y,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,4.0,FEVER,Pyrexia,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-11-18,2011-11-18,2011-11-22,2011-11-22,11.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,5.0,CHEST CONGESTION,Pulmonary congestion,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-11-21,2011-11-21,2011-12-06,2011-12-06,14.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,6.0,COUGH,Cough,"RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS",2011-12-06,2011-12-06,2012-01-03,2012-01-03,29.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,7.0,DIZZINESS,Dizziness,NERVOUS SYSTEM DISORDERS,2011-12-06,2011-12-06,2012-01-03,2012-01-03,29.0,N,UNLIKELY,2.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,8.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-13,2011-12-13,2011-12-20,2011-12-20,36.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-106-001,01106001,106,79.0,YEARS,F,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,Y,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,Positive (High),2.0,9.0,BACK PAIN,Back pain,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2011-12-13,2011-12-13,2012-01-03,2012-01-03,36.0,N,UNLIKELY,2.0,1,1.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,1.0,MULTIPLE HEPATIC ABSCESSES,Liver abscess,INFECTIONS AND INFESTATIONS,2012-01-19,2012-01-19,2012-02-06,2012-02-06,3.0,Y,NOT RELATED,1.0,5,5.0,DRUG WITHDRAWN,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,FATAL,Y,Y,Y,Y
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,2.0,DISEASE PROGRESSION OF PANCREATIC CANCER,Pancreatic carcinoma metastatic,"NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)",2012-02-06,2012-02-06,,,21.0,Y,NOT RELATED,1.0,4,4.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,INDIGESTION,Dyspepsia,GASTROINTESTINAL DISORDERS,2012-01-12,2012-01-12,,,-5.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-01-16,2012-01-16,2012-01-19,2012-01-19,-1.0,N,NOT RELATED,1.0,2,2.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,N
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,EDEMA ANKLES/FEET,Oedema peripheral,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-10,2012-01-10,,,-7.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,TASTE ALTERATION,Dysgeusia,NERVOUS SYSTEM DISORDERS,2012-01-03,2012-01-03,,,-14.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,MUSCLE WEAKNESS,Muscular weakness,MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS,2012-01-03,2012-01-03,,,-14.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-12,2012-01-12,,,-5.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,N
CO-101-001,CO-101-001-106-002,01106002,106,78.0,YEARS,F,BLACK OR AFRICAN AMERICAN,3.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,9.0,BLOOD BILIRUBIN INCREASE(CS),Blood bilirubin increased,INVESTIGATIONS,2012-01-11,2012-01-11,2012-01-13,2012-01-13,-6.0,N,NOT RELATED,1.0,3,3.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,N
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,1.0,CHOLANGITIS SECONDARY TO STENT INFECTION,Cholangitis,HEPATOBILIARY DISORDERS,2012-05-05,2012-05-05,2012-05-08,2012-05-08,75.0,Y,DEFINITELY,4.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,2.0,CHOLANGITIS SECONDARY TO STENT INFECTION,Device related infection,INFECTIONS AND INFESTATIONS,2012-05-05,2012-05-05,2012-05-08,2012-05-08,75.0,Y,DEFINITELY,4.0,3,3.0,,"CONCOMITANT MEDICATION REQUIRED, PROCEDURE TREATMENT REQUIRED",CONTINUOUS,RECOVERED/RESOLVED,N,Y,Y,Y
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,DIARRHEA,Diarrhoea,GASTROINTESTINAL DISORDERS,2012-02-16,2012-02-16,,,-5.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,ABDOMINAL GAS,Flatulence,GASTROINTESTINAL DISORDERS,2012-02-21,2012-02-21,,,1.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-106-003,01106003,106,72.0,YEARS,M,ASIAN,2.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,HYPOKALEMIA,Hypokalaemia,METABOLISM AND NUTRITION DISORDERS,2012-02-09,2012-02-09,,,-12.0,N,NOT RELATED,1.0,1,1.0,,"CONCOMITANT MEDICATION REQUIRED, NONE",CONTINUOUS,,N,N,Y,N
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,1.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-03,2011-12-03,2011-12-04,2011-12-04,11.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,2.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-09,2011-12-09,2011-12-12,2011-12-12,17.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,3.0,NAUSEA,Nausea,GASTROINTESTINAL DISORDERS,2011-12-18,2011-12-18,2012-03-11,2012-03-11,26.0,N,DEFINITELY,4.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,4.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2011-12-18,2011-12-18,2012-01-11,2012-01-11,26.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,NONE,CONTINUOUS,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,5.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-01-11,2012-01-11,2012-02-15,2012-02-15,50.0,N,POSSIBLE/PROBABLE,3.0,1,1.0,,NONE,INTERMITTENT,RECOVERED/RESOLVED,N,N,N,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,6.0,INSOMNIA,Insomnia,PSYCHIATRIC DISORDERS,2012-01-17,2012-01-17,,,56.0,N,POSSIBLE/PROBABLE,3.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,INTERMITTENT,,N,N,Y,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,7.0,LEFT EAR ACTINIC KERATOSIS,Actinic keratosis,SKIN AND SUBCUTANEOUS TISSUE DISORDERS,2012-01-17,2012-01-17,,,56.0,N,NOT RELATED,1.0,1,1.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,8.0,LEFT HAND WOUND,Wound,"INJURY, POISONING AND PROCEDURAL COMPLICATIONS",2012-01-30,2012-01-30,2012-02-29,2012-02-29,69.0,N,NOT RELATED,1.0,1,1.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,RECOVERED/RESOLVED,N,N,Y,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,9.0,DEPRESSION,Depression,PSYCHIATRIC DISORDERS,2012-02-15,2012-02-15,,,85.0,N,NOT RELATED,1.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,10.0,FATIGUE,Fatigue,GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS,2012-02-15,2012-02-15,,,85.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,11.0,MULTIPLE SMALL BLOOD CLOTS,Thrombosis,VASCULAR DISORDERS,2012-03-07,2012-03-07,,,106.0,N,NOT RELATED,1.0,2,2.0,,CONCOMITANT MEDICATION REQUIRED,CONTINUOUS,,N,N,Y,Y
CO-101-001,CO-101-001-110-001,01110001,110,61.0,YEARS,M,WHITE,5.0,USA,UNITED STATES,North America,1.0,Y,Y,N,Y,N,Gemcitabine,Gemcitabine,2.0,Gemcitabine,2.0,N/A,3.0,12.0,WEIGHT LOSS,Weight decreased,INVESTIGATIONS,2012-01-17,2012-01-17,,,56.0,N,UNLIKELY,2.0,2,2.0,,NONE,CONTINUOUS,,N,N,N,Y
